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The NCAPG/LCORL locus is a major QTL on bovine chromosome 6 (BTA6) that 
influences growth and composition in cattle. Genetic variation at this locus is associated with 
alterations in the developmental program of individuals throughout life that may be detected 
through transcriptional variation. Here, we propose to characterize how the landscape of 
transcriptomes differ between individuals with alternative NCAPG/LCORL 
haplotypes/genotypes. Charolais calves (n=804) were genotyped using the Illumina® BovSNP50 
BeadChip and their sires (n=38) were genotyped with the BovineHD BeadChip. Additionally, 53 
calves were genotyped on the BovineHD BeadChip (770k) platform for use in further analyses. 
The 38 sires and 53 calves genotyped on the 770k platform were used to impute the calf 
genotypes, resulting in approximately 638,230 markers per individual used for GWAS analyses. 
Twenty-four animals were selected based on alternative homozygous NCAPG/LCORL 
haplotypes/genotypes (i.e. 12 “QQ” and 12 “qq”, where “Q” is the QTL allele associated with 
increased birth weight and “q” the alternative allele) and a muscle biopsy was taken from each 
animal at 300 days of age. Total RNA was isolated and used for NGS library construction and 
libraries were sequenced on a HiSeq2500 using single-end chemistry. Sequencing yielded 898 
million reads (average >30 million reads/sample) that were mapped to the bovine reference 
genome (Build UMD3.1). Differential gene expression was analyzed using edgeR. Five hundred 
and seven (507) genes were found to be differentially expressed (FDR P-value < 0.01) in QQ 
compared to qq animals, including LCORL which was upregulated. Network inferring using 
weighted gene co-expression network analysis (WGCNA) revealed eleven co-expression gene 
network modules significantly correlated with genotype. Of these, the LCORL containing 
module (Blue) showed the highest positive correlation. Gene Ontology enrichment analysis and 
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Ingenuity Pathway Analysis (IPA) revealed an up- and downregulation of lean growth and fat 
synthesis pathways, respectively, associated with our list of differentially expressed genes; 
additionally, enrichment and activation of growth and metabolism related-pathways was reported 
for WGCNA Blue module. Our results suggest that LCORL overexpression may be driving 
increased cellular metabolism and, consequently, lean growth. Additionally, it suggests that 
LCORL may be part of a larger complex gene network underlying growth and development, and 
that the overexpression of this gene may influence the expression pattern of other genes in the 
same network. Our results provide valuable insights into the molecular mechanisms underlying 
the phenotypic variation between calves with alternative NCAPG/LCORL genotypes. The 
characterization of these molecular changes will allow us to better understand the regulation of 
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Chapter 1: Review of Literature 
Introduction 
Livestock production is one of the major components of a country’s economy, providing 
important commodities such as meat and dairy products [1]. The majority of modern livestock 
breeds were initially selected mainly for traits such as hair color, shape, and size. However, due 
to an increased consumer demand for healthier products with reduced fat content, the livestock 
industry has changed, giving more attention to improving animal growth and body composition. 
The improvement in nutrition and genetic selection, as well as the development of better 
techniques for body composition estimation has allowed livestock producers to selectively breed 
individuals that grow faster and more efficiently. Additionally, it has helped the industry to select 
meat animals that are leaner and more muscular in order to meet the consumer demands [2]. 
However, selection for economically important traits, such as those related to meat quality 
characteristics and lean growth, is still challenging. These traits are often genetically complex 
and, for many, the genes and polymorphisms underlying their phenotypic variation are still 
unknown. Therefore, achieving excellence in livestock production depends on continued 
research.  
Animal growth and development are continuous and dynamic processes that have 
important implications in livestock production. Growth can be roughly described as the overall 
and normal increase of animal size due to an increase in body height, weight, length, and girth 
and can be achieved by one or more of the following cellular processes: hypertrophy, 
hyperplasia, or accretion [3, 4]. Briefly, growth can occur through increase in cell size (i.e. 
hypertrophy), increase in cell quantity (i.e. hyperplasia), and/or accretion of material between 
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cells (i.e. accretion) [3]. Development, on the other hand, can be described as changes in body 
composition, structure and abilities [4, 5]. It involves cellular changes that allow tissues and 
organs to assume specialized and more complex roles and functions as growth progresses [3]. 
Changes during growth and development may significantly affect animal productivity. 
Therefore, understanding what factors and mechanisms may be underlying growth-related traits 
is essential for improving the production efficiency for our livestock species. Of particular 
importance, is the understanding of the genetic, biochemical, and physiological interrelationships 
influencing animal growth and development.  
Economically important growth- and development-related traits, such as muscle growth 
and lipid deposition, are genetically complex in nature and thus, are controlled by many genes or 
regions of the genome called quantitative trait loci (QTL). QTL mapping aims to identify genes 
affecting phenotypes of interest, as well as to understand gene function. Ultimately, this 
approach is often used for the elucidation of a causative quantitative trait nucleotide (QTN), i.e. 
identification of a polymorphism responsible for important phenotypic differences in the trait 
under investigation that can be used for animal selection.  
In cattle, the identification of QTL influencing desirable traits is of continual interest, 
given that the study of these regions may reveal important information regarding phenotypic 
variation observed within and between different cattle populations. More than a decade ago, the 
development of polymorphic markers and genetic maps allowed us to perform QTL mapping and 
genome wide association studies (GWAS) in cattle, identifying many QTL associated with 
desirable traits [6, 7]. However, due to limited sample size (<300 animals), many of these 
reported studies lacked the statistical power to detect more than genes with very large effects [6, 
8]. Additionally, the low density of markers previously used in QTL mapping studies negatively 
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affected mapping resolution, only localizing QTL to very large chromosomal regions (several 
megabases) and making it difficult to identify appropriate positional candidate genes [6]. Despite 
these limitations, highly significant QTL on bovine chromosome 6 (BTA6) were detected and 
shown to influence several growth- and development- related traits including growth and carcass 
traits [9], carcass weight [8], birth weight and pre‐weaning average daily gain [10], size and 
dairy character [11], and rib thickness and marbling score [12]. 
Recent completion of the cattle genome sequence [13] and the development of high-
density single nucleotide polymorphism (SNP) panels – such as the BovineSNP50 BeadChip 
[14] and BovineHD BeadChip panels containing 54,609 and 777,000 SNPs probes, respectively 
– have revolutionized QTL mapping studies. It is now possible to not only detect novel QTL, but 
also improve the resolution of the location of QTL mapped with older methods [6]. Using these 
tools, several independent studies have described this QTL on BTA6 in different cattle 
populations and breeds as having a major influence on growth and composition traits; the 
primary action is on lean growth [15-23]. In fact, genetic markers in two candidate genes in this 
QTL, non‐SMC condensin I complex subunit G (NCAPG), and ligand dependent nuclear 
receptor corepressor‐like (LCORL), have been associated with several economically important 
cattle production traits, including growth and lipid deposition [15], carcass weight, ribeye area 
and backfat traits [17],  average daily feed intake and average daily gain [19], and bovine fetal 
growth [22], suggesting the association of this locus with cattle growth and development. Herein, 
this QTL is referred as the NCAPG/LCORL locus.  
The NCAPG/LCORL locus 
Setoguchi et al. [17] was the first group to make significant improvements in map 
position and gene identification for the QTL on BTA6, reporting the presence of this QTL 
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influencing variation in carcass weight, ribeye area, and backfat traits. Using large Japanese 
Black and Japanese Brown half‐sib families, they refined the position of this QTL from a 17-cM 
region to a critical region of 591 Kb comprising four candidate genes: family with sequence 
similarity 184, member B (FAM184); DDB1 and CUL4 associated factor 16 (DCAF16); non-
structural maintenance of chromosomes (SMC) condensin I complex subunit G (NCAPG); and 
ligand dependent nuclear receptor corepressor‐like (LCORL). After sequencing of the identified 
genes, this study also detected a polymorphism in exon 9 of the NCAPG gene (c.1326T>G) 
changing Ile-442 to Met and suggested it as a positional candidate for the causative quantitative 
trait nucleotide (QTN).  
Considering the assumption that NCAPG was the causative gene underlying the 
phenotypic variation associated with the NCAPG/LCORL QTL, two main studies have 
investigated the role of this gene and its putative QTN in cattle growth and development. 
Eberlein et al. [22] aimed to further investigate the effects of the proposed QTN on bovine fetal 
growth. For this study, they used a unique structured F2 cattle resource population generated 
from the founder breeds Charolais and Holstein cattle by multiple ovulation embryo transfer 
(MOET). This method enabled the investigation of both fetal- and maternal-specific genetic 
components influencing bovine fetal growth; their findings demonstrated that the phenotypic 
variation observed was highly influenced by the fetal genotype. Additionally, further gene 
expression analysis on NCAPG in placental and fetal tissues revealed reduced NCAPG transcript 
levels and increased fetal growth associated with the NCAPG c1326G allele for the putative 
QTN. 
A metabolomics study by Weikard et al. [15] using the same population as Eberlein et al. 
[22] also aimed to further investigate the NCAPG putative QTN. Using a combination of genetic 
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association analyses, phenotypic monitoring and metabolomics profiling, this study investigated 
the effects of the NCAPG c1326T>G polymorphism on the metabolome of animals with 
alternative NCAPG genotypes. Samples were collected during the period of 180 to 270 days after 
birth, which was determined as the most divergent growth period between genotypes. Their 
findings reported significant differences in growth and lipid deposition physiological pathways 
between animals with alternative genotypes for the NCAPG putative QTN, thus suggesting the 
influence of the NCAPG c.1326G allele on cattle growth and composition traits. More 
specifically, this study reported an association of the NCAPG c1326T>G polymorphism with 
variation in the circulating levels of plasma arginine, symmetric dimethylarginine (SDMA), and 
linoleycarnitine. Arginine has been reported to affect animal growth by activating the mTOR 
pathway [24], a pathway involved in protein synthesis processes, as well as growth. Therefore, 
these results may suggest a role of NCAPG on cattle growth via arginine.  
Although these studies have shown significant evidence of the role of NCAPG 
c.1326T>G as the causative variant underlying phenotypic variation, a growing number of 
evidence suggest that LCORL may be the causative gene instead. Previous studies by both 
ourselves [25] and Gutiérrez-Gil et al. [26] suggest that the NCAPG putative QTN is not the 
causative variant for the phenotypic variation observed. In fact, these studies have excluded this 
polymorphism as the causative variant, suggesting that the QTN responsible remains undefined 
(data is further discussed in Chapter 2). Briefly, results from our preliminary data suggest that 
another polymorphism, likely associated with the LCORL gene, may be the actual causative 
variation [25]. 
Lindholm-Perry et al. [19] have proposed an association between LCORL and phenotypic 
variation associated with the NCAPG/LCORL region. This study aimed to evaluate the potential 
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of LAP3, NCAPG, and LCORL as positional candidate genes for average daily feed intake 
(ADFI) and average daily gain (ADG) in cattle with extreme phenotypes for these traits. 
Although this study identified significant associations of the NCAPG putative QTN with ADFI 
and ADG, they also identified markers located further downstream and within the LCORL gene 
which were more significant, suggesting a potential role of LCORL as a causative gene for the 
phenotypic variation. Another recent research by the same group [27] aimed to investigate the 
correlation between feed intake and different growth phenotypes with differential expression of 
NCAPG and LCORL in adipose and muscle tissue from beef cattle. Their results revealed a 
positive correlation between LCORL expression and ADFI in muscle tissue of steers, as well as a 
negative correlation between LCORL expression and ADFI in bovine adipose tissue. These 
findings support the results obtained from the first study, and suggest that the expression of 
LCORL may be associated with variation in ADFI; furthermore, it suggests its influence in cattle 
lean growth. 
A recent study by Han et al. [28] investigated the presence of SNPs in the LCORL gene, 
as well as its promoter region, and aimed to identify the relationships of these SNPs with carcass 
and growth traits in Qinchuan beef cattle. Several polymorphisms were detected in the promoter 
region of LCORL (~3000bp upstream of gene), as well as exons and intron region. Remarkably, 
a SNP located in an intron (INT+52098A>G) was significantly associated with carcass and 
slaughter weight; animals with the AG genotype for this SNP had superior slaughter and carcass 
weight compared to homozygous individuals. These findings suggest that polymorphisms in this 
gene, and not NCAPG, may be responsible for phenotypic variation associated with the 
NCAPG/LCORL QTL, offering support to the conclusions made by Gutiérrez-Gil et al. [20] and 
ourselves [25]. 
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These studies reveal that the NCAPG/LCORL locus have great influence on economically 
relevant traits in cattle. A great amount of evidence show that genetic variation at this locus is 
associated with alterations in cattle growth and development, altering body growth and 
composition, especially lean growth. Additionally, these studies show an influence of this locus 
on phenotypes of cattle in several developmental periods, suggesting that genetic variation at the 
NCAPG/LCORL locus may cause stable alterations in the developmental program of individuals 
and continue throughout the growth phase.  
As described, a QTN on NCAPG has been proposed. However, great controversy can be 
observed in the literature regarding whether NCAPG or LCORL are the causative genes 
responsible for the phenotypic variation observed. Therefore, further research is necessary in 
order to elucidate the effect of these genes on cattle growth and development and, ultimately, 
identify the causative variation responsible. Although we do not currently know the specific 
QTN underlying the phenotypic variation, the presence of polymorphisms in either NCAPG or 
LCORL may disrupt the overall gene expression in individuals, causing phenotypic variation. 
These gene expression differences can be detected by transcriptional analysis.  
Influence of NCAPG/LCORL on growth and development phenotypes across 
multiple species 
Interestingly, the influence of the NCAPG/LCORL orthologous locus on growth and 
development traits has also been reported in other mammalian species including humans [29-41], 
dogs [42], horses [43-47], pigs [48], chickens [49], and sheep [50], thus supporting the 
significance of this QTL in cattle. In humans, this locus has been associated with adult human 
height in several populations, including European [30, 32, 36], Japanese [39], and African 
American [33, 37, 38]. Shriner et al. [33], in a study aimed at the identification of genetic 
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variants affecting adult human height in African Americans, reported that the presence of genetic 
variation in the NCAPG/LCORL locus influences overall stature and height within and across 
highly ethnically diverse human populations. Differently than what is observed in other species, 
less than 1% of phenotypic variance is associated with this locus in humans; this is likely due to 
the many genes affecting the phenotypes observed, as well as population structure (e.g no 
selection). Recently, a meta-analysis of several independent human studies proposed that the 
same genetic variants in the NCAPG/LCORL locus associated with increased adult-size were also 
associated with increased human birth weight and growth velocity during development [40]. 
Remarkably, the relationship between NCAPG/LCORL variation and growth velocity is 
comparable to what is observed in cattle, where genetic variation at the NCAPG/LCORL locus 
causes alterations during early developmental stages and continue throughout the life of the 
animal.  
The NCAPG/LCORL locus has been associated with height and body size in several horse 
breeds [43-46]. A study by Makvandi-Nejad et al. [44] on the genetics of size in horses reported 
that polymorphism in the NCAPG/LCORL locus may be responsible for the great majority of 
phenotypic variation observed between horse breeds with extreme size differences, thus 
suggesting that the locus was under high selection pressure during breed domestication, playing a 
major role in the evolution of horse size. In fact, their haplotype analysis demonstrated that 
larger breeds of horses carry a single common haplotype, while smaller breeds have five 
different haplotypes. Tetens et al. [45] in a GWAS in German Warmblood horses reported a 
major QTL mapping to the NCAPG/LCORL locus responsible for nearly 18% of the variation 
observed in horses wither height. Additionally, a subsequent study by Staiger et al. [51] in 
Tennessee Walking horses identified the NCAPG/LCORL locus as having major influence on 
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body size. Interestingly, further improvements of this QTL position suggested that LCORL, 
instead of NCAPG, may be the causative gene in this breed [51].  
In dogs, a study by Vaysse et al. [42] aimed at the detection of genomic regions 
associated with phenotypic differences between dog breeds reported the association of the 
NCAPG/LCORL locus with variation in overall size; this locus was associated with SNPs with 
high Fst statistics, indicating a large amount of variation between breeds with size differences. 
Similarly to horses, this also suggests that this locus was under strong selection in many breeds. 
In pigs, a study using sequence data covering the entire genome of several individuals compared 
the genome sequences of data from European domestic and European wild boars [48]. This 
approach revealed a selective sweep near to the NCAPG/LCORL locus likely due to selection of 
this locus for economically desirable traits, such as lean growth, size, and growth rate.  
These studies provide evidence that the NCAPG/LCORL orthologous locus in this species 
significantly influences animal growth and mature size, suggesting its role in the mechanisms 
underlying growth and development traits in mammals. As in cattle, in none of these species has 
a specific polymorphism been determined within this locus. Interestingly, several of the studies 
in the different species described above have reported the association of significant 
polymorphisms within and/or upstream of LCORL with phenotypic variation [40, 43, 44, 47-49].  
NCAPG and LCORL function 
NCAPG is a regulatory subunit of the condensin I complex in mammals that is 
responsible for the condensation and compaction of chromosomes during mitosis [52], which are 
essential processes for proper chromosome segregation. This gene may also be involved in the 
process of gene “bookmarking”, i.e. a mechanism of epigenetic memory by which the pattern of 
genes active and inactive before cell division are transmitted through mitosis to the daughter 
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cells [53]. This transmission of gene expression patterns has been reported to occur via 
mechanisms based on modulation of chromatin structure, including chromatin remodeling by 
histone deacetylases and methylation of specific DNA regions. The association of NCAPG with 
proteins involved in DNA methylation mechanisms suggests an association between 
condensation, bookmarking, and methylation processes. Briefly, NCAPG has been reported to 
associate with a de novo methyltransferase (DNA methyltransferase 3β - DNMT3B) [54] 
involved in DNA methylation during embryogenesis and cellular differentiation in mammals 
[55]. In cattle, expression of this gene has been shown in the pancreas, liver, skin, and intestines. 
Additionally, it has been shown to be expressed in several fetal tissues including fetal and 
maternal placenta , liver, bone, kidney and skeletal muscle [22].  
The LCORL gene was first described in mice together with its major homologue, ligand 
dependent nuclear receptor corepressor (LCOR) [56]. Both genes are homologues of the MBLK-
1, a transcription factor reported in the honeybee brain, and are known to encode transcription 
factors which recognize the same DNA element (5’-CCCTATCGATCGATCTCTACCT-3’), 
activating transcription of their target genes. Although the current literature with biological 
information regarding this gene is still limited, LCORL has been reported to be involved in 
ubiquitination events; it interacts with a polyubiquitin encoding gene, ubiquitin C (UBC), 
involved in several cellular processes including cell cycle regulation, protein degradation and 
cell signaling [57, 58]. Furthermore, LCORL interacts with a known transcriptional repressor (C‐
terminal binding protein 1; CTBP1) involved in the regulation of cellular proliferation and gene 
expression during development [59, 60]. In cattle, expression of LCORL has been reported  in the 
liver, intestines, and fetal tissue. However, expression of this gene in other bovine tissues is yet 
to be determined. 
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The currently defined functions of both NCAPG and LCORL suggest an involvement of 
these genes in fundamental processes of cellular division, cell cycle control, transcriptional 
regulation, and cell-signaling. Therefore, disruption of these genes may affect cattle growth and 
development related pathways.  
It is important to note that, although several information regarding NCAPG functions, the 
current literature with biological information regarding LCORL is still very limited. In fact, 
despite studies have suggested the association of this gene with cattle economically important 
traits, there is no detailed information concerning the actual mechanisms by which LCORL may 
affect growth and composition. Therefore, further research is needed to better understand the role 
of these genes, especially LCORL, in cattle growth and development.  
Transcriptional Analysis 
 All somatic cells in multicellular organisms share the same genome and, therefore, the 
same collection of genes. However, not all genes in the genome are actively transcribed in every 
cell; different cells present a distinct subset and combinations of genes that are actively 
transcribed. In other words, different cells show different patterns of gene expression. Variations 
in gene expression influence several physical, developmental, and biochemical differences 
between cells and tissues and may play a crucial role in the differences between cell phenotypes 
[61].  
The entire collection of transcripts of messenger RNAs (mRNAs) expressed by the 
genome is called the transcriptome; this term can be used to describe the set of mRNA transcripts 
of a given cell, as well as of an entire organism [61, 62]. Differently than the genome, which is 
roughly stable, the transcriptome is subject to variation, which can be induced by many factors, 
such as environmental conditions and developmental stage. Because the transcriptome includes 
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all mRNAs transcripts of a cell, it represents the collection of genes that are being actively 
transcribed at any given time. Therefore, by examining the transcriptomes of different cells or 
tissues, one can investigate the differences in gene expression between them and better 
understand how changes in the transcriptome may influence the overall phenotype of an 
organism [61]. 
Until recently, hybridization-based microarray technologies were the standard tools used 
for transcriptomic studies [63-65]. Briefly, for differential gene expression analyses using DNA 
microarrays, mRNA from two conditions of interest are first converted into complementary 
DNA (cDNA) libraries, which are then labeled with two different fluorescent dyes: red and 
green. Following, these libraries are mixed and hybridized to a microarray slide containing 
thousands of probes corresponding to different genes. After washing away the unbound 
molecules, bound fluorescent nucleic acid samples can be detected using a laser microscope. The 
expressed genes can be identified by the color of the dots generated (red, green, or yellow, which 
is the result of the combination of red and green) and expression levels can be measured by the 
intensity of the fluorescent signal [65].  
Although microarrays are incredibly useful for the detection of differentially expressed 
genes between two or more conditions, these technologies suffer from a number of inherent 
limitations, including cost, nonspecific binding of transcripts to several probes [66], limited 
dynamic range of transcript detection due to background and saturation signals [67, 68], poor 
sensitivity, and need of an existing genome sequence [67]. The development of high-throughput 
next-generation DNA sequencing (NGS) technologies [69] has provided a new method that 
revolutionized transcriptomic studies. This method, called RNA-Sequencing (RNA-Seq), 
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reduces, and in some cases eliminates, the limitations imposed by microarrays and serves as a 
great alternative to those technologies [67, 70].  
A typical RNA-Seq experiment starts with the extraction and purification of total cellular 
RNAs. For the purpose of differential gene expression studies, total RNA is then enriched for 
mRNA molecules, which can be done by directly selecting mRNA via polyA-based capture 
methods, or by selectively removing ribosomal RNA (rRNA). In order to meet the requirements 
for the most current sequencing platforms, the RNA is fragmented into pieces that are on average 
200bp. After quality assessment of these fragments, the obtained RNA is converted into a library 
of double-stranded cDNA fragments with sequencing adapters and indices (for later molecule 
identification) attached to one or both ends (single-end or pair-end sequencing, respectively). 
Following, these libraries are loaded into a flow cell and sequenced using a high-throughput 
platform, obtaining short sequences of usually 30 to 400bp on average from one or both ends. 
After sequencing, the resulting reads can be aligned to the reference genome of interest or 
assembled de novo (if a reference genome is not available), and the levels of expression for each 
gene can be measured and compared between different conditions [67]. 
Although results from gene expression quantification analyses are at some level 
comparable between RNA-Seq and microarrays [71], RNA-Seq offers many advantages over 
microarrays and has become the standard method for transcriptomic studies. For example, RNA-
Seq allows the detection of transcripts even if a reference genome sequence for the organism 
under study is not yet available [67]. Furthermore, differently than microarrays, RNA-Seq 
presents very low levels of background and saturation signals and, therefore, is able to detect 
very low and very high levels of gene expression. This technology is also capable of detecting 
variation, such as the presence of SNPs, in the transcribed regions sequenced [72, 73]. Lastly, 
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RNA-Seq requires lower amounts of RNA for analysis and the costs of this technology are 
relatively lower than that of microarrays [67].  
Like microarrays, RNA-Seq also offers some limitations. As previously mentioned, non-
specific hybridization of transcripts to several probes is a common concern when considering 
microarrays, especially in cases where genes with high sequence similarity are of interest. 
Although RNA-Seq can potentially eliminate ambiguities in sequence detection, these 
technologies may present ambiguities during reads mapping to the genome, given that sequenced 
reads may potentially map to multiple regions. However, this issue may be alleviated by the use 
of paired-end sequencing as well as corrections during data analysis [74]. Potential biases 
introduced during library preparation have also been reported as limitations of RNA-Seq 
technologies. For instance, RNA fragmentation in the first steps of library preparation may result 
in positional [75] or sequence-specific biases [76, 77] in sequenced fragments, where positional 
bias refers to fragments located more towards the 5’ or 3’ end of transcripts, and sequence-
specific bias refers to cases in which the sequence close to the 5’ or 3’ end of a fragment 
influences its chances of being selected for sequencing. A number of data analysis tools to 
correct for fragment biases are, however, available, such as the likelihood based approach 
proposed by Robert et al. [78]. Additionally, biases inherent to PCR amplification during library 
construction have also been reported [67, 77-80], which may result in, for example, over and 
under estimation of long and short fragments, respectively. Nonetheless, a wide range of data 
analysis tools have been proposed for correction of such biases [77, 81-83], thus reducing the 
impact of these issues in the final results.  
Despite the limitations imposed by RNA-Seq, studies applying this method have 
expanded our understanding of the complexity and magnitude of eukaryotic transcriptomes, and 
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have revealed several molecular mechanisms underlying important complex animal traits. RNA-
Seq is the most comprehensive technology currently available for transcriptomic studies, being a 
valuable tool for the understanding of the molecular basis of animal growth and development.  
Gene Network and Pathway Analyses 
 Analysis of differential gene expression using RNA-Seq identifies expression differences 
of individual genes between two or more conditions at a given time over the entire expression 
range, yielding a list of differentially expressed genes that may be associated with a phenotype of 
interest. However, this list is not very informative in the context of biological mechanisms and 
pathways underlying the phenotype under investigation. Despite understanding which genes 
and/or genomic regions are associated with a particular trait, one may be also interested in 
understanding which networks of genes may be influencing such trait, as well as which groups of 
genes function in the same biological pathways. Two widely used approaches for understanding 
expression data, weighted gene co-expression network analysis (WGCNA) [84, 85] and pathway 
analysis, can complement the results obtained with RNA-Seq experiments and provide a more 
complete understanding of the molecular mechanisms and pathways underlying complex traits.  
WGCNA 
 The analysis of gene co-expression networks have been widely used in genetic studies in 
order to explore the “system-level functionality of genes” [84]. As a systems biology approach, 
gene co-expression networks combine gene expression and phenotypic data to better understand 
the molecular architecture of complex traits. Weighted Gene Co-expression Network Analysis 
(WGCNA) is a relatively recent gene co-expression network based approach, widely used in the 
analysis of gene expression data for the identification of functional gene modules [84, 86, 87].  
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 WGCNA allows one to identify clusters (modules) of co-expressed genes (i.e. highly 
correlated genes with similar expression patterns), intramodular hubs, and network nodes. 
Additionally, it allows for the investigation of the relationships between the detected modules, as 
well as the correlation between co-expression modules and specific sample traits, such as 
genotype or phenotypes of interest. A typical gene co-expression analysis involves several steps, 
which are briefly described below.  
Correlation networks are built based on calculated correlations between measurements, 
which can be described as a n x m matrix X = [xil], where rows indicate network nodes (i = 
1,…,n) and columns indicate sample measurements (l = 1,…,m). In the context of gene 
expression data, network nodes correspond to genes, while the sample measurements correspond 
the gene expression data [85]. The first step for WGCNA is to define a gene co-expression 
similarity measure, which is then used to define the correlation network.  The gene co-expression 
similarity measure between two genes (i and j) is usually denoted as Sij, and can be defined as the 
Pearson correlation between the expression values of gene i and j across multiple samples [84, 
85].  
Two approaches have been used for the calculation of a gene co-expression similarity 
measure: unsigned and signed. In an unsigned approach, the absolute value of the correlation 
between the expression profiles of genes i and j is used ( sijunsigned = |cor(xi, xj)| ). However, 
because it takes an absolute value, this approach does not differentiate between activation or 
repression of gene expression, missing relevant biological information. Therefore, the use a 
signed network approach is preferred, in which the sign of the correlation of the genes’ 
expression profiles is preserved. In this approach, a simple transformation method is used for the 
calculation of the gene co-expression similarity measure (  sijsigned = 0.5 + 0.5cor(xi, xj)  ). In both 
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unsigned and signed approaches, the value of the similarity measure varies between 0 and 1. In a 
signed network, however, two negatively correlated genes have a similarity value of 0; two genes 
with zero correlation have a similarity of 0.5; and two positively correlated genes have a 
similarity of 1 [85]. 
After the calculation of the gene co-expression similarity measure, we end up with a co-
expression similarity matrix S = [sij]. The next step in the analysis is to convert this matrix into 
an adjacency matrix A = [aij], i.e. correlation network, which is used to quantify the strength of 
the correlation between genes.  This adjacency matrix is obtained by applying a ‘hard’ or ‘soft’ 
threshold procedure on S = [sij]. Using a ‘hard’ threshold generates an unweighted network 
adjacency, in which two genes are considered linked if the absolute value of their correlation 
equals or exceeds the hard threshold parameter τ (aij = 1  if  sij ≥ τ ). However, although widely 
used, because hard thresholding considers gene co-expression as binary information, it may lead 
to loss of co-expression information. For example, if the hard threshold parameter is defined to 
be 0.7, two nodes with a similarity value of 0.69 will not pass the threshold and will not be 
considered connected (aij = 0  if  sij < τ ). Therefore, the use of a soft thresholding procedure is 
preferred, in which the adjacency can take continuous values between 0 and 1. With this method, 
a weighted network is generated by using the power function aij = (sij)β , where β is defined as 
the soft threshold parameter of choice (β ≥1). The scale-free topology criterion can be applied in 
order to define an appropriate value for the soft threshold parameter, i.e. the smallest value of β 
for which the scale free topology is reached [84, 85]. 
After constructing the network, module detection can be performed. Modules consist of a 
group of genes with similar expression profiles across all samples; in other words, modules are 
groups of highly interconnected genes [84]. In WGCNA, module detection is performed by first 
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calculating a topological overlap measure (TOM) of network interconnectedness, which defines 
the proximity between genes; 1 is the maximum proximity between two genes, while 0 is the 
minimum proximity [84, 85, 88]. These proximity values are then used as input for an average 
linkage hierarchical clustering that groups genes with coherent expression patterns into network 
modules; modules correspond to branches of the hierarchical clustering dendogram [85, 89].  
Finally, the gene expression profiles can be summarized by calculating module eigengene 
values for each module. The module eigengene consists of the first principal component of the 
expression matrix and is considered as the best measure of the gene expression profile of a given 
module. This value can be used, for example, to find biologically significant modules that are 
correlated with a particular trait of interest; this can be achieved by calculating the Pearson 
correlation between the module eigengene and the desired trait information, which yields an 
eigengene significance value. Additionally, one can also obtain a measure of module 
membership (MM), also known as module-eigengene based connectivity (kME), which is the 
Pearson correlation between each gene’s expression profile and the module eigengene values. 
This allows for the quantification of the similarity of all genes on the analysis to every module, 
as well as for the identification of intramodular hub genes [84, 85, 87].  
Given that coordinately co-expressed genes encode interacting proteins, studying patterns 
of gene co-expression may provide substantial information about the molecular basis of cellular 
processes [90]. Therefore, the analysis of gene expression data using WGCNA provides a 
powerful tool for the investigation of potential interactions between genes, as well as for the 
identification of genes and gene modules underlying complex traits and phenotypic variation.  
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Pathway Analysis 
 Despite understanding which genes have similar expression patterns or may interact in a 
same network and/or module, it is particularly important to understand the underlying biology of 
differentially expressed genes and gene modules associated with traits of interest. Therefore, 
analyzing gene expression data at the functional level is essential to better understand the 
molecular mechanisms and pathways underlying complex traits. This can be accomplished by 
the performance of pathway analysis, which aims to identify the biological pathways in which 
genes are involved, as well as predict with pathways may be activated or inactivated for a given 
gene expression data. 
 Several approaches for the performance of pathway analysis are currently available. For 
instance, over-representation analysis (ORA) has been extensively used for the interpretation of 
differential gene expression data [91, 92]. The basic hypothesis behind this method is that, if the 
number of given differentially expressed genes within a certain biological pathway is greater 
than the number of genes that would be expected by chance, that pathway is considered 
overrepresented and, therefore, relevant to that particular dataset [93]. This method takes two 
separate inputs: (1) a list of significantly differentially expressed genes, referred as a gene subset; 
(2) a list of all the genes measured in the expression experiment, referred as the gene universe. 
For the gene subset, the pathways associated with every gene are determined based on a selected 
pathway database, and the number of input genes associated with each pathway are counted. The 
same is done for the gene universe. Next, the pathways are tested for over-representation in the 
gene subset using an appropriate statistical test (e.g. hypergeometric test, chi-square, binomial 
distribution).  
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This method has been widely used for the analysis of over-representation of Gene 
Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. 
However, some limitations of this approach deserve some attention. First, ORA considers genes 
and pathways as independent entities, which does not fit the reality of biological data. [93, 94] 
As previously mentioned with WGCNA, one of the goals of gene expression analysis is to 
understand how genes interact in a particular gene network and/or pathway, and how they may 
affect each other’s expression patterns. This assumption ignores these relationships between 
genes and pathways, therefore yielding biased biological information. Additionally, ORA does 
not take into account the expression patterns of genes; as previously described, its only input is a 
gene list [94]. Therefore, it is not possible to evaluate which genes may be significantly affecting 
a pathway, or predict pathway activation or inhibition using this method.  
Another widely used pathway analysis approach is the Functional Class Scoring (FCS) 
method, which accounts for not only the effects of large changes in gene expression on the 
overall state of a pathway, but also for the effects of smaller coordinated changes. This method 
takes as an input all genes measured in the expression experiment, together with their expression 
values (such as fold change and p-values), which allows for a more comprehensive pathway 
analysis. First, the inputted expression values are used for the calculation of a gene-level statistic, 
which involves the identification of the set of differentially expressed genes within the entire 
dataset. This statistic can be calculated by using one of the following tests: ANOVA, Q-statistic, 
t-test, or Z-score. Second, the calculated gene-level statistics for all genes belonging to a same 
pathway are combined into a pathway-level statistic (e.g. Kolmogorov-Smirnov statistic, 
Wilcoxon sum rank statistic, max-mean statistic, or chi-squared test). Finally, the significance of 
this pathway-level statistic can be assessed [93, 94]. One of the advantages of FCS over ORA is 
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that, because FCS takes into account expression data associated with a gene list, researchers do 
not need to previously select a list of differentially expressed genes based on harsh and arbitrary 
cut-offs. This allows for the detection of subtle differences between pathways which would have 
not been detected by ORA [93]. However, FCS also presents some limitations. This method still 
considers pathways independently from each other, ignoring interactions and overlapping 
between them [95].  
Lastly, the increasing development and improvement of pathway annotation knowledge 
bases have promoted the integration of pathway topology information with pathway analysis 
approaches [96]. These pathway topology based (PTB) methodologies are very similar to ORA 
and FCS, given that they undergo the same basic steps. However, PTB also takes into account 
pathway topology information, such as information regarding interactions between gene products 
in a particular pathway, as well as how and where these interactions occur [94, 97]. Because it 
accounts for pathway topology, PTBs can account for biologically relevant information, such as 
genes with greater influence over the pathway and causal relationships between interacting 
genes. Additionally, these methods are able to perform a more precise pathway analysis than the 
previously mentioned approaches [93].    
Although pathway analysis methods are great tools for the interpretation of gene 
expression data from transcriptional analyses, several challenges in the use of these 
methodologies still exist. One of the issues is the low annotation coverage; because our current 
knowledge regarding the functions and pathways of many genes is still limited, pathway analyses 
rarely produce complete results from a list of expressed genes. In fact, a surprisingly large 
number of genes are still not annotated or annotated incorrectly. Additionally, the lack of 
standardization of pathway ontologies and related languages across different databases and 
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methodologies makes the biological interpretation and report of pathway analyses results 
somewhat challenging. However, despite these issues, the application of pathway analysis 
methodologies is essential to understand the underlying biology of differentially expressed genes 
associated with traits of interest. With the development of new and better technologies for the 
functional annotation of genes, as well as the improvement of pathway analysis methodologies, 
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Chapter 2: Transcriptional Analysis of Muscle from 
Cattle with Alternative NCAPG/LCORL QTL 
Genotypes 
Introduction 
Quantitative Trait Loci (QTL) mapping in livestock animals allows the identification and 
characterization of genes underlying phenotypic variation in traits of economic relevance. In 
cattle, a QTL on bovine chromosome 6 (BTA6) – the NCAPG/LCORL locus – has been 
identified by several independent studies, using different cattle populations and breeds, as having 
a major influence on growth and composition; the primary action is on lean growth [1-9]. More 
specifically, this locus has been associated with carcass composition [10], carcass weight [10, 
11], size and dairy character [12], birth weight [2, 4, 13], pre-weaning average daily gain [13], 
rib fat thickness and marbling score [14], and increase in body frame size [15].  
Setoguchi et al. [1] reported the association of this QTL with variation in carcass weight, 
ribeye area, and back fat, and refined its position to a 591 Kb region that comprised four 
candidate genes: family with sequence similarity 184, member B (FAM184); DDB1 and CUL4 
associated factor 16 (DCAF16);  non-SMC condensin I complex subunit G (NCAPG); and ligand 
dependent nuclear receptor corepressor-like (LCORL). Also, they identified a polymorphism in 
the NCAPG gene, NCAPG c.1326T>G, that produced a nonsynonymous amino acid substitution 
(Ile442Met). This polymorphism has been proposed by other studies to be the causative 
mutation, referred to as a Quantitative Trait Nucleotide (QTN), responsible for the phenotypic 
variation observed [1-3].  
 34 
Eberlein et al. [2] evaluated the effect of the proposed QTN on bovine fetal growth, 
investigating both maternal and fetal genetic contributions to this trait. Their findings 
demonstrated a potential correlation between increased fetal growth and decreased NCAPG 
expression due to the presence of the NCAPG c.1326G allele. Weikard et al. [3] also investigated 
the effects of the NCAPG putative QTN, however on the metabolism of animals with alternative 
NCAPG genotypes. Their results report significant differences in growth and lipid deposition 
pathways, suggesting the influence of the NCAPG c.1326G allele on cattle growth and 
composition traits. 
Although these and other studies have shown significant evidence of the role of NCAPG 
c.1326T>G as the causative variant, studies conducted by Gutiérrez-Gil et al. [16] and ourselves 
[17] suggest the QTN responsible is yet to be determined. Gutiérrez-Gil et al. [16] attempted to 
refine the position of the QTL, which was previously associated with birth weight (BW), birth 
body length (BBL), and bone weight (BONE). Of their four sires identified as heterozygous for 
the QTL, only two presented a heterozygous genotype for the NCAPG c.1326T>G 
polymorphism, while two were homozygous for the c.1326G allele. Moreover, in contrast to 
what was proposed by Eberlein et al. [2], the QTN allele associated with high BW, BBL, and 
BONE was in phase with the c.1326T allele.  
In our previous work, a genome wide association study (GWAS) of growth- and carcass-
related phenotypes using 1,645 Simmental-Angus steers resulted in several significant 
haplotypes comprising both NCAPG and LCORL genes [17]. Considering that most of the 
significant haplotypes identified were closer to the 3’-end of NCAPG, as well as the high linkage 
disequilibrium (LD) observed between the genetic markers in this locus, we decided to genotype 
82 sires for the NCAPG c.1326T>G polymorphism reported in previous studies.  In this study, 
 35 
we defined Q as the allele causing the significant effect on the traits studied, and q as the 
alternative allele. All sires expected to have at least one copy of the Q haplotype had at least one 
copy of the c.1326G allele, supporting the results from previous studies that suggest the c.1326G 
allele as the causative variant. Conversely, although the majority of the qq sires were 
homozygous for the c.1326T allele, five of them were actually heterozygous, revealing the 
presence of the c.1326G allele associated with q haplotypes. Also, three Qq sires were 
homozygous for the c.1326G allele. This is in direct contrast with the conclusions made by 
Eberlein et al [2] and Weikard et al [3], who support the NCAPG c.1326G allele as the causative 
variant, and supports the conclusions of Gutierrez-Gil et al. [7] that the NCAPG polymorphism is 
not the causative mutation underlying this QTL. Instead, we suggest that another polymorphism 
is underlying for these effects [17].  
Similar influence of the NCAPG/LCORL locus has also been identified within several 
other mammalian species, including humans [18-24], dogs [25], horses [26, 27], pigs [28], 
chickens [29], and sheep [30]. The presence of this orthologous locus in different species defines 
its universal role in the mechanisms underlying animal growth and development. In none of 
these species has a specific polymorphism been determined within the genic regions. 
Furthermore, in several of them [26-29, 31, 32], as well as in our preliminary data [17], the most 
significant associations are with markers upstream and/or within LCORL. This position not only 
suggests that the causative QTN is more likely to be associated with LCORL instead of NCAPG, 
but it also implies that regulatory mutations controlling the expression of LCORL, and not a 
mutation that alters the LCORL protein itself, may be responsible for the phenotypic effects 
observed. 
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LCORL is known to encode a transcription factor that interacts with ubiquitin C, a 
polyubitquitin encoding gene involved in ubiquitination events, acting in cell cycle regulation, 
protein degradation and cell signaling [33, 34]. Additionally, it interacts with a transcriptional 
repressor (C-terminal binding protein 1; CTBP1) that participates in the process of cellular 
proliferation and gene expression during development [35, 36]. The presence of polymorphisms 
in this gene has been proposed to have a potential role in weight gain in beef steers [6, 37], and 
height in humans [20, 21] and horses [26, 27, 38]. 
Genetic variation at the NCAPG/LCORL locus causes permanent stable alterations in the 
developmental program of individuals throughout life. Although we do not currently know the 
specific QTN responsible for the phenotypic variation observed, we hypothesize that the 
phenotypes associated with this QTL have unique underlying molecular signatures that can be 
detected by transcriptional variation. We believe that the gene expression patterns influenced by 
these molecular signatures could potentially indicate the mode of action for this QTL. 
Furthermore, it could help us identify the causative gene responsible for phenotypic variation and 
the mechanism by which it exerts its effect. Therefore, we used RNA-Sequencing (RNA-Seq) in 
order to characterize the transcriptional changes that differ between individuals with alternative 
haplotypes/genotypes at the NCAPG/LCORL locus. With this approach, we determined the 
underlying molecular changes that give rise to the phenotypic differences associated with this 
locus. Whether the unknown QTN directly (i.e. alters activity of either gene throughout animal 
development) or indirectly (i.e. exerts its effect during early developmental stages promoting 
permanent/stable changes in the developmental program of the animal) influences phenotypic 
variation, characterization of the molecular alterations underlying these effects is crucial to fully 
understand the regulation of animal growth and composition.   
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Materials and Methods 
Selection of Animals 
Due to the specific QTN being unknown, a GWAS analysis was conducted in a 
population of Charolais-sired calves to select calves with appropriate genotypes for the 
NCAPG/LCORL locus. A sample of 804 Charolais x Simmental-Angus crossbred calves raised at 
the University of Illinois-Dixon Springs Agricultural Center and their 38 sires were genotyped 
on the Illumina® BovSNP50 BeadChip (50k) and BovineHD BeadChip (770k) platforms, 
respectively. Additionally, 53 of those calves were genotyped on the BovineHD BeadChip 
(770k) platform. 
The 38 sires and the 53 calves genotyped on the 770k platform were pooled and used as 
the reference population for genotype imputation of the calves. Prior to imputation, quality 
control measures were completed using GoldenHelix SNP & Variation Suite (version 7.6.11) 
(Golden Helix, Inc., Bozeman, MT, www.goldenhelix.com). Individuals or markers with more 
than 10% missing genotypes and markers with minor allele frequency less than 1% were 
excluded from the analysis.  After quality control measures there were 39,843 and 684,068 
markers from the BovSNP50 and the BovineHD, respectively, and 791 calves and 91 animals in 
the reference population (38 sires and 53 calves).   
A Hidden Markov Model (HMM) procedure as implemented in BEAGLE (version 3.3.2) 
[39] was used for genotype imputation.  The default parameters of BEAGLE were used with 10 
phasing iterations. Four haplotype pairs were sampled for each individual during each iteration 
of phasing.  The 91 animal HD genotypes were phased and then used as a reference panel to 
impute genotypes in the 791 calves.  The r2 score generated by BEAGLE was used as a 
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threshold for imputation quality and only markers exceeding an r2 of 0.5 were included in further 
analyses. In order to assess the accuracy of imputation, the 53 calves genotyped on the 
BovineHD assay were compared to their imputed genotypes. Concordance was assessed using 
Plink v 1.06 [40]. 
Using birth weight (BW) as the indicator trait, a GWAS was conducted on the calves’ 
imputed genotypes (n = 791) using haplotype trend regression in GoldenHelix SVS (version 
7.6.11). Twenty-four animals were selected based on alternative NCAPG/LCORL 
haplotypes/genotypes: 12 QQ and 12 qq where Q is the QTL allele associated with increasing 
BW and q the alternative allele. 
Sample collection and RNA isolation 
At 300 days of age, a biopsy sample of the longissimus dorsi muscle was collected from 
each of the 24 selected calves on the left-side, 5cm cranial to the hook bone and half way 
between the axis and transverse processes of the lumbar vertebrae. A biopsy core muscle (100-
200mg) was removed using a biopsy needle (Bar MAGNUM; 12 gauge x 16cm). Tissue samples 
were transferred directly from the biopsy needle to cryotubes and immediately frozen in liquid 
nitrogen. 
Total RNA was extracted from the muscle samples using TRIzol® Reagent (Life 
Technologies, Carlsbad, CA) according to the manufacturer’s protocol. Then, a 5µg sample of 
the total RNA was purified using the RNeasy Mini Kit (Qiagen, Inc., Valencia, CA). Sample 
quality was assessed using an Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, 
CA). High quality samples (RIN > 7.0) were used to construct sequencing libraries. 
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Library preparation and RNA-Sequencing 
Next Generation Sequencing (NGS) libraries were constructed using the Illumina’s 
TruSeq Stranded mRNA Library Preparation Kit (Illumina, Inc., San Diego, CA). All libraries 
were indexed, pooled and quantitated by qPCR. The pool was sequenced over four lanes for 101 
cycles on a HiSeq 2500 (single-end chemistry) using a HiSeq SBS sequencing kit version 4. 
Fastq files were processed and demultiplexed with bcltofastq 1.8.4 (Illumina, CA).  
Low quality reads, low quality bases, and adapter sequences were trimmed using 
Trimmomatic (version 0.33) [41]. Reads were assessed for quality with FastQC (version 0.11.3) 
[42] and mapped to the bovine reference genome (Build UMD3.1, Ensembl release 84) using 
STAR (version 2.4.2a) [43]. Read counts were obtained using the featureCounts function of the 
Rsubread package (version 1.4.6-p5) [44] that allowed counting the number of reads assigned to 
genes.  
RNA-Sequencing data analysis  
Data analysis was conducted using R version 3.2.4 (R Core Team 2016) and packages 
noted below. 
Quality control and normalization 
Quality control and normalization of the raw count data obtained from featureCounts was 
performed using the R/Bioconductor package edgeR (version 3.12.0) [45]. In order to ensure that 
a gene was retained if expressed in only one of the two groups, genes containing less than 1 
Count Per Million (CPM) mapped reads in at least 12 samples were filtered out from the initial 
24616 genes dataset, resulting in 11310 genes which were subjected to further analyses. 
Normalization factors were calculated using the Trimmed Mean of M-values (TMM) 
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normalization method [45] in edgeR to account for compositional biases in libraries between 
each pair of samples. 
Removal of batch effects 
The sva function of the R/Bioconductor package SVA (version 3.18.0) [46] was used to 
estimate and remove surrogate variables for unknown batch effects and other sources of variation 
present in the data. This function returns four components, including the component sv, which 
consists of a matrix in which the columns correspond to the surrogate variables it estimates. 
These estimated values can then be used in combination with the edgeR package in downstream 
analyses of differential gene expression.  
Following removal of variation due to surrogate variables, samples were analyzed using a 
Principal Component Analysis (PCA) in order to assess the overall similarity between samples. 
For that, the R function dist was used to calculate the Euclidian distance between samples. To 
prevent the distance measure from being dictated by a few greatly variable genes, and to obtain 
an overall equal contribution from all genes, this function was applied on regularized log-
transformed (rlog) data. 
Statistical analysis of differential gene expression 
Differential gene expression analysis of the RNA-Seq data was performed with the 
R/Bioconductor package edgeR (version 3.12.0) [45]. Samples were fitted to a negative-binomial 
general linear model and tested for differential gene expression between the two genotype groups 
using a likelihood-ratio test. The surrogate variables estimated with sva were included in this 
model. To normalize gene-level variance, the biological coefficient of variation (BCV) was 
calculated using Cox-Reid dispersion for negative binomial general linear models. The p-values 
of differential expression tests were corrected for multiple-hypothesis testing using Benjamini-
 41 
Hochberg false discovery rate (FDR) correction. The threshold for significance was set to FDR 
P-value < 0.01. 
Weighted Gene Correlation Network Analysis (WGCNA) 
A one-way ANOVA was performed for the entire dataset using edgeR. For the overall 
ANOVA test, raw P-values for each gene were adjusted using the FDR method. A set of 3250 
genes passed the significant threshold (FDR P-value < 0.25) and was used to conduct a Weighted 
Gene Correlation Network Analysis (WGCNA) [47, 48]. This method uses a distance metric, 
allowing the clustering of genes into gene modules (with >20 genes), such that all genes 
belonging to the same module exhibit similar patterns of expression across all samples. WGCNA 
computationally assesses the different expression patterns in the data. The R/Bioconductor 
package WGCNA (version 1.51) [48] was used for gene clustering using the 
blockwiseModules() function, which automatically performs all steps necessary for module 
detection. The default values of the blockwiseModules() function were used except for: soft 
thresholding power β = 20, networkType = ‘signed’, minModuleSize = 20, and mergeCutHeight 
= 0.15. This function outputs module colors and module eigengenes, which summarize the 
expression pattern of all genes in one module. The eigengene values were later subjected to a QQ 
versus qq genotype group comparison to determine modules related to group differences. 
To analyze the correlation between gene modules and the two different genotype groups, 
a gene significance variable was calculated by correlating genes and genotype using a Pearson 
correlation method. For this, the trait genotype was treated as a binary variable. Then, Pearson 
correlation was calculated between gene expression values and genotype.  
Also, the measure of module membership (MM), also known as module-eigengene based 
connectivity (kME), was quantified for each gene module, which is the Pearson correlation 
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between the module eigengene values and the gene expression profile. This allows for the 
quantification of the similarity of all genes on the analysis to every module.  
The modules calculated by WGCNA whose expression were correlated with genotype 
were exported to Cytoscape v3.4.0 [49] for visualization of module structure and network 
connections.  
Gene Ontology (GO) enrichment analysis 
Modules whose expression were correlated with genotype, and the list of differentially 
expressed genes were tested for enriched Gene Ontology (GO) terms using the GOstats 
R/Bioconductor package (version 2.36.0) [50]. 
Bovine Ensembl gene IDs were primarily used in the previous steps of the analysis. 
Entrez IDs corresponding to our Ensembl gene IDs, as required by the GOstats package, were 
obtained using the R/Bioconductor bovine annotation package org.Bt.eg.db (version 3.2.3) [51]. 
Of the 11310 genes in our dataset, 10895 remained after conversion to Entrez gene IDs. Genes 
assigned to more than one Entrez ID and/or Entrez IDs assigned to more than one Ensembl gene 
ID were manually curated based on the gene2ensembl gene conversion spreadsheet available at: 
ftp://ftp.ncbi.nih.gov/gene/DATA/gene2ensembl.gz. This file reports matches between NCBI 
and Ensembl annotation based on comparison of RNA and protein features. When the Ensembl 
gene ID or Entrez ID was not present in such file, curation was performed by nucleotide Blast 
(megablast option) of the Ensembl nucleotide sequences against the NCBI database (threshold E-
value < 1e-40).  
GO terms associated with the obtained Entrez IDs were also retrieved from the 
org.Bt.eg.db package and a GO enrichment over representation analysis was performed using a 
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conditional Hypergeometric test with the package GOstats. Conditional tests for over-
representation were conducted for all DEG genes, as well as for each WGCNA gene module. 
Functional and Pathway Analysis 
 Functional and pathway analyses for the list of DEG and for the two WGCNA modules 
with the highest positive (Blue) and negative (Turquoise) correlation with the QQ genotype were 
performed with the Ingenuity Pathway Analysis (IPA) software (Qiagen) using the core analysis 
option, which identifies overrepresented canonical pathways, affected biological processes, 
upstream regulators that may be affecting gene expression, as well as networks of interactions 
among the genes in the dataset provided and related molecules. IPA uses two different statistics 
in its core analysis: (1) P-value, calculated using a right-tailed Fisher’s exact test, used to identify 
overrepresented canonical pathways and biological processes; (2) Z-score, which serves as a 
measure of activation or inhibition of the canonical pathways and biological functions predicted 
by IPA; a z-score above 2 indicates activation, as a z-score less than -2 indicates inhibition.  
 All DEG significant at FDR P-value < 0.01 were submitted to IPA. Each Entrez ID was 
mapped to its corresponding gene object in the IPA Knowledge Base. The analysis was run using 
IPA’s default settings with no fold-change cut-off and no FDR cut-off, given that all submitted 
genes have been previously filtered at FDR P-value < 0.01. 
 For each WGCNA module, all genes present in each module that remained after gene ID 
conversion were submitted to IPA. Each Entrez ID was mapped to its corresponding gene object 
in the IPA Knowledge Base. Default settings were used for the analysis with no fold-change cut-
off no FDR cut-off in order to obtain an overall picture of all genes in the module. 
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Validation of gene expression using RT-qPCR 
 Quantitative reverse transcription-polymerase chain reaction (RT-qPCR) was performed 
to validate the expression values detected for LCORL with RNA-Seq. First, synthesis of cDNA 
was carried out with ProtoScript®  First Strand cDNA Synthesis Kit (New England Biolabs Inc.) 
following manufacturer procedures. Quantitative polymerase chain reaction (qPCR) was 
performed using PrimeTime® qPCR Assays FAM™/ZEN™/Iowa Black® (Integrative DNA 
Technologies, IA) as instructed by the manufacturer. For normalization, beta-2-microglobulin 
(B2M) was chosen as an endogenous control. All primers and probes were purchased from 
Integrative DNA Technologies (IDT). The custom designed primer and probe sequences are 
listed in Supplemental table 1. Primer efficiencies were evaluated and determined to be between 
90 and 100%..   
Quantitative PCR was performed on a 96 well plate with three replicates per sample. A 
StepOnePlusTM qPCR machine was used for amplification and quantification of cDNA synthesis. 
Additionally, the StepOne Software v2.1 (Applied Biosystems, Foster, CA) was used to analyze 
the qPCR results and identify threshold values. The cycle threshold values were normalized to 
the expression of B2M and the 2-∆∆Ct method [52] was used for comparing the gene expression 
values of LCORL. 
Results 
Genotype Imputation and GWAS analysis 
Using the r2 score generated by BEAGLE as a threshold for imputation quality, the 
genotype imputation of the 791 calves resulted in 630,230 markers at a r2 of 0.5. Concordance 
between the 53 calves genotyped on the BovineHD assay and their imputed genotypes was found 
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to be 95.75%. As expected, the QTL associated with NCAPG/LCORL was detected by the 
GWAS analysis. Calf BW presented the strongest statistical association using individual single 
nucleotide polymorphisms (SNP) markers, and thus was used as the indicator trait in additional 
haplotype-based analyses to refine the position of the QTL (Fig 1). Although there were many 
significant haplotype associations due to high LD, a region upstream of LCORL showed the 
greatest number of associated haplotypes (Fig 1C). 
Based on this haplotype analysis, the frequency of the Q-bearing haplotype was estimated 
at 42%. Calves with alternative QTL haplotypes were selected by manual examination of marker 
genotypes within the QTL interval (Fig 2). Twelve calves of each putative QTL genotype were 
selected. Both sexes were equally represented within each genotype group.  
RNA-Sequencing 
The single-end sequencing yielded a total of 898,353,420 reads (average of 
approximately 37 million reads per library), which were 100bp long. After removal of low 
quality reads, low quality bases, and adapter sequences with the Trimmomatic software, a total 
of 896,666,911 reads remained and were aligned to the reference bovine genome (Build 
UMD3.1, Ensembl release 84) resulting in 95% of the reads uniquely mapped (Supplemental 
table 2). Also, an average of 74.7% of the reads were uniquely assigned to genes, according to 
the results from featureCounts (Supplemental table 2). 
Removal of batch effects 
The sva function estimated 5 surrogate variables, which were adjusted for in the 
statistical model used in further analyses. Among the surrogate variables estimated, SV2 
matched our records for the calves’ gender, confirming the accuracy of the SVA software in 
estimating external sources of variation in high-throughput experiments (Fig 3).  
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After removing the variation due to surrogate variables, all of the normalized gene 
expression data was evaluated using PCA. Plotting of the first (PC1) and second (PC2) principal 
components revealed that expression values from the same genotype are more related to one 
another than between genotypes (Fig 4). 
Differential gene expression 
A total of 507 differentially expressed genes (DEG) were detected between QQ and qq 
calves (FDR P-value < 0.01), including 167 upregulated and 340 downregulated genes, revealing 
a considerable difference in gene expression between animals with alternative NCAPG/LCORL 
genotypes. LCORL was found to be upregulated (FDR P-value = 9.94E-03); qPCR results also 
showed a slight upregulation of LCORL (Fold change = 1.487739) in QQ compared to qq 
animals. The complete list of DEG, together with their respective FDR P-values, is available in 
Table 1. A scaled heatmap of the DEG list was produced using the normalized log2 of counts in 
order to visualize the differences of expression patterns between QQ and qq animals (Fig 5).  
WGCNA 
A total of 11 modules ranging from 47 to 991 genes were detected, plus the ‘module 0’ 
consisting of 51 genes that did not fit any of the other patterns. In order to visualize the 
correlation between gene modules and the two different genotype groups, the GS values obtained 
from the Pearson correlation between gene expression values and genotype were converted into 
colors and plotted together with a cluster dendogram of modules generated by WGCNA (Fig 6). 
For example, the expression of genes assigned to the Blue module appears to be positively 
correlated with the QQ genotype (genotype “red”). Conversely, genes within the Turquoise 
module are negatively correlated with the QQ genotype (genotype “blue”). 
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These inferences were confirmed by calculating the Pearson correlation between module 
eigengene values and genotype. Module eigengene is an optimal summary of the gene expression 
profiles of a given module. Thus, calculating the correlation between these values and genotype 
can be used to show the direction and strength of association between module and genotype 
(Table 2). By examining Table 2, we can confirm the high positive correlation between the Blue 
module and the QQ genotype (r = 0.88; P-value = 1.00e-08), and the high negative correlation 
between the Turquoise module and the QQ genotype (r = -0.87; P-value = 2.00e-08), as inferred 
from Fig 6. 
Using the GS and kME measures, genes that have a high correlation with genotype as 
well as module membership were identified. Fig 7 shows scatterplots of GS versus kME values 
for the two modules with the highest positive (Blue) and negative (Turquoise) correlation with 
the QQ genotype (Table 2). LCORL belongs to the module with the highest positive correlation 
with the QQ genotype (LCORL kME for Blue module = 0.5767299), suggesting a relationship 
between the overexpression of LCORL and the QQ genotype. A total of 838 genes are assigned 
to this module, including 126 of the DEG identified between genotypes; all 126 DEG in this 
module are upregulated. The Turquoise module had the highest negative correlation with 
genotype and has 991 genes assigned, including 165 DEG, all of which are downregulated. Table 
1 shows which WGCNA inferred module our DEG were assigned to.  
GO enrichment analysis 
Enrichment analysis of the list of DEG after proper gene ID conversion (488 genes 
remained after conversion to Entrez gene IDs and gene symbols) identified overrepresented GO 
terms in the three ontologies: Biological Process (BP), Molecular Function (MF), and Cellular 
Component (CC).  
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A total of 2643 GO BP terms were found associated with 185 of the differentially 
expressed genes. From those, 40 GO BP terms were found to be significantly overrepresented (P-
value < 0.01) (Table 3). For GO MF conditional test for overrepresentation, 520 GO MF terms 
were associated with 168 DEG; 14 of those terms had a P-value < 0.01 (Table 4). Finally, 341 
GO CC terms were identified, from which 17 were significantly overrepresented (P-value < 
0.01) (Table 5). GO CC terms were associated with 193 DEG. It is noteworthy that, in all three 
ontologies, there are several GO terms associated with growth and metabolism. 
The module having the highest positive correlation with the QQ genotype, which 
includes LCORL, revealed a total of 25 GO BP terms (Table 6), 6 GO MF terms (Table 7), and 
14 GO CC terms (Table 8) significantly overrepresented (P-value < 0.01). Remarkably, the ten 
most significant GO BP terms associated with this module are directly associated with 
metabolism and growth.   
Additionally, 23 GO BP terms (Table 9), 4 GO MF terms (Table 10), and 10 GO CC 
terms (Table 11) were significantly enriched (P-value < 0.01) for the module with the highest 
negative correlation with the QQ genotype. 
Functional and Pathway Analysis 
 The pathway analysis performed by IPA identified the canonical pathways most 
significant to each data set provided. IPA determines the significance of the association between 
the genes in the data set and the canonical pathways in the IPA Knowledge Base based on two 
main values: (1) the ratio of genes in the data set that passed the filters determined by the user 
divided by the total number of genes that make up for that particular pathway; (2) a P-value < 
0.05 (-log(P-value) >1.3) determining the probability that the association between the genes in 
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the data set that were mapped to the pathway, and the canonical pathway is explained by random 
chance alone.  
IPA’s canonical pathway analysis identified a total of 39 enriched canonical pathways for 
the 453 DEG that were successfully mapped to the IPA Knowledge Base. For the WGCNA 
module with the highest positive correlation with the QQ genotype (Blue module), 44 canonical 
pathways were significantly enriched for all the 762 genes in the module that were mapped to the 
Ingenuity database. Additionally, for the WGCNA module with the highest negative correlation 
with the QQ genotype (Turquoise module), IPA acknowledged 148 significantly enriched 
canonical pathways for the 901 genes in the module successfully mapped to the IPA Knowledge 
Base. The complete list of significantly enriched canonical pathways identified by IPA for each 
data set can be found in Tables 12, 13 and 14, respectively. 
The functional analysis in IPA identified the biological functions and processes that were 
significantly enriched in each data set provided at a P-value < 0.05 (-log(P-Value) >1.3). IPA 
describes its functional categories in three different hierarchical levels: High-level category; 
Mid-level function; and specific function annotations within the high-level and mid-level 
categories. The complete list of the first and third levels of significantly represented biological 
functions for the 453 mapped DEG, and WGCNA’s Blue and Turquoise modules are presented 
in Tables 15, 16, and 17, respectively. 
Discussion 
The identification and characterization of the molecular mechanisms influencing animal 
growth and development are extremely valuable for improving production efficiency in the 
livestock industry. RNA-Seq, a high-throughput sequencing method, has been widely used in 
transcriptional analysis of model and non-model organisms [53-57]. Here, this technology was 
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used to perform a transcriptional analysis of bovine muscle samples for animals with alternative 
NCAPG/LCORL genotypes in order to assess the transcriptomic differences underlying the 
phenotypic variation between the two groups. 
Regulatory mutations upstream of LCORL may be influencing its expression and the 
phenotypic variation observed 
In our preliminary data [17], results from a GWAS analysis of growth and carcass 
phenotypes using a sample of Simmental-Angus steers revealed several significant haplotypes 
encompassing both NCAPG and LCORL. Additionally, the study presented a region ~300kb 
upstream of LCORL showing markers with the highest statistical associations with BW. This is 
consistent with the GWAS results presented here in an independent population, which also 
revealed the greatest number of markers associated with increased BW in a region upstream of 
LCORL (Fig 1C). The same can be observed in studies in pigs [28], humans [31], horses [32], 
and chickens [29].  
A recent study by Tozaki et al. [32] with Thoroughbreds horses analyzed the relationship 
between different genotypes for the SNP BIEC2-808543, localized upstream of LCORL [26, 27], 
and composition traits, such as body weight, withers height, and circumference of the cannon 
bone. This study revealed a significant association of this SNP with skeletal frame and body 
composition traits in Thoroughbreds horses, supporting our hypothesis that the variation 
responsible for the phenotypic differences observed are associated with LCORL, and not 
NCAPG, as suggested by other studies [1-3].  
Tozaki et al. [32] also suggested that, because the BIEC2-808543 polymorphism affects a 
putative binding site for the transcription factor TFIID, its presence upstream of LCORL may 
disrupt its expression levels by a regulation mechanism, causing phenotypic variation. This, 
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together with our differential expression analyses results, propose that the presence of significant 
associations upstream of LCORL indicate that the phenotypic effects may be due to a difference 
in the expression levels of this gene caused by the presence of regulatory mutations upstream of 
LCORL, instead of mutations in the gene itself. Our results reveal a total of 507 differentially 
expressed genes (DEG) between QQ and qq calves (FDR P-value < 0.01), including LCORL, 
which was found to be upregulated (FDR P-value = 9.94E-03). Considering LCORL 
overexpression and our GWAS results from both current and previous data, we propose that a 
regulatory mutation localized upstream of LCORL may be influencing LCORL expression and 
phenotypic variation.  
Overall transcriptional and functional differences between QQ and qq animals 
 Our differential gene expression and functional analyses results revealed significant 
transcriptomic and functional differences between animals with alternative NCAPG/LCORL 
genotypes.  
For our list of DEG, a total of 40 GO terms for biological processes were significantly 
enriched. It is noteworthy that several of these processes are directly associated with growth and 
metabolism, such as ‘peptide metabolic process’, ‘amide biosynthetic process’, ‘organonitrogen 
compound biosynthetic process’, ‘translation’, and ‘cytoplasmic translation’ (Table 3). 
Interestingly, the majority of genes associated with the above mentioned processes are 
upregulated - including several ribosome protein, mitochondrial ribosome protein, and ATP 
synthase related genes - indicating that metabolism and growth mechanisms, such as translation, 
protein synthesis, and cell proliferation, may be increased in QQ compared to qq animals. 
Additionally, several processes associated with fat synthesis and lipid metabolism were enriched 
for our list of DEG, including ‘small molecule metabolic process’, ‘lipid localization’, 
 52 
‘monocarboxylic acid metabolic process’, ‘regulation of lipid storage’, ‘fatty acid biosynthetic 
process’, and ‘unsaturated fatty acid metabolic process’ (Table 3). However, the majority of 
genes associated with these processes are downregulated, indicating decreased fat synthesis and 
metabolism in QQ animals. The same pattern is observed in the GO enrichment analysis results 
for molecular function (Table 4) and cellular component (Table 5) categories. Therefore, we 
propose that the QQ genotype for the NCAPG/LCORL locus is associated with an upregulation 
and downregulation of lean growth and fat synthesis processes, respectively.  
This hypothesis is supported by our results from IPA’s canonical pathways enrichment 
analysis, which revealed an enrichment of pathways involved in RNA translation, processing and 
protein synthesis (‘EIF2 signaling’, ‘regulation of eIF4 and p70S6K signaling’, ‘mTOR 
signaling’), indicating an increase in cell proliferation and growth, including myoblast 
proliferation. Actually, the upregulation of several ribosomal proteins associated with these 
pathways (RPL5, RPL6, RPL7, RPL13, RPL22, RPL30, RPL31, RPL23A, RPL27A, RPL36A, 
RPLP1, RPS3, RPS7, RPS12, RPS18, RPS20, RPS23, RPS24, RPS25, RPS28, RPS29, RPS3A, 
RPS4X) and the downregulation of the eukaryotic translation initiation factor 4E binding protein 
2 (EIF4BP2), a repressor of translation initiation [58] associated with all three pathways, offer 
support to the possibility of greater RNA translation and protein synthesis in QQ calves. 
Furthermore, the enrichment of the ‘oxidative phosphorylation’ canonical pathway indicates 
increased mitochondrial activity and ATP production necessary during cell growth, proliferation  
and differentiation.  In fact, several studies have shown increased mitochondrial biogenesis and 
activity during myogenesis [59-61].  
Numerous pathways involved in adipogenesis and lipid metabolism were also enriched 
for our list of DEG, such as ‘glucocorticoid receptor signaling’,  ‘pentose phosphate pathway’, 
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‘TR/RXR activation’, ‘stearate biosynthesis I’, ‘LXR/RXR activation’, ‘adipogenesis pathway’, 
and ‘fatty acid biosynthesis initiation II’ (Table 12). Because, most genes associated with these 
pathways are downregulated, they are likely inactivated, indicating reduced fat synthesis in QQ 
animals.  
Further functional analysis with IPA revealed that the majority of lipid metabolism 
related functions associated with our DEG are likely inactivated (negative z-scores), with some 
predicted to be significantly inactivated (z-scores < -2), such as ‘synthesis of lipid’, ‘synthesis of 
fatty acid’, ‘synthesis of long-chain fatty acid’, ‘fatty acid metabolism’, and ‘biosynthesis of 
polyunsaturated fatty acids’ (Table 15). Conversely, biological functions, such as ‘protein 
synthesis’, ‘expression of protein’, ‘translation’, and ‘metabolism of protein’, are likely activated 
(positive z-scores) (Table 15). These results are in accordance with our GO and canonical 
pathways enrichment analyses results, supporting our hypothesis that animals with the QQ 
genotype for the NCAPG/LCORL locus are characterized by increased lean growth and 
decreased fat synthesis.   
Relevant co-expression gene network modules underlying phenotypic variation 
Using WGCNA, we identified 11 co-expression network modules ranging from 47 to 991 
genes, as well as a ‘module 0’ consisting of 51 genes that did not match any of the expression 
patterns. This technique allowed us to better understand how genes may interact in the same gene 
networks and pathways, and which gene modules may be more strongly underlying the 
phenotypic variation observed between calves with alternative NCAPG/LCORL genotypes. 
In addition to being up-regulated, LCORL is placed in the module with the highest positive 
correlation with the QQ genotype (i.e. Blue module) (Fig 7), suggesting that its overexpression 
may be directly or indirectly influencing phenotypic variation. Remarkably, all genes in this 
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module have a positive direction of expression, with 126 of its genes significantly upregulated, 
including LCORL, indicating that biological processes and pathways associated with this module 
may be upregulated in QQ animals.  
According to our GO enrichment analysis, module Blue is associated with a total of 25 
significantly enriched GO BP terms directly associated with metabolism and growth 
mechanisms, including ‘amide biosynthetic process’,  ‘translation’, ‘peptide metabolic process’, 
‘organonitrogen compound biosynthetic process’, and ‘cytoplasmic translation’ (Table 6). These 
processes, as well as the top GO MF and GO CC enriched terms for this module (Tables 7 and 
8), suggest that metabolism and growth mechanisms, such as translation, protein synthesis, and 
cell proliferation, may be increased in QQ compared to qq animals and that this gene module 
may be accountable for this increase.  
IPA’s canonical pathways enrichment analysis also identified several enriched pathways 
related to growth and metabolism mechanisms, including pathways involved in protein synthesis 
(‘EIF2 signaling’, ‘regulation of eIF4 and p70S6K’, and ‘mTOR signaling’), suggesting 
increased protein synthesis, cell proliferation and growth. In fact, the association of several 
significantly upregulated ribosomal protein genes with these pathways (RPL5, RPL6, RPL7, 
RPL13, RPL22, RPL30, RPL31, RPL23A, RPL27A, RPL36A, RPLP1, RPS3, RPS7, RPS12, 
RPS18, RPS20, RPS23, RPS24, RPS25, RPS28, RPS29, RPS3A, RPS4X) offers support to these 
results and indicates that this module may be controlling increased RNA translation and protein 
synthesis activities. 
Interestingly, further IPA functional analysis revealed that this module is associated with 
several specific biological functions and processes involved in growth and metabolism (Table 
16).  In the most significantly enriched category (cell death and survival), we can observe that 
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most functions involving cell death and apoptosis are predicted to be inactivated (negative z-
scores). In fact, the processes of ‘cell death of muscle cells’ and ‘apoptosis of muscle cells’ are 
significantly predicted to be inactivated (z-scores < -2), indicating that this gene module may be 
driving increased proliferation of muscle cells. This can be confirmed by the likely activation 
(positive z-scores) of several processes in different major categories involving muscle cells 
proliferation and muscle formation, such as ‘quantity of muscle cells’, ‘quantity of muscle’, and 
‘differentiation of muscle cell lines’, as well as the significant predicted activation (z-scores > 2) 
of processes such as ‘cell cycle progression of muscle cells’ and ‘formation of muscle’. 
Furthermore, other categories associated with gene expression (‘transcription of RNA’, 
‘transcription of DNA’, ‘expression of mRNA’), protein synthesis (‘translation’, ‘synthesis of 
protein’, ‘metabolism of protein’), cell cycle (‘cell cycle progression’), organismal development 
(‘size of animal’), skeletal and muscular system development, cell morphology and cellular 
function and maintenance (‘repair of cells’) are predicted to be also likely activated (positive z-
scores), indicating that this gene module is underlying increased growth and metabolism, 
including increased muscle deposition, in the animals selected for the NCAPG/LCORL QQ 
genotype.  
Based on these results, LCORL, due to its differential expression and presence in the 
WGCNA Blue module, remains the most likely candidate gene for the QTN. Given the increased 
expression of both LCORL and the 126 DEG in this module, we propose that LCORL 
overexpression may be driving increased cellular metabolism and, consequently, lean growth, 
suggesting a molecular signature of the NCAPG/LCORL QTN. All things considered, it is of our 
interest to investigate whether LCORL, a known transcription factor, is affecting or even driving 
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the expression pattern for the entire module of genes, or if it is being controlled by an upstream 
“master regulator” of expression.  
Our results are also consistent with other reports in the literature, such as the metabolomics 
study by Weikard et al. [3]. Although the individuals in this study were selected according to 
alternative genotypes at the proposed NCAPG c.1326T>G QTN, their results report the existence 
of differences in the metabolomics profiles between the two genotype groups that are in 
accordance with upregulation of the same pathways reported in our current findings. Based on 
our data, we believe, however, that such differences are due to a QTN associated with LCORL 
instead of NCAPG. The NCAPG c.1326G polymorphism, in the population used by Weikard et 
al. [3], was likely in complete LD with a still undefined QTN underlying LCORL differential 
expression, leading to their incorrect conclusion that the NCAPG polymorphism is the causative 
QTN. The degree of LD can be confirmed by the data presented in Fig 2. It is interesting to note 
that even in this population of crossbred calves, the Q-bearing, long-range haplotype is highly 
conserved with QQ calves sharing a homozygous segment of more than 600kb that encompasses 
both the NCAPG and LCORL genes (Fig 2). Also of note is the observation that qq calves do not 
share a common haplotype, indicating that the q allele is likely ancestral and shows significant 
LD decay among q-bearing haplotypes. This is also consistent with observations in other species 
[27]. 
Lindholm-Perry et al. [37] assessed the correlation between feed intake and different growth 
phenotypes with transcript and protein abundance of NCAPG and LCORL in adipose and muscle 
tissue from beef cattle. Their results revealed a positive correlation between LCORL expression 
and average daily feed intake (ADFI), concluding that the expression of this gene may be 
“contributing to or responding to” variation in ADFI. However, based on our data, we are 
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inclined to believe that ADFI does not cause alterations in LCORL expression, but that an 
upregulation of metabolic pathways associated with QQ genotype, as well as LCORL 
overexpression, are increasing ADFI. In addition, this study reported great variability of LCORL 
expression consistent to our RNA-Seq results, demonstrating that variations in LCORL 
expression are possible to be detected in cattle populations. Lindholm-Perry et al. [37] does not 
draw a relationship between differential LCORL expression and alternative QTL genotypes. 
However, their population’s breed composition implies the presence of the Q allele and its 
possible influence in LCORL expression. This is also consistent with our observation that 
LCORL expression may be influenced by genetic variation associated with this QTL. 
The WGCNA module Turquoise had the highest negative correlation with genotype. All 
genes included in this module (991 genes) have a negative direction of expression, being 165 
genes significantly downregulated.  IPA’s canonical pathways analysis for the Turquoise module 
(Table 14) revealed an enrichment and inactivation (z-score < -2) of the ‘AMPK signaling’ 
canonical pathway. AMP-activated protein kinase (AMPK) activation has been reported to inhibit 
ATP-consuming biosynthetic processes, such as protein synthesis and lipogenesis, while 
inducing ATP-generating pathways [62, 63]; in fact, AMPK has been shown to inhibit the mTOR 
pathway, a major player in protein synthesis and biomass production [64]. Therefore, the 
inactivation of the AMPK signaling pathway supports our hypothesis of increased protein 
synthesis and, consequently, lean growth in QQ animals; the activation of the mTOR signaling 
pathway detected for the entire DEG list and Blue module offers support to these results.  
Although the inactivation of the AMPK signaling pathway also leads to increased 
lipogenesis, the downregulation of several adipogenesis- and lipogenesis-related genes in our 
DEG list (e.g. LEP, SCD, FASN, LDLR, ACACA, LIPE, DGAT2, ELOVL5, PPARG) suggests 
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that these processes may be occurring at a reduced rate. This is supported by the enrichment and 
likely inactivation (negative z-scores) of pathways which downregulation is linked to decreased 
fat synthesis, including ‘PI3K signaling in B lymphocytes’ [65], ‘IGF-1 signaling’ and ‘insulin 
receptor signaling’ [66, 67], and ‘p70S6k signaling’ [68]. Other pathways involved in fat 
synthesis and metabolism are also shown to be altered in the Turquoise module, including 
‘TR/RXR’ activation’, ‘glucocorticoid receptor signaling’, ‘adipogenesis pathway’, and ‘fatty 
acid activation’. Although a prediction of activation or inactivation of these pathways could not 
be made by IPA, we suggest that, due to the downregulated genes associated with these 
pathways, they are likely inactivated, indicating reduced fat synthesis in QQ animals.  
The canonical pathway ‘growth hormone signaling’ is predicted to be inactivated. Although 
growth hormone (GH) deficiency has been associated with increased fat deposition [69], 
decreased activity of this pathway has also been associated with inhibited differentiation of 
preadipocytes into adipocytes; this can be confirmed by the significant downregulation of the 
growth hormone receptor gene (GHR) associated with this pathway, which mRNA is increased 
after preadipocytes differentiate into adipocytes [70, 71], suggesting that differentiation is 
occurring at low levels, if any.  
Interestingly, two canonical pathways are predicted to be activated (positive z-scores) in the 
Turquoise module: the ‘PPARα/RXRα activation’ pathway and the ‘PTEN signaling’ pathway. 
The activation of these pathways is associated with lipid degradation [72] and decreased fat 
synthesis and body fat accumulation [73-75], respectively.  
It is important to observe that some pathways which inactivation is associated with increased 
fat synthesis are predicted to be, indeed, inactivated in this module (‘ERK5 signaling’ [76] and 
‘AMPK signaling’). However, as previously, mentioned, the downregulation of adipogenesis- 
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and lipogenesis-related genes in our DEG list suggests that, despite the activity of such 
pathways, fat synthesis may be occurring at a reduced rate. Moreover, the same predictions are 
not observed in the IPA results for the overall DEG list or Blue module; in fact, the most 
significant enriched canonical pathways for the Blue module are among the top 10 enriched 
canonical pathways for the DEG overall analysis, indicating that Blue module may be playing a 
bigger role in determining the phenotypic variation than the Turquoise module. This is also 
confirmed by the strong positive correlation and negative correlation of the Blue and Turquoise 
modules, respectively, with the QQ genotype. 
LCORL may be part of a larger complex gene network underlying growth and composition  
Insulin-like growth factor 2 (IGF2) is among the upregulated genes (FDR P-value = 
4.45E-03) that belong to the same WGCNA module as LCORL. Insulin-like growth factors 
compose a family of hormones that control hyperplasia and differentiation in the body. IGF2 is a 
maternal imprinted fetal cell growth and differentiation factor widely studied due to its 
implications in mammal’s growth and development traits, such as muscle growth and myoblast 
proliferation and differentiation [77-85]. In cattle, this gene is located on chromosome 29 [86, 
87], where QTLs influencing milk and meat production have been previously identified [88-90]. 
Additionally, polymorphisms in this gene have been associated to rib-eye area and carcass 
percent in beef cattle [91], backfat thickness and average daily gain [92], body weight [93, 94] 
and daily weight gain [93].  
Several genes involved in growth and composition traits have been proposed to interact 
with IGF2. Pleiomorphic adenoma gene 1 (PLAG1), a transcription factor whose locus in cattle 
has been associated with stature [95], carcass weight [5],  early life body weight, peripubertal 
weight and growth [96], calving ease, carcass, weaning and yearling weights [97], and birth 
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weight [98], has been reported to target IGF2, activating its transcription [99, 100]. PLAG1 
expression  has been shown to be increased by the DNA-binding protein high mobility group 
AT-hook 2 (HMGA2) [101], another transcription factor associated with height and birth weight 
in humans [31, 102] and cattle  [97, 103], meat quality and carcass traits in pigs [104], body size 
in dogs [105], and body size in horses [27]. By increasing PLAG1 expression, HMGA2 indirectly 
activates IGF2. This gene has been also shown to regulate myoblast proliferation and 
myogenesis by activating the transcription of IGF2BP2 (also found in WGCNA Blue module), 
an IGF2 binding protein which binds to IGF2 mRNA increasing its translation [106, 107].  
Several of the same studies reporting the association of HMGA2 and PLAG1 with growth 
and composition have also reported the association of the NCAPG/LCORL locus with these traits 
[5, 18, 27, 28, 31, 97, 103, 108, 109], suggesting that HMGA2, PLAG1, IGF2, NCAPG and 
LCORL may be part of the same complex genetic network underlying growth and development 
mechanisms. This may also indicate that, as HMGA2 and PLAG1, the transcription factor 
LCORL may be directly or indirectly regulating IGF2 expression within this network, affecting 
important biological pathways influencing the phenotypic variation observed. 
Although there are no previous reports in the literature of an interaction between LCORL 
and IGF2, our WGCNA data suggests three different genes as possible mediators of an indirect 
interaction between both genes (Fig. 8). Among them, we have Glutaredoxin 3 (GLRX3), an 
oxidoreductase enzyme involved in cellular growth and inhibition of apoptosis . Several studies 
have indicated the potential role of GLRX3 in growth and development in mammals: Fernandez 
et al. [110] has reported GLRX3 as part of a QTL associated with mean weight of shoulders and 
backfat thickness in pigs; Cheng et al. [111] in a study using GLRX3 knockout mice 
demonstrated that the absence of this gene might be responsible for embryonic growth defects 
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and lethality due to defects during mitotic progression; finally, Canton et al. [112] in a clinical 
study have reported a genomic deletion covering GLRX3 as the main candidate for growth 
impairment of prenatal onset in one of the children born with low birth weight and length. 
Canton et al. [112] also proposed IGF2BP2 as having a putative role in the control of growth for 
another patient in the same study. As previously mentioned, IGF2BP2 binds to IGF2 mRNA 
increasing its translation [106, 107]. Interestingly, our WGCNA inferred network also predicted 
an interaction between IGF2BP2 and GLRX3 (data not shown), suggesting that both genes may 
be acting together in the same gene network. Thus, the co-expression of GLRX3 with LCORL, 
IGF2BP2 and IGF2 in our WGCNA inferred network, and the involvement of these genes in 
growth and development, may indicate that GLRX3 is acting together with LCORL, IGF2BP2 
and IGF2 as part of the same gene network and biological pathways, possibly mediating an 
interaction between LCORL and IGF2, and influencing the phenotypes observed.  
Animal growth and development involve high-energy demanding processes - such as bone, 
muscle, and fat tissue deposition - leading to increased mitochondrial activity. Several studies 
have shown that mitochondrial biogenesis and activity drastically increases during myogenesis; 
especially during differentiation of myoblasts into myotubes [59-61]. In fact, oxidative 
phosphorylation provides around 60% of the energy required for this differentiation [113]. 
Transmembrane protein 126A (TMEM126A) and mitochondrial ribosomal protein L11 
(MRPL11) are two other potential mediators for the proposed interaction between LCORL and 
IGF2. TMEM126A encodes a mitochondrial transmembrane protein which mRNAs are translated 
in the surface of the mitochondria, suggesting a mechanism for fast supply of mitochondrial 
membrane proteins in high-energy demanding biological processes [114]. Interestingly, this gene 
has been reported as part of a QTL associated with body size growth in mice, indicating its role 
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during growth and development [115]. MRPL11, another mitochondria-related gene, encodes a 
39S subunit component of the mitochondrial ribosome [116-118] and plays a crucial role during 
synthesis and regulation of around 13 mitochondrial proteins part of the oxidative 
phosphorylation (OXPHOS) complexes in mammals [116, 118-121]. Both TMEM126A and 
MRPL11 are significantly upregulated in WGCNA module Blue (FDR P-value = 2.62E-06 and 
FDR P-value = 6.26E-03, respectively), suggesting increased mitochondrial activity in QQ 
animals. Whether LCORL, IGF2, or both genes are affecting the expression levels of 
TMEM126A and MRPL11 is not possible to assume based on our WGCNA inferred data; 
nevertheless, we propose that the activation of growth and development processes by IGF2 and 
LCORL is promoting mitochondrial activity and, therefore, increased expression of these genes. 
However, further investigation on the relationship between these four genes is necessary. 
The visualization of WGCNA module Blue using Cytoscape allowed us a better 
understanding of the module’s inferred structure and network connections and provided us with 
an important insight into how LCORL may be interacting with other members in the network, 
including IGF2. Although neither of these genes are the most highly connected hubs in this 
module (data not shown), their biological functions and reported roles in growth and 
development traits in several species suggest they are likely playing a crucial role within this 
module and could be influencing the expression patterns of other nodes in the network. 
Therefore, we propose that LCORL and IGF2 may be acting together as part of the same gene 
network and biological pathways underlying the phenotypic variation observed between calves 
with alternative NCAPG/LCORL genotypes.  
Upstream regulators predicted with IPA 
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 The upstream regulator analysis tool provided by IPA aims to identify potential upstream 
transcriptional regulators that may be influencing the gene expression patterns in the dataset 
provided, as well as downstream biological pathways. IPA considers an upstream transcriptional 
regulator basically any molecule capable of affecting the expression of other molecules, 
including transcription factors, microRNAs, kinases, compounds, drugs or any gene or small 
molecule reported to affect gene expression [122]. Here, we identified several transcriptional 
regulators that appear to be influencing differential gene expression and which activities support 
our hypothesis for increased lean growth and decreased fat synthesis in QQ compared to qq 
calves. 
 For our list of DEG, IPA identified a total 1142 potential upstream transcriptional 
regulators (P-value < 0.05). From these, 92 were predicted to be inactivated (z-score < -2) and 31 
were predicted to be activated (z-score > 2) (Table 18).  
 The v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog 
(MYCN), a transcriptional regulator involved in the positive regulation of gene expression and 
cell proliferation, was associated with the highest z-score. This regulator targets most of the 
upregulated ribosomal genes in the dataset, suggesting its involvement in the positive regulation 
of protein synthesis, cell proliferation, and growth. 
Among the activated transcriptional regulators, several appear to be negatively regulating 
the expression of genes involved in fat synthesis and lipid metabolism. For example, insulin 
induced gene 1 (INSIG1) and insulin induced gene 2 (INSIG2) – both genes involved in the 
regulation of cholesterol metabolism and lipogenesis [123] – appear to target many genes in 
common; all of them are downregulated in the DEG dataset and most are involved in fat 
synthesis and lipid metabolism (SCD, LDLR, G6PD, FASN, ELOVL6, ACLY, ACACA), 
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suggesting that these upstream regulators may be influencing reduced fat synthesis in QQ 
animals.   The corepressor group nuclear receptor corepressor (N-cor) is another transcriptional 
regulator which is targeting many downregulated genes related to fat synthesis and lipid 
metabolism (SCD, PLIN1, G6PD, FASN, FABP4, ESR1, ELOVL6, ELOVL5, CIDEC), indicating 
it may be driving their underexpression and, therefore, influencing reduced fat synthesis. In fact, 
this transcriptional regulator has been reported to repress adipogenesis by decreasing the 
transcriptional activity of the peroxisome proliferator-activated receptor gama (PPARG) [124], 
supporting these results. 
  Interestingly, PPARG is among the downregulated genes in our DEG list included in the 
list of inhibited upstream regulators predicted by IPA (PPARG, CSF1, NCOA2, SPI1, STAT5B, 
IDH1, CCDC3). The transcription factor PPARG plays a crucial role in stimulating adipogenesis 
and targets many fat cell-specific genes [124, 125]. Thus, its downregulation and predicted 
inactivation, as well as downregulation of most of its target adipogenesis-related genes in the 
dataset (e.g. SCD, PLIN1, PLIN4, PDE3B, LIPE, LDLR, INSIG1, FASN, FABP4, ELOVL6) 
suggests it may be influencing reduced adipogenesis and fat synthesis in QQ animals. Similarly, 
the downregulation of the predicted upstream regulator coiled-coil domain containing 3 
(CCDC3) – a gene which expression has been associated with the positive regulation of 
adipogenesis and lipid biosynthetic processes [126, 127] - and downregulation of its target genes 
(ACACA, DGAT2, FASN, LEP) also indicate reduced adipogenesis and fat synthesis in QQ 
animals. The upstream regulators CSF1, NCOA2, STAT5B and IDH1 have also been associated 
with similar events [128-136].  
 The upstream regulator analysis the WGCNA module Blue identified a total of 193 
upstream regulators, from which 13 were predicted to be inactivated (z-score < -2) and 16 were 
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predicted to be activated (z-score > 2). Among the activated upstream regulators, the v-myc 
avian myelocytomatosis viral oncogene homolog (MYC) is a transcription regulator which, as 
MYCN, has been reported to activate genes involved in ribosomal and mitochondrial biogenesis, 
as well as cell-cycle progression [137]. Among the upregulated genes in module Blue, MYC 
appears to be driving the overexpression of many ribosomal proteins (e.g. RPS7, RPS23, RPS20, 
RPS18, RPS12, RPLP1, RPL7, RPL6, RPL5, RPL30, RPL22, RPL13), supporting its role in 
ribosomal biogenesis and cell-cycle progression. Additionally, this gene appears to target 
TMEM126A, a transmembrane mitochondrial protein which we have proposed as a potential 
mediator for an indirect interaction between LCORL and IGF2 in our WGCNA inferred Blue 
module.  
 Interestingly, lysine (K)-specific demethylase 5A (KDM5A) is among the inhibited 
upstream regulators predicted by IPA. KDM5A is known to repress genes involved in the 
regulation of metabolism. Loss of this transcription regulator has been shown to promote cell 
differentiation by increasing mitochondrial activity [138, 139]; in fact, loss of KDM5A has been 
reported to promote myogenic differentiation [139]. This transcription regulator is known to 
negatively regulate several mitochondrial and cell cycle genes by the demethylation of 
trimethylated histone 3 on lysine 4 (H3K4me3); therefore, these target genes must be 
upregulated in order for differentiation to occur. This can be confirmed by the significant 
upregulation of its target genes in the dataset, all of which are mitochondrial genes (TOMM6, 
MRPL11, GADD45GIP1, COX17), demonstrating an increase in mitochondrial activity and, 
therefore, cell differentiation. Note that KDM5A appears to target MRPL11, another 
mitochondrial gene which we have proposed as a mediator for the interaction between LCORL 
and IGF2. Additionally, KDM5A is part of the 165 downregulated genes in the Turquoise 
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module, demonstrating that the downregulation of genes in that module may be influencing the 
upregulation of genes in the Blue module and, therefore, promoting increased lean growth and 
reduced fat synthesis.  
 The rapamycin insensitive companion of mTOR (RICTOR) is found among the top 
inhibited upstream regulators predicted by IPA for module Blue, as well as DEG list. The 
mammalian TOR (mTOR) pathway is known to regulate growth processes, including protein 
synthesis, cell growth and proliferation. mTOR is composed of two protein complexes, mTORC1 
and mTORC2. mTORC1 is characterized by the protein RAPTOR and is involved in the positive 
regulation of protein synthesis, while mTORC2 is characterized by the protein RICTOR [140]. 
Downregulation of RICTOR has been reported to significantly increase protein synthesis by 
increasing phosphorylation of two substrates of mTOR (S6 kinase and 4EBP-1), which are 
necessary for mTORC1 activity [141]. This is supported by the upregulation of several ribosomal 
protein genes targeted by RICTOR in module Blue, demonstrating that inhibition of RICTOR 
may be driving increased expression of these genes and, consequently, increased protein 
synthesis and cell growth in QQ animals. These results can also be confirmed by the activation 
of the mTOR pathway for WGCNA module Blue.  
 Two transcription regulators targeting LCORL were identified by IPA in the WGCNA 
module Blue: cyclin D1 (CCND1) and cyclin dependent kinase 4 (CDK4). Although IPA was not 
able to successfully predict if these regulators are activated or inactivated, CCND1 seems to be 
slightly activated (z-score = 0.896) (data for upstream regulators with -2 < z-scores < 2 are not 
shown). Also, CDK4 is one of the upregulated genes in this module. Cyclin/Cdks complexes 
play an important role in cell cycle progression, acting on different phases of the cycle. The 
complex involving CCND1 and CDK4 (Cyclin D1/Cdk4 complex) has been reported to act 
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during the G1 phase of the cell cycle; it phoshorylates Rb family proteins, inhibiting their 
transcriptional suppressor activity and activating E2F-dependent transcription. This promotes the 
transition from the G1 to the S phase, DNA synthesis and, consequently, cellular growth [142, 
143]. This complex has been also reported to phosphorylate SMAD3, disabling its anti-
proliferative function [144]. 
Molenaar et al. [145] in a study with neuroblastoma reported that silencing of the 
CCND1/CDK4 complex was associated with an increase in LCORL expression in human 
neuroblasts. Although their results suggest that these molecules may negatively regulate LCORL 
expression, we propose the contrary. That is the only study reporting an association between the 
CCND1/CDK4 complex with LCORL expression, indicating that further research is necessary in 
order to investigate the actual effect of CCND1/CDK4 expression on LCORL. Additionally, 
further research regarding their relationship in other tissues, such as muscle tissue, may be 
necessary. The involvement of these genes with cell cycle progression and growth suggests they 
may interact in the same biological pathways underlying growth and development. Based on our 
results, we propose that CCND1 and CDK4 expression may influence LCORL overexpression, 
which would then activate downstream growth pathways. The presence and upregulation of 
CDK4 in module Blue offers support to this hypothesis. Furthermore, IGF2 overexpression has 
been reported to increase CCND1 expression [146], suggesting that IGF2 may be indirectly 
activating LCORL via CCND1, also supporting our hypothesis of an indirect interaction between 
the two genes.  
 Remarkably, ligand dependent nuclear receptor corepressor (LCOR), a major LCORL 
homologue, was predicted by IPA as one of the upstream regulators in the analysis including the 
entire DEG list, as well as only the DEG in the WGCNA Blue module (data not shown). LCOR 
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and LCORL were first identified in mice and are homologues of the MBLK-1, a transcription 
factor reported in the honeybee brain [147]. Both genes encode transcription factors which 
recognize the same DNA element (5’-CCCTATCGATCGATCTCTACCT-3’) and activate 
transcription of their target genes. Additionally, both genes appear to interact with each other and 
to function jointly [147].  
IPA upstream analysis results are based on literature reports from mainly humans, mice 
and rat. Although many studies have been performed regarding LCOR functional mechanisms 
and interactions, studies involving LCORL are limited. Additionally, while some research 
involving LCORL have been performed in cattle, pigs, horses, and other species, not many are 
reported in humans, mice or rat. For this reason, it is possible that IPA has failed to identify 
LCORL as a potential upstream regulator in our dataset. However, considering LCOR and 
LCORL similarities, transcription factor roles, and their suggested complementary activity, we 
propose that LCORL may also be a potential upstream regulator and may be driving the 
expression pattern of genes in QQ calves.  
 LCOR is targeting two genes in our DEG list: cyclin dependent kinase inhibitor 1A 
(CDKN1A) and tissue factor pathway inhibitor (TFPI2). LCOR has been reported to inhibit 
CDKN1A and TFPI2 expression [148]. CDKN1A is a widely studied cyclin-dependent kinase 
inhibitor which blocks the activity of Cyclin/Cdk complexes, negatively regulating cell cycle 
progression [142, 149, 150]. CDKN1A is indeed downregulated in our study and is placed in the 
WGCNA Turquoise module, thus supporting LCOR (and possibly LCORL) regulation of this 
gene and role in cell proliferation and growth. This also offers support to our hypothesis that 
LCORL interacts with the CCND1/CDK4 complex in promoting cell cycle progression; 
CCND1/CDK4 may induce LCORL expression, which would then inhibit CDKN1A, promoting 
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cell cycle progression and growth. Although LCOR is expected to decrease TFPI2 expression, 
this gene is found upregulated in our study; further investigation is needed to better understand 
the interaction between the two genes. TFPI2 is a member of the Kunitz-type family of serine 
protease inhibitors. It has been reported to play a role in proteinase inhibition, coagulation, 
regulation of extracellular matrix digestion and remodeling, and inhibition tumor growth and 
metastasis [151, 152]. 
 Interestingly, IGF2 and PLAG1 are also predicted as a potential upstream regulators in 
our DEG list, being slightly inactivated (z-score = -0.218) and activated (z-score = 0.919), 
respectively. As expected, PLAG1 is targeting IGF2 and likely driving its overexpression. The 
prediction of LCOR (and possibly LCORL), PLAG1 and IGF2 as potential upstream regulators 
for our DEG list offers support to our hypothesis that these genes may be part of a larger 
complex gene network underlying growth and composition.  
Conclusions  
A more rigorous comparison of the relationship between the genotypic and phenotypic 
variation is necessary. Although a QTN responsible for these phenotypic effects has been 
proposed, additional data, including that from our laboratory, suggest that the causative mutation 
most likely impacts the regulation of LCORL expression. The results presented here suggest that 
overexpression of LCORL may be directly or indirectly responsible for the up- and down-
regulation of gene pathways associated with lean tissue growth and fat synthesis, respectively.  
Additionally, we propose that LCORL may be part of a larger gene network underlying growth 
and composition in cattle.  
The understanding of the molecular mechanisms underlying animal growth and 
development is essential for improving livestock production efficiency. The genetic variation 
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within the NCAPG/LCORL locus may allow us to define events that take place during early 
developmental stages and that have permanent and stable effects throughout the life of the 
animal, especially during the growth phase of production. Characterizing the mechanisms by 
which this molecular variation affects the expression patterns of genes and the functions of 
downstream gene networks and pathways will provide us a better understanding of how it affects 
animal growth and development. Additionally, this will allow us to identify specific genetic and 
environmental factors that can be considered for the improvement of cattle production efficiency. 
Importantly, these insights can be applied to other economically important species, given that the 












Fig 1. GWAS analysis reveals a highly significant association of the NCAPG/LCORL locus on BTA6 with 
calves’ BW. (A-C) Manhattan plots of haplotype trend regression analysis of birth weight (BW) for Charolais X 
Simmental-Angus crossbred calves raised at the University of Illinois-Dixon Springs Agricultural Center (n = 791). 
Calves were genotyped using the Illumina Bovine 50K BeadChip and imputed to 630,230 markers using BEAGLE. 






Fig 2. Graphical representation of genotypes for selected calves having QQ (top panel) or qq (bottom panel) 
haplotypes.  Blue and yellow represent each of the alternative homozygous genotypes for each SNP marker. Green 
indicates heterozygosity. The red box corresponds to the region containing the most significant SNP haplotypes 









Fig 3. Barplot representing the effect of surrogate variable 2 (SV2) on the 24 samples analyzed. The samples 
with values sv > 0.0 correspond to female animals, while samples with values sv < 0.0 correspond to male animals, 
matching the 12 female and 12 male animals present in the dataset. Black represents animals with qq genotype and 
red represents animals with the QQ genotype. 
 
 




Fig 5. Differences of gene expression patterns between QQ and qq animals. Scaled heatmap of the 507 
differentially expressed genes identified in QQ vs qq animals (FDR P-value < 0.01). The log2 of counts was used as 
the expression measure. Each row represents one gene and each column represents one sample; samples with the 
same genotype (QQ or qq) cluster together. Using a scale of standard deviations from the mean expression level, the 
change in expression level is shown as red (higher expression) or blue (lower expression) relative to the mean across 




Fig 6.  WGCNA hierarchical cluster tree of the 3250 genes showing the relationship between gene modules 
and genotype.  The first color band (Module colors) allows a visual comparison of module assignments based on 
the dynamic hybrid branch cutting method provided by WGCNA. The second color band (Genotype) provides the 
visualization of the GS measures, where “red” intensity indicates a high positive correlation with the QQ genotype, 
and “blue” indicates a high negative correlation with the QQ genotype.  
 
 
Fig 7. Gene Significance (GS.genotype) versus module membership (kME) for the modules with the highest 
positive (Blue) and negative (Turquoise) correlations with QQ genotype. Overall GS.genotype and kME are 






Fig 8. Node and edge graph for the interactions between LCORL and IGF2 within WGCNA Blue module. The 
topological overlap measure from WGCNA was displayed using Cytoscape to illustrate the sub network from 
module assembled from LCORL’s nearest neighbors that share a connection with IGF2. The rest of Blue module’s 
network is not represented here. Connections between genes are represented by edges (strength not represented). 
The color red represents levels of overexpression; Circle size represents FDR P-value of differential expression 

















Table 1. Complete list of the 507 differentially expressed genes (FDR P-value < 0.01), together with their 
respective fold-change in the logarithmic scale (logFC), FDR P-values (FDR), and assigned WGCNA module. 
 
Ensembl Gene ID Entrez 
Gene ID 
Gene Symbol Module 
number 
Module color logFC Up/Down FDR 
ENSBTAG00000043567 -- -- 0 Grey -0.529529996 Down 1.12E-03 
ENSBTAG00000012067 529859 EPG5 1 Turquoise -0.572807012 Down 3.45E-09 
ENSBTAG00000002392 101906436 LOC101906436 1 Turquoise -0.639108113 Down 3.10E-06 
ENSBTAG00000010120 510924 HERC3 1 Turquoise -0.465773988 Down 5.63E-06 
ENSBTAG00000001335 280805 GHR 1 Turquoise -0.414062382 Down 7.98E-06 
ENSBTAG00000016194 513776 FBXO32 1 Turquoise -0.708917037 Down 1.14E-05 
ENSBTAG00000003581 515928 SETD7 1 Turquoise -0.5554546 Down 1.29E-05 
ENSBTAG00000019124 782397 EIF4EBP2 1 Turquoise -0.496400338 Down 1.63E-05 
ENSBTAG00000037383 504288 AKAP13 1 Turquoise -0.511989806 Down 2.49E-05 
ENSBTAG00000019954 508717 ABHD2 1 Turquoise -0.674387775 Down 2.55E-05 
ENSBTAG00000011011 512652 SSH2 1 Turquoise -0.427215524 Down 4.28E-05 
ENSBTAG00000002485 286798 TNS1 1 Turquoise -0.465958396 Down 4.73E-05 
ENSBTAG00000007441 508557 SEC23IP 1 Turquoise -0.307486558 Down 5.12E-05 
ENSBTAG00000002606 505423 LGR4 1 Turquoise -0.334952608 Down 5.25E-05 
ENSBTAG00000000911 539313 UBE2H 1 Turquoise -0.362936649 Down 5.41E-05 
ENSBTAG00000016229 539139 KLF9 1 Turquoise -0.419962246 Down 5.61E-05 
ENSBTAG00000002880 504625 SORBS1 1 Turquoise -0.545743899 Down 7.20E-05 
ENSBTAG00000044160 783065 MCCC2 1 Turquoise -0.518484238 Down 7.25E-05 
ENSBTAG00000038794 521172 TMEM245 1 Turquoise -0.635853722 Down 8.46E-05 
ENSBTAG00000002303 281196 GLG1 1 Turquoise -0.440761834 Down 8.46E-05 
ENSBTAG00000001274 541235 PPM1L 1 Turquoise -0.495649301 Down 9.16E-05 
ENSBTAG00000016979 100125779 PCYT1A 1 Turquoise -0.454095082 Down 9.16E-05 
ENSBTAG00000018718 515551 LOC515551 1 Turquoise -0.730570733 Down 1.07E-04 
ENSBTAG00000019358 616238 RNF214 1 Turquoise -0.406527871 Down 1.11E-04 
ENSBTAG00000020312 508162 NCOA2 1 Turquoise -0.468686127 Down 1.16E-04 
ENSBTAG00000008083 614959 SEL1L 1 Turquoise -0.478691705 Down 1.48E-04 
ENSBTAG00000018694 531552 ACSS3 1 Turquoise -0.585272603 Down 1.51E-04 
ENSBTAG00000010819 539099 HMBOX1 1 Turquoise -0.415750096 Down 1.70E-04 
ENSBTAG00000021037 281010 ARNT 1 Turquoise -0.321637203 Down 1.76E-04 
ENSBTAG00000011056 541272 IDS 1 Turquoise -0.58874775 Down 1.79E-04 
ENSBTAG00000007962 516579 ATP9A 1 Turquoise -0.472537961 Down 1.81E-04 
ENSBTAG00000002126 287019 PFKFB2 1 Turquoise -0.523490921 Down 1.90E-04 
ENSBTAG00000006679 407219 MITF 1 Turquoise -0.358053397 Down 1.90E-04 
ENSBTAG00000018404 282004 PRKG1 1 Turquoise -0.772544401 Down 2.05E-04 
ENSBTAG00000013464 540395 CEP97 1 Turquoise -0.379158734 Down 2.32E-04 
ENSBTAG00000015698 100139246 FYCO1 1 Turquoise -0.390040308 Down 2.65E-04 
ENSBTAG00000002783 100125835 PCYOX1 1 Turquoise -0.424658 Down 3.12E-04 
ENSBTAG00000017280 280677 C3 1 Turquoise -0.906799702 Down 3.38E-04 
ENSBTAG00000002896 531602 KPNA6 1 Turquoise -0.317304836 Down 3.38E-04 
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Ensembl Gene ID Entrez 
Gene ID 
Gene Symbol Module 
number 
Module color logFC Up/Down FDR 
ENSBTAG00000008022 538209 PTGFRN 1 Turquoise -0.639157393 Down 3.48E-04 
ENSBTAG00000019781 523441 CLASP1 1 Turquoise -0.323174339 Down 3.52E-04 
ENSBTAG00000008535 540586 SOCS7 1 Turquoise -0.518884046 Down 3.81E-04 
ENSBTAG00000006066 614834 CDS2 1 Turquoise -0.32901997 Down 4.13E-04 
ENSBTAG00000011337 518403 ANKRD33B 1 Turquoise -0.586544149 Down 4.18E-04 
ENSBTAG00000017164 539286 LARP4 1 Turquoise -0.33427761 Down 4.18E-04 
ENSBTAG00000019441 513972 MED28 1 Turquoise -0.322109884 Down 4.18E-04 
ENSBTAG00000007439 509726 TENM4 1 Turquoise -1.016445119 Down 4.19E-04 
ENSBTAG00000017745 522155 IL6ST 1 Turquoise -0.398983873 Down 4.86E-04 
ENSBTAG00000014334 514402 ZFYVE26 1 Turquoise -0.343124601 Down 5.02E-04 
ENSBTAG00000027182 537614 NR3C2 1 Turquoise -0.363707039 Down 5.51E-04 
ENSBTAG00000007371 535352 SCAMP1 1 Turquoise -0.378825639 Down 6.56E-04 
ENSBTAG00000005504 511340 TP53INP2 1 Turquoise -0.612956903 Down 7.82E-04 
ENSBTAG00000010442 535887 PANK1 1 Turquoise -0.558592878 Down 7.91E-04 
ENSBTAG00000016471 286844 PDPR 1 Turquoise -0.40042638 Down 8.02E-04 
ENSBTAG00000005946 100141289 USP13 1 Turquoise -0.367973949 Down 8.22E-04 
ENSBTAG00000013716 505531 NR2C2 1 Turquoise -0.314827887 Down 8.76E-04 
ENSBTAG00000014843 281706 COPB2 1 Turquoise -0.302798528 Down 8.76E-04 
ENSBTAG00000021000 789845 KIAA2018 1 Turquoise -0.38999085 Down 9.81E-04 
ENSBTAG00000001619 504658 SERINC5 1 Turquoise -0.711903429 Down 9.97E-04 
ENSBTAG00000014818 526379 MYLK3 1 Turquoise -0.899667378 Down 1.02E-03 
ENSBTAG00000004860 537062 SLC27A6 1 Turquoise -1.069627253 Down 1.04E-03 
ENSBTAG00000000283 281094 CSF1 1 Turquoise -0.788030153 Down 1.04E-03 
ENSBTAG00000008353 513497 CDKN1A 1 Turquoise -0.502428778 Down 1.10E-03 
ENSBTAG00000002393 618886 C23H6orf89 1 Turquoise -0.366072328 Down 1.21E-03 
ENSBTAG00000020050 515309 MLEC 1 Turquoise -0.483082156 Down 1.36E-03 
ENSBTAG00000015887 539458 FOXJ3 1 Turquoise -0.255135545 Down 1.37E-03 
ENSBTAG00000015220 528046 AGO4 1 Turquoise -0.286984106 Down 1.39E-03 
ENSBTAG00000009109 532541 CASD1 1 Turquoise -0.284181754 Down 1.39E-03 
ENSBTAG00000000928 506538 SPECC1 1 Turquoise -0.443641795 Down 1.43E-03 
ENSBTAG00000005138 539340 BCL9L 1 Turquoise -0.357412452 Down 1.50E-03 
ENSBTAG00000014786 506557 PBRM1 1 Turquoise -0.303079452 Down 1.57E-03 
ENSBTAG00000014387 512665 PRKAB2 1 Turquoise -0.350692865 Down 1.77E-03 
ENSBTAG00000012259 512573 PNPO 1 Turquoise -0.371209155 Down 1.84E-03 
ENSBTAG00000034436 100138102 PDPK1 1 Turquoise -0.349559689 Down 1.87E-03 
ENSBTAG00000007100 521387 TRAPPC10 1 Turquoise -0.294023737 Down 1.96E-03 
ENSBTAG00000003983 616315 TOM1L2 1 Turquoise -0.293648328 Down 2.10E-03 
ENSBTAG00000005863 541204 ATF7 1 Turquoise -0.361979342 Down 2.12E-03 
ENSBTAG00000007909 513730 NOTCH2 1 Turquoise -0.571618984 Down 2.26E-03 
ENSBTAG00000004204 617309 GPR107 1 Turquoise -0.496613526 Down 2.26E-03 
ENSBTAG00000020988 513688 KIZ 1 Turquoise -0.582662411 Down 2.26E-03 
ENSBTAG00000009272 505848 ELMSAN1 1 Turquoise -0.374553528 Down 2.35E-03 
ENSBTAG00000011234 535530 FOXO3 1 Turquoise -0.402237856 Down 2.35E-03 
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ENSBTAG00000017090 781661 SMCR8 1 Turquoise -0.471197254 Down 2.38E-03 
ENSBTAG00000001463 535030 TNKS 1 Turquoise -0.402663472 Down 2.39E-03 
ENSBTAG00000001629 540926 SCMH1 1 Turquoise -0.320778415 Down 2.46E-03 
ENSBTAG00000012099 617988 TMEM87B 1 Turquoise -0.43059185 Down 2.58E-03 
ENSBTAG00000014422 615443 MTMR10 1 Turquoise -0.234000177 Down 2.58E-03 
ENSBTAG00000030556 507766 ZNF217 1 Turquoise -0.583142708 Down 2.61E-03 
ENSBTAG00000020552 789222 PRDM2 1 Turquoise -0.281325748 Down 2.61E-03 
ENSBTAG00000014465 281375 SERPINE1 1 Turquoise -0.813928038 Down 2.77E-03 
ENSBTAG00000004991 505465 IKBKAP 1 Turquoise -0.32112202 Down 2.93E-03 
ENSBTAG00000035995 -- -- 1 Turquoise -0.47061216 Down 2.95E-03 
ENSBTAG00000035226 782528 TOR1AIP1 1 Turquoise -0.257285829 Down 2.98E-03 
ENSBTAG00000021678 518976 SLC31A1 1 Turquoise -0.346379592 Down 3.04E-03 
ENSBTAG00000040569 539974 NLRX1 1 Turquoise -0.357311275 Down 3.15E-03 
ENSBTAG00000015625 613489 DCTN4 1 Turquoise -0.289391464 Down 3.18E-03 
ENSBTAG00000011823 514447 CLSTN1 1 Turquoise -0.352717348 Down 3.19E-03 
ENSBTAG00000022570 782922 LOC782922 1 Turquoise -0.80028085 Down 3.42E-03 
ENSBTAG00000004945 100138953 BBS7 1 Turquoise -0.666136037 Down 3.44E-03 
ENSBTAG00000004974 512177 ZDHHC23 1 Turquoise -0.567980452 Down 3.44E-03 
ENSBTAG00000010977 281170 FRZB 1 Turquoise -0.519326035 Down 3.44E-03 
ENSBTAG00000017278 353160 ACBD5 1 Turquoise -0.335330148 Down 3.44E-03 
ENSBTAG00000018024 532076 NR1D2 1 Turquoise -0.307599421 Down 3.48E-03 
ENSBTAG00000004091 540249 GTF3C4 1 Turquoise -0.490249634 Down 3.52E-03 
ENSBTAG00000013899 505723 LARP4B 1 Turquoise -0.262213862 Down 3.52E-03 
ENSBTAG00000017860 -- -- 1 Turquoise -0.56756446 Down 3.55E-03 
ENSBTAG00000019900 521633 LNPEP 1 Turquoise -0.670434507 Down 3.71E-03 
ENSBTAG00000030174 513996 ACOX1 1 Turquoise -0.38629071 Down 3.71E-03 
ENSBTAG00000015607 541094 ERMP1 1 Turquoise -0.513042061 Down 3.85E-03 
ENSBTAG00000014605 504512 ETV6 1 Turquoise -0.478606315 Down 3.89E-03 
ENSBTAG00000017746 615883 SLIT3 1 Turquoise -0.570150127 Down 3.95E-03 
ENSBTAG00000000529 505504 BTBD9 1 Turquoise -0.328669176 Down 4.18E-03 
ENSBTAG00000006013 520927 NT5DC3 1 Turquoise -0.608218128 Down 4.28E-03 
ENSBTAG00000013495 537096 WDFY3 1 Turquoise -0.33527458 Down 4.35E-03 
ENSBTAG00000033268 539762 ZFHX4 1 Turquoise -0.454372725 Down 4.35E-03 
ENSBTAG00000018790 539988 BVES 1 Turquoise -0.315432307 Down 4.38E-03 
ENSBTAG00000011333 531418 CLASP2 1 Turquoise -0.262828266 Down 4.40E-03 
ENSBTAG00000013371 517231 KIAA0226L 1 Turquoise -0.582693367 Down 4.43E-03 
ENSBTAG00000016943 781355 NEK7 1 Turquoise -0.288276824 Down 4.54E-03 
ENSBTAG00000020387 506615 KIAA0430 1 Turquoise -0.241161995 Down 4.66E-03 
ENSBTAG00000033339 540159 ANKLE2 1 Turquoise -0.249407715 Down 4.89E-03 
ENSBTAG00000012991 518308 PRUNE2 1 Turquoise -0.894296182 Down 4.97E-03 
ENSBTAG00000016694 784489 KIAA0319L 1 Turquoise -0.266581 Down 4.97E-03 
ENSBTAG00000006817 527418 CBL 1 Turquoise -0.478716971 Down 5.02E-03 
ENSBTAG00000047605 100298868 LOC100298868 1 Turquoise -0.787233785 Down 5.05E-03 
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ENSBTAG00000020472 507962 KDM5A 1 Turquoise -0.358828961 Down 5.09E-03 
ENSBTAG00000009091 100048947 RNASEL 1 Turquoise -0.636908605 Down 5.48E-03 
ENSBTAG00000007512 282271 PLA2G15 1 Turquoise -0.322203129 Down 5.48E-03 
ENSBTAG00000012314 281276 LDLR 1 Turquoise -0.518027258 Down 5.54E-03 
ENSBTAG00000017509 527123 MYPN 1 Turquoise -0.26067278 Down 5.57E-03 
ENSBTAG00000001176 539619 LRRN1 1 Turquoise -0.519305355 Down 5.72E-03 
ENSBTAG00000014927 526949 OXSR1 1 Turquoise -0.252888505 Down 5.79E-03 
ENSBTAG00000012969 541161 DKK2 1 Turquoise -0.943768029 Down 5.93E-03 
ENSBTAG00000007378 515213 CLIP4 1 Turquoise -0.285860455 Down 5.93E-03 
ENSBTAG00000019472 281946 NR3C1 1 Turquoise -0.333699192 Down 6.06E-03 
ENSBTAG00000012193 537659 TTC28 1 Turquoise -0.330818359 Down 6.21E-03 
ENSBTAG00000003857 510837 SUSD6 1 Turquoise -0.430712213 Down 6.47E-03 
ENSBTAG00000017306 539274 AKNA 1 Turquoise -0.619788803 Down 6.57E-03 
ENSBTAG00000012371 532189 CPD 1 Turquoise -0.393024469 Down 6.68E-03 
ENSBTAG00000012673 534048 CDK18 1 Turquoise -0.469704621 Down 6.70E-03 
ENSBTAG00000032881 535202 SLCO5A1 1 Turquoise -0.659695108 Down 6.71E-03 
ENSBTAG00000000827 536532 TAOK1 1 Turquoise -0.500267991 Down 6.74E-03 
ENSBTAG00000010958 -- -- 1 Turquoise -0.467667802 Down 6.89E-03 
ENSBTAG00000001164 511425 ACAD10 1 Turquoise -0.33287256 Down 7.43E-03 
ENSBTAG00000019725 517544 UBE4A 1 Turquoise -0.272317096 Down 7.53E-03 
ENSBTAG00000017803 539180 RAB14 1 Turquoise -0.231220083 Down 7.82E-03 
ENSBTAG00000017527 526200 AIM1 1 Turquoise -0.456620109 Down 7.82E-03 
ENSBTAG00000009708 512868 SMYD4 1 Turquoise -0.462875458 Down 7.86E-03 
ENSBTAG00000012433 515939 DENND1B 1 Turquoise -0.330454602 Down 7.86E-03 
ENSBTAG00000033735 783379 KIAA1033 1 Turquoise -0.319346957 Down 7.86E-03 
ENSBTAG00000047135 613757 GORASP1 1 Turquoise -0.266886844 Down 7.86E-03 
ENSBTAG00000021818 338066 CD97 1 Turquoise -0.308114595 Down 7.94E-03 
ENSBTAG00000008844 783970 EXTL3 1 Turquoise -0.374218437 Down 7.99E-03 
ENSBTAG00000006161 280855 MET 1 Turquoise -0.310838205 Down 7.99E-03 
ENSBTAG00000021064 -- -- 1 Turquoise -0.526367264 Down 8.52E-03 
ENSBTAG00000019759 523752 IDE 1 Turquoise -0.299369893 Down 8.72E-03 
ENSBTAG00000019338 407110 IL13RA1 1 Turquoise -0.290070365 Down 8.86E-03 
ENSBTAG00000032517 616240 BCL7A 1 Turquoise -0.480240533 Down 8.94E-03 
ENSBTAG00000032637 504440 EXOC1 1 Turquoise -0.247909655 Down 9.33E-03 
ENSBTAG00000007111 504235 STEAP3 1 Turquoise -0.352095715 Down 9.33E-03 
ENSBTAG00000017450 533510 KLHL24 1 Turquoise -0.347793467 Down 9.33E-03 
ENSBTAG00000001632 515032 NBR1 1 Turquoise -0.227412738 Down 9.43E-03 
ENSBTAG00000005444 516332 UGGT1 1 Turquoise -0.391841998 Down 9.73E-03 
ENSBTAG00000009482 541306 AFF4 1 Turquoise -0.398800332 Down 9.84E-03 
ENSBTAG00000008766 317654 SLC9A1 1 Turquoise -0.332514396 Down 9.84E-03 
ENSBTAG00000021208 528960 RRM2B 1 Turquoise -0.388482362 Down 9.87E-03 
ENSBTAG00000009795 574400 SF3B5 2 Blue 0.493637032 Up 5.10E-07 
ENSBTAG00000000451 529762 TMEM126A 2 Blue 0.451048467 Up 2.62E-06 
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ENSBTAG00000009336 781644 LXN 2 Blue 1.001824222 Up 7.46E-06 
ENSBTAG00000000250 510680 HDHD3 2 Blue 0.710565462 Up 2.94E-05 
ENSBTAG00000001092 507308 PHOSPHO2 2 Blue 0.354205754 Up 6.28E-05 
ENSBTAG00000017368 287023 YBX1 2 Blue 0.380781159 Up 1.07E-04 
ENSBTAG00000015844 360007 TFPI2 2 Blue 0.434974378 Up 1.46E-04 
ENSBTAG00000021394 510040 FITM1 2 Blue 0.367914198 Up 1.51E-04 
ENSBTAG00000015648 509302 DNAJC21 2 Blue 0.399323792 Up 3.12E-04 
ENSBTAG00000017009 614078 CMC2 2 Blue 0.343750444 Up 3.38E-04 
ENSBTAG00000006214 532684 LOXL2 2 Blue 0.366169432 Up 3.38E-04 
ENSBTAG00000014372 777769 SMARCD3 2 Blue 0.300900133 Up 3.98E-04 
ENSBTAG00000017181 613568 MACROD1 2 Blue 0.36853945 Up 4.19E-04 
ENSBTAG00000002468 282877 RPS28 2 Blue 0.343748828 Up 5.36E-04 
ENSBTAG00000010738 616723 CCL14 2 Blue 0.371587575 Up 6.38E-04 
ENSBTAG00000011176 519224 TPRKB 2 Blue 0.300009055 Up 6.60E-04 
ENSBTAG00000023523 613960 GKAP1 2 Blue 0.353389836 Up 6.68E-04 
ENSBTAG00000002182 100295800 COX17 2 Blue 0.341787029 Up 6.98E-04 
ENSBTAG00000006703 515331 PTGDR 2 Blue 0.55218218 Up 7.22E-04 
ENSBTAG00000046573 -- -- 2 Blue 0.592602726 Up 7.63E-04 
ENSBTAG00000009211 617703 UBE2S 2 Blue 0.274337606 Up 8.03E-04 
ENSBTAG00000020139 514966 RPL7 2 Blue 0.312503026 Up 8.36E-04 
ENSBTAG00000013358 540129 RPS23 2 Blue 0.499608082 Up 8.36E-04 
ENSBTAG00000005057 507725 FAM204A 2 Blue 0.393931445 Up 8.45E-04 
ENSBTAG00000017733 280740 CA2 2 Blue 0.652973144 Up 8.76E-04 
ENSBTAG00000019542 515194 MRPL39 2 Blue 0.270353566 Up 9.16E-04 
ENSBTAG00000018320 533285 RPLP1 2 Blue 0.371001409 Up 9.82E-04 
ENSBTAG00000010948 532777 CLIC2 2 Blue 0.475245201 Up 9.97E-04 
ENSBTAG00000010723 509914 PFDN6 2 Blue 0.290050712 Up 1.06E-03 
ENSBTAG00000033015 509273 FAHD1 2 Blue 0.303853873 Up 1.21E-03 
ENSBTAG00000010907 767949 PPP1R1A 2 Blue 0.350417735 Up 1.54E-03 
ENSBTAG00000012751 100125777 BTBD6 2 Blue 0.318273169 Up 1.69E-03 
ENSBTAG00000037937 -- -- 2 Blue 1.137828466 Up 1.71E-03 
ENSBTAG00000014423 616065 RPL22 2 Blue 0.297986886 Up 1.80E-03 
ENSBTAG00000012880 100848156 DNLZ 2 Blue 0.301172078 Up 1.92E-03 
ENSBTAG00000017482 509394 ISYNA1 2 Blue 0.449236571 Up 2.01E-03 
ENSBTAG00000046394 507168 RPL23A 2 Blue 0.289131122 Up 2.06E-03 
ENSBTAG00000017604 514541 RAB13 2 Blue 0.306155252 Up 2.08E-03 
ENSBTAG00000007836 280701 PPA1 2 Blue 0.28599108 Up 2.08E-03 
ENSBTAG00000003989 505642 GSTO1 2 Blue 0.531327744 Up 2.09E-03 
ENSBTAG00000020733 337888 RPS15A 2 Blue 0.311974644 Up 2.22E-03 
ENSBTAG00000039520 529990 SIRPB1 2 Blue 1.214927663 Up 2.22E-03 
ENSBTAG00000022825 615390 BRI3 2 Blue 0.28656341 Up 2.28E-03 
ENSBTAG00000031723 511051 RPL6 2 Blue 0.297337889 Up 2.39E-03 
ENSBTAG00000001937 616275 ANAPC11 2 Blue 0.26530755 Up 2.47E-03 
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ENSBTAG00000037457 100337206 MBD2 2 Blue 0.277628734 Up 2.47E-03 
ENSBTAG00000021979 520875 EEF1B2 2 Blue 0.33690139 Up 2.47E-03 
ENSBTAG00000015338 509563 DSCC1 2 Blue 0.483397692 Up 2.47E-03 
ENSBTAG00000005620 326588 RPS3 2 Blue 0.312699888 Up 2.50E-03 
ENSBTAG00000002026 515238 RPL5 2 Blue 0.308399536 Up 2.68E-03 
ENSBTAG00000019891 101907103 MRPL40 2 Blue 0.289444847 Up 2.96E-03 
ENSBTAG00000016637 506275 WBP4 2 Blue 0.292422532 Up 3.18E-03 
ENSBTAG00000010756 280933 ST7 2 Blue 0.287414972 Up 3.20E-03 
ENSBTAG00000015182 514624 STARD10 2 Blue 0.676964184 Up 3.20E-03 
ENSBTAG00000010959 327693 HINT1 2 Blue 0.246748253 Up 3.21E-03 
ENSBTAG00000009908 282053 RPS3A 2 Blue 0.314811633 Up 3.52E-03 
ENSBTAG00000014057 536838 SLC35A1 2 Blue 0.278536321 Up 3.83E-03 
ENSBTAG00000012078 404082 TMEM176A 2 Blue 0.567957254 Up 3.85E-03 
ENSBTAG00000016643 527518 CYB561D1 2 Blue 0.507629624 Up 3.98E-03 
ENSBTAG00000019147 513222 RPS20 2 Blue 0.286352415 Up 4.11E-03 
ENSBTAG00000008288 533620 ANKRD26 2 Blue 0.519036558 Up 4.12E-03 
ENSBTAG00000015579 508953 TMEM160 2 Blue 0.320728755 Up 4.18E-03 
ENSBTAG00000039728 -- -- 2 Blue 0.469318818 Up 4.20E-03 
ENSBTAG00000017191 515358 LOC515358 2 Blue 0.243567196 Up 4.23E-03 
ENSBTAG00000047299 100126445 DGCR6L 2 Blue 0.339473333 Up 4.35E-03 
ENSBTAG00000027361 618530 ROMO1 2 Blue 0.250865431 Up 4.38E-03 
ENSBTAG00000013066 281240 IGF2 2 Blue 0.348986952 Up 4.45E-03 
ENSBTAG00000014863 444863 GYPC 2 Blue 0.322598309 Up 4.45E-03 
ENSBTAG00000013264 530464 RPS24 2 Blue 0.2760495 Up 4.46E-03 
ENSBTAG00000018800 614241 RPS4X 2 Blue 0.268358067 Up 4.50E-03 
ENSBTAG00000019995 504867 C29H11orf73 2 Blue 0.266817019 Up 4.66E-03 
ENSBTAG00000014226 505603 RPL34 2 Blue 0.292324417 Up 4.66E-03 
ENSBTAG00000020504 615387 CDK2AP1 2 Blue 0.29528853 Up 4.66E-03 
ENSBTAG00000003579 513977 FBXW4 2 Blue 0.325290189 Up 4.81E-03 
ENSBTAG00000038330 516108 LOC516108 2 Blue 0.264828375 Up 4.82E-03 
ENSBTAG00000021694 521442 SPAST 2 Blue 0.233189288 Up 4.96E-03 
ENSBTAG00000031797 540432 MANF 2 Blue 0.262753343 Up 4.96E-03 
ENSBTAG00000012699 506018 EXOSC1 2 Blue 0.264522525 Up 4.97E-03 
ENSBTAG00000034992 508412 MCTS1 2 Blue 0.261592753 Up 5.02E-03 
ENSBTAG00000046319 338063 NDUFA7 2 Blue 0.272060026 Up 5.07E-03 
ENSBTAG00000002648 326602 RPS18 2 Blue 0.293368003 Up 5.07E-03 
ENSBTAG00000012144 616678 ZMYND19 2 Blue 0.287760911 Up 5.48E-03 
ENSBTAG00000019253 508165 RPL36A 2 Blue 0.270377729 Up 5.49E-03 
ENSBTAG00000009345 515126 AMZ2 2 Blue 0.250189075 Up 5.57E-03 
ENSBTAG00000015117 504718 GADD45GIP1 2 Blue 0.257240504 Up 5.71E-03 
ENSBTAG00000019701 534279 RPL31 2 Blue 0.296147273 Up 5.72E-03 
ENSBTAG00000048280 100190887 C5H12orf73 2 Blue 0.360233656 Up 5.80E-03 
ENSBTAG00000011374 539123 S1PR3 2 Blue 0.480055347 Up 5.80E-03 
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ENSBTAG00000021188 538054 MRPL16 2 Blue 0.249112884 Up 5.93E-03 
ENSBTAG00000008977 505031 TOMM6 2 Blue 0.222952939 Up 6.06E-03 
ENSBTAG00000015006 515990 MRPL11 2 Blue 0.236624043 Up 6.26E-03 
ENSBTAG00000001948 780809 VTI1B 2 Blue 0.263871642 Up 6.26E-03 
ENSBTAG00000045943 281689 CHRNG 2 Blue 0.926233662 Up 6.26E-03 
ENSBTAG00000029906 100313253 MIR133A-2 2 Blue 0.679429863 Up 6.44E-03 
ENSBTAG00000047954 100125581 ZNF75D 2 Blue 0.26631037 Up 6.57E-03 
ENSBTAG00000016676 782020 PTER 2 Blue 0.276505348 Up 6.59E-03 
ENSBTAG00000000943 789857 ZNF286A 2 Blue 0.263915661 Up 6.70E-03 
ENSBTAG00000027772 282052 RPS25 2 Blue 0.280949362 Up 6.74E-03 
ENSBTAG00000004799 512632 DENND2A 2 Blue 0.372041764 Up 7.01E-03 
ENSBTAG00000025666 286884 RPS29 2 Blue 0.352243536 Up 7.14E-03 
ENSBTAG00000016224 505507 RPS7 2 Blue 0.294358257 Up 7.21E-03 
ENSBTAG00000038351 -- -- 2 Blue 0.580609225 Up 7.30E-03 
ENSBTAG00000019648 327682 GNB2L1 2 Blue 0.275931648 Up 7.35E-03 
ENSBTAG00000019543 617277 TCEB2 2 Blue 0.219256592 Up 7.43E-03 
ENSBTAG00000005536 282462 MEA1 2 Blue 0.292504883 Up 7.60E-03 
ENSBTAG00000031682 538489 ZNF484 2 Blue 0.665225799 Up 7.66E-03 
ENSBTAG00000021720 510058 MRPL27 2 Blue 0.257785785 Up 7.86E-03 
ENSBTAG00000004328 511215 CHST10 2 Blue 0.272854482 Up 7.86E-03 
ENSBTAG00000002060 100336099 RPL19 2 Blue 0.289254448 Up 7.86E-03 
ENSBTAG00000000825 516004 MRPS26 2 Blue 0.36612885 Up 7.86E-03 
ENSBTAG00000012649 613630 LSM8 2 Blue 0.272640407 Up 7.88E-03 
ENSBTAG00000025211 513047 ING1 2 Blue 0.24865469 Up 8.13E-03 
ENSBTAG00000006881 353217 SLC35B1 2 Blue 0.233888201 Up 8.24E-03 
ENSBTAG00000011249 789811 MOB2 2 Blue 0.273395075 Up 8.52E-03 
ENSBTAG00000002575 614837 SSU72 2 Blue 0.237520252 Up 8.69E-03 
ENSBTAG00000001360 326582 RPS12 2 Blue 0.283825033 Up 9.25E-03 
ENSBTAG00000032869 100140137 RNASE10 2 Blue 0.558362347 Up 9.31E-03 
ENSBTAG00000012044 508221 RPL13 2 Blue 0.306300501 Up 9.33E-03 
ENSBTAG00000016278 513031 RPL30 2 Blue 0.264727481 Up 9.37E-03 
ENSBTAG00000011902 533602 WASH1 2 Blue 0.247338227 Up 9.42E-03 
ENSBTAG00000005349 404190 RPL27A 2 Blue 0.266322655 Up 9.51E-03 
ENSBTAG00000016522 509050 C21H15orf40 2 Blue 0.323089062 Up 9.67E-03 
ENSBTAG00000000542 513777 CFAP36 2 Blue 0.311512215 Up 9.84E-03 
ENSBTAG00000047051 -- -- 2 Blue 0.458972257 Up 9.84E-03 
ENSBTAG00000046561 540095 LCORL 2 Blue 0.451480798 Up 9.94E-03 
ENSBTAG00000037440 100847180 LOC100847180 2 Blue 0.302062915 Up 9.95E-03 
ENSBTAG00000004688 533726 DHCR24 3 Brown -0.863832111 Down 2.32E-09 
ENSBTAG00000017567 281590 ACACA 3 Brown -1.368335908 Down 7.47E-07 
ENSBTAG00000015690 510990 PLIN4 3 Brown -0.743603703 Down 8.61E-07 
ENSBTAG00000016223 534933 SCRN1 3 Brown -1.091908668 Down 1.56E-06 
ENSBTAG00000001368 531137 LGALS3BP 3 Brown -0.843891403 Down 2.62E-06 
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ENSBTAG00000003359 617293 ELOVL5 3 Brown -0.993419653 Down 3.87E-06 
ENSBTAG00000047957 101906058 LOC101906058 3 Brown -1.70506312 Down 4.72E-06 
ENSBTAG00000045728 280924 SCD 3 Brown -1.743882012 Down 5.63E-06 
ENSBTAG00000015919 518368 PARM1 3 Brown -0.794574276 Down 5.63E-06 
ENSBTAG00000019512 281179 G6PD 3 Brown -1.228887057 Down 1.13E-05 
ENSBTAG00000040490 509875 CCDC3 3 Brown -1.259034243 Down 1.60E-05 
ENSBTAG00000015980 281152 FASN 3 Brown -1.444364452 Down 1.75E-05 
ENSBTAG00000001942 513214 SNX27 3 Brown -0.385065829 Down 2.21E-05 
ENSBTAG00000016740 511135 ACLY 3 Brown -1.196494184 Down 3.15E-05 
ENSBTAG00000021029 505048 PRR5L 3 Brown -1.575012445 Down 4.12E-05 
ENSBTAG00000013303 506459 ACSS2 3 Brown -1.157317025 Down 4.22E-05 
ENSBTAG00000002983 504454 NT5C1A 3 Brown -0.414075068 Down 4.28E-05 
ENSBTAG00000019379 527604 TUSC5 3 Brown -1.554809854 Down 8.46E-05 
ENSBTAG00000005523 541295 XYLT1 3 Brown -0.828089102 Down 9.58E-05 
ENSBTAG00000004432 540275 CHRDL1 3 Brown -0.891395132 Down 9.59E-05 
ENSBTAG00000008528 282476 SLC25A1 3 Brown -0.741385889 Down 1.04E-04 
ENSBTAG00000020527 281235 IDH1 3 Brown -0.800676683 Down 1.07E-04 
ENSBTAG00000012338 508724 FAH 3 Brown -0.786588946 Down 1.19E-04 
ENSBTAG00000004063 338050 SERPINA5 3 Brown -0.636889477 Down 1.48E-04 
ENSBTAG00000018566 282069 SFRP5 3 Brown -1.121721984 Down 1.51E-04 
ENSBTAG00000012012 281110 CYB5A 3 Brown -0.638090292 Down 1.58E-04 
ENSBTAG00000011666 515940 THRSP 3 Brown -1.749111258 Down 2.32E-04 
ENSBTAG00000013527 514939 PGD 3 Brown -0.724377724 Down 2.73E-04 
ENSBTAG00000011839 407767 HMGCS1 3 Brown -0.39148792 Down 2.90E-04 
ENSBTAG00000015241 511716 EPHX2 3 Brown -0.830654362 Down 3.07E-04 
ENSBTAG00000010564 533333 ELOVL6 3 Brown -1.640910767 Down 3.11E-04 
ENSBTAG00000007969 534607 CIDEC 3 Brown -1.456953367 Down 4.60E-04 
ENSBTAG00000015350 520598 PLIN1 3 Brown -1.13324779 Down 5.25E-04 
ENSBTAG00000014611 533166 SORL1 3 Brown -0.752041543 Down 5.48E-04 
ENSBTAG00000020313 538717 FNBP1 3 Brown -0.666008614 Down 5.75E-04 
ENSBTAG00000010464 786290 MN1 3 Brown -0.491301231 Down 6.24E-04 
ENSBTAG00000004246 541220 H6PD 3 Brown -0.598845395 Down 6.98E-04 
ENSBTAG00000038321 286879 LIPE 3 Brown -1.014646839 Down 7.63E-04 
ENSBTAG00000004035 516333 SDK1 3 Brown -0.675741095 Down 7.63E-04 
ENSBTAG00000010125 282376 STAT5B 3 Brown -0.315837608 Down 7.63E-04 
ENSBTAG00000002714 281790 GNAI1 3 Brown -0.80082711 Down 8.76E-04 
ENSBTAG00000006035 282459 PPP1R1B 3 Brown -0.703459297 Down 8.76E-04 
ENSBTAG00000004368 541127 NFATC3 3 Brown -0.284981167 Down 8.85E-04 
ENSBTAG00000030599 508379 SMOC1 3 Brown -0.795125821 Down 1.02E-03 
ENSBTAG00000014911 280836 LEP 3 Brown -1.960004869 Down 1.02E-03 
ENSBTAG00000018082 614254 QPRT 3 Brown -1.112329726 Down 1.02E-03 
ENSBTAG00000010677 535165 LIMCH1 3 Brown -0.505730645 Down 1.10E-03 
ENSBTAG00000012540 280801 GAT 3 Brown -1.678246211 Down 1.10E-03 
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ENSBTAG00000039231 615685 MTURN 3 Brown -0.590798849 Down 1.17E-03 
ENSBTAG00000046708 100299267 PDP2 3 Brown -0.935560633 Down 1.19E-03 
ENSBTAG00000025868 783470 TLN1 3 Brown -0.357116061 Down 1.29E-03 
ENSBTAG00000011934 282856 PCK2 3 Brown -1.490969714 Down 1.36E-03 
ENSBTAG00000025496 508954 SORD 3 Brown -0.708437815 Down 1.36E-03 
ENSBTAG00000005144 508493 PNPLA2 3 Brown -0.412156984 Down 1.39E-03 
ENSBTAG00000010742 521231 PKD2L1 3 Brown -1.763316562 Down 1.43E-03 
ENSBTAG00000015419 526631 ARHGEF37 3 Brown -0.563006526 Down 1.43E-03 
ENSBTAG00000038116 511904 TGOLN2 3 Brown -0.382778307 Down 1.51E-03 
ENSBTAG00000046547 -- -- 3 Brown -1.393729124 Down 1.56E-03 
ENSBTAG00000013099 504584 ALDOC 3 Brown -0.755307187 Down 1.58E-03 
ENSBTAG00000003192 512099 TBC1D16 3 Brown -0.443884918 Down 1.69E-03 
ENSBTAG00000016864 512242 LBP 3 Brown -1.173571107 Down 1.95E-03 
ENSBTAG00000004278 535740 APMAP 3 Brown -0.583980996 Down 1.97E-03 
ENSBTAG00000001154 404129 DGAT2 3 Brown -1.185997677 Down 2.19E-03 
ENSBTAG00000013943 782419 ZNF703 3 Brown -0.436077405 Down 2.34E-03 
ENSBTAG00000035998 516210 CKB 3 Brown -1.356452089 Down 2.34E-03 
ENSBTAG00000017594 512451 ZHX3 3 Brown -0.369010054 Down 2.47E-03 
ENSBTAG00000005218 533323 PDE3B 3 Brown -0.986885093 Down 2.56E-03 
ENSBTAG00000039366 515418 LOC515418 3 Brown -0.822989072 Down 2.58E-03 
ENSBTAG00000007806 541099 MTPN 3 Brown -0.321237084 Down 2.85E-03 
ENSBTAG00000005710 281941 NCAM1 3 Brown -0.661146549 Down 3.08E-03 
ENSBTAG00000003758 445425 TKT 3 Brown -0.746972962 Down 3.12E-03 
ENSBTAG00000019343 286808 MDFI 3 Brown -1.282815408 Down 3.34E-03 
ENSBTAG00000009570 101902412 C7H19orf80 3 Brown -1.705800679 Down 3.44E-03 
ENSBTAG00000003457 515654 ATF5 3 Brown -0.830488573 Down 3.52E-03 
ENSBTAG00000007773 282118 VCAM1 3 Brown -0.664957127 Down 3.52E-03 
ENSBTAG00000014103 512450 SH3GL2 3 Brown -1.105876706 Down 3.70E-03 
ENSBTAG00000020936 444867 NOD2 3 Brown -0.641417496 Down 4.08E-03 
ENSBTAG00000047766 507436 G0S2 3 Brown -1.133888681 Down 4.35E-03 
ENSBTAG00000007731 -- -- 3 Brown -0.321904483 Down 4.35E-03 
ENSBTAG00000022255 280675 AR 3 Brown -0.485535354 Down 4.37E-03 
ENSBTAG00000009711 504844 RPA1 3 Brown -0.27254934 Down 4.40E-03 
ENSBTAG00000000081 286797 COL4A3BP 3 Brown -0.267489888 Down 4.57E-03 
ENSBTAG00000005678 505842 AACS 3 Brown -0.544071045 Down 4.61E-03 
ENSBTAG00000037526 281759 FABP4 3 Brown -1.208978315 Down 4.73E-03 
ENSBTAG00000047609 527051 CIDEA 3 Brown -1.32563749 Down 5.48E-03 
ENSBTAG00000021934 614455 RETSAT 3 Brown -0.572625819 Down 5.48E-03 
ENSBTAG00000014979 526668 MFSD12 3 Brown -0.44778668 Down 5.48E-03 
ENSBTAG00000021338 514557 OAF 3 Brown -0.498923466 Down 5.49E-03 
ENSBTAG00000004172 514102 SETD1B 3 Brown -0.355819598 Down 5.57E-03 
ENSBTAG00000015406 535628 ZNF750 3 Brown -0.79278699 Down 5.72E-03 
ENSBTAG00000016412 527124 CDKN2B 3 Brown -1.293900829 Down 6.32E-03 
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ENSBTAG00000018413 506745 FAM46B 3 Brown -0.546192558 Down 6.39E-03 
ENSBTAG00000005359 534069 TGFB2 3 Brown -0.398646085 Down 6.44E-03 
ENSBTAG00000000422 101905039 TSHZ1 3 Brown -0.344065208 Down 6.47E-03 
ENSBTAG00000008541 493719 MGST1 3 Brown -0.938614324 Down 6.55E-03 
ENSBTAG00000038323 281787 GLYAT 3 Brown -1.523271516 Down 6.68E-03 
ENSBTAG00000023907 508076 COL18A1 3 Brown -0.52102212 Down 6.90E-03 
ENSBTAG00000001592 511899 INSIG1 3 Brown -0.740704689 Down 7.09E-03 
ENSBTAG00000010264 789838 FBXL18 3 Brown -0.391486992 Down 7.09E-03 
ENSBTAG00000003568 506545 CLDN10 3 Brown -1.679675782 Down 7.93E-03 
ENSBTAG00000017020 281658 S100G 3 Brown -1.233116602 Down 7.99E-03 
ENSBTAG00000018460 520133 ADAMTS16 3 Brown -1.025211102 Down 7.99E-03 
ENSBTAG00000009543 520669 ESYT1 3 Brown -0.392247217 Down 8.14E-03 
ENSBTAG00000026376 615361 SNN 3 Brown -0.46528862 Down 8.52E-03 
ENSBTAG00000006689 538466 TECTB 3 Brown -1.750994364 Down 9.33E-03 
ENSBTAG00000001333 281993 PPARG 3 Brown -0.714954918 Down 9.43E-03 
ENSBTAG00000020985 282105 TYRP1 4 Yellow 0.992535936 Up 4.75E-05 
ENSBTAG00000012926 616003 TM6SF1 4 Yellow 0.382185448 Up 1.90E-04 
ENSBTAG00000010910 617407 MYEOV2 4 Yellow 0.276762218 Up 2.18E-03 
ENSBTAG00000007812 338084 NDUFA13 4 Yellow 0.282842518 Up 3.52E-03 
ENSBTAG00000004348 618609 MRPL21 4 Yellow 0.316018745 Up 3.52E-03 
ENSBTAG00000006342 327699 ATPIF1 4 Yellow 0.332978659 Up 5.02E-03 
ENSBTAG00000002094 506492 ATP5J2 4 Yellow 0.345925692 Up 5.39E-03 
ENSBTAG00000014130 614700 MGC148714 4 Yellow 0.315517335 Up 5.63E-03 
ENSBTAG00000008314 286840 SDHB 4 Yellow 0.270540768 Up 5.79E-03 
ENSBTAG00000015156 327690 NDUFB1 4 Yellow 0.282402545 Up 6.09E-03 
ENSBTAG00000039582 282289 NDUFC1 4 Yellow 0.306155506 Up 6.74E-03 
ENSBTAG00000017496 338040 ATP5I 4 Yellow 0.286576461 Up 7.77E-03 
ENSBTAG00000005868 533227 HEBP1 4 Yellow 0.687419048 Up 8.41E-03 
ENSBTAG00000017298 533224 AAMDC 4 Yellow 0.26762301 Up 8.49E-03 
ENSBTAG00000008390 613403 DNAJC10 4 Yellow 0.230148065 Up 9.46E-03 
ENSBTAG00000011256 537282 MYO1B 5 Green 0.425264938 Up 6.36E-05 
ENSBTAG00000033089 615191 PTPLA 5 Green 0.367188369 Up 4.18E-04 
ENSBTAG00000002000 618131 TIMM8B 5 Green 0.318761049 Up 7.22E-04 
ENSBTAG00000009689 541216 RWDD1 5 Green 0.321125306 Up 7.22E-04 
ENSBTAG00000033284 616237 CHCHD7 5 Green 0.287657998 Up 2.47E-03 
ENSBTAG00000011528 615202 SMIM11 5 Green 0.287816579 Up 2.58E-03 
ENSBTAG00000006970 509966 OLA1 5 Green 0.289546548 Up 3.43E-03 
ENSBTAG00000002137 515509 SUGT1 5 Green 0.294948542 Up 5.54E-03 
ENSBTAG00000024561 326601 H3F3A 5 Green 0.255692807 Up 6.57E-03 
ENSBTAG00000014891 507066 SRSF7 5 Green 0.252240069 Up 9.55E-03 
ENSBTAG00000034496 101907965 LOC101907965 5 Green 0.239502889 Up 9.63E-03 
ENSBTAG00000020346 615530 CCDC92 6 Red 0.447687269 Up 8.30E-07 
ENSBTAG00000013799 783612 LOC783612 6 Red 0.81881734 Up 8.76E-04 
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ENSBTAG00000046548 404124 ST6GALNAC4 6 Red 0.388463515 Up 1.36E-03 
ENSBTAG00000020477 539220 AHSA1 6 Red 0.269140956 Up 2.77E-03 
ENSBTAG00000002716 516314 NOL10 6 Red 0.488106197 Up 3.33E-03 
ENSBTAG00000021611 614192 C15H11orf74 6 Red 0.309024672 Up 4.89E-03 
ENSBTAG00000018071 505645 TMOD4 6 Red 0.321213091 Up 4.96E-03 
ENSBTAG00000038652 510193 LOC510193 6 Red 0.46169791 Up 5.23E-03 
ENSBTAG00000013750 100125310 B3GALNT2 6 Red 0.379485619 Up 7.86E-03 
ENSBTAG00000021549 618691 PHPT1 6 Red 0.25551778 Up 7.94E-03 
ENSBTAG00000016133 509115 MRPS7 6 Red 0.238460897 Up 8.55E-03 
ENSBTAG00000011515 281485 SELL 7 Black -1.189832505 Down 4.72E-06 
ENSBTAG00000020054 537922 TNFRSF21 7 Black -0.595278659 Down 1.90E-04 
ENSBTAG00000007103 281874 ITGAL 7 Black -0.771305576 Down 2.93E-04 
ENSBTAG00000046324 100297676 LOC100297676 7 Black -0.80344395 Down 3.12E-04 
ENSBTAG00000023144 407152 PTPRC 7 Black -0.747028015 Down 4.95E-04 
ENSBTAG00000007079 540990 LCP1 7 Black -0.701414098 Down 5.50E-04 
ENSBTAG00000031851 617434 SELPLG 7 Black -0.716931492 Down 6.03E-04 
ENSBTAG00000026326 614645 SPN 7 Black -0.697189503 Down 6.60E-04 
ENSBTAG00000001785 505080 TGM3 7 Black -0.821227482 Down 7.13E-04 
ENSBTAG00000019686 513641 NCKAP1L 7 Black -0.599151771 Down 1.00E-03 
ENSBTAG00000031160 789205 IGLL1 7 Black -0.905893334 Down 1.76E-03 
ENSBTAG00000047700 524810 LOC524810 7 Black -1.260100809 Down 2.58E-03 
ENSBTAG00000006984 518609 CD55 7 Black -0.632436414 Down 2.58E-03 
ENSBTAG00000014237 517887 CYTH4 7 Black -0.647894178 Down 3.50E-03 
ENSBTAG00000020872 493645 C5AR1 7 Black -0.900431428 Down 3.68E-03 
ENSBTAG00000027051 518283 PTAFR 7 Black -0.739868753 Down 4.90E-03 
ENSBTAG00000021709 507100 SPI1 7 Black -0.540563617 Down 4.96E-03 
ENSBTAG00000003305 281345 NCF1 7 Black -0.716535451 Down 4.97E-03 
ENSBTAG00000019428 407771 CCR1 7 Black -0.710188538 Down 5.02E-03 
ENSBTAG00000004767 515515 SYK 7 Black -0.791155414 Down 5.49E-03 
ENSBTAG00000007828 513589 SLA 7 Black -0.620901872 Down 5.69E-03 
ENSBTAG00000000431 -- -- 7 Black -0.940444767 Down 5.93E-03 
ENSBTAG00000031814 514346 SDS 7 Black -0.598487601 Down 6.57E-03 
ENSBTAG00000016004 516540 METAP1 7 Black -0.270368867 Down 6.57E-03 
ENSBTAG00000013334 511511 CSF3R 7 Black -0.697493696 Down 7.86E-03 
ENSBTAG00000017328 404103 LOC404103 7 Black -0.697484003 Down 7.86E-03 
ENSBTAG00000011146 614242 RAB8B 7 Black -0.24602265 Down 7.86E-03 
ENSBTAG00000003326 539780 NAIP 7 Black -0.612305753 Down 8.92E-03 
ENSBTAG00000017875 538835 ARHGAP30 7 Black -0.53669027 Down 8.99E-03 
ENSBTAG00000006661 538477 RALA 8 Pink 0.357067559 Up 3.86E-03 
ENSBTAG00000009042 541097 ATXN7L2 8 Pink 0.368528928 Up 5.02E-03 
ENSBTAG00000032021 505238 RALB 8 Pink 0.272648927 Up 5.79E-03 
ENSBTAG00000012805 526460 TSPAN13 8 Pink 0.310973656 Up 8.23E-03 
ENSBTAG00000004720 -- -- 9 Magenta -0.861163548 Down 3.30E-05 
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ENSBTAG00000046671 100298456 WFS1 9 Magenta -0.745691131 Down 8.46E-05 
ENSBTAG00000007159 407238 ESR1 9 Magenta -0.576014782 Down 1.43E-04 
ENSBTAG00000006037 534658 WISP2 9 Magenta -0.965019878 Down 2.16E-04 
ENSBTAG00000010647 505824 NTRK2 9 Magenta -1.00315359 Down 3.81E-04 
ENSBTAG00000010830 533894 LRP1 9 Magenta -0.474938277 Down 1.03E-03 
ENSBTAG00000010793 515235 CCDC80 9 Magenta -0.490489715 Down 1.46E-03 
ENSBTAG00000015536 615304 CPNE3 9 Magenta -0.373058184 Down 2.22E-03 
ENSBTAG00000030845 -- -- 9 Magenta -0.712416408 Down 3.78E-03 
ENSBTAG00000047998 -- -- 9 Magenta -0.36860631 Down 4.78E-03 
ENSBTAG00000006276 511774 C1QTNF1 9 Magenta -0.453441396 Down 6.84E-03 
ENSBTAG00000037508 537712 EBF1 9 Magenta -0.529930744 Down 7.43E-03 
ENSBTAG00000006222 506114 TFDP2 10 Purple -0.393344222 Down 7.98E-06 
ENSBTAG00000013555 539315 ACVR1B 10 Purple -0.496306537 Down 1.07E-04 
ENSBTAG00000001468 540852 SAMD4A 10 Purple -0.382878663 Down 1.07E-04 
ENSBTAG00000014667 789468 PAIP2B 10 Purple -0.457194637 Down 1.43E-04 
ENSBTAG00000015369 539519 MLLT11 10 Purple -1.367820516 Down 1.48E-04 
ENSBTAG00000004189 783217 MLXIP 10 Purple -0.427259156 Down 1.90E-04 
ENSBTAG00000011772 -- -- 10 Purple -0.366304603 Down 6.60E-04 
ENSBTAG00000020835 507534 KIAA0513 10 Purple -0.46086336 Down 1.42E-03 
ENSBTAG00000027868 505383 LOC505383 10 Purple -0.613366618 Down 5.79E-03 
ENSBTAG00000035081 101902670 LOC101902670 10 Purple -0.283727251 Down 6.30E-03 
ENSBTAG00000047174 -- -- 10 Purple -0.338736626 Down 9.94E-03 
ENSBTAG00000043563 3283887 ND5 11 GreenYellow -0.909914806 Down 6.64E-10 
ENSBTAG00000043546 3283888 ND6 11 GreenYellow -0.982232401 Down 1.22E-09 
ENSBTAG00000043559 3283885 ND4L 11 GreenYellow -0.904172458 Down 3.45E-09 
ENSBTAG00000043564 3283881 ATP8 11 GreenYellow -0.824001853 Down 1.35E-06 
ENSBTAG00000010334 506884 SYTL3 11 GreenYellow -0.920687739 Down 2.18E-06 
ENSBTAG00000043558 3283877 ND1 11 GreenYellow -0.662009922 Down 2.38E-06 
ENSBTAG00000043577 3283886 ND4 11 GreenYellow -0.633578483 Down 3.10E-06 
ENSBTAG00000043571 3283878 ND2 11 GreenYellow -0.693024158 Down 3.69E-06 
ENSBTAG00000002623 534171 SAMSN1 11 GreenYellow -0.967561811 Down 3.76E-05 
ENSBTAG00000015297 100299906 BANK1 11 GreenYellow -2.263315157 Down 4.22E-05 
ENSBTAG00000043550 3283889 CYTB 11 GreenYellow -0.574503441 Down 6.15E-05 
ENSBTAG00000043561 3283879 COX1 11 GreenYellow -0.532652992 Down 1.21E-04 
ENSBTAG00000043584 3283882 ATP6 11 GreenYellow -0.549268133 Down 1.25E-04 
ENSBTAG00000043556 3283880 COX2 11 GreenYellow -0.46822429 Down 5.59E-04 
ENSBTAG00000002175 505945 SRPK2 11 GreenYellow -0.361423289 Down 7.63E-04 






Table 2. Correlation coefficients between module eigengene values and genotype. 
 
Module Pearson’s correlation (r) P-Value 
Turquoise -0.87 2.00E-08 
Green-yellow -0.86 6.00E-08 
Purple -0.80 2.00E-06 
Brown -0.78 8.00E-06 
Black -0.75 3.00E-05 
Magenta -0.67 4.00E-04 
Yellow 0.73 6.00E-05 
Pink 0.74 4.00E-05 
Red 0.77 1.00E-05 
Green 0.78 8.00E-06 

















Table 3. Significant GO BP overrepresented terms (P-value < 0.01) for the list of DEG. Count represents the 
number of DEG associated with each term. 
 
GOBPID P-value Count Term Genes 
GO:0006518 1.06E-06 34 peptide metabolic process 
IDH1, RPS3A, RPS28, RPS29, RPS12, RPS3, RPS18, 
GNB2L1, RPS15A, NDUFA7, RPL27A, NOD2, RPS7, 
RPL23A, RPL36A, RPL13, MCTS1, MRPS7, MRPL27, 
RPL6, RPL30, RPS20, RPL7, RPL5, MRPL11, MRPS26, 
EEF1B2, IDE, RPS24, RPLP1, RPL31, MRPL16, RPS23, 
RPS4X 
GO:0043604 2.69E-06 32 amide biosynthetic process 
RPS3A, RPS28, RPS29, RPS12, RPS3, RPS18, GNB2L1, 
RPS15A, NDUFA7, RPL27A, NOD2, RPS7, RPL23A, 
RPL36A, RPL13, MCTS1, MRPS7, MRPL27, RPL6, 
RPL30, RPS20, RPL7, RPL5, MRPL11, MRPS26, 
EEF1B2, RPS24, RPLP1, RPL31, MRPL16, RPS23, 
RPS4X 
GO:1901566 2.65E-05 41 organonitrogen compound biosynthetic process 
ACACA, RPS3A, RPS28, RPS29, RPS12, RPS3, RPS18, 
GNB2L1, ATPIF1, ATP8, ATP6, RPS15A, ATP5I, 
NDUFA7, RPL27A, NOD2, RPS7, ATP5J2, RPL23A, 
RPL36A, RPL13, MCTS1, MRPS7, MRPL27, RPL6, 
PNPO, RPL30, RPS20, RPL7, RPL5, MRPL11, MRPS26, 
EEF1B2, RPS24, RPLP1, TGFB2, RPL31, MRPL16, 
RPS23, RPS4X, QPRT 
GO:0006412 8.90E-05 25 translation 
RPS3A, RPS28, RPS29, RPS12, RPS3, RPS18, GNB2L1, 
RPS15A, NDUFA7, RPS7, RPL23A, RPL36A, RPL13, 
MRPS7, MRPL27, RPS20, RPL5, MRPL11, MRPS26, 
EEF1B2, RPS24, RPLP1, MRPL16, RPS23, RPS4X 
GO:0044281 9.88E-05 46 small molecule metabolic process 
C3, CA2, LEP, SCD, FASN, IDH1, IGF2, LDLR, NCF1, 
ACACA, GLYAT, PLA2G15, STAT5B, SDHB, LIPE, 
PFKFB2, GNB2L1, HINT1, ATPIF1, ND2, COX1, ATP8, 
ATP6, ND4L, ND4, ND5, CYTB, ATP5I, NDUFA7, 
DGAT2, ATP5J2, FAH, SORD, ISYNA1, OLA1, ACLY, 
INSIG1, PNPO, ACOX1, SDS, PTGDR, PTAFR, 
MACROD1, QPRT, ELOVL5, LOC782922 
GO:0002181 3.23E-04 6 cytoplasmic translation RPL27A, MCTS1, RPL6, RPL30, RPL7, RPL31 
GO:0010876 3.88E-04 10 lipid localization C3, LDLR, PPARG, STAT5B, COL4A3BP, SERPINA5, DGAT2, PNPLA2, FITM1, LBP 
GO:1901564 4.44E-04 18 organonitrogen compound metabolic process 
GLYAT, PLA2G15, STAT5B, COL4A3BP, PFKFB2, 
HINT1, ND2, COX1, ND4L, ND4, ND5, CYTB, BTBD9, 
FAH, OLA1, SDS, PTGDR, MACROD1 
GO:0032787 4.81E-04 16 monocarboxylic acid metabolic process 
C3, LEP, SCD, FASN, IDH1, NCF1, ACACA, GLYAT, 
PLA2G15, STAT5B, PFKFB2, INSIG1, ACOX1, SDS, 
ELOVL5, LOC782922 
GO:0042278 4.81E-04 16 purine nucleoside metabolic process 
ACACA, PFKFB2, ND2, COX1, ATP8, ATP6, ND4L, 
ND4, ND5, CYTB, ATP5I, NDUFA7, ATP5J2, OLA1, 
PTGDR, MACROD1 
GO:0046034 6.55E-04 13 ATP metabolic process PFKFB2, ND2, COX1, ATP8, ATP6, ND4L, ND4, ND5, CYTB, ATP5I, NDUFA7, ATP5J2, OLA1 
GO:1901657 1.13E-03 16 glycosyl compound metabolic process 
ACACA, PFKFB2, ND2, COX1, ATP8, ATP6, ND4L, 
ND4, ND5, CYTB, ATP5I, NDUFA7, ATP5J2, OLA1, 
PTGDR, MACROD1 
GO:0009144 1.32E-03 13 purine nucleoside triphosphate metabolic process 
PFKFB2, ND2, COX1, ATP8, ATP6, ND4L, ND4, ND5, 
CYTB, ATP5I, NDUFA7, ATP5J2, OLA1 
GO:0009199 1.32E-03 13 ribonucleoside triphosphate metabolic process 
PFKFB2, ND2, COX1, ATP8, ATP6, ND4L, ND4, ND5, 
CYTB, ATP5I, NDUFA7, ATP5J2, OLA1 
GO:0042742 1.54E-03 5 defense response to bacterium NCF1, SERPINE1, NOD2, LBP, ROMO1 
GO:0010883 1.56E-03 4 regulation of lipid storage C3, PPARG, PNPLA2, FITM1 
GO:0009119 1.67E-03 15 ribonucleoside metabolic process 
ACACA, PFKFB2, ND2, COX1, ATP8, ATP6, ND4L, 
ND4, ND5, CYTB, ATP5I, NDUFA7, ATP5J2, OLA1, 
PTGDR 
GO:0006163 1.93E-03 16 purine nucleotide metabolic process 
ACACA, PFKFB2, GNB2L1, HINT1, ND2, COX1, ATP8, 
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GO:0009259 2.23E-03 16 ribonucleotide metabolic process 
ACACA, PFKFB2, GNB2L1, HINT1, ND2, COX1, ATP8, 
ATP6, ND4L, ND4, ND5, CYTB, ATP5I, NDUFA7, 
ATP5J2, OLA1 
GO:0006633 2.45E-03 7 fatty acid biosynthetic process LEP, SCD, FASN, ACACA, INSIG1, ELOVL5, LOC782922 
GO:0009126 2.46E-03 13 purine nucleoside monophosphate metabolic process 
PFKFB2, ND2, COX1, ATP8, ATP6, ND4L, ND4, ND5, 
CYTB, ATP5I, NDUFA7, ATP5J2, OLA1 
GO:0010891 2.53E-03 2 negative regulation of sequestering of triglyceride PPARG, PNPLA2 
GO:0046645 2.53E-03 2 positive regulation of gamma-delta T cell activation STAT5B, NOD2 
GO:0006641 2.57E-03 5 triglyceride metabolic process C3, LIPE, DGAT2, PNPLA2, INSIG1 
GO:0033559 3.23E-03 5 unsaturated fatty acid metabolic process SCD, NCF1, ACOX1, ELOVL5, LOC782922 
GO:0042773 3.25E-03 6 ATP synthesis coupled electron transport ND2, ND4L, ND4, ND5, CYTB, NDUFA7 
GO:0009161 3.41E-03 13 ribonucleoside monophosphate metabolic process 
PFKFB2, ND2, COX1, ATP8, ATP6, ND4L, ND4, ND5, 
CYTB, ATP5I, NDUFA7, ATP5J2, OLA1 
GO:0000027 4.19E-03 4 ribosomal large subunit assembly RPL23A, RPL6, RPL5, MRPL11 
GO:0044249 4.75E-03 80 cellular biosynthetic process 
USP13, C3, LEP, SCD, ARNT, FASN, IDH1, IGF2, 
NCF1, ACACA, PPARG, RPS3A, SFRP5, TYRP1, 
STAT5B, PPP1R1B, RPS28, LIPE, RPS29, YBX1, RPS12, 
RPS3, RPS18, GNB2L1, HINT1, ATPIF1, ATP8, ATP6, 
RPS15A, ATP5I, NDUFA7, NDUFA13, DGAT2, 
RPL27A, ESR1, NOD2, ETV6, LGR4, RPS7, ATP5J2, 
RPL23A, RPL36A, RPL13, MCTS1, MRPS7, ISYNA1, 
FITM1, MRPL27, RPL6, ACLY, INSIG1, PNPO, RPL30, 
RPS20, MED28, SDS, RPL7, RPL5, MRPL11, MRPS26, 
EEF1B2, RPS24, KPNA6, LOXL2, AAMDC, RPLP1, 
TGFB2, RPL31, CIDEC, ZNF750, MRPL16, MLLT11, 
RPS23, MTPN, RPS4X, QPRT, CDS2, SSU72, ELOVL5, 
LOC782922 
GO:0006638 4.92E-03 5 neutral lipid metabolic process C3, LIPE, DGAT2, PNPLA2, INSIG1 
GO:0006753 5.42E-03 18 nucleoside phosphate metabolic process 
ACACA, PFKFB2, GNB2L1, HINT1, ATPIF1, ND2, 
COX1, ATP8, ATP6, ND4L, ND4, ND5, CYTB, ATP5I, 
NDUFA7, ATP5J2, OLA1, QPRT 
GO:0022900 5.77E-03 7 electron transport chain ND2, COX2, ND4L, ND4, ND5, CYTB, NDUFA7 
GO:1901615 5.92E-03 12 organic hydroxy compound metabolic process 
LDLR, TYRP1, PLA2G15, LIPE, DGAT2, BTBD9, 
SORD, ISYNA1, INSIG1, PNPO, PTAFR, TGFB2 
GO:1901701 6.38E-03 14 cellular response to oxygen-containing compound 
IGF2, SERPINE1, PPARG, STAT5B, GNB2L1, DGAT2, 
ESR1, NOD2, LBP, FBXO32, RAB13, PTGDR, PTAFR, 
ROMO1 
GO:0071396 7.05E-03 8 cellular response to lipid SERPINE1, PPARG, DGAT2, ESR1, LBP, FBXO32, PTGDR, PTAFR 
GO:0035767 7.32E-03 2 endothelial cell chemotaxis MET, RAB13 
GO:0051901 7.32E-03 2 positive regulation of mitochondrial depolarization GNB2L1, MLLT11 
GO:0046503 8.44E-03 3 glycerolipid catabolic process PLA2G15, LIPE, PNPLA2 
GO:0006793 9.75E-03 45 phosphorus metabolic process 
C3, PPA1, MET, IDH1, IGF2, ACACA, PRKG1, 
PLA2G15, PPP1R1B, COL4A3BP, PFKFB2, GNB2L1, 
HINT1, ATPIF1, ND2, COX1, ATP8, ATP6, ND4L, ND4, 
ND5, CYTB, ATP5I, NDUFA7, DGAT2, NOD2, PRR5L, 
ATP5J2, KIAA0430, PHOSPHO2, ISYNA1, OLA1, 
FITM1, ACLY, PNPO, CKB, PTAFR, CDKN2B, WASH1, 
TGFB2, PPM1L, QPRT, CDS2, SSU72, PHPT1 
GO:0006629 9.85E-03 23 lipid metabolic process 
C3, LEP, SCD, FASN, IDH1, LDLR, NCF1, ACACA, 
PLA2G15, STAT5B, COL4A3BP, LIPE, DGAT2, 
PNPLA2, ISYNA1, FITM1, ACLY, INSIG1, ACOX1, 
WASH1, CDS2, ELOVL5, LOC782922 
 
 92 
Table 4. Significant GO MF over-represented terms (P-value < 0.01) for the list of DEG. Count represents the 
number of DEG associated with each term. 
 
GOMFID P-value Count Term 
Genes 
GO:0003735 1.34E-11 28 structural constituent of ribosome 
RPS3A, RPS28, RPS29, RPS12, RPS3, RPS18, 
RPS15A, NDUFA7, RPL27A, RPS7, RPL23A, 
RPL36A, RPL13, MRPS7, MRPL27, RPL6, 
RPL30, RPS20, RPL7, RPL5, MRPL11, 
MRPS26, RPS24, RPLP1, RPL31, MRPL16, 
RPS23, RPS4X 
GO:0003954 7.97E-06 9 NADH dehydrogenase activity NDUFB1, ND1, ND2, ND4L, ND4, ND5, ND6, NDUFA7, NDUFA13 
GO:0008137 3.81E-05 8 NADH dehydrogenase (ubiquinone) activity ND1, ND2, ND4L, ND4, ND5, ND6, NDUFA7, NDUFA13 
GO:0016655 8.80E-05 8 oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor 
ND1, ND2, ND4L, ND4, ND5, ND6, NDUFA7, 
NDUFA13 
GO:0019843 8.80E-05 8 rRNA binding LIPE, RPS18, RPL23A, MRPS7, RPL5, MRPL11, MRPL16, RPS4X 
GO:0016823 2.60E-03 2 hydrolase activity, acting on acid carbon-carbon bonds, in ketonic substances FAH, FAHD1 
GO:0017147 2.60E-03 2 Wnt-protein binding FRZB, SFRP5 
GO:0047961 2.60E-03 2 glycine N-acyltransferase activity GAT, GLYAT 
GO:0004867 5.77E-03 4 serine-type endopeptidase inhibitor activity SERPINE1, SERPINA5, TFPI2, LOC404103 
GO:0004312 7.53E-03 2 fatty acid synthase activity FASN, ELOVL5 
GO:0004857 7.71E-03 9 enzyme inhibitor activity C3, SERPINE1, PPP1R1B, GNB2L1, ATPIF1, SERPINA5, TFPI2, LOC404103, CDKN2B 
GO:0016491 8.20E-03 24 oxidoreductase activity 
SCD, FASN, IDH1, NCF1, TYRP1, SDHB, 
PDPR, NDUFB1, ND1, ND2, COX1, COX2, 
ND4L, ND4, ND5, ND6, CYTB, NDUFA7, 
NDUFA13, SORD, PNPO, ACOX1, LOXL2, 
LOC782922 
GO:0005246 8.78E-03 3 calcium channel regulator activity PRKG1, TSPAN13, PHPT1 


















Table 5. Significant GO CC over-represented terms (P-value < 0.01) for the list of DEG. Count represents the 
number of DEG associated with each term. 
 
GOCCID P-value Count Term Genes 
GO:0044391 1.83E-11 26 ribosomal subunit 
RPS25, RPS3A, RPS28, RPS12, RPS3, RPS18, RPS15A, RPL27A, RPS7, RPL23A, 
RPL36A, MCTS1, MRPS7, MRPL27, RPL6, RPL30, RPS20, RPL7, RPL5, 
MRPL11, MRPS26, RPS24, RPL31, MRPL16, RPS23, RPS4X 
GO:0022627 3.82E-10 13 cytosolic small ribosomal subunit 
RPS25, RPS3A, RPS28, RPS12, RPS3, RPS18, RPS15A, RPS7, MCTS1, RPS20, 
RPS24, RPS23, RPS4X 
GO:0005829 1.58E-05 42 cytosol 
USP13, GHR, IDH1, NCF1, ACACA, COPB2, PPARG, PRKG1, RPS25, RPS3A, 
RPS28, COL4A3BP, LIPE, RPS12, RPS3, RPS18, GNB2L1, RPS15A, RPL27A, 
ESR1, NOD2, C29H11orf73, RPS7, RPL23A, RPL36A, MCTS1, FAHD1, PFDN6, 
RPL6, RPL30, SNX27, RPS20, RPL7, RPL5, IDE, RPS24, WASH1, RPL31, 
RPS23, MTPN, RPS4X, PHPT1 
GO:0031966 7.22E-05 35 mitochondrial membrane 
NDUFC1, SLC25A1, SDHB, RPS3, NDUFB1, ND1, ND2, COX1, COX2, ATP8, 
ATP6, ND4L, ND4, ND5, ND6, CYTB, ATP5I, NDUFA7, NDUFA13, MGST1, 
TOMM6, ATP5J2, SORD, MRPS7, FAHD1, MRPL27, MRPL11, MRPS26, 
TMEM126A, MRPL16, CDS2, SNN, TIMM8B, ROMO1, MRPL21 
GO:0005739 1.91E-04 56 mitochondrion 
GAT, CYB5A, IDH1, GLYAT, PLA2G15, NDUFC1, SLC25A1, COL4A3BP, 
SDHB, PDPR, LIPE, RPS3, GNB2L1, NDUFB1, ATPIF1, ND1, ND2, COX1, 
COX2, ATP8, ATP6, ND4L, ND4, ND5, ND6, CYTB, ATP5I, NDUFA7, 
NDUFA13, DGAT2, MGST1, GADD45GIP1, TOMM6, ATP5J2, TMEM160, 
SORD, MRPS7, FAHD1, MRPL27, HDHD3, ACLY, MRPL11, MRPS26, CKB, 
IDE, TMEM126A, ACSS3, MRPL16, MACROD1, CMC2, CDS2, SNN, CHCHD7, 
TIMM8B, ROMO1, MRPL21 
GO:0019866 3.66E-04 29 organelle inner membrane 
NDUFC1, SLC25A1, SDHB, RPS3, NDUFB1, ND1, ND2, COX1, COX2, ATP8, 
ATP6, ND4, ND5, CYTB, ATP5I, NDUFA7, NDUFA13, ATP5J2, MRPS7, 
FAHD1, MRPL27, MRPL11, MRPS26, TMEM126A, MRPL16, CDS2, TIMM8B, 
ROMO1, MRPL21 
GO:0022625 4.06E-04 8 cytosolic large ribosomal subunit RPL27A, RPL23A, RPL36A, RPL6, RPL30, RPL7, RPL5, RPL31 




NDUFC1, SDHB, NDUFB1, ND1, ND2, COX1, ATP8, ATP6, ND4, ND5, ATP5I, 
ATP5J2 
GO:0031975 8.43E-04 37 envelope 
NDUFC1, SLC25A1, SDHB, RPS3, NDUFB1, ND1, ND2, COX1, COX2, ATP8, 
ATP6, ND4L, ND4, ND5, ND6, CYTB, ATP5I, NDUFA7, NDUFA13, MGST1, 
TOMM6, ATP5J2, SORD, MRPS7, FAHD1, MRPL27, MRPL11, MRPS26, 
TMEM126A, SCRN1, MRPL16, CDS2, SNN, CHCHD7, TIMM8B, ROMO1, 
MRPL21 
GO:0098803 8.59E-04 10 respiratory chain complex NDUFC1, SDHB, NDUFB1, ND1, ND2, COX1, COX2, ND4, ND5, CYTB 
GO:0045263 2.06E-03 4 
proton-transporting ATP 
synthase complex, 
coupling factor F(o) 
ATP8, ATP6, ATP5I, ATP5J2 
GO:0005746 2.34E-03 9 mitochondrial respiratory chain NDUFC1, SDHB, NDUFB1, ND1, ND2, COX1, ND4, ND5, NDUFA13 
GO:0005737 3.55E-03 154 cytoplasm 
USP13, PPA1, CA2, GAT, GHR, SCD, ARNT, CYB5A, FASN, IDH1, LDLR, 
NCF1, ACACA, COPB2, FABP4, GLYAT, GNAI1, PPARG, PRKG1, RPS25, 
RPS3A, TYRP1, PLA2G15, NDUFC1, STAT5B, PPP1R1B, SLC25A1, RPS28, 
COL4A3BP, TNS1, SDHB, PDPR, LIPE, RPS29, YBX1, SLC9A1, RPS12, RPS3, 
RPS18, GNB2L1, NDUFB1, HINT1, ATPIF1, ND1, ND2, COX1, COX2, ATP8, 
ATP6, ND4L, ND4, ND5, ND6, CYTB, RPS15A, ATP5I, SERPINA5, NDUFA7, 
NDUFA13, ACBD5, SLC35B1, DGAT2, RPL27A, ESR1, NOD2, MGST1, ETV6, 
GADD45GIP1, C29H11orf73, TOMM6, RPS7, TMOD4, ATP5J2, CLDN10, 
KIAA0430, SRSF7, RPL23A, RPL36A, RPL13, MCTS1, TMEM160, SORD, 
MRPS7, FAHD1, ISYNA1, PFDN6, OLA1, FITM1, MRPL27, HDHD3, RPL6, 
ACLY, INSIG1, PNPO, RPL30, SNX27, RPS20, KIZ, FBXO32, CFAP36, MED28, 
ACOX1, SDS, ZFYVE26, RAB13, RPL7, RPL5, SUGT1, MRPL11, MRPS26, CKB, 
METAP1, UBE4A, EEF1B2, SPAST, IDE, CDKN2B, TMEM126A, RPS24, ACSS3, 
KPNA6, AAMDC, HEBP1, RPLP1, WASH1, TGFB2, RPL31, CIDEC, SCRN1, 
APMAP, MRPL16, UBE2H, MLLT11, RPS23, MTPN, MACROD1, GKAP1, 
CMC2, RPS4X, RAB8B, CDS2, SSU72, SNN, TM6SF1, CHCHD7, ANAPC11, 
ELOVL5, UBE2S, TIMM8B, ROMO1, MRPL21, PHPT1, VTI1B, LOC78292 
GO:1990204 3.68E-03 9 oxidoreductase complex NCF1, NDUFC1, SDHB, NDUFB1, ND1, ND2, ND4, ND5, CYTB 
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Table 5. (Cont.) 
 
GOCCID P-value Count Term Genes 
GO:0016021 6.81E-03 59 integral component of membrane 
GHR, MET, SCD, ST7, CYB5A, LDLR, NCF1, SELL, CHRNG, ITGAL, NCAM1, 
TYRP1, NDUFC1, SLC25A1, SLC9A1, NDUFB1, ND1, ND2, COX1, COX2, 
ATP8, ATP6, ND4L, ND4, ND5, ND6, CYTB, CD97, NDUFA13, ACBD5, 
SLC35B1, TMEM176A, DGAT2, MGST1, LGR4, ATP5J2, CLDN10, PNPLA2, 
ABHD2, TMEM160, FITM1, INSIG1, PTGDR, PTAFR, TMEM245, SPAST, 
TSPAN13, TMEM126A, APMAP, LRRN1, PPM1L, CDS2, SMIM11, SNN, BRI3, 
TM6SF1, ELOVL5, ROMO1, VTI1B 
GO:0031932 6.99E-03 2 TORC2 complex PRR5L, RPL23A 
GO:0016020 7.72E-03 106 membrane 
CA2, GHR, MET, SCD, ST7, CYB5A, LDLR, NCF1, SELL, S100G, CHRNG, 
COPB2, GNAI1, ITGAL, NCAM1, TYRP1, NDUFC1, SLC25A1, SDHB, LIPE, 
SLC9A1, RPS12, RPS3, RPS18, GNB2L1, NDUFB1, HINT1, ND1, ND2, COX1, 
COX2, ATP8, ATP6, ND4L, ND4, ND5, ND6, CYTB, RPS15A, ATP5I, SERPINA5, 
NDUFA7, CD97, NDUFA13, ACBD5, SLC35B1, TMEM176A, DGAT2, ESR1, 
NOD2, MGST1, TOMM6, LGR4, RPS7, ATP5J2, CLDN10, KIAA0430, MCTS1, 
PNPLA2, ABHD2, TMEM160, SORD, MRPS7, FAHD1, OLA1, FITM1, MRPL27, 
ACLY, INSIG1, SNX27, RPS20, MED28, ZFYVE26, RAB13, PTGDR, MRPL11, 
MRPS26, PTAFR, TMEM245, SPAST, IDE, TSPAN13, TMEM126A, RPS24, 
LGALS3BP, KPNA6, LOXL2, WASH1, RPL31, SCRN1, APMAP, MRPL16, 
LRRN1, RPS23, PPM1L, RAB8B, CDS2, SMIM11, SNN, BRI3, TM6SF1, ELOVL5, 






























Table 6. Significant GO BP over-represented terms for WGCNA Blue module (P-value < 0.01). Count 
represents the total number of genes associated with each term (including not DEG present in the module).  
 
GOBPID P-value Count Term Genes 
GO:0043604 4.43E-38 106 amide biosynthetic process 
RPSA, RPL24, RPS3A, RPS28, RPL9, RPL10, RPS27A, RPS29, 
EEF1G, RPS12, RPS3, RPS18, GNB2L1, RPS15A, RPL26, NDUFA7, 
RPL12, RPL27, RPS8, RPL18A, RPL27A, RPL37A, RPL23, RPS7, 
MRPS2, MRPL9, RPS5, RPS16, MRPL20, CARS2, MRPL55, RPL35A, 
EIF3H, RPL15, RPL23A, RPL29, CNOT7, RPL36A, RPL13, MCTS1, 
DHFR, RPL18, RPS26, MRPL52, EIF1, MRPL27, MRPL37, RPL4, 
MRPS16, RPL6, EIF2D, RPL11, RPL30, RPS20, MRPL51, RPL17, 
ASNS, RPS15, METTL17, RPL7, RPL5, EIF3K, RPL35, MRPL11, 
MRPS26, RPS19, MRPS30, EEF1D, EEF1B2, AIMP2, EIF2B4, 
SERP1, RPS24, MRPL24, RPLP1, RPL10A, RPS9, RPL31, MRPL18, 
RPL8, RPS13, MRPL16, RPS11, RPL14, COA3, RPS23, NPM1, 
RPS4X, MRPL14, MRPL22, RPS21, UBA52, RPL38, RPL32, RPS27, 
EIF3G, GATC, MRPL13, MRPS34, RPL28, RPL13A, RPL37, RPL36, 
RSL24D1, RPS6, RPS17 
GO:0006412 2.67E-37 65 translation 
RPSA, RPL24, RPS3A, RPS28, RPL10, RPS27A, RPS29, RPS12, 
RPS18, RPS15A, RPL12, RPL27, RPS8, RPL18A, RPL37A, RPL23, 
RPS7, MRPL9, RPS16, MRPL20, CARS2, MRPL55, EIF3H, RPL23A, 
RPL36A, RPL13, RPL18, RPS26, MRPL52, EIF1, MRPL27, MRPL37, 
RPL11, RPS20, RPS15, METTL17, RPL5, RPL35, MRPL11, RPS19, 
MRPS30, AIMP2, EIF2B4, RPS24, MRPL24, RPL10A, MRPL18, 
RPS13, RPS11, RPL14, RPS23, RPS4X, MRPL14, MRPL22, RPS21, 
UBA52, RPL38, RPL32, RPS27, MRPL13, RPL28, RPL37, RSL24D1, 
RPS6, RPS17 
GO:0006518 1.58E-35 106 peptide metabolic process 
RPSA, RPL24, RPS3A, RPS28, RPL9, RPL10, RPS27A, RPS29, 
EEF1G, RPS12, RPS3, RPS18, GNB2L1, RPS15A, RPL26, NDUFA7, 
RPL12, RPL27, RPS8, RPL18A, RPL27A, RPL37A, RPL23, RPS7, 
MRPS2, MRPL9, RPS5, RPS16, MRPL20, CARS2, MRPL55, RPL35A, 
EIF3H, RPL15, RPL23A, RPL29, CNOT7, RPL36A, RPL13, MCTS1, 
RPL18, RPS26, MRPL52, EIF1, MRPL27, MRPL37, RPL4, MRPS16, 
RPL6, EIF2D, RPL11, RPL30, RPS20, MRPL51, RPL17, RPS15, 
METTL17, RPL7, RPL5, EIF3K, RPL35, MRPL11, MRPS26, RPS19, 
MRPS30, EEF1D, EEF1B2, AIMP2, EIF2B4, SERP1, RPS24, 
MRPL24, RPLP1, RPL10A, RPS9, GSTA4, RPL31, MRPL18, RPL8, 
RPS13, MRPL16, RPS11, RPL14, COA3, RPS23, NPM1, RPS4X, 
MRPL14, MRPL22, RPS21, UBA52, RPL38, RPL32, RPS27, EIF3G, 
GATC, MRPL13, MRPS34, RPL28, RPL13A, RPL37, RPL36, GSTA3, 
RSL24D1, RPS6, RPS17 
GO:1901566 1.33E-25 117 organonitrogen compound biosynthetic process 
EDNRA, GNAS, RPSA, RPL24, RPS3A, AQP1, RPS28, RPL9, RPL10, 
RPS27A, RPS29, EEF1G, RPS12, RPS3, RPS18, GNB2L1, RPS15A, 
RPL26, NDUFA7, RPL12, RPL27, RPS8, RPL18A, RPL27A, RPL37A, 
RPL23, RPS7, MRPS2, MRPL9, RPS5, RPS16, MRPL20, CARS2, 
MRPL55, RPL35A, EIF3H, RPL15, RPL23A, RPL29, CNOT7, 
RPL36A, RPL13, MCTS1, RPL18, RPS26, MRPL52, EIF1, MRPL27, 
MRPL37, STOML2, RPL4, MRPS16, ADSL, RPL6, PARK7, EIF2D, 
RPL11, RPL30, RPS20, MRPL51, RPL17, ASNS, RPS15, METTL17, 
RPL7, RPL5, EIF3K, UQCC3, RPL35, HMBS, PPOX, MRPL11, 
MRPS26, RPS19, MRPS30, EEF1D, APRT, EEF1B2, AIMP2, EIF2B4, 
SERP1, RPS24, MRPL24, RPLP1, RPL10A, RPS9, RPL31, MRPL18, 
RPL8, RPS13, MRPL16, RPS11, RPL14, COA3, RPS23, NPM1, 
RPS4X, MRPL14, MRPL22, RPS21, UBA52, RPL38, RPL32, RPS27, 
EIF3G, ADI1, GATC, ATP5E, MRPL13, MRPS34, RPL28, RPL13A, 
RPL37, RPL36, RSL24D1, RPS6, RPS17 
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Table 6. (Cont. ) 
 
GOBPID P-value Count Term Genes 
GO:0034641 4.14E-12 221 cellular nitrogen compound metabolic process 
PIN4, TXN, ENO1, IGF2, MYF6, MYOG, EDNRA, GNAS, HSPA8, 
RPSA, NR2F2, RPL24, RPS3A, TREX1, CITED1, CSNK2A2, AQP1, 
PFDN5, RPS28, RPL9, RPL10, NEDD8, RPS27A, RPS29, H2AFZ, 
YBX1, EEF1G, RPS12, RPS3, RPS18, GNB2L1, HINT1, RPS15A, 
RPL26, NDUFA7, RPL12, RPL27, RPS8, RPL18A, RPL27A, RPL37A, 
BABAM1, FAM175A, COMMD5, RPL23, HNRNPA1, RPS7, 
RNASEH2C, MRPS2, MRPL9, RPS5, HSF1, RPS16, MRPL20, CARS2, 
MRPL55, RPL35A, EIF3H, RPL15, RPL23A, RPL29, POP5, OSGEP, 
TRMT112, EXOSC9, CNOT7, AHCY, RPL36A, MCEE, PPIL1, RPL13, 
JMJD6, MCTS1, WDR55, DHFR, DUSP11, PKN1, ATF4, RPL18, 
RPS26, RSRC1, MRPL52, WRAP53, EIF1, MRPL27, MRPL37, 
COMMD9, STOML2, RPL4, C18H19orf40, MRPS16, GTF2E2, ADSL, 
RPL6, PARK7, RNF25, EIF2D, ZSCAN26, RPL11, RPL30, DPY30, 
RPS20, MUM1, MRPL51, RPL17, ASNS, COMMD7, RPS15, ZNF205, 
METTL17, SNRPD2, RPL7, RPL5, EIF3K, PTGDR, UQCC3, RPL35, 
HMBS, SSBP1, PPOX, ISG20L2, MRPL11, MRPS26, RPS19, MRPS30, 
EEF1D, DQX1, ERCC8, APRT, EEF1B2, NHP2, AIMP2, EIF2B4, 
NSA2, ZNF639, ZNF227, UXT, NSMCE4A, SERP1, RPS24, MRPL24, 
LOXL2, NAT14, THOC5, EXOSC3, RPLP1, RPL10A, NABP2, RPS9, 
GSTA4, IRAK1, INTS9, BUD31, ZNF274, TEFM, POLR2F, RPL31, 
MRPL18, RFX2, TFDP1, RPL8, LSM1, RPS13, MRPL16, PLK1, 
POLR1D, RPS11, RPL14, COA3, RPS23, DGCR8, DRAP1, TCEB1, 
XBP1, SF3B5, MACROD1, LSM8, CINP, RNF168, NPM1, ENY2, 
RPS4X, POLR2I, SNRPC, MRPL14, MED29, MRPL22, POLB, LSM3, 
SSU72, RPS21, UBA52, SNRPF, RPL38, RPL32, ERCC1, RPS27, 
EIF3G, GATC, ZNF34, TATDN3, COMMD4, ATP5E, POLR2L, 
PTOV1, POLD4, MRPL13, QDPR, POLR3K, MRPS34, RPL28, 
RPL13A, COMMD3, RPL37, RPL36, GSTA3, SNRPN, ALKBH8, 
RSL24D1, RPS6, RPS17 
GO:0009059 1.12E-11 167 macromolecule biosynthetic process 
TXN, IGF2, MYF6, MYOG, HSPA8, RPSA, NR2F2, PPM1A, RPL24, 
RPS3A, CITED1, CSNK2A2, PFDN5, RPS28, RPL9, RPL10, NEDD8, 
RPS27A, RPS29, H2AFZ, YBX1, EEF1G, RPS12, RPS3, RPS18, 
GNB2L1, HINT1, RPS15A, RPL26, NDUFA7, RPL12, RPL27, RPS8, 
RPL18A, RPL27A, PTGES3, RPL37A, COMMD5, RPL23, RPS7, 
MRPS2, MRPL9, RPS5, HSF1, RPS16, MRPL20, CARS2, MRPL55, 
RPL35A, EIF3H, RPL15, RPL23A, RPL29, CNOT7, RPL36A, RPL13, 
JMJD6, MCTS1, PKN1, ATF4, RPL18, RPS26, MRPL52, WRAP53, 
EIF1, MRPL27, MRPL37, COMMD9, STOML2, RPL4, SERPINH1, 
MRPS16, GTF2E2, RPL6, PARK7, RNF25, EIF2D, ZSCAN26, RPL11, 
RPL30, DPY30, RPS20, MRPL51, RPL17, COMMD7, RPS15, ZNF205, 
METTL17, RPL7, RPL5, EIF3K, RPL35, SSBP1, MRPL11, MRPS26, 
RPS19, MRPS30, EEF1D, EEF1B2, AIMP2, EIF2B4, ZNF639, 
ZNF227, UXT, SERP1, RPS24, MRPL24, LOXL2, NAT14, THOC5, 
RPLP1, RPL10A, RPS9, IRAK1, ZNF274, TEFM, POLR2F, RPL31, 
MRPL18, RFX2, TFDP1, RPL8, RPS13, MRPL16, PLK1, POLR1D, 
RPS11, RPL14, COA3, RPS23, DRAP1, TCEB1, XBP1, CINP, 
RNF168, NPM1, ENY2, RPS4X, POLR2I, MRPL14, MED29, MRPL22, 
POLB, SSU72, RPS21, UBA52, RPL38, RPL32, RPS27, EIF3G, GATC, 
ZNF34, COMMD4, POLR2L, PTOV1, POLD4, MRPL13, POLR3K, 
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GOBPID P-value Count Term Genes 
GO:0044260 3.94E-10 255 cellular macromolecule metabolic process 
PIN4, TXN, CALR, CCT8, IGF2, MYF6, MYOG, GNAS, HSPA8, 
HSPE1, RPSA, NR2F2, PPM1A, PRDX1, RPL24, RPS3A, TREX1, 
CITED1, CSNK2A2, PFDN5, RPS28, RPL9, RPL10, NEDD8, RPS27A, 
RPS29, H2AFZ, YBX1, EEF1G, RPS12, RPS3, RPS18, GNB2L1, 
HINT1, RPS15A, RPL26, NDUFA7, TFPI2, RPL12, RPL27, RPS8, 
RPL18A, CD63, PKIG, RPL27A, PEBP1, PTGES3, PSENEN, RPL37A, 
BABAM1, CCT3, FAM175A, COMMD5, RPL23, GADD45G, 
HNRNPA1, RPS7, RNASEH2C, MRPS2, MRPL9, UBE2J2, RPS5, 
HSF1, RPS16, MRPL20, CARS2, MRPL55, RPL35A, EIF3H, SPRY1, 
RPL15, RPL23A, RPL29, POP5, OSGEP, TRMT112, EXOSC9, 
CNOT7, RPL36A, PPIL1, RPL13, JMJD6, MCTS1, FKBP4, WDR55, 
DUSP11, PKN1, ATF4, RPL18, CTDNEP1, RPS26, RSRC1, MRPL52, 
WRAP53, EIF1, NLE1, PFDN6, MRPL27, MRPL37, COMMD9, 
STOML2, RPL4, CDK4, C18H19orf40, SERPINH1, MRPS16, 
GTF2E2, RPL6, PSMB7, PARK7, RNF25, EIF2D, ZSCAN26, RPL11, 
COPS6, RPL30, DPY30, RPS20, MUM1, MRPL51, CHCHD4, RPL17, 
COMMD7, RPS15, ZNF205, METTL17, SNRPD2, RPL7, ZNHIT1, 
RPL5, EIF3K, PSMA1, RPL35, HMBS, SSBP1, MRPL11, MRPS26, 
RPS19, MRPS30, LAMTOR5, EEF1D, DQX1, P4HA1, ERCC8, 
METTL21C, EEF1B2, NHP2, AIMP2, EIF2B4, NSA2, ZRANB1, 
ZNF639, ZNF227, UXT, DOHH, NSMCE4A, SERP1, RPS24, MRPL24, 
FLOT1, LOXL2, NAT14, THOC5, PPP2R3C, EXOSC3, RPLP1, 
RPL10A, WASH1, NABP2, RPS9, IRAK1, INTS9, BUD31, ZNF274, 
TEFM, POLR2F, RPL31, MRPL18, RFX2, TFDP1, RPL8, LSM1, 
PIN1, RPS13, CLPP, MRPL16, PLK1, POLR1D, RPS11, RPL14, 
TMUB1, COA3, RPS23, DGCR8, DRAP1, TCEB1, UBE2D2, XBP1, 
THBS4, SF3B5, MACROD1, LSM8, CINP, RNF168, NPM1, ENY2, 
RPS4X, ANAPC13, POLR2I, SNRPC, MRPL14, MED29, MRPL22, 
POLB, LSM3, SSU72, BLOC1S1, RPS21, UBA52, SNRPF, RPL38, 
RPL32, FIS1, ERCC1, RPS27, EIF3G, GATC, ZNF34, TATDN3, 
ANAPC11, LAMTOR2, PFDN1, COMMD4, UBE2F, POLR2L, 
RNF170, APOPT1, UBE2S, PTOV1, POLD4, MRPL13, LCMT1, 
POLR3K, MRPS34, RPL28, RPL13A, COMMD3, RPL37, RPL36, 
CDC26, SNRPN, ALKBH8, RSL24D1, RPS6, RPS17 
GO:0019538 2.38E-09 188 protein metabolic process 
PIN4, TXN, CALR, CCT8, GJA1, IGF2, PLAU, HSPA8, HSPE1, RPSA, 
NR2F2, PPM1A, PRDX1, RPL24, RPS3A, CSNK2A2, PFDN5, RPS28, 
RPL9, RPL10, RPS27A, RPS29, EEF1G, RPS12, RPS3, RPS18, 
GNB2L1, RPS15A, RPL26, NDUFA7, TFPI2, RPL12, RPL27, RPS8, 
RPL18A, PKIG, RPL27A, CASP3, PEBP1, PSENEN, RPL37A, 
BABAM1, CCT3, RPL23, GADD45G, RPS7, MRPS2, MRPL9, 
UBE2J2, RPS5, HSF1, RPS16, MRPL20, CARS2, MRPL55, RPL35A, 
EIF3H, SPRY1, RPL15, RPL23A, RPL29, TRMT112, CNOT7, RPL36A, 
PPIL1, RPL13, JMJD6, MCTS1, FKBP4, DUSP11, PKN1, RPL18, 
CTDNEP1, RPS26, RSRC1, MRPL52, EIF1, NLE1, PFDN6, MRPL27, 
MRPL37, STOML2, RPL4, CDK4, SERPINH1, MRPS16, RPL6, 
PSMB7, PARK7, RNF25, EIF2D, RPL11, COPS6, PSMD8, RPL30, 
DPY30, RPS20, MRPL51, CHCHD4, RPL17, RPS15, METTL17, RPL7, 
ZNHIT1, RPL5, EIF3K, PSMA1, RPL35, HMBS, MRPL11, MRPS26, 
RPS19, MRPS30, LAMTOR5, EEF1D, P4HA1, ERCC8, METTL21C, 
EEF1B2, AIMP2, EIF2B4, ZRANB1, DOHH, SERP1, RPS24, MRPL24, 
FLOT1, LOXL2, PPP2R3C, RPLP1, RPL10A, WASH1, RPS9, IRAK1, 
RPL31, MRPL18, RPL8, PIN1, RPS13, CLPP, MRPL16, PLK1, 
CASP6, RPS11, RPL14, TMUB1, COA3, RPS23, TCEB1, UBE2D2, 
XBP1, THBS4, MACROD1, RNF168, NPM1, ENY2, RPS4X, 
ANAPC13, MRPL14, MRPL22, SSU72, BLOC1S1, RPS21, UBA52, 
RPL38, RPL32, FIS1, RPS27, EIF3G, GATC, ANAPC11, LAMTOR2, 
PFDN1, UBE2F, RNF170, APOPT1, UBE2S, MRPL13, LCMT1, 
MRPS34, RPL28, RPL13A, RPL37, RPL36, CDC26, RSL24D1, RPS6, 
RPS17 
GO:0071826 4.19E-08 28 ribonucleoprotein complex subunit organization 
RPSA, RPL24, RPL10, RPL12, RPS5, MRPL20, EIF3H, RPL23A, 
CNOT7, MCTS1, RPL6, EIF2D, RPL11, RPS15, SNRPD2, RPL5, 
EIF3K, MRPL11, RPS19, RPS10, SNRPC, LSM3, SNRPF, RPL38, 
RPS27, EIF3G, RPL13A, RSL24D1 
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GOBPID P-value Count Term Genes 
GO:0044249 9.27E-08 183 cellular biosynthetic process 
TXN, IGF2, MYF6, MYOG, EDNRA, GNAS, HSPA8, RPSA, NR2F2, 
PPM1A, RPL24, RPS3A, CITED1, CSNK2A2, AQP1, PFDN5, RPS28, 
RPL9, RPL10, NEDD8, RPS27A, RPS29, H2AFZ, YBX1, EEF1G, 
RPS12, RPS3, RPS18, GNB2L1, HINT1, RPS15A, RPL26, NDUFA7, 
RPL12, RPL27, RPS8, RPL18A, RPL27A, PTGES3, RPL37A, 
COMMD5, RPL23, RPS7, MRPS2, MRPL9, RPS5, HSF1, RPS16, 
MRPL20, CARS2, MRPL55, RPL35A, EIF3H, RPL15, RPL23A, 
RPL29, CNOT7, RPL36A, RPL13, JMJD6, MCTS1, DHFR, PKN1, 
ATF4, RPL18, CTDNEP1, ISYNA1, RPS26, MRPL52, WRAP53, EIF1, 
FITM1, MRPL27, MRPL37, COMMD9, STOML2, RPL4, MRPS16, 
GTF2E2, ADSL, RPL6, PARK7, RNF25, EIF2D, ZSCAN26, RPL11, 
RPL30, DPY30, RPS20, MRPL51, RPL17, ASNS, COMMD7, RPS15, 
ZNF205, METTL17, RPL7, RPL5, EIF3K, UQCC3, RPL35, HMBS, 
SSBP1, PPOX, MRPL11, MRPS26, RPS19, MRPS30, EEF1D, APRT, 
EEF1B2, AIMP2, EIF2B4, ZNF639, ZNF227, UXT, SERP1, RPS24, 
MRPL24, LOXL2, NAT14, THOC5, RPLP1, RPL10A, RPS9, IRAK1, 
ZNF274, TEFM, POLR2F, RPL31, MRPL18, RFX2, TFDP1, RPL8, 
RPS13, RBP1, MRPL16, PLK1, POLR1D, RPS11, RPL14, COA3, 
RPS23, DRAP1, TCEB1, XBP1, CINP, RNF168, NPM1, ENY2, RPS4X, 
POLR2I, MRPL14, MED29, MRPL22, POLB, SSU72, RPS21, UBA52, 
RPL38, RPL32, RPS27, EIF3G, ADI1, GATC, ZNF34, COMMD4, 
ATP5E, POLR2L, PTOV1, POLD4, MRPL13, QDPR, POLR3K, 
MRPS34, RPL28, RPL13A, COMMD3, RPL37, RPL36, RSL24D1, 
RPS6, RPS17 
 
GO:0000027 1.32E-07 10 ribosomal large subunit assembly 
RPL24, RPL10, RPL12, MRPL20, RPL23A, RPL6, RPL11, RPL5, 
MRPL11, RSL24D1 
GO:0042273 6.95E-05 7 ribosomal large subunit biogenesis RPL26, RPL35A, WDR55, NLE1, RPL7, RPL35, RPL14 
GO:0006364 1.23E-04 13 rRNA processing PIN4, RPS28, RPL26, RPS7, TRMT112, WDR55, RPL11, RPL7, RPL35, NHP2, NSA2, RPL14, RPS17 
GO:0000028 2.21E-04 6 ribosomal small subunit assembly RPSA, RPS5, RPS15, RPS19, RPS10, RPS27 
GO:0006396 1.12E-03 43 RNA processing 
PIN4, HSPA8, RPS28, YBX1, RPL26, HNRNPA1, RPS7, RPS16, POP5, 
OSGEP, TRMT112, EXOSC9, CNOT7, PPIL1, JMJD6, WDR55, 
RSRC1, RPL11, SNRPD2, RPL7, RPL35, DQX1, NHP2, NSA2, RPS24, 
THOC5, EXOSC3, INTS9, BUD31, LSM1, RPS13, RPL14, DGCR8, 
SF3B5, LSM8, SNRPC, LSM3, SSU72, RPS21, SNRPF, SNRPN, 
ALKBH8, RPS17 
GO:0042274 1.19E-03 3 ribosomal small subunit biogenesis RPS28, RPS7, RPS17 
GO:0070925 1.24E-03 25 organelle assembly 
RPSA, RPL24, CBY1, RPL10, RPL12, IFT46, RPS5, MRPL20, 
RPL23A, RPL6, RPL11, TCAP, RPS15, RPL5, MRPL11, RPS19, ARL6, 
















Table 6. (Cont.) 
 
GOBPID P-value Count Term Genes 
GO:0071704 2.40E-03 288 organic substance metabolic process 
PIN4, TXN, CALR, CCT8, ENO1, GJA1, IGF2, MYF6, MYOG, PLAU, 
EDNRA, GNAS, HSPA8, HSPE1, RPSA, NR2F2, PPM1A, PRDX1, 
RPL24, RPS3A, TREX1, CITED1, CSNK2A2, AQP1, PFDN5, RPS28, 
RPL9, RPL10, NEDD8, RPS27A, RPS29, H2AFZ, YBX1, GCSH, 
EEF1G, RPS12, RPS3, RPS18, GNB2L1, HINT1, RPS15A, RPL26, 
NDUFA7, TFPI2, RPL12, RPL27, RPS8, RPL18A, CD63, PKIG, 
RPL27A, CASP3, PEBP1, PTGES3, PSENEN, RPL37A, BABAM1, 
CCT3, FAM175A, COMMD5, RPL23, GADD45G, HNRNPA1, RPS7, 
RNASEH2C, MRPS2, MRPL9, UBE2J2, RPS5, HSF1, RPS16, 
MRPL20, CARS2, DTNBP1, MRPL55, RPL35A, EIF3H, SPRY1, 
RPL15, RPL23A, RPL29, POP5, OSGEP, TRMT112, EXOSC9, 
CNOT7, AHCY, RPL36A, MCEE, PPIL1, RPL13, JMJD6, MCTS1, 
FKBP4, WDR55, DHFR, DUSP11, PKN1, ATF4, RPL18, CTDNEP1, 
HAGH, ISYNA1, RPS26, RSRC1, MRPL52, WRAP53, EIF1, NLE1, 
PFDN6, FITM1, MRPL27, MRPL37, COMMD9, STOML2, RPL4, 
CDK4, C18H19orf40, SERPINH1, MRPS16, GTF2E2, ADSL, RPL6, 
PSMB7, ACADS, PARK7, RNF25, EIF2D, ZSCAN26, RPL11, COPS6, 
PSMD8, RPL30, DPY30, RPS20, MUM1, MRPL51, CHCHD4, RPL17, 
ASNS, COMMD7, RPS15, ZNF205, METTL17, SNRPD2, RPL7, 
ZNHIT1, RPL5, EIF3K, PTGDR, UQCC3, PSMA1, RPL35, HMBS, 
SSBP1, PPOX, ISG20L2, MRPL11, MRPS26, RPS19, MRPS30, 
LAMTOR5, EEF1D, DQX1, P4HA1, ERCC8, APRT, METTL21C, 
EEF1B2, NHP2, AIMP2, EIF2B4, NSA2, ZRANB1, ZNF639, ZNF227, 
UXT, DOHH, NSMCE4A, SERP1, RPS24, SACM1L, MRPL24, FLOT1, 
LOXL2, NAT14, THOC5, PPP2R3C, ACTC1, EXOSC3, RPLP1, 
RPL10A, WASH1, NABP2, RPS9, GSTA4, IRAK1, INTS9, BUD31, 
ZNF274, TEFM, POLR2F, RPL31, MRPL18, RFX2, TFDP1, RPL8, 
LSM1, PIN1, RPS13, CLPP, RBP1, MRPL16, PLK1, CASP6, POLR1D, 
RPS11, RPL14, TMUB1, COA3, GDE1, RPS23, DGCR8, DRAP1, 
TCEB1, UBE2D2, XBP1, THBS4, SF3B5, MACROD1, LSM8, CINP, 
RNF168, NPM1, ENY2, RPS4X, ANAPC13, POLR2I, SNRPC, 
MRPL14, MED29, MRPL22, POLB, LSM3, SSU72, BLOC1S1, RPS21, 
UBA52, SNRPF, RPL38, RPL32, FIS1, ERCC1, RPS27, EIF3G, ADI1, 
GATC, ZNF34, TATDN3, ANAPC11, LAMTOR2, PFDN1, COMMD4, 
UBE2F, ATP5E, POLR2L, RNF170, APOPT1, UBE2S, PTOV1, 
POLD4, MRPL13, LCMT1, QDPR, POLR3K, MRPS34, RPL28, 
RPL13A, COMMD3, RPL37, RPL36, GSTA3, CDC26, SNRPN, 
ALKBH8, RSL24D1, RPS6, RPS17 
GO:0031017 4.62E-03 3 exocrine pancreas development IGF2, PPDPF, XBP1 
GO:0046688 4.62E-03 3 response to copper ion AQP1, PARK7, LOXL2 
GO:0022613 5.11E-03 12 ribonucleoprotein complex biogenesis 
EIF3H, CNOT7, MCTS1, EIF2D, SNRPD2, EIF3K, SNRPC, LSM3, 
SNRPF, RPL38, EIF3G, RPL13A 
 
GO:0034622 5.27E-03 38 cellular macromolecular complex assembly 
RPSA, RPL24, RPL10, RPL12, RPS5, MRPL20, EIF3H, RPL23A, 
CDC42EP2, CNOT7, MCTS1, STX4, PFDN6, RPL6, EIF2D, RPL11, 
TCAP, RPS15, SNRPD2, RPL5, EIF3K, UQCC3, MRPL11, RPS19, 
ARL6, WASH1, COA3, ARPC2, RPS10, SNRPC, LSM3, SNRPF, 
RPL38, RPS27, EIF3G, UBE2S, RPL13A, RSL24D1 
GO:0006414 6.59E-03 7 translational elongation EEF1G, RPS5, EEF1D, EEF1B2, RPLP1, RPS9, GATC 
GO:0016447 6.61E-03 4 
somatic recombination of 
immunoglobulin gene 
segments 









Table 7. Significant GO MF over-represented terms for WGCNA Blue module (P-value < 0.01). Count 
represents the total number of genes associated with each term (including not DEG present in the module).  
 
GOMFID P-value Count Term Genes 
GO:0003735 1.40E-56 86 structural constituent of ribosome 
RPSA, RPL24, RPS3A, RPS28, RPL9, RPL10, RPS27A, RPS29, RPS12, RPS3, 
RPS18, RPS15A, RPL26, NDUFA7, RPL12, RPL27, RPS8, RPL18A, RPL27A, 
RPL37A, RPL23, RPS7, MRPS2, MRPL9, RPS5, RPS16, MRPL20, MRPL55, 
RPL35A, RPL15, RPL23A, RPL29, RPL36A, RPL13, RPL18, RPS26, 
MRPL52, MRPL27, MRPL37, RPL4, MRPS16, RPL6, RPL11, RPL30, RPS20, 
MRPL51, RPL17, RPS15, RPL7, RPL5, RPL35, MRPL11, MRPS26, RPS19, 
MRPS30, RPS24, MRPL24, RPLP1, RPL10A, RPS9, RPL31, MRPL18, RPL8, 
RPS13, MRPL16, RPS11, RPL14, RPS23, RPS10, RPS4X, MRPL14, MRPL22, 
RPS21, UBA52, RPL38, RPL32, RPS27, MRPL13, MRPS34, RPL28, RPL13A, 
RPL37, RPL36, RSL24D1, RPS6, RPS17 
GO:0044822 1.13E-19 83 poly(A) RNA binding 
PIN4, TXN, UBB, HSPA8, HSPE1, PRDX1, RPL24, RPS25, RPS28, RPL10, 
RPS27A, RPS12, RPS18, GNB2L1, RPS15A, RPL26, RPL12, RPL27, RPS8, 
RPL18A, RPL27A, PEBP1, RPL37A, CCT3, RPL23, HNRNPA1, RPS7, 
MRPL9, RPS16, MRPL20, RPL35A, EIF3H, RPL15, RPL23A, RPL29, 
EXOSC9, MRPL27, MRPL37, RPL4, SERPINH1, RPL6, RPP25L, RPL11, 
SRP14, RPL7A, RPS20, RPL17, RPS15, SNRPD2, RPL7, RPL5, ISG20L2, 
MRPL11, MRPS26, RPS19, MRPS30, DQX1, NHP2, NSA2, RPS24, RPS9, 
RPL31, RPL8, MRPS28, LSM1, RPS11, RPL14, RPS23, MANF, GRWD1, 
RPS10, LSM8, RPS4X, MRPL14, MRPL22, LSM3, RPL32, RPS27, RPL28, 
RPL36, SNRPN, RSL24D1, RPS17 
GO:0019843 4.15E-09 15 rRNA binding RPL9, RPS18, RPL12, RPS5, MRPL20, RPL23A, RPL11, MRPL11, RPS9, RPL8, RPS13, MRPL16, RPS11, RPS4X, RPL37 
GO:0003723 7.50E-04 25 RNA binding 
YBX1, EEF1G, CNOT7, JMJD6, MCTS1, DUSP11, RPL18, WRAP53, EIF1, 
PCBP1, ZC3H14, EIF2D, RPL30, EIF3K, EEF1D, EEF1B2, EIF2B4, 
THOC5, EXOSC3, RPL10A, NPM1, SNRPF, RPL38, EIF3G, ALKBH8 
GO:0005488 2.74E-03 287 binding 
PIN4, RNASE10, PPA1, CA2, OXT, TXN, CALR, CCT8, S1PR1, ENO1, GJA1, 
IGF2, MYF6, MYOG, UBB, CHRNG, CLTB, CXCR4, GNAS, HSPA8, HSPE1, 
ITGA5, RPSA, NR2F2, PPM1A, PRDX1, RPL24, RPS25, TREX1, CITED1, 
CSNK2A2, AQP1, PFDN5, RPS28, RPL9, RPL10, RPS27A, RPS29, H2AFZ, 
YBX1, EEF1G, RPS12, RPS3, CALM, TPT1, RPS18, GNB2L1, HINT1, 
RPS15A, RPL26, FAHD2A, RPL12, RPL27, RPS8, RPL18A, S100A13, 
RPL27A, KRIT1, PEBP1, TPM2, RPL37A, CCT3, FAM175A, C29H11orf73, 
RPL23, HNRNPA1, FDX1L, RPS7, MRPL9, UBE2J2, RPS5, HSF1, RPS16, 
MRPL20, CARS2, RPL35A, EIF3H, RPL15, HSPH1, RPL23A, RPL29, 
PHOSPHO2, NUDT17, SEPHS1, DRG2, OSGEP, CDC42EP2, EXOSC9, 
CNOT7, THAP3, MCEE, JMJD6, MCTS1, FKBP4, STX4, DHFR, CNIH4, 
DUSP11, PKN1, ATF4, RPL18, FAHD1, HAGH, DNAJC21, WRAP53, EIF1, 
PFDN6, PCBP1, MRPL27, MRPL37, STOML2, COX11, RPL4, CDK4, 
C18H19orf40, SERPINH1, GTF2E2, RPL6, ACADS, RHOT1, PARK7, 
ZC3H14, GLRX3, RNF25, HAGHL, EIF2D, RPP25L, ZSCAN26, RABAC1, 
RPL11, SRP14, FAM96A, C19H17orf49, RPL30, RPL7A, DPY30, RPS20, 
TCAP, MUM1, RPL17, MYLPF, ASNS, COMMD7, SNX5, RAB13, RPS15, 
SRPX2, ZNF205, METTL17, SNRPD2, RPL7, ZNHIT1, RPL5, EIF3K, 
UQCC3, PSMA1, RPL35, SSBP1, CCRL2, ISG20L2, MRPL11, MRPS26, 
RPS19, MRPS30, LAMTOR5, EEF1D, FRRS1, DQX1, P4HA1, ERCC8, ARL6, 
APRT, EEF1B2, NHP2, TIMM9, SPAST, EIF2B4, NSA2, ZRANB1, ZNF639, 
ZNF227, STAC, UXT, DOHH, SDF4, RPS24, FLOT1, LOXL2, NAT14, 
THOC5, PPP2R3C, ACTC1, EXOSC3, RPL10A, WASH1, CMTM8, NABP2, 
MAPKAP1, RPS9, GSTA4, IRAK1, ZNF274, TEFM, POLR2F, RPL31, 
MRPL18, RFX2, TFDP1, RSPO3, RPL8, SEC23B, MRPS28, LSM1, PIN1, 
RPS13, RAB28, CLEC1A, RBP1, MRPL16, PLK1, CNN3, POLR1D, RPS11, 
RPL14, HSPB8, GDE1, RERG, ARL3, RPS23, DGCR8, DRAP1, MANF, 
MYOZ2, GRWD1, ARPC2, RPS10, UBE2D2, XBP1, THBS4, LSM8, RNF168, 
NPM1, MYL12B, ENY2, SEC61A2, RPS4X, POLR2I, SNRPC, MRPL14, 
MRPL22, POLB, LSM3, SNRPF, RPL38, RPL32, FIS1, ERCC1, RPS27, 
EIF3G, ADI1, GATC, ZNF34, TATDN3, ANAPC11, LIN7B, LAMTOR2, 
PFDN1, B9D2, UBE2F, IFT27, POLR2L, RNF170, UBE2S, MRPL13, 
ACBD6, S100A14, POLR3K, RPL28, RPL13A, RPL37, RPL36, INSL6, 
SNRPN, ALKBH8, PTER, RSL24D1, RPS17 
GO:0015035 6.12E-03 4 Protein disulfide oxidoreductase actvity TXN, GLRX3, CHCHD4, GLRX 
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Table 8. Significant GO CC over-represented terms for WGCNA Blue module (P-value < 0.01). Count 
represents the number of genes associated with each term (including not DEG present in the module).  
 
GOCCID P-value Count Term Genes 
GO:0005840 4.62E-55 97 ribosome 
RPSA, RPL24, RPS25, RPS3A, RPS28, RPL9, RPL10, RPS27A, RPLP0, RPS29, RPS12, 
RPS3, RPS18, RPS15A, RPL26, NDUFA7, RPL12, RPL27, RPS8, RPL18A, RPL27A, 
RPL37A, RPL23, RPS7, MRPS2, MRPL9, RPS5, RPS16, MRPL20, MRPL55, RPL35A, 
RPL15, RPL23A, RPL29, RPL36A, RPL13, MCTS1, RPL18, RPS26, MRPL52, MRPL27, 
MRPL37, RPL4, MRPS16, RPL6, MRPL45, EIF2D, MRPL54, RPL11, RPL30, RPS20, 
MRPL51, RPL17, RPS15, MRPL50, METTL17, RPL7, RPL5, RPL35, MRPL11, 
MRPS26, RPS19, MRPS30, RPS24, MRPL24, RPLP1, RPL10A, RPS9, RPL31, 
MRPL18, RPL8, MRPS28, RPS13, MRPL16, RPS11, RPL14, RPS23, RPS10, MRPL30, 
RPS4X, MRPL14, MRPL22, RPS21, UBA52, RPL38, RPL32, RPS27, MRPL48, 
MRPL13, MRPS34, RPL28, RPL13A, RPL37, RPL36, RSL24D1, RPS6, RPS17 
GO:0022625 8.84E-33 36 cytosolic large ribosomal subunit 
RPL24, RPL9, RPL10, RPL26, RPL12, RPL27, RPL18A, RPL27A, RPL37A, RPL23, 
RPL35A, RPL15, RPL23A, RPL29, RPL36A, RPL18, RPL4, RPL6, RPL11, RPL30, 
RPL7A, RPL17, RPL7, RPL5, RPL35, RPL31, RPL8, RPL14, UBA52, RPL38, RPL32, 
RPL28, RPL13A, RPL37, RPL36, RSL24D1 
GO:0022627 3.77E-25 28 cytosolic small ribosomal subunit 
RPSA, RPS25, RPS3A, RPS28, RPS27A, RPS12, RPS3, RPS18, RPS15A, RPS8, RPS7, 
RPS5, RPS16, MCTS1, EIF2D, RPS20, RPS15, RPS19, RPS24, RPS9, RPS13, RPS11, 
RPS23, RPS10, RPS4X, RPS21, RPS27, RPS6 
GO:0043228 1.53E-16 180 non-membrane-bounded organelle 
PIN4, CCT8, GJA1, HSPA8, RPSA, RPL24, RPS25, RPS3A, CBY1, RPS28, RPL9, 
RPL10, TNNT2, RPS27A, RPLP0, RPS29, H2AFZ, YBX1, RPS12, RPS3, CALM, TPT1, 
RPS18, GNB2L1, RPS15A, RPL26, NDUFA7, RPL12, RPL27, RPS8, RPL18A, RPL27A, 
KRIT1, TPM2, RPL37A, CCT3, RPL23, HNRNPA1, RPS7, IFT46, MRPS2, MRPL9, 
RPS5, RPS16, MRPL20, MRPL55, RPL35A, RPL15, RPL23A, RPL29, POP5, UBXN6, 
CDC42EP2, EXOSC9, CNOT7, RPL36A, RPL13, JMJD6, MCTS1, FKBP4, WDR55, 
ATF4, RPL18, RPS26, MRPL52, NLE1, MRPL27, MRPL37, STOML2, RPL4, MRPS16, 
RRS1, RPL6, PARK7, MRPL45, GLRX3, EIF2D, MRPL54, RPL11, SRP14, RPL30, 
RPL7A, RPS20, TCAP, NUDC, MRPL51, RPL17, MYLPF, DCTN3, RPS15, SRPX2, 
MRPL50, METTL17, RPL7, ZNHIT1, RPL5, RPL35, SSBP1, ISG20L2, MRPL11, 
MRPS26, RPS19, MRPS30, EEF1D, ARL6, NHP2, SPAST, NSA2, ENKD1, UXT, 
NSMCE4A, SERP1, RPS24, MRPL24, FLOT1, LOXL2, PPP2R3C, ACTC1, EXOSC3, 
RPLP1, RPL10A, WASH1, RPS9, IRAK1, ZNF274, TEFM, RPL31, MRPL18, SERGEF, 
RPL8, MRPS28, LSM1, RPS13, RAB28, MRPL16, PLK1, POLR1D, RPS11, RPL14, 
ARL3, RPS23, DGCR8, MYOZ2, GRWD1, ARPC2, RPS10, RNF168, NPM1, MYL12B, 
MRPL30, RPS4X, POLR2I, MRPL14, MRPL22, POLB, LSM3, RPS21, UBA52, RPL38, 
RPL32, ERCC1, RPS27, MRPL48, ANAPC11, B9D2, POLR2L, POLD4, MRPL13, 
S100A14, POLR3K, MRPS34, CCDC106, RPL28, RPL13A, RPL37, RPL36, ALKBH8, 
RSL24D1, RPS6, RPS17 
GO:0005829 9.39E-14 101 cytosol 
TXN, CCT8, ENO1, GJA1, HSPA8, RPSA, PPM1A, RPL24, RPS25, RPS3A, TREX1, 
CITED1, PFDN5, RPS28, RPL9, RPL10, RPS27A, RPS12, RPS3, CALM, RPS18, 
GNB2L1, RPS15A, RPL26, RPL12, RPL27, RPS8, RPL18A, S100A13, RPL27A, 
RPL37A, CCT3, C29H11orf73, RPL23, RPS7, RPS5, RPS16, DTNBP1, RPL35A, 
RPL15, RPL23A, RPL29, CHMP3, AHCY, RPL36A, MCTS1, FKBP4, RPL18, FAHD1, 
PFDN6, RPL4, RPL6, PARK7, RNF25, EIF2D, RPL11, RPL30, RPL7A, RPS20, RPL17, 
ASNS, RPS15, SNRPD2, RPL7, RPL5, RPL35, RPS19, ARL6, AIMP2, RPS24, WASH1, 
RPS9, RPL31, RPL8, RPS13, RBP1, RPS11, RPL14, RERG, RPS23, ARPC2, RPS10, 
XBP1, RPS4X, BLOC1S1, RPS21, UBA52, SNRPF, RPL38, RPL32, FIS1, RPS27, 
PFDN1, LCMT1, RPL28, RPL13A, RPL37, RPL36, ALKBH8, RSL24D1, RPS6 
GO:0044446 5.68E-05 154 intracellular organelle part 
CCT8, GJA1, UCP3, CLTB, RPSA, RPL24, RPS3A, TREX1, CSNK2A2, AQP1, RPS28, 
RPL9, RPL10, TNNT2, YBX1, RPS12, CALM, TPT1, RPS18, RPS15A, RPL26, 
SLC35B1, RPL12, RPL27, RPS8, RPL18A, CD63, RPL27A, KRIT1, PSENEN, RPL37A, 
SSR4, BABAM1, CCT3, FAM175A, TOMM6, IFT46, MRPL9, UBE2J2, RPS5, RPS16, 
SSR2, DTNBP1, RPL35A, TMEM256, RPL15, RPL23A, RPL29, SEPHS1, CHMP3, 
UBXN6, RPL36A, PPIL1, MCTS1, FKBP4, STX4, ATF4, CTDNEP1, FITM1, MRPL37, 
STOML2, COX11, RPL4, EMC8, TOMM22, BCAP29, RPL6, RHOT1, MRPL45, 
MRPL54, DHRS7C, COPS6, RPL30, RPS20, NUDC, CHCHD4, RPL17, MYLPF, 
DCTN3, SNX5, RAB13, RPS15, MRPL50, SNRPD2, RPL7, UQCC3, RPL35, PPOX, 
RPS19, MRPS30, LAMTOR5, DQX1, ARL6, TIMM9, SPAST, EMC4, ENKD1, UXT, 
SERP1, TMEM126A, RPS24, SACM1L, MRPL24, FLOT1, PPP2R3C, ACTC1, RPL10A, 
WASH1, BUD31, RPL31, MRPL18, TMEM147, SEC23B, RAB28, SLC35A4, RPL14, 
COA3, ARL3, KRTCAP2, TIMM17B, ARPC2, XBP1, LSM8, RNF168, MYL12B, 
SEC61A2, MRPL30, RPS4X, ANAPC13, MRPL14, POLB, SLC25A26, LSM3, RPS21, 
UBA52, SNRPF, RPL38, RPL32, FIS1, RPS27, LAMTOR2, B9D2, ATP5E, RNF170, 
UBE2S, ROMO1, RPL28, RPL13A, RPL37, RPL36, CDC26, VTI1B, SNRPN, RPS6 
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Table 8. (Cont.) 
 
GOCCID P-value Count Term Genes 
GO:0015934 1.85E-04 9 large ribosomal subunit 
MRPL55, MRPL52, MRPL27, MRPL51, MRPL11, RPL10A, MRPL16, MRPL22, 
MRPL13 
GO:0005622 2.97E-04 405 intracellular 
PIN4, PPA1, CA2, OXT, TXN, CALR, CCT8, S1PR1, ENO1, GJA1, MYF6, MYOG, UBB, 
UCP3, CLTB, CXCR4, GNAS, HSPA8, HSPE1, RPSA, NR2F2, PPM1A, PRDX1, RPL24, 
RPS25, RPS3A, TREX1, CITED1, CSNK2A2, AQP1, PFDN5, CBY1, RPS28, RPL9, 
RPL10, NEDD8, TNNT2, RPS27A, RPLP0, RPS29, H2AFZ, YBX1, GCSH, EEF1G, 
RPS12, RPS3, CALM, TPT1, RPS18, GNB2L1, HINT1, RPS15A, RPL26, NDUFA7, 
SLC35B1, TFPI2, RPL12, RPL27, RPS8, RPL18A, S100A13, CD63, RPL27A, KRIT1, 
CASP3, PEBP1, PTGES3, PSENEN, TPM2, RPL37A, SSR4, BABAM1, GADD45GIP1, 
CCT3, FAM175A, COMMD5, C29H11orf73, TRAPPC5, RPL23, GADD45G, TOMM6, 
HNRNPA1, FDX1L, RPS7, IFT46, RNASEH2C, MRPS2, MRPL9, UBE2J2, RPS5, HSF1, 
RPS16, MRPL20, SSR2, CARS2, DTNBP1, MRPL55, RPL35A, EIF3H, TMEM256, 
SPRY1, RPL15, HSPH1, RPL23A, RPL29, POP5, NIPA2, SEPHS1, DRG2, OSGEP, 
CHMP3, UBXN6, CDC42EP2, FIBIN, EXOSC9, CNOT7, AHCY, RPL36A, MCEE, 
PPIL1, RPL13, JMJD6, MCTS1, FKBP4, STX4, WDR55, CNIH4, DUSP11, TMEM160, 
PKN1, ATF4, RPL18, CTDNEP1, FAHD1, HAGH, HDDC2, ISYNA1, RPS26, RSRC1, 
MRPL52, BOLA1, WRAP53, NLE1, PFDN6, PCBP1, FITM1, MRPL27, MRPL37, 
COMMD9, STOML2, COX11, RPL4, CDK4, HDHD3, EMC8, PSMG3, TOMM22, 
C18H19orf40, SERPINH1, MRPS16, GTF2E2, RRS1, BCAP29, RPL6, PSMB7, ACADS, 
RHOT1, PARK7, ZC3H14, MRPL45, GLRX3, RNF25, EIF2D, MRPL54, DHRS7C, 
RPP25L, ZSCAN26, RABAC1, RPL11, COPS6, SRP14, FAM96A, C19H17orf49, PSMD8, 
RPL30, RPL7A, DPY30, RPS20, TCAP, NUDC, MUM1, MRPL51, CFAP36, CHCHD4, 
PDCL3, RPL17, MYLPF, ASNS, COMMD7, DCTN3, SNX5, RAB13, RPS15, SRPX2, 
MRPL50, ZNF205, METTL17, SNRPD2, RPL7, ZNHIT1, RPL5, EIF3K, GLRX, UQCC3, 
PSMA1, RPL35, SSBP1, PPOX, ISG20L2, MRPL11, MRPS26, RPS19, MRPS30, 
LAMTOR5, CERCAM, EEF1D, DQX1, P4HA1, ERCC8, ARL6, APRT, METTL21C, 
NXT1, EEF1B2, NHP2, AIMP2, TIMM9, SPAST, MTMR9, EIF2B4, NSA2, MRFAP1L1, 
CPSF3L, EMC4, ZRANB1, ZNF639, ARL14EP, ZNF227, STAC, ENKD1, UXT, 
NSMCE4A, ACOT9, SERP1, SDF4, TMEM126A, RPS24, SACM1L, TNFAIP8L1, 
MRPL24, FLOT1, LOXL2, THOC5, PPP2R3C, ACTC1, EXOSC3, RANBP1, RPLP1, 
RPL10A, WASH1, NABP2, MAPKAP1, RPS9, GSTA4, IRAK1, INTS9, BUD31, ZNF274, 
TEFM, POLR2F, RPL31, MRPL18, SERGEF, RFX2, TFDP1, TMEM147, RPL8, 
SEC23B, MRPS28, KLHDC2, LSM1, PIN1, RPS13, CLPP, RAB28, AP2S1, RBP1, 
MRPL16, PLK1, CASP6, POLR1D, RPS11, SLC35A4, RPL14, TMUB1, HSPB8, COA3, 
GDE1, RERG, ARL3, MAB21L1, RPS23, DGCR8, DRAP1, KRTCAP2, MANF, MYOZ2, 
GRWD1, TIMM17B, ARPC2, TCEB1, RPS10, UBE2D2, KLHDC3, XBP1, THBS4, 
SF3B5, HN1, MACROD1, LSM8, CINP, RNF168, GKAP1, NPM1, MYL12B, ENY2, 
CMC2, SEC61A2, MRPL30, RPS4X, ANAPC13, POLR2I, UBL5, SNRPC, MRPL14, 
MED29, MRPL22, POLB, SLC25A26, LSM3, SSU72, BLOC1S1, RPS21, UBA52, SNRPF, 
RPL38, RPL32, FIS1, ERCC1, RPS27, EIF3G, ADI1, GATC, MRPL48, ZNF34, TATDN3, 
HSPB3, ANAPC11, LAMTOR2, PFDN1, B9D2, COMMD4, UBE2F, IFT27, ATP5E, 
POLR2L, RNF170, APOPT1, UBE2S, PTOV1, OXLD1, POLD4, MRPL13, LCMT1, 
QDPR, ACBD6, S100A14, POLR3K, MRPS34, CCDC106, ROMO1, RPL28, RPL13A, 
COMMD3, RPL37, RPL36, GSTA3, CDC26, VTI1B, SNRPN, ALKBH8, RSL24D1, RPS6, 
PLEKHO1, RPS17 

















Table 8. (Cont.) 
 
GOCCID P-value Count Term Genes 
GO:0005737 1.11E-03 335 cytoplasm 
PIN4, PPA1, CA2, OXT, TXN, CALR, CCT8, S1PR1, ENO1, GJA1, UBB, UCP3, CLTB, 
CXCR4, GNAS, HSPA8, HSPE1, RPSA, PPM1A, PRDX1, RPL24, RPS25, RPS3A, 
TREX1, CITED1, AQP1, PFDN5, CBY1, RPS28, RPL9, RPL10, TNNT2, RPS27A, 
RPLP0, RPS29, YBX1, GCSH, EEF1G, RPS12, RPS3, CALM, TPT1, RPS18, GNB2L1, 
HINT1, RPS15A, RPL26, NDUFA7, SLC35B1, RPL12, RPL27, RPS8, RPL18A, S100A13, 
CD63, RPL27A, KRIT1, CASP3, PEBP1, PTGES3, PSENEN, TPM2, RPL37A, SSR4, 
BABAM1, GADD45GIP1, CCT3, COMMD5, C29H11orf73, TRAPPC5, RPL23, 
GADD45G, TOMM6, HNRNPA1, FDX1L, RPS7, IFT46, MRPS2, MRPL9, UBE2J2, 
RPS5, HSF1, RPS16, MRPL20, SSR2, CARS2, DTNBP1, MRPL55, RPL35A, EIF3H, 
TMEM256, SPRY1, RPL15, HSPH1, RPL23A, RPL29, NIPA2, DRG2, OSGEP, CHMP3, 
UBXN6, CDC42EP2, FIBIN, CNOT7, AHCY, RPL36A, MCEE, RPL13, MCTS1, FKBP4, 
STX4, WDR55, CNIH4, TMEM160, PKN1, ATF4, RPL18, CTDNEP1, FAHD1, HAGH, 
HDDC2, ISYNA1, RPS26, RSRC1, MRPL52, BOLA1, WRAP53, PFDN6, PCBP1, FITM1, 
MRPL27, MRPL37, COMMD9, STOML2, COX11, RPL4, CDK4, HDHD3, EMC8, 
TOMM22, SERPINH1, MRPS16, BCAP29, RPL6, PSMB7, ACADS, RHOT1, PARK7, 
MRPL45, GLRX3, RNF25, EIF2D, MRPL54, DHRS7C, RABAC1, RPL11, COPS6, 
SRP14, FAM96A, RPL30, RPL7A, DPY30, RPS20, TCAP, NUDC, MRPL51, CFAP36, 
CHCHD4, PDCL3, RPL17, MYLPF, ASNS, COMMD7, DCTN3, SNX5, RAB13, RPS15, 
SRPX2, MRPL50, METTL17, SNRPD2, RPL7, RPL5, EIF3K, GLRX, UQCC3, PSMA1, 
RPL35, SSBP1, PPOX, MRPL11, MRPS26, RPS19, MRPS30, LAMTOR5, CERCAM, 
EEF1D, DQX1, P4HA1, APRT, NXT1, EEF1B2, NHP2, AIMP2, TIMM9, SPAST, 
MTMR9, EIF2B4, MRFAP1L1, CPSF3L, EMC4, ZRANB1, ARL14EP, STAC, UXT, 
ACOT9, SDF4, TMEM126A, RPS24, SACM1L, TNFAIP8L1, MRPL24, FLOT1, THOC5, 
PPP2R3C, ACTC1, RPLP1, RPL10A, WASH1, NABP2, MAPKAP1, RPS9, GSTA4, 
IRAK1, ZNF274, TEFM, RPL31, MRPL18, SERGEF, TMEM147, RPL8, SEC23B, 
MRPS28, LSM1, PIN1, RPS13, CLPP, RAB28, AP2S1, RBP1, MRPL16, PLK1, CASP6, 
RPS11, SLC35A4, RPL14, TMUB1, HSPB8, COA3, GDE1, RERG, RPS23, DGCR8, 
KRTCAP2, MYOZ2, GRWD1, TIMM17B, ARPC2, RPS10, KLHDC3, XBP1, THBS4, 
MACROD1, GKAP1, NPM1, MYL12B, CMC2, SEC61A2, MRPL30, RPS4X, UBL5, 
MRPL14, MRPL22, POLB, SLC25A26, LSM3, SSU72, BLOC1S1, RPS21, UBA52, 
SNRPF, RPL38, RPL32, FIS1, ERCC1, RPS27, EIF3G, ADI1, GATC, MRPL48, 
TATDN3, HSPB3, ANAPC11, LAMTOR2, PFDN1, B9D2, COMMD4, UBE2F, ATP5E, 
RNF170, APOPT1, UBE2S, PTOV1, OXLD1, MRPL13, LCMT1, QDPR, ACBD6, 
S100A14, MRPS34, CCDC106, ROMO1, RPL28, RPL13A, COMMD3, RPL37, RPL36, 
GSTA3, VTI1B, SNRPN, ALKBH8, RSL24D1, RPS6, PLEKHO1, RPS17 
GO:0005730 1.44E-03 42 nucleolus 
PIN4, HSPA8, RPS25, RPS27A, RPS3, RPL23, RPS7, POP5, EXOSC9, JMJD6, WDR55, 
RPL18, NLE1, RRS1, RPL11, SRP14, RPL7A, RPL5, ISG20L2, EEF1D, NHP2, NSA2, 
EXOSC3, RPS9, ZNF274, SERGEF, RPL8, RPS13, PLK1, POLR1D, RPS11, RPS23, 
DGCR8, GRWD1, RPS10, NPM1, POLR2I, ANAPC11, POLR2L, POLR3K, CCDC106, 
RSL24D1 
GO:0043229 4.90E-03 99 intracellular organelle 
TXN, S1PR1, MYF6, MYOG, UBB, CXCR4, GNAS, NR2F2, PPM1A, PRDX1, CITED1, 
PFDN5, NEDD8, RPLP0, RPS29, GCSH, EEF1G, GNB2L1, TFPI2, S100A13, PEBP1, 
TPM2, COMMD5, C29H11orf73, TRAPPC5, GADD45G, RNASEH2C, NIPA2, DRG2, 
OSGEP, CDC42EP2, FIBIN, CNOT7, AHCY, MCEE, RPL13, CNIH4, TMEM160, PKN1, 
HDDC2, RPS26, BOLA1, PCBP1, COMMD9, CDK4, HDHD3, PSMB7, GLRX3, RNF25, 
RPP25L, ZSCAN26, RABAC1, TCAP, MUM1, CFAP36, COMMD7, SRPX2, ZNF205, 
METTL17, EIF3K, PSMA1, METTL21C, EEF1B2, AIMP2, CPSF3L, ZNF227, ACOT9, 
LOXL2, RPLP1, IRAK1, RFX2, TFDP1, KLHDC2, LSM1, RERG, MAB21L1, DRAP1, 
MANF, MYOZ2, THBS4, HN1, MACROD1, CINP, GKAP1, CMC2, SSU72, EIF3G, 
GATC, ZNF34, TATDN3, HSPB3, COMMD4, APOPT1, PTOV1, OXLD1, QDPR, 
COMMD3, PLEKHO1, RPS17 
GO:0005925 7.40E-03 21 focal adhesion GJA1, PLAU, HSPA8, RPS3, RPS18, RPS8, RPL37A, RPL23, RPS7, RPS5, RPL18, RPL7A, FLOT1, ACTC1, RPS9, RPL31, RPL8, RPS13, RPS11, ARPC2, RPS17 
GO:0030055 8.24E-03 21 cell-substrate junction 
GJA1, PLAU, HSPA8, RPS3, RPS18, RPS8, RPL37A, RPL23, RPS7, RPS5, RPL18, 







Table 9. Significant GO BP over-represented terms for WGCNA Turquoise module (P-value < 0.01). Count 
represents the number of genes associated with each term (including not DEG present in the module).  
 
GOBPID P-value Count Term Genes 
GO:0008544 3.01E-04 8 epidermis development CLIC5, IGF1R, IGFBP5, LGR4, STK4, MAFG, 
GAB1, RBPJ 
GO:0006891 4.69E-04 5 intra-Golgi vesicle-mediated transport COPA, COPB2, GOSR1, ARCN1, COPG2 
GO:0048663 1.24E-03 3 neuron fate commitment TGFBR1, ID2, RBPJ 
GO:0006903 2.39E-03 3 vesicle targeting YKT6, GOSR1, TMED10 
GO:0048009 2.61E-03 2 insulin-like growth factor receptor signaling 
pathway 
IGF1R, PIK3R1 
GO:0060055 2.64E-03 2 angiogenesis involved in wound healing SERPINE1, B4GALT1 
GO:0030879 2.82E-03 5 mammary gland development B4GALT1, IGF1R, MAPK1, IGFBP5, ID2 
GO:0090090 3.37E-03 4 negative regulation of canonical Wnt 
signaling pathway 
FRZB, STK4, G3BP1, CYLD 
GO:0001890 4.40E-03 5 placenta development MAPK1, STK4, RTCB, GAB1, RBPJ 
GO:0006890 4.53E-03 4 retrograde vesicle-mediated transport, Golgi 
to ER 
COPA, COPB2, TMED10, ARCN1 
GO:0033036 5.10E-03 18 macromolecule localization ARHGDIA, FYTTD1, QKI, LGR4, YKT6, 
SELENBP1, SLC15A4, GOSR1, MPP7, TMED10, 
ARCN1, MTM1, LMAN2L, RAB1B, SEC22C, 
GPR89, RBPJ, NR1D1 
GO:0050435 6.20E-03 3 beta-amyloid metabolic process IDE, BECN1, TMED10 
GO:0044744 7.35E-03 7 protein targeting to nucleus PIK3R1, TGFBR1, CHP1, KPNA6, CYLD, HES1, 
KPNA1 
GO:1902593 7.35E-03 7 single-organism nuclear import PIK3R1, TGFBR1, CHP1, KPNA6, CYLD, HES1, 
KPNA1 
GO:0045332 7.64E-03 2 phospholipid translocation ATP8A1, TMEM30A 
GO:0048711 7.64E-03 2 positive regulation of astrocyte 
differentiation 
ID2, HES1 
GO:0048715 7.64E-03 2 negative regulation of oligodendrocyte 
differentiation 
ID2, HES1 
GO:0061419 7.64E-03 2 positive regulation of transcription from 
RNA polymerase II promoter in response to 
hypoxia 
HIF1A, RBPJ 
GO:0071468 7.64E-03 2 cellular response to acidic pH SLC9A1, CHP1 
GO:0071526 7.64E-03 2 semaphorin-plexin signaling pathway MET, ARHGDIA 
GO:0006888 9.30E-03 5 ER to Golgi vesicle-mediated transport COPA, COPB2, YKT6, GOSR1, SEC22C 
GO:0070647 9.49E-03 19 protein modification by small protein 
conjugation or removal 
USP13, TGFBR1, USP37, SPSB1, KCTD13, 
UVSSA, FBXL20, DDB1, CHP1, FBXO32, UBE4A, 
RNF144B, CYLD, CAND1, UBE2H, RNF141, 
MOCS3, FBXO25, MARCH8 











Table 10. Significant GO MF over-represented terms for WGCNA Turquoise module (P-value < 0.01). Count 
represents the number of genes associated with each term (including not DEG present in the module).  
 
GOMFID P-value Count Term Genes  
GO:0043559 1.36E-04 3 insulin binding IGF1R, PIK3R1, IDE 
GO:0042562 6.28E-03 3 hormone binding IGF1R, PIK3R1, IDE 
GO:0003873 7.71E-03 2 6-phosphofructo-2-kinase activity PFKFB2, PFKFB3 





Table 11. Significant GO MF over-represented terms for WGCNA Turquoise module (P-value < 0.01). Count 
represents the number of genes associated with each term (including not DEG present in the module).  
 
GOCCID P-value Count Term symbols 
GO:0030660 4.81E-05 6 Golgi-associated vesicle 
membrane 
COPA, CLTC, COPB2, ARCN1, COPG2, GPR89 
GO:0030137 5.93E-05 5 COPI-coated vesicle COPA, COPB2, TMED10, ARCN1, COPG2 
GO:0030126 3.54E-04 4 COPI vesicle coat COPA, COPB2, ARCN1, COPG2 
GO:0016021 3.87E-04 65 integral component of 
membrane 
GHR, MET, NNT, PAM, LDLR, NPR3, DAG1, DHRS3, ABCC1, 
CLIC5, B4GALT1, ICAM1, IGF1R, IL2RG, ITGA2, ITGAV, 
MGAT4A, SLC2A4, TGFBR1, SLC25A16, ITGB6, ATP6V0A1, 
SLC9A1, ATP8A1, CD97, MAOB, ACBD5, HMGCR, MBOAT7, 
SEC61A1, LGR4, TMEM30A, YKT6, TMEM201, EMP2, 
TMEM106A, ABHD2, TMEM106B, CD164, SLC15A4, GOSR1, 
SERAC1, TMEM245, RNF144B, TMEM164, SLC25A35, 
TMED10, NCEH1, CYP2U1, ACP2, LMAN2L, MPZ, LRRN1, 
SERINC1, ATG9A, MARCH8, PPM1L, CD99L2, SMIM14, 
CDS2, SEC22C, ZDHHC20, COMT, GPR89, SLC46A3 
GO:0044425 5.31E-04 51 membrane part COPA, GHR, MET, NNT, PAM, NPR3, DHRS3, ABCC1, CLIC5, 
COPB2, EPB41, ICAM1, IGF1R, IL2RG, AP2B1, MGAT4A, 
PIK3R1, TGFBR1, SLC25A16, ATP6V0A1, ATP8A1, CD97, 
MAOB, ACBD5, MBOAT7, TMEM201, TMEM106A, ABHD2, 
TMEM106B, CD164, SLC15A4, GOSR1, CDH13, SERAC1, 
TMEM245, RNF144B, TMEM164, SLC25A35, ARCN1, NCEH1, 
ACP2, COPG2, LRRN1, ATG9A, MARCH8, PPM1L, CD99L2, 
ZDHHC20, COMT, GPR89, SLC46A3 
GO:0031410 1.22E-03 23 cytoplasmic vesicle COPA, PAM, CLTC, CLIC5, COPB2, AP2B1, SLC2A4, 
ATP6V0A1, YWHAZ, ATP8A1, TMEM30A, YKT6, EMP2, CHP1, 
BECN1, TMED10, ARCN1, ANXA7, COPG2, AMOTL2, ATG9A, 
MARCH8, GPR89 
GO:0030140 3.65E-03 3 trans-Golgi network transport 
vesicle 
CLTC, SLC2A4, TMED10 
GO:0030117 5.02E-03 6 membrane coat COPA, CLTC, COPB2, AP2B1, ARCN1, COPG2 
GO:0008305 5.63E-03 3 integrin complex ITGA2, ITGAV, ITGB6 







Table 12. Significantly enriched Canonical Pathways identified by IPA for the set of 453 DEG. Pathways were 
considered significantly enriched if P-value < 0.05 (-log(P-value) >1.3). Column ‘Ratio’ represents the number of 
genes in the data set mapped to the pathway divided by the total number of genes that make up that pathway; ‘z-
score’ represents the predicted pathway activation (z-score > 2), inhibition (z-score < -2), or inability to predict (z-
score not available), ‘Down’ and ‘Up’ indicate the number of downregulated and upregulated genes, respectively, 
mapped to the pathway by the total number of genes that make up that pathway. 
 
Ingenuity Canonical Pathways -log(p-value) P-value Ratio z-score Down Up 
EIF2 Signaling 12 1.00E-12 0.118 3.051 3/221 (1%) 23/221 (10%) 
Oxidative Phosphorylation 10 1.00E-10 0.156  10/109 (9%) 7/109 (6%) 
Mitochondrial Dysfunction 7.73 1.86E-08 0.105  11/171 (6%) 7/171 (4%) 
Regulation of eIF4 and p70S6K 
Signaling 
6.74 1.82E-07 0.102  4/157 (3%) 12/157 (8%) 
mTOR Signaling 6.03 9.33E-07 0.0854 0 5/199 (3%) 12/199 (6%) 
AMPK Signaling 3.78 1.66E-04 0.0688 0 12/189 (6%) 1/189 (1%) 
Glucocorticoid Receptor Signaling 3.46 3.47E-04 0.0557  15/287 (5%) 1/287 (0%) 
Pentose Phosphate Pathway 3.02 9.55E-04 0.3  3/10 (30%) 0/10 (0%) 
TR/RXR Activation 3 1.00E-03 0.0816  8/98 (8%) 0/98 (0%) 
PI3K Signaling in B Lymphocytes 2.85 1.41E-03 0.0703 -2.121 9/128 (7%) 0/128 (0%) 
Pentose Phosphate Pathway (Oxidative 
Branch) 
2.6 2.51E-03 0.5  2/4 (50%) 0/4 (0%) 
Acetate Conversion to Acetyl-CoA 2.6 2.51E-03 0.5  2/4 (50%) 0/4 (0%) 
Granulocyte Adhesion and Diapedesis 2.4 3.98E-03 0.0565  9/177 (5%) 1/177 (1%) 
Inflammasome pathway 2.05 8.91E-03 0.143  3/21 (14%) 0/21 (0%) 
Stearate Biosynthesis I (Animals) 2 1.00E-02 0.0976  4/41 (10%) 0/41 (0%) 
LXR/RXR Activation 1.88 1.32E-02 0.0579 -1 7/121 (6%) 0/121 (0%) 
Ethanol Degradation IV 1.84 1.45E-02 0.12  2/25 (8%) 1/25 (4%) 
STAT3 Pathway 1.75 1.78E-02 0.0685 0 4/73 (5%) 1/73 (1%) 
Acetyl-CoA Biosynthesis III (from 
Citrate) 
1.68 2.09E-02 1  1/1 (100%) 0/1 (0%) 
Sorbitol Degradation I 1.68 2.09E-02 1  1/1 (100%) 0/1 (0%) 
Adipogenesis pathway 1.66 2.19E-02 0.0522  7/134 (5%) 0/134 (0%) 
Growth Hormone Signaling 1.58 2.63E-02 0.0617 -1 4/81 (5%) 1/81 (1%) 
Aryl Hydrocarbon Receptor Signaling 1.57 2.69E-02 0.05  6/140 (4%) 1/140 (1%) 
Oleate Biosynthesis II (Animals) 1.54 2.88E-02 0.154  2/13 (15%) 0/13 (0%) 
PPARα/RXRα Activation 1.49 3.24E-02 0.0449 0.707 8/178 (4%) 0/178 (0%) 
Role of JAK2 in Hormone-like 
Cytokine Signaling 
1.48 3.31E-02 0.0882  3/34 (9%) 0/34 (0%) 
Hepatic Fibrosis / Hepatic Stellate Cell 
Activation 
1.43 3.72E-02 0.0437  7/183 (4%) 1/183 (1%) 
PTEN Signaling 1.42 3.80E-02 0.0504 1.342 6/119 (5%) 0/119 (0%) 
Protein Ubiquitination Pathway 1.39 4.07E-02 0.0392  4/255 (2%) 6/255 (2%) 
Complement System 1.39 4.07E-02 0.0811  3/37 (8%) 0/37 (0%) 
Palmitate Biosynthesis I (Animals) 1.39 4.07E-02 0.5  1/2 (50%) 0/2 (0%) 
Fatty Acid Biosynthesis Initiation II 1.39 4.07E-02 0.5  1/2 (50%) 0/2 (0%) 
Cell Cycle: G1/S Checkpoint 
Regulation 
1.36 4.37E-02 0.0625  3/64 (5%) 1/64 (2%) 
Agranulocyte Adhesion and Diapedesis 1.36 4.37E-02 0.0423  7/189 (4%) 1/189 (1%) 
PXR/RXR Activation 1.34 4.57E-02 0.0615  4/65 (6%) 0/65 (0%) 
γ-linolenate Biosynthesis II (Animals) 1.32 4.79E-02 0.118  2/17 (12%) 0/17 (0%) 
Sumoylation Pathway 1.31 4.90E-02 0.0521 1 5/96 (5%) 0/96 (0%) 




Table 13. Significantly enriched Canonical Pathways identified by IPA for WGCNA Blue module (762 genes). 
Pathways were considered significantly enriched if P-value < 0.05 (-log(P-value) >1.3). Column ‘Ratio’ represents 
the number of genes in the data set mapped to the pathway divided by the total number of genes that make up that 
pathway; ‘z-score’ represents the predicted pathway activation (z-score > 2), inhibition (z-score < -2), or inability to 
predict (z-score not available); ‘Down’ and ‘Up’ columns not shown given that genes have not been filtered by 
differential expression; all genes in the Blue module have a positive logFC (>0.00). 
 
Ingenuity Canonical Pathways -log(p-value) P-value Ratio z-score 
EIF2 Signaling 61.9 1.26E-62 0.371 6.487 
Regulation of eIF4 and p70S6K Signaling 24.1 7.94E-25 0.261 1.633 
mTOR Signaling 21.7 2.00E-22 0.216 2.53 
Protein Ubiquitination Pathway 3.68 2.09E-04 0.0824  
Nucleotide Excision Repair Pathway 2.95 1.12E-03 0.171  
Hereditary Breast Cancer Signaling 2.9 1.26E-03 0.0915  
Assembly of RNA Polymerase II Complex 2.82 1.51E-03 0.14  
Huntington's Disease Signaling 2.75 1.78E-03 0.0747 0 
Mechanisms of Viral Exit from Host Cells 2.59 2.57E-03 0.146  
NRF2-mediated Oxidative Stress Response 2.55 2.82E-03 0.0777 3 
Methylglyoxal Degradation I 2.46 3.47E-03 0.667  
Androgen Signaling 2.31 4.90E-03 0.0901  
Endoplasmic Reticulum Stress Pathway 2.28 5.25E-03 0.19  
Cell Cycle: G1/S Checkpoint Regulation 2.2 6.31E-03 0.109 1.342 
Arsenate Detoxification I (Glutaredoxin) 2.17 6.76E-03 0.5  
Ascorbate Recycling (Cytosolic) 2.17 6.76E-03 0.5  
Hypoxia Signaling in the Cardiovascular System 2.17 6.76E-03 0.108  
Virus Entry via Endocytic Pathways 2.07 8.51E-03 0.0882  
Agrin Interactions at Neuromuscular Junction 2.03 9.33E-03 0.101 2.236 
CREB Signaling in Neurons 1.95 1.12E-02 0.0707 2.646 
CXCR4 Signaling 1.93 1.17E-02 0.0727 3.317 
Actin Nucleation by ARP-WASP Complex 1.91 1.23E-02 0.107 2.449 
Regulation of Cellular Mechanics by Calpain Protease 1.88 1.32E-02 0.105 2.236 
Vitamin-C Transport 1.87 1.35E-02 0.2  
UDP-N-acetyl-D-glucosamine Biosynthesis II 1.79 1.62E-02 0.333  
Cell Cycle: G2/M DNA Damage Checkpoint Regulation 1.59 2.57E-02 0.102 -2.236 
TWEAK Signaling 1.55 2.82E-02 0.118 2 
Cell Cycle Regulation by BTG Family Proteins 1.51 3.09E-02 0.114  
Glioma Invasiveness Signaling 1.48 3.31E-02 0.0857 2.449 
Tec Kinase Signaling 1.48 3.31E-02 0.0647 2.828 
Methylthiopropionate Biosynthesis 1.46 3.47E-02 1  
Asparagine Biosynthesis I 1.46 3.47E-02 1  
Phospholipase C Signaling 1.45 3.55E-02 0.0591 3.162 
Glioma Signaling 1.44 3.63E-02 0.0727 2.449 
Heme Biosynthesis II 1.44 3.63E-02 0.222  
Regulation of Actin-based Motility by Rho 1.43 3.72E-02 0.0769 2.646 
Unfolded protein response 1.43 3.72E-02 0.0926  
Ephrin Receptor Signaling 1.42 3.80E-02 0.0632 2.646 
Clathrin-mediated Endocytosis Signaling 1.4 3.98E-02 0.0609  
Glucocorticoid Receptor Signaling 1.4 3.98E-02 0.0557  
Neurotrophin/TRK Signaling 1.33 4.68E-02 0.0789 1.633 
Signaling by Rho Family GTPases 1.33 4.68E-02 0.0567 3.317 
Estrogen-mediated S-phase Entry 1.32 4.79E-02 0.125  
Thrombin Signaling 1.32 4.79E-02 0.0591 3.162 
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Table 14. Significantly enriched Canonical Pathways identified by IPA for WGCNA Turquoise module (901 
genes). Pathways were considered significantly enriched if P-value < 0.05 (-log(P-value) >1.3). Column ‘Ratio’ 
represents the number of genes in the data set mapped to the pathway divided by the total number of genes that 
make up that pathway; ‘z-score’ represents the predicted pathway activation (z-score > 2), inhibition (z-score < -2), 
or inability to predict (z-score not available); ‘Down’ and ‘Up’ columns not shown given that genes have not been 
filtered by differential expression; all genes in the Turquoise module have a negative logFC (<0.00). 
 
Ingenuity Canonical Pathways -log(p-value) P-value Ratio z-score 
Caveolar-mediated Endocytosis Signaling 5.95 1.12E-06 0.197  
AMPK Signaling 5.93 1.17E-06 0.127 -2.828 
ERK5 Signaling 5.03 9.33E-06 0.19 -2.309 
TR/RXR Activation 4.9 1.26E-05 0.153  
Non-Small Cell Lung Cancer Signaling 4.8 1.58E-05 0.169 -1.508 
UVA-Induced MAPK Signaling 4.69 2.04E-05 0.147 -3.742 
PI3K Signaling in B Lymphocytes 4.64 2.29E-05 0.133 -3.357 
IGF-1 Signaling 4.49 3.24E-05 0.142 -1.508 
PPARα/RXRα Activation 4.26 5.50E-05 0.112 1.069 
Telomerase Signaling 4.25 5.62E-05 0.135 -1.508 
Glucocorticoid Receptor Signaling 4.14 7.24E-05 0.0941  
Type II Diabetes Mellitus Signaling 4.12 7.59E-05 0.126 -0.905 
Insulin Receptor Signaling 4.09 8.13E-05 0.121 -1.807 
Virus Entry via Endocytic Pathways 4.08 8.32E-05 0.137  
p70S6K Signaling 3.96 1.10E-04 0.122 -2.138 
Growth Hormone Signaling 3.9 1.26E-04 0.148 -2.53 
PTEN Signaling 3.9 1.26E-04 0.126 2.496 
Glioma Signaling 3.72 1.91E-04 0.127 -2.887 
PI3K/AKT Signaling 3.7 2.00E-04 0.121 -0.277 
FLT3 Signaling in Hematopoietic Progenitor Cells 3.7 2.00E-04 0.141  
FAK Signaling 3.63 2.34E-04 0.131  
IL-4 Signaling 3.51 3.09E-04 0.135  
Role of NFAT in Cardiac Hypertrophy 3.36 4.37E-04 0.099 -3.441 
Agrin Interactions at Neuromuscular Junction 3.27 5.37E-04 0.145 -2.828 
Prolactin Signaling 3.2 6.31E-04 0.133 -2.53 
ErbB Signaling 3.12 7.59E-04 0.122  
ErbB4 Signaling 3.12 7.59E-04 0.139 -2.828 
STAT3 Pathway 3.07 8.51E-04 0.137 -1.897 
HIPPO signaling 3.07 8.51E-04 0.128 1 
14-3-3-mediated Signaling 2.98 1.05E-03 0.108  
Huntington's Disease Signaling 2.93 1.17E-03 0.0871 -2.111 
Chronic Myeloid Leukemia Signaling 2.89 1.29E-03 0.115  
Adipogenesis pathway 2.85 1.41E-03 0.104  
mTOR Signaling 2.77 1.70E-03 0.0905 -1.886 
ERK/MAPK Signaling 2.77 1.70E-03 0.0905 -2 
Prostate Cancer Signaling 2.74 1.82E-03 0.117  
Melanoma Signaling 2.73 1.86E-03 0.145  
Renal Cell Carcinoma Signaling 2.72 1.91E-03 0.123 -2.828 
Macropinocytosis Signaling 2.72 1.91E-03 0.123 -3 
JAK/Stat Signaling 2.64 2.29E-03 0.12 -1.897 
Regulation of the Epithelial-Mesenchymal Transition Pathway 2.62 2.40E-03 0.0899  
Neuregulin Signaling 2.45 3.55E-03 0.114 -2.333 
HER-2 Signaling in Breast Cancer 2.45 3.55E-03 0.114  
VEGF Signaling 2.43 3.72E-03 0.107 -1.667 
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Table 14. (Cont.) 
 
Ingenuity Canonical Pathways -log(p-value) P-value Ratio z-score 
Pancreatic Adenocarcinoma Signaling 2.43 3.72E-03 0.102 -2.333 
Th2 Pathway 2.4 3.98E-03 0.0933 -1.897 
Molecular Mechanisms of Cancer 2.39 4.07E-03 0.0722  
CNTF Signaling 2.35 4.47E-03 0.127 -2.828 
Notch Signaling 2.35 4.47E-03 0.158  
Mitochondrial L-carnitine Shuttle Pathway 2.34 4.57E-03 0.235  
Endometrial Cancer Signaling 2.31 4.90E-03 0.125  
Role of Tissue Factor in Cancer 2.31 4.90E-03 0.0984  
Breast Cancer Regulation by Stathmin1 2.3 5.01E-03 0.0837  
VDR/RXR Activation 2.3 5.01E-03 0.115 1.342 
PXR/RXR Activation 2.27 5.37E-03 0.123  
Pyridoxal 5'-phosphate Salvage Pathway 2.27 5.37E-03 0.123  
Erythropoietin Signaling 2.26 5.50E-03 0.114  
Aryl Hydrocarbon Receptor Signaling 2.25 5.62E-03 0.0929  
UVB-Induced MAPK Signaling 2.23 5.89E-03 0.121 -2.828 
Semaphorin Signaling in Neurons 2.21 6.17E-03 0.132  
Melanocyte Development and Pigmentation Signaling 2.21 6.17E-03 0.105 -3.162 
p53 Signaling 2.18 6.61E-03 0.0991 0 
Androgen Signaling 2.18 6.61E-03 0.0991 -1.134 
Unfolded protein response 2.17 6.76E-03 0.13  
Calcium Transport I 2.16 6.92E-03 0.3  
EGF Signaling 2.15 7.08E-03 0.118 -2.828 
Actin Cytoskeleton Signaling 2.14 7.24E-03 0.0789 -3.153 
Paxillin Signaling 2.13 7.41E-03 0.0973 -3 
IL-3 Signaling 2.12 7.59E-03 0.108  
ErbB2-ErbB3 Signaling 2.11 7.76E-03 0.116 2.121 
CDK5 Signaling 2.09 8.13E-03 0.101 -2.333 
NF-κB Signaling 2.08 8.32E-03 0.0833 -3.357 
Clathrin-mediated Endocytosis Signaling 2.08 8.32E-03 0.0812  
Myc Mediated Apoptosis Signaling 2.08 8.32E-03 0.114  
HGF Signaling 2.07 8.51E-03 0.0957 -2.714 
RANK Signaling in Osteoclasts 2.03 9.33E-03 0.099 -3 
NF-κB Activation by Viruses 2.03 9.33E-03 0.105 3 
Acetate Conversion to Acetyl-CoA 2.01 9.77E-03 0.5  
Protein Ubiquitination Pathway 1.98 1.05E-02 0.0745  
B Cell Receptor Signaling 1.97 1.07E-02 0.0811 -3.357 
Th1 and Th2 Activation Pathway 1.97 1.07E-02 0.0811  
Wnt/β-catenin Signaling 1.95 1.12E-02 0.0828 1 
Renin-Angiotensin Signaling 1.94 1.15E-02 0.0917 -3.317 
PDGF Signaling 1.9 1.26E-02 0.1 -3 
RAR Activation 1.87 1.35E-02 0.0789  
Acute Myeloid Leukemia Signaling 1.87 1.35E-02 0.0989 -2.121 
Regulation of eIF4 and p70S6K Signaling 1.85 1.41E-02 0.0828 -1.897 
Angiopoietin Signaling 1.84 1.45E-02 0.104 -0.447 
Estrogen-Dependent Breast Cancer Signaling 1.84 1.45E-02 0.104  
Fatty Acid Activation 1.82 1.51E-02 0.231  
CD40 Signaling 1.81 1.55E-02 0.103 -2.828 
Cyclins and Cell Cycle Regulation 1.81 1.55E-02 0.103  
Regulation of IL-2 Expression in Activated and Anergic T 
Lymphocytes 
1.77 1.70E-02 0.101  
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Ingenuity Canonical Pathways -log(p-value) P-value Ratio z-score 
Calcium Signaling 1.77 1.70E-02 0.0787 -1.89 
Estrogen Receptor Signaling 1.75 1.78E-02 0.0859  
Thrombopoietin Signaling 1.74 1.82E-02 0.108 -2.646 
Cardiac Hypertrophy Signaling 1.71 1.95E-02 0.0723 -4 
Lymphotoxin β Receptor Signaling 1.68 2.09E-02 0.104 -2.646 
Aldosterone Signaling in Epithelial Cells 1.67 2.14E-02 0.0783 -2.887 
HIF1α Signaling 1.66 2.19E-02 0.087  
PKCθ Signaling in T Lymphocytes 1.66 2.19E-02 0.0833 -3.317 
FcγRIIB Signaling in B Lymphocytes 1.65 2.24E-02 0.113 -2.449 
nNOS Signaling in Skeletal Muscle Cells 1.65 2.24E-02 0.2  
HMGB1 Signaling 1.64 2.29E-02 0.0827 -3.162 
UDP-N-acetyl-D-glucosamine Biosynthesis II 1.63 2.34E-02 0.333  
Gap Junction Signaling 1.63 2.34E-02 0.0774  
Rac Signaling 1.62 2.40E-02 0.0855 -3.162 
B Cell Activating Factor Signaling 1.61 2.45E-02 0.125 -2.236 
Th1 Pathway 1.59 2.57E-02 0.0815 -2.828 
Stearate Biosynthesis I (Animals) 1.57 2.69E-02 0.122  
Fc Epsilon RI Signaling 1.57 2.69E-02 0.084  
RAN Signaling 1.57 2.69E-02 0.188  
Melatonin Signaling 1.55 2.82E-02 0.0986 -1.633 
Role of JAK1 and JAK3 in γc Cytokine Signaling 1.55 2.82E-02 0.0986  
Cardiac β-adrenergic Signaling 1.55 2.82E-02 0.0803 -0.707 
eNOS Signaling 1.54 2.88E-02 0.0774 -3 
G Beta Gamma Signaling 1.52 3.02E-02 0.0909 -2.828 
Natural Killer Cell Signaling 1.51 3.09E-02 0.082  
iCOS-iCOSL Signaling in T Helper Cells 1.51 3.09E-02 0.082 -3.162 
γ-linolenate Biosynthesis II (Animals) 1.5 3.16E-02 0.176  
Apoptosis Signaling 1.5 3.16E-02 0.0899 1.414 
Mouse Embryonic Stem Cell Pluripotency 1.49 3.24E-02 0.0849 -3 
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid 
Arthritis 
1.47 3.39E-02 0.069  
Glioblastoma Multiforme Signaling 1.47 3.39E-02 0.0755 -2.309 
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid 
Arthritis 
1.46 3.47E-02 0.0647  
Hereditary Breast Cancer Signaling 1.45 3.55E-02 0.0775  
Nur77 Signaling in T Lymphocytes 1.45 3.55E-02 0.102  
Antiproliferative Role of Somatostatin Receptor 2 1.44 3.63E-02 0.0933 -1.134 
IL-8 Signaling 1.44 3.63E-02 0.0711 -3.742 
Axonal Guidance Signaling 1.43 3.72E-02 0.06  
Death Receptor Signaling 1.42 3.80E-02 0.087 -1.414 
Ovarian Cancer Signaling 1.42 3.80E-02 0.0764  
Dopamine-DARPP32 Feedback in cAMP Signaling 1.42 3.80E-02 0.0741 -2.714 
IL-15 Signaling 1.41 3.89E-02 0.0921  
Neurotrophin/TRK Signaling 1.41 3.89E-02 0.0921 -2.646 
Retinoic acid Mediated Apoptosis Signaling 1.39 4.07E-02 0.0984 -2.449 
Dopamine Receptor Signaling 1.39 4.07E-02 0.0909  
Inositol Pyrophosphates Biosynthesis 1.39 4.07E-02 0.25  
Role of Oct4 in Mammalian Embryonic Stem Cell Pluripotency 1.38 4.17E-02 0.109  
Synaptic Long Term Depression 1.38 4.17E-02 0.0753 -2.111 
GNRH Signaling 1.37 4.27E-02 0.0775 -3.162 
Gα12/13 Signaling 1.35 4.47E-02 0.0769 -2.53 
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Ingenuity Canonical Pathways -log(p-value) P-value Ratio z-score 
Role of NFAT in Regulation of the Immune Response 1.34 4.57E-02 0.0703 -3.464 
Nitric Oxide Signaling in the Cardiovascular System 1.34 4.57E-02 0.0796 -2.121 
Tight Junction Signaling 1.33 4.68E-02 0.0719  
Cell Cycle: G1/S Checkpoint Regulation 1.3 5.01E-02 0.0938 0 
IL-2 Signaling 1.3 5.01E-02 0.0938 -2.449 









































Table 15. Functional categories significantly represented for the set of 453 DEG. The first and third levels of 
functional categories are shown (‘Category’ and ‘Function Annnotation’). Categories were considered significantly 
enriched if P-value < 0.05. Column ‘Activation z-score’ represents the predicted function activation (z-score > 2),  
inhibition (z-score < -2), or inability to predict (z-score not available). 
 
Category Function Annotation P-value Activation z-score # Genes 
Lipid Metabolism concentration of acylglycerol 1.51E-14 -1.469 39 
Lipid Metabolism concentration of triacylglycerol 2.20E-14 -1.517 37 
Lipid Metabolism concentration of fatty acid 1.35E-09 1.269 28 
Lipid Metabolism concentration of lipid 3.26E-09 -1.217 55 
Lipid Metabolism concentration of 1,2-
dipalmitoylphosphatidylcholine 
7.60E-08 -2.236 5 
Lipid Metabolism concentration of cholesterol 2.51E-07 0.572 25 
Lipid Metabolism concentration of phosphatidylcholine 6.42E-07 -1.416 9 
Lipid Metabolism concentration of malonyl-coenzyme A 9.47E-06 -1.106 5 
Lipid Metabolism concentration of phospholipid 1.03E-04 -1.444 15 
Lipid Metabolism concentration of 18:1(n-9) fatty acids 4.29E-04  2 
Lipid Metabolism synthesis of triacylglycerol 1.78E-09 -1.723 13 
Lipid Metabolism synthesis of acylglycerol 9.79E-09 -1.621 15 
Lipid Metabolism synthesis of lipid 1.62E-07 -3.341 46 
Lipid Metabolism synthesis of fatty acid 2.50E-06 -2.507 24 
Lipid Metabolism synthesis of long chain fatty acid 7.52E-06 -2.195 6 
Lipid Metabolism synthesis of eicosanoid 1.31E-04 -2.557 16 
Lipid Metabolism synthesis of palmitic acid 6.77E-04  3 
Lipid Metabolism synthesis of acyl-coenzyme A 6.78E-04  4 
Lipid Metabolism homeostasis of lipid 6.55E-09  21 
Lipid Metabolism metabolism of triacylglycerol 6.67E-09 -1.794 15 
Lipid Metabolism metabolism of acylglycerol 3.05E-08 -1.658 17 
Lipid Metabolism fatty acid metabolism 2.35E-07 -3.557 40 
Lipid Metabolism metabolism of eicosanoid 4.45E-05 -2.724 18 
Lipid Metabolism metabolism of prostaglandin 3.87E-04 -1.744 13 
Lipid Metabolism metabolism of acetyl-coenzyme A 6.77E-04  3 
Lipid Metabolism lipolysis of adipose tissue 1.38E-08 0.215 10 
Lipid Metabolism lipolysis 2.42E-07 0.277 13 
Lipid Metabolism lipolysis of adipocytes 1.65E-06 -0.137 7 
Lipid Metabolism lipolysis of cells 9.34E-06 0.624 8 
Lipid Metabolism lipolysis of fibroblast cell lines 3.64E-05 0.493 6 
Lipid Metabolism lipolysis of fatty acid 4.59E-04  3 
Lipid Metabolism storage of lipid 2.41E-08 -1.644 13 
Lipid Metabolism storage of triacylglycerol 5.15E-07 -1.664 6 
Lipid Metabolism storage of fatty acid 8.85E-06  3 
Lipid Metabolism accumulation of lipid 5.81E-07 -0.751 25 
Lipid Metabolism accumulation of lipid droplets 1.12E-06 -0.388 8 
Lipid Metabolism accumulation of triacylglycerol 2.93E-04 -0.227 9 
Lipid Metabolism conversion of fatty acid 5.84E-06 -1.526 8 
Lipid Metabolism conversion of lipid 1.49E-05 -1.854 14 
Lipid Metabolism conversion of acyl-coenzyme A 7.91E-05 -1.964 4 
Lipid Metabolism conversion of acetyl-coenzyme A 8.58E-05  3 
Lipid Metabolism conversion of malonyl-coenzyme A 4.29E-04  2 
Lipid Metabolism quantity of steroid 5.92E-06 0.136 31 
Lipid Metabolism quantity of monounsaturated fatty acids 1.35E-05 0.517 5 
Lipid Metabolism quantity of diacylglycerol 1.90E-04 -0.359 7 
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Lipid Metabolism quantity of palmitoleic acid 2.91E-04  3 
Lipid Metabolism quantity of 1-palmitoyl-2-linoleoyl-sn-glycero-
3-phosphocholine 
4.29E-04  2 
Lipid Metabolism oxidation of acyl-coenzyme A 6.07E-06 -0.762 4 
Lipid Metabolism oxidation of fatty acid 1.65E-05 -0.345 15 
Lipid Metabolism oxidation of lipid 7.95E-05 -0.553 16 
Lipid Metabolism oxidation of palmitoyl-coenzyme A 1.69E-04  3 
Lipid Metabolism modification of long-chain acyl-coenzyme A 3.47E-05  4 
Lipid Metabolism biosynthesis of polyunsaturated fatty acids 4.85E-05 -2.557 17 
Lipid Metabolism biosynthesis of stearic acid 8.58E-05  3 
Lipid Metabolism abnormal quantity of lipid 5.06E-05  13 
Lipid Metabolism abnormal quantity of triacylglycerol 7.91E-05  4 
Lipid Metabolism hydrolysis of triacylglycerol 5.29E-05 -1.992 6 
Lipid Metabolism deposition of lipid 3.56E-04 -0.762 6 
Lipid Metabolism uptake of lipid 6.37E-04 -2.921 12 
Lipid Metabolism influx of cholesterol 6.77E-04  3 
Molecular Transport concentration of acylglycerol 1.51E-14 -1.469 39 
Molecular Transport concentration of triacylglycerol 2.20E-14 -1.517 37 
Molecular Transport concentration of fatty acid 1.35E-09 1.269 28 
Molecular Transport concentration of lipid 3.26E-09 -1.217 55 
Molecular Transport concentration of 1,2-
dipalmitoylphosphatidylcholine 
7.60E-08 -2.236 5 
Molecular Transport concentration of cholesterol 2.51E-07 0.572 25 
Molecular Transport concentration of phosphatidylcholine 6.42E-07 -1.416 9 
Molecular Transport concentration of D-glucose 1.02E-06 -0.308 26 
Molecular Transport concentration of malonyl-coenzyme A 9.47E-06 -1.106 5 
Molecular Transport concentration of hormone 9.74E-06 -1.565 27 
Molecular Transport concentration of phospholipid 1.03E-04 -1.444 15 
Molecular Transport concentration of 18:1(n-9) fatty acids 4.29E-04  2 
Molecular Transport accumulation of lipid 5.81E-07 -0.751 25 
Molecular Transport accumulation of triacylglycerol 2.93E-04 -0.227 9 
Molecular Transport uptake of D-glucose 4.03E-06 -1.501 19 
Molecular Transport uptake of lipid 6.37E-04 -2.921 12 
Molecular Transport quantity of steroid 5.92E-06 0.136 31 
Molecular Transport quantity of monounsaturated fatty acids 1.35E-05 0.517 5 
Molecular Transport quantity of insulin in blood 1.19E-04 -1.974 15 
Molecular Transport quantity of diacylglycerol 1.90E-04 -0.359 7 
Molecular Transport quantity of glycogen 2.53E-04 -0.395 9 
Molecular Transport quantity of palmitoleic acid 2.91E-04  3 
Molecular Transport quantity of 1-palmitoyl-2-linoleoyl-sn-glycero-
3-phosphocholine 
4.29E-04  2 
Molecular Transport release of glycerol 1.57E-05 -0.883 6 
Molecular Transport abnormal quantity of lipid 5.06E-05  13 
Molecular Transport abnormal quantity of triacylglycerol 7.91E-05  4 
Molecular Transport deposition of lipid 3.56E-04 -0.762 6 
Molecular Transport influx of cholesterol 6.77E-04  3 
Small Molecule Biochemistry concentration of acylglycerol 1.51E-14 -1.469 39 
Small Molecule Biochemistry concentration of triacylglycerol 2.20E-14 -1.517 37 
Small Molecule Biochemistry concentration of fatty acid 1.35E-09 1.269 28 
Small Molecule Biochemistry concentration of lipid 3.26E-09 -1.217 55 
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Small Molecule Biochemistry concentration of 1,2-
dipalmitoylphosphatidylcholine 
7.60E-08 -2.236 5 
Small Molecule Biochemistry concentration of cholesterol 2.51E-07 0.572 25 
Small Molecule Biochemistry concentration of phosphatidylcholine 6.42E-07 -1.416 9 
Small Molecule Biochemistry concentration of D-glucose 1.02E-06 -0.308 26 
Small Molecule Biochemistry concentration of malonyl-coenzyme A 9.47E-06 -1.106 5 
Small Molecule Biochemistry concentration of hormone 9.74E-06 -1.565 27 
Small Molecule Biochemistry concentration of phospholipid 1.03E-04 -1.444 15 
Small Molecule Biochemistry concentration of 18:1(n-9) fatty acids 4.29E-04  2 
Small Molecule Biochemistry synthesis of triacylglycerol 1.78E-09 -1.723 13 
Small Molecule Biochemistry synthesis of acylglycerol 9.79E-09 -1.621 15 
Small Molecule Biochemistry synthesis of lipid 1.62E-07 -3.341 46 
Small Molecule Biochemistry synthesis of fatty acid 2.50E-06 -2.507 24 
Small Molecule Biochemistry synthesis of long chain fatty acid 7.52E-06 -2.195 6 
Small Molecule Biochemistry synthesis of eicosanoid 1.31E-04 -2.557 16 
Small Molecule Biochemistry synthesis of glycerol 2.91E-04  3 
Small Molecule Biochemistry synthesis of D-hexose 4.84E-04 -1.43 8 
Small Molecule Biochemistry synthesis of polyols 6.20E-04 -0.075 9 
Small Molecule Biochemistry synthesis of palmitic acid 6.77E-04  3 
Small Molecule Biochemistry synthesis of acyl-coenzyme A 6.78E-04  4 
Small Molecule Biochemistry homeostasis of lipid 6.55E-09  21 
Small Molecule Biochemistry homeostasis of D-glucose 1.57E-07  21 
Small Molecule Biochemistry metabolism of triacylglycerol 6.67E-09 -1.794 15 
Small Molecule Biochemistry metabolism of acylglycerol 3.05E-08 -1.658 17 
Small Molecule Biochemistry fatty acid metabolism 2.35E-07 -3.557 40 
Small Molecule Biochemistry metabolism of dicarboxylic acid 3.64E-05  6 
Small Molecule Biochemistry metabolism of eicosanoid 4.45E-05 -2.724 18 
Small Molecule Biochemistry metabolism of oxalacetic acid 1.12E-04  4 
Small Molecule Biochemistry metabolism of citric acid 2.91E-04  3 
Small Molecule Biochemistry metabolism of prostaglandin 3.87E-04 -1.744 13 
Small Molecule Biochemistry metabolism of acetyl-coenzyme A 6.77E-04  3 
Small Molecule Biochemistry lipolysis of adipose tissue 1.38E-08 0.215 10 
Small Molecule Biochemistry lipolysis 2.42E-07 0.277 13 
Small Molecule Biochemistry lipolysis of adipocytes 1.65E-06 -0.137 7 
Small Molecule Biochemistry lipolysis of cells 9.34E-06 0.624 8 
Small Molecule Biochemistry lipolysis of fibroblast cell lines 3.64E-05 0.493 6 
Small Molecule Biochemistry lipolysis of fatty acid 4.59E-04  3 
Small Molecule Biochemistry storage of lipid 2.41E-08 -1.644 13 
Small Molecule Biochemistry storage of triacylglycerol 5.15E-07 -1.664 6 
Small Molecule Biochemistry storage of fatty acid 8.85E-06  3 
Small Molecule Biochemistry accumulation of lipid 5.81E-07 -0.751 25 
Small Molecule Biochemistry accumulation of lipid droplets 1.12E-06 -0.388 8 
Small Molecule Biochemistry accumulation of triacylglycerol 2.93E-04 -0.227 9 
Small Molecule Biochemistry uptake of D-glucose 4.03E-06 -1.501 19 
Small Molecule Biochemistry uptake of lipid 6.37E-04 -2.921 12 
Small Molecule Biochemistry conversion of fatty acid 5.84E-06 -1.526 8 
Small Molecule Biochemistry conversion of lipid 1.49E-05 -1.854 14 
Small Molecule Biochemistry conversion of acyl-coenzyme A 7.91E-05 -1.964 4 
Small Molecule Biochemistry conversion of acetyl-coenzyme A 8.58E-05  3 
Small Molecule Biochemistry conversion of malonyl-coenzyme A 4.29E-04  2 
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Small Molecule Biochemistry quantity of steroid 5.92E-06 0.136 31 
Small Molecule Biochemistry quantity of monounsaturated fatty acids 1.35E-05 0.517 5 
Small Molecule Biochemistry quantity of insulin in blood 1.19E-04 -1.974 15 
Small Molecule Biochemistry quantity of diacylglycerol 1.90E-04 -0.359 7 
Small Molecule Biochemistry quantity of palmitoleic acid 2.91E-04  3 
Small Molecule Biochemistry quantity of 1-palmitoyl-2-linoleoyl-sn-glycero-
3-phosphocholine 
4.29E-04  2 
Small Molecule Biochemistry oxidation of acyl-coenzyme A 6.07E-06 -0.762 4 
Small Molecule Biochemistry oxidation of fatty acid 1.65E-05 -0.345 15 
Small Molecule Biochemistry oxidation of lipid 7.95E-05 -0.553 16 
Small Molecule Biochemistry oxidation of palmitoyl-coenzyme A 1.69E-04  3 
Small Molecule Biochemistry release of glycerol 1.57E-05 -0.883 6 
Small Molecule Biochemistry modification of long-chain acyl-coenzyme A 3.47E-05  4 
Small Molecule Biochemistry biosynthesis of polyunsaturated fatty acids 4.85E-05 -2.557 17 
Small Molecule Biochemistry biosynthesis of stearic acid 8.58E-05  3 
Small Molecule Biochemistry abnormal quantity of lipid 5.06E-05  13 
Small Molecule Biochemistry abnormal quantity of triacylglycerol 7.91E-05  4 
Small Molecule Biochemistry hydrolysis of triacylglycerol 5.29E-05 -1.992 6 
Small Molecule Biochemistry incorporation of D-glucose 2.07E-04 -0.943 4 
Small Molecule Biochemistry deposition of lipid 3.56E-04 -0.762 6 
Small Molecule Biochemistry pentose shunt of D-glucose 4.59E-04  3 
Small Molecule Biochemistry influx of cholesterol 6.77E-04  3 
Cell Morphology morphology of adipocytes 9.91E-11  20 
Cell Morphology morphology of connective tissue cells 6.16E-10  29 
Cell Morphology morphology of cells 3.00E-07  103 
Cell Morphology morphology of blood cells 6.90E-05  27 
Cell Morphology morphology of leukocytes 1.96E-04  21 
Cell Morphology morphology of phagocytes 2.33E-04  12 
Cell Morphology size of connective tissue cells 2.20E-10  20 
Cell Morphology size of adipocytes 2.42E-09  17 
Cell Morphology size of cells 2.54E-06  34 
Cell Morphology size of white adipocytes 4.01E-04  6 
Cell Morphology remyelination of axons 4.59E-04  3 
Connective Tissue Development and Function morphology of adipocytes 9.91E-11  20 
Connective Tissue Development and Function mass of connective tissue 1.04E-10  25 
Connective Tissue Development and Function mass of adipose tissue 1.23E-10  24 
Connective Tissue Development and Function mass of white adipose tissue 5.82E-07  8 
Connective Tissue Development and Function mass of fat pad 2.45E-06  13 
Connective Tissue Development and Function mass of mesenteric fat 2.07E-04  4 
Connective Tissue Development and Function mass of inguinal fat pad 2.95E-04  5 
Connective Tissue Development and Function mass of brown adipose tissue 4.43E-04  4 
Connective Tissue Development and Function mass of parametrial fat pad 4.59E-04  3 
Connective Tissue Development and Function mass of epigonadal fat pad 5.05E-04  6 
Connective Tissue Development and Function size of connective tissue cells 2.20E-10  20 
Connective Tissue Development and Function size of adipose tissue 1.05E-09  18 
Connective Tissue Development and Function size of adipocytes 2.42E-09  17 
Connective Tissue Development and Function size of connective tissue 7.70E-09  21 
Connective Tissue Development and Function size of fat pad 7.91E-05  4 
Connective Tissue Development and Function size of white adipocytes 4.01E-04  6 
Connective Tissue Development and Function quantity of adipose tissue 6.15E-10 -0.601 28 
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Connective Tissue Development and Function quantity of connective tissue 7.37E-06 0.035 37 
Connective Tissue Development and Function quantity of subcutaneous fat 7.46E-06 -1.912 9 
Connective Tissue Development and Function quantity of adipocytes 9.44E-06 0.431 7 
Connective Tissue Development and Function quantity of white adipose tissue 3.65E-05 0.095 10 
Connective Tissue Development and Function quantity of brown adipose tissue 1.70E-04 0.436 7 
Connective Tissue Development and Function lipolysis of adipose tissue 1.38E-08 0.215 10 
Connective Tissue Development and Function lipolysis of adipocytes 1.65E-06 -0.137 7 
Connective Tissue Development and Function lipolysis of fibroblast cell lines 3.64E-05 0.493 6 
Connective Tissue Development and Function differentiation of connective tissue 1.90E-08 -1.897 50 
Connective Tissue Development and Function differentiation of connective tissue cells 3.07E-07 -1.339 43 
Connective Tissue Development and Function differentiation of adipocytes 1.54E-04 -0.793 18 
Connective Tissue Development and Function differentiation of bone cells 3.11E-04 -1.935 24 
Connective Tissue Development and Function function of adipose tissue 3.52E-06  8 
Connective Tissue Development and Function function of white adipose tissue 1.35E-05  5 
Connective Tissue Development and Function adipogenesis 2.06E-04 -2.367 13 
Connective Tissue Development and Function adipogenesis of cells 4.10E-04 -2.564 10 
Connective Tissue Development and Function bone mineral density of trabecular bone 2.07E-04 -2 4 
Connective Tissue Development and Function bone mineral density of skeleton 2.14E-04 -0.431 6 
Tissue Morphology morphology of adipocytes 9.91E-11  20 
Tissue Morphology morphology of white adipose tissue 1.51E-10  16 
Tissue Morphology morphology of connective tissue 4.21E-10  49 
Tissue Morphology morphology of connective tissue cells 6.16E-10  29 
Tissue Morphology morphology of lymphoid tissue 1.55E-07  38 
Tissue Morphology morphology of lymphoid organ 3.67E-07  35 
Tissue Morphology morphology of spleen 1.28E-05  26 
Tissue Morphology morphology of brown adipose tissue 2.11E-04  7 
Tissue Morphology mass of connective tissue 1.04E-10  25 
Tissue Morphology mass of adipose tissue 1.23E-10  24 
Tissue Morphology mass of white adipose tissue 5.82E-07  8 
Tissue Morphology mass of fat pad 2.45E-06  13 
Tissue Morphology mass of mesenteric fat 2.07E-04  4 
Tissue Morphology mass of inguinal fat pad 2.95E-04  5 
Tissue Morphology mass of liver tissue 4.29E-04  2 
Tissue Morphology mass of brown adipose tissue 4.43E-04  4 
Tissue Morphology mass of parametrial fat pad 4.59E-04  3 
Tissue Morphology mass of epigonadal fat pad 5.05E-04  6 
Tissue Morphology size of connective tissue cells 2.20E-10  20 
Tissue Morphology size of adipose tissue 1.05E-09  18 
Tissue Morphology size of adipocytes 2.42E-09  17 
Tissue Morphology size of connective tissue 7.70E-09  21 
Tissue Morphology size of fat pad 7.91E-05  4 
Tissue Morphology size of white adipocytes 4.01E-04  6 
Tissue Morphology size of vascular lesion 4.84E-04  8 
Tissue Morphology size of lesion 6.91E-04  20 
Tissue Morphology size of lymphoid organ 8.07E-04  8 
Tissue Morphology quantity of adipose tissue 6.15E-10 -0.601 28 
Tissue Morphology quantity of connective tissue 7.37E-06 0.035 37 
Tissue Morphology quantity of subcutaneous fat 7.46E-06 -1.912 9 
Tissue Morphology quantity of adipocytes 9.44E-06 0.431 7 
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Tissue Morphology quantity of B lymphocytes 9.62E-06 -1.24 25 
Tissue Morphology quantity of stem cells 1.90E-05 -1.588 10 
Tissue Morphology quantity of leukocytes 2.50E-05 -0.774 49 
Tissue Morphology quantity of white adipose tissue 3.65E-05 0.095 10 
Tissue Morphology quantity of cells 3.80E-05 -0.326 82 
Tissue Morphology quantity of blood cells 8.18E-05 -0.628 52 
Tissue Morphology quantity of lymphocytes 8.42E-05 -1.3 39 
Tissue Morphology quantity of mononuclear leukocytes 9.51E-05 -1.329 40 
Tissue Morphology quantity of phagocytes 9.72E-05 -0.478 26 
Tissue Morphology quantity of myeloid cells 1.57E-04 0.243 28 
Tissue Morphology quantity of brown adipose tissue 1.70E-04 0.436 7 
Tissue Morphology quantity of lymphatic system cells 2.16E-04 -1.499 40 
Tissue Morphology quantity of neutrophils 2.46E-04 1.294 16 
Tissue Morphology quantity of T lymphocytes 2.51E-04 -1.426 30 
Tissue Morphology quantity of granulocytes 3.14E-04 1.456 20 
Tissue Morphology quantity of CD4+ T-lymphocytes 3.92E-04 -1.198 12 
Tissue Morphology quantity of breast cancer cell lines 7.28E-04 -0.235 5 
Tissue Morphology lipolysis of adipose tissue 1.38E-08 0.215 10 
Tissue Morphology lipolysis of adipocytes 1.65E-06 -0.137 7 
Tissue Morphology abnormal morphology of adipose tissue 6.18E-06  13 
Tissue Morphology abnormal morphology of lymphoid organ 2.55E-05  25 
Tissue Morphology abnormal morphology of fat pad 2.61E-04  7 
Tissue Morphology abnormal morphology of spleen 6.78E-04  17 
Tissue Morphology abnormal morphology of white adipose tissue 6.78E-04  4 
Digestive System Development and Function morphology of liver 5.77E-09  30 
Digestive System Development and Function morphology of digestive system 6.55E-07  44 
Digestive System Development and Function mass of liver 3.01E-07  15 
Digestive System Development and Function mass of liver tissue 4.29E-04  2 
Digestive System Development and Function abnormal morphology of hepatobiliary system 5.63E-06  20 
Digestive System Development and Function abnormal morphology of liver 2.96E-05  18 
Digestive System Development and Function function of liver 8.39E-05  10 
Digestive System Development and Function response of liver 1.90E-04 0.893 21 
Digestive System Development and Function inflammation of liver 4.04E-04 1.187 20 
Hepatic System Development and Function morphology of liver 5.77E-09  30 
Hepatic System Development and Function mass of liver 3.01E-07  15 
Hepatic System Development and Function mass of liver tissue 4.29E-04  2 
Hepatic System Development and Function abnormal morphology of hepatobiliary system 5.63E-06  20 
Hepatic System Development and Function abnormal morphology of liver 2.96E-05  18 
Hepatic System Development and Function function of liver 8.39E-05  10 
Hepatic System Development and Function response of liver 1.90E-04 0.893 21 
Hepatic System Development and Function inflammation of liver 4.04E-04 1.187 20 
Organ Morphology morphology of liver 5.77E-09  30 
Organ Morphology morphology of lymphoid organ 3.67E-07  35 
Organ Morphology morphology of spleen 1.28E-05  26 
Organ Morphology morphology of epididymis 5.10E-04  9 
Organ Morphology morphology of kidney 5.31E-04  18 
Organ Morphology morphology of heart 5.58E-04  27 
Organ Morphology mass of liver 3.01E-07  15 
Organ Morphology mass of genitourinary system 1.70E-05  22 
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Organ Morphology mass of accessory sex gland 2.07E-04  5 
Organ Morphology mass of brain 3.52E-04  7 
Organ Morphology mass of liver tissue 4.29E-04  2 
Organ Morphology mass of epigonadal fat pad 5.05E-04  6 
Organ Morphology mass of epididymis 6.34E-04  5 
Organ Morphology abnormal morphology of lymphoid organ 2.55E-05  25 
Organ Morphology abnormal morphology of liver 2.96E-05  18 
Organ Morphology abnormal morphology of rete testis 6.77E-04  3 
Organ Morphology abnormal morphology of spleen 6.78E-04  17 
Organ Morphology quantity of ovarian follicle 2.17E-04 -2.521 9 
Organ Morphology quantity of zigzag hair 4.29E-04  2 
Organ Morphology size of uterus 4.59E-04  3 
Organ Morphology size of lymphoid organ 8.07E-04  8 
Organismal Development morphology of liver 5.77E-09  30 
Organismal Development morphology of body cavity 1.55E-07  77 
Organismal Development morphology of spleen 1.28E-05  26 
Organismal Development morphology of kidney 5.31E-04  18 
Organismal Development morphology of heart 5.58E-04  27 
Organismal Development mass of liver 3.01E-07  15 
Organismal Development mass of organism 3.44E-06 -1.552 25 
Organismal Development mass of genitourinary system 1.70E-05  22 
Organismal Development mass of accessory sex gland 2.07E-04  5 
Organismal Development mass of brain 3.52E-04  7 
Organismal Development mass of liver tissue 4.29E-04  2 
Organismal Development mass of epigonadal fat pad 5.05E-04  6 
Organismal Development mass of epididymis 6.34E-04  5 
Organismal Development abnormal morphology of body cavity 4.55E-06  63 
Organismal Development abnormal morphology of hepatobiliary system 5.63E-06  20 
Organismal Development abnormal morphology of liver 2.96E-05  18 
Organismal Development abnormal morphology of abdomen 1.18E-04  46 
Organismal Development abnormal morphology of spleen 6.78E-04  17 
Organismal Development lean body mass 5.38E-06 -0.263 11 
Organismal Development development of genitourinary system 2.63E-05 -3.025 52 
Organismal Development development of body trunk 6.13E-05 -3.93 60 
Organismal Development development of reproductive system 4.55E-04 -2.674 38 
Organismal Development development of abdomen 5.18E-04 -2.08 31 
Organismal Development development of bone marrow cells 6.19E-04 -1.353 10 
Organismal Development growth of organism 8.16E-05 -2.366 44 
Organismal Development differentiation of gamma-delta T lymphocytes 2.07E-04 -1.982 4 
Organismal Development size of body 3.31E-04 -4.819 43 
Organismal Development size of uterus 4.59E-04  3 
Organismal Development formation of mammary lobuloalveolar unit 3.50E-04  4 
Organismal Development formation of mammary gland 5.61E-04 -2.404 14 
Cellular Development differentiation of cells 5.82E-09 -3.447 115 
Cellular Development differentiation of connective tissue 1.90E-08 -1.897 50 
Cellular Development differentiation of connective tissue cells 3.07E-07 -1.339 43 
Cellular Development differentiation of lymphatic system cells 3.21E-05 -2.271 35 
Cellular Development differentiation of adipocytes 1.54E-04 -0.793 18 
Cellular Development differentiation of mononuclear leukocytes 1.72E-04 -2.069 31 
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Cellular Development differentiation of lymphocytes 1.73E-04 -1.711 29 
Cellular Development differentiation of gamma-delta T lymphocytes 2.07E-04 -1.982 4 
Cellular Development differentiation of leukocytes 2.25E-04 -2.351 35 
Cellular Development differentiation of bone cells 3.11E-04 -1.935 24 
Cellular Development development of bone marrow cell lines 1.96E-05  6 
Cellular Development development of neutrophils 1.12E-04  4 
Cellular Development development of bone marrow cells 6.19E-04 -1.353 10 
Cellular Development cell proliferation of tumor cell lines 2.96E-05 -2.345 77 
Cellular Development cell proliferation of leukocyte cell lines 5.17E-04 -2.101 14 
Cellular Development expansion of leukocytes 1.13E-04 0.343 15 
Cellular Development expansion of blood cells 2.77E-04 0.605 16 
Cellular Development expansion of lymphocytes 4.24E-04 0.04 13 
Cellular Development proliferation of B lymphocytes 2.70E-04 -0.256 19 
Cellular Development proliferation of leukemia cell lines 3.02E-04 -1.309 15 
Cellular Development proliferation of immune cells 4.93E-04 -0.037 39 
Cellular Development arrest in proliferation of tumor cell lines 5.52E-04  10 
Cellular Development adipogenesis of cells 4.10E-04 -2.564 10 
Cellular Development remyelination of axons 4.59E-04  3 
Protein Synthesis synthesis of protein 1.14E-08 0.365 35 
Protein Synthesis expression of protein 5.92E-07 0.709 26 
Protein Synthesis quantity of protein in blood 8.45E-07 -0.221 35 
Protein Synthesis quantity of cytokine 2.55E-06 1.246 21 
Protein Synthesis quantity of insulin in blood 1.19E-04 -1.974 15 
Protein Synthesis quantity of leptin in blood 5.52E-04 0.497 10 
Protein Synthesis translation 2.43E-06 0.913 21 
Protein Synthesis translation of protein 6.53E-06 0.664 20 
Protein Synthesis translation of mRNA 1.75E-05 0.692 15 
Protein Synthesis metabolism of protein 1.05E-05 0.492 51 
Protein Synthesis assembly of exocyst 4.29E-04  2 
Cell Death and Survival necrosis 1.20E-08 -0.359 128 
Cell Death and Survival necrosis of malignant tumor 5.91E-08 -2.693 31 
Cell Death and Survival necrosis of tumor 1.83E-07 -2.787 34 
Cell Death and Survival necrosis of liver 1.33E-04 1.943 17 
Cell Death and Survival cell death of tumor 6.71E-08 -2.787 35 
Cell Death and Survival cell death of cancer cells 1.73E-07 -2.693 30 
Cell Death and Survival cell death 1.81E-07 0.55 150 
Cell Death and Survival cell death of tumor cells 3.24E-07 -2.787 33 
Cell Death and Survival cell death of osteosarcoma cells 7.84E-07 -3.207 14 
Cell Death and Survival cell death of tumor cell lines 3.27E-05 0.985 74 
Cell Death and Survival cell death of adipocytes 5.79E-05 0.651 5 
Cell Death and Survival cell viability 2.65E-07 -4.205 72 
Cell Death and Survival cell survival 1.45E-06 -4.373 73 
Cell Death and Survival apoptosis of tumor cell lines 4.09E-06 0.346 65 
Cell Death and Survival apoptosis 1.46E-04 1.593 110 
Cell Death and Survival apoptosis of splenocytes 1.87E-04 -2.449 6 
Cell Death and Survival apoptosis of leukocyte cell lines 4.05E-04 0.594 13 
Cell Death and Survival apoptosis of hematopoietic cell lines 5.39E-04 0.625 14 
Tissue Development differentiation of connective tissue 1.90E-08 -1.897 50 
Tissue Development differentiation of connective tissue cells 3.07E-07 -1.339 43 
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Tissue Development differentiation of adipocytes 1.54E-04 -0.793 18 
Tissue Development differentiation of gamma-delta T lymphocytes 2.07E-04 -1.982 4 
Tissue Development differentiation of bone cells 3.11E-04 -1.935 24 
Tissue Development function of adipose tissue 3.52E-06  8 
Tissue Development function of white adipose tissue 1.35E-05  5 
Tissue Development accumulation of cells 2.19E-05 -1.23 23 
Tissue Development accumulation of blood cells 4.20E-05 -1.604 20 
Tissue Development accumulation of leukocytes 5.38E-05 -1.405 19 
Tissue Development accumulation of mononuclear leukocytes 5.72E-05 -1.715 13 
Tissue Development accumulation of lymphocytes 9.74E-05 -1.946 12 
Tissue Development accumulation of memory T lymphocytes 6.77E-04  3 
Tissue Development development of neutrophils 1.12E-04  4 
Tissue Development development of bone marrow cells 6.19E-04 -1.353 10 
Tissue Development homeostasis of tissue 2.64E-04  10 
Tissue Development formation of mammary lobuloalveolar unit 3.50E-04  4 
Tissue Development formation of gland 5.29E-04 -2.589 16 
Tissue Development formation of mammary gland 5.61E-04 -2.404 14 
Tissue Development remyelination of axons 4.59E-04  3 
Tissue Development generation of cells 7.81E-04 -3.933 85 
Cellular Movement cell movement of phagocytes 2.14E-08 -2.424 41 
Cellular Movement cell movement of myeloid cells 4.87E-08 -2.527 40 
Cellular Movement cell movement of neutrophils 1.38E-07 -3.155 26 
Cellular Movement cell movement of granulocytes 3.69E-07 -3.133 29 
Cellular Movement cell movement of blood cells 4.38E-07 -2.418 53 
Cellular Movement cell movement of leukocytes 1.11E-06 -2.236 47 
Cellular Movement cell movement 1.88E-05 -3.31 98 
Cellular Movement cell movement of lymphatic system cells 4.64E-04 -0.975 24 
Cellular Movement cell movement of mononuclear leukocytes 5.06E-04 -0.883 26 
Cellular Movement cell movement of macrophages 7.74E-04 -1.703 17 
Cellular Movement chemotaxis of myeloid cells 1.84E-07 -2.029 25 
Cellular Movement chemotaxis of blood cells 3.76E-07 -2.08 28 
Cellular Movement chemotaxis 7.16E-07 -2.39 37 
Cellular Movement chemotaxis of phagocytes 1.10E-06 -2.356 24 
Cellular Movement chemotaxis of leukocytes 1.18E-06 -2.08 27 
Cellular Movement chemotaxis of granulocytes 1.82E-05 -2.177 16 
Cellular Movement chemotaxis of neutrophils 4.25E-05 -2.474 14 
Cellular Movement leukocyte migration 7.34E-07 -2.164 52 
Cellular Movement migration of cells 1.66E-05 -3.107 89 
Cellular Movement migration of myeloid cells 1.86E-04 -2.382 14 
Cellular Movement cellular infiltration 1.62E-05 -2.078 29 
Cellular Movement cellular infiltration by leukocytes 6.22E-05 -1.959 25 
Cellular Movement cell rolling of granulocytes 2.44E-04 -2.093 6 
Cellular Movement cell rolling of neutrophils 3.48E-04 -2.093 5 
Cellular Movement cell rolling of lymphoma cell lines 4.29E-04  2 
Cellular Movement cell rolling of leukemia cell lines 6.77E-04  3 
Cellular Movement invasion of lung cancer cell lines 3.41E-04 -1.602 10 
Cellular Movement invasion of tumor cell lines 5.76E-04 -1.405 36 
Cellular Movement invasion of cells 5.93E-04 -1.128 44 
Cellular Movement deadhesion of T lymphocytes 4.29E-04  2 
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Cellular Movement localization of alpha islet cells 4.29E-04  2 
Cellular Movement release of cells 5.50E-04 -1.342 5 
Hematological System Development and Function cell movement of phagocytes 2.14E-08 -2.424 41 
Hematological System Development and Function cell movement of neutrophils 1.38E-07 -3.155 26 
Hematological System Development and Function cell movement of granulocytes 3.69E-07 -3.133 29 
Hematological System Development and Function cell movement of leukocytes 1.11E-06 -2.236 47 
Hematological System Development and Function cell movement of mononuclear leukocytes 5.06E-04 -0.883 26 
Hematological System Development and Function cell movement of macrophages 7.74E-04 -1.703 17 
Hematological System Development and Function morphology of lymphoid tissue 1.55E-07  38 
Hematological System Development and Function morphology of lymphoid organ 3.67E-07  35 
Hematological System Development and Function morphology of spleen 1.28E-05  26 
Hematological System Development and Function chemotaxis of phagocytes 1.10E-06 -2.356 24 
Hematological System Development and Function chemotaxis of leukocytes 1.18E-06 -2.08 27 
Hematological System Development and Function chemotaxis of granulocytes 1.82E-05 -2.177 16 
Hematological System Development and Function chemotaxis of neutrophils 4.25E-05 -2.474 14 
Hematological System Development and Function quantity of B lymphocytes 9.62E-06 -1.24 25 
Hematological System Development and Function quantity of leukocytes 2.50E-05 -0.774 49 
Hematological System Development and Function quantity of blood cells 8.18E-05 -0.628 52 
Hematological System Development and Function quantity of lymphocytes 8.42E-05 -1.3 39 
Hematological System Development and Function quantity of mononuclear leukocytes 9.51E-05 -1.329 40 
Hematological System Development and Function quantity of phagocytes 9.72E-05 -0.478 26 
Hematological System Development and Function quantity of myeloid cells 1.57E-04 0.243 28 
Hematological System Development and Function quantity of neutrophils 2.46E-04 1.294 16 
Hematological System Development and Function quantity of T lymphocytes 2.51E-04 -1.426 30 
Hematological System Development and Function quantity of granulocytes 3.14E-04 1.456 20 
Hematological System Development and Function quantity of CD4+ T-lymphocytes 3.92E-04 -1.198 12 
Hematological System Development and Function detachment of leukocytes 2.11E-05  4 
Hematological System Development and Function abnormal morphology of lymphoid organ 2.55E-05  25 
Hematological System Development and Function abnormal morphology of spleen 6.78E-04  17 
Hematological System Development and Function accumulation of blood cells 4.20E-05 -1.604 20 
Hematological System Development and Function accumulation of leukocytes 5.38E-05 -1.405 19 
Hematological System Development and Function accumulation of mononuclear leukocytes 5.72E-05 -1.715 13 
Hematological System Development and Function accumulation of lymphocytes 9.74E-05 -1.946 12 
Hematological System Development and Function accumulation of memory T lymphocytes 6.77E-04  3 
Hematological System Development and Function adhesion of phagocytes 4.47E-05 -2.162 13 
Hematological System Development and Function adhesion of immune cells 4.00E-04 -3.141 21 
Hematological System Development and Function adhesion of neutrophils 7.01E-04 -2.579 8 
Hematological System Development and Function cellular infiltration by leukocytes 6.22E-05 -1.959 25 
Hematological System Development and Function development of neutrophils 1.12E-04  4 
Hematological System Development and Function development of bone marrow cells 6.19E-04 -1.353 10 
Hematological System Development and Function expansion of leukocytes 1.13E-04 0.343 15 
Hematological System Development and Function expansion of lymphocytes 4.24E-04 0.04 13 
Hematological System Development and Function response of neutrophils 1.24E-04 -1.478 9 
Hematological System Development and Function differentiation of mononuclear leukocytes 1.72E-04 -2.069 31 
Hematological System Development and Function differentiation of lymphocytes 1.73E-04 -1.711 29 
Hematological System Development and Function differentiation of gamma-delta T lymphocytes 2.07E-04 -1.982 4 
Hematological System Development and Function differentiation of leukocytes 2.25E-04 -2.351 35 
Hematological System Development and Function cell rolling of granulocytes 2.44E-04 -2.093 6 
Hematological System Development and Function cell rolling of neutrophils 3.48E-04 -2.093 5 
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Hematological System Development and Function cell-cell adhesion of leukocytes 2.48E-04  5 
Hematological System Development and Function binding of professional phagocytic cells 2.64E-04 -3.068 10 
Hematological System Development and Function binding of leukocytes 4.24E-04 -3.534 13 
Hematological System Development and Function proliferation of B lymphocytes 2.70E-04 -0.256 19 
Hematological System Development and Function proliferation of immune cells 4.93E-04 -0.037 39 
Hematological System Development and Function deadhesion of T lymphocytes 4.29E-04  2 
Hematological System Development and Function cell proliferation of leukocyte cell lines 5.17E-04 -2.101 14 
Hematological System Development and Function size of lymphoid organ 8.07E-04  8 
Immune Cell Trafficking cell movement of phagocytes 2.14E-08 -2.424 41 
Immune Cell Trafficking cell movement of neutrophils 1.38E-07 -3.155 26 
Immune Cell Trafficking cell movement of granulocytes 3.69E-07 -3.133 29 
Immune Cell Trafficking cell movement of leukocytes 1.11E-06 -2.236 47 
Immune Cell Trafficking cell movement of lymphatic system cells 4.64E-04 -0.975 24 
Immune Cell Trafficking cell movement of mononuclear leukocytes 5.06E-04 -0.883 26 
Immune Cell Trafficking cell movement of macrophages 7.74E-04 -1.703 17 
Immune Cell Trafficking leukocyte migration 7.34E-07 -2.164 52 
Immune Cell Trafficking chemotaxis of phagocytes 1.10E-06 -2.356 24 
Immune Cell Trafficking chemotaxis of leukocytes 1.18E-06 -2.08 27 
Immune Cell Trafficking chemotaxis of granulocytes 1.82E-05 -2.177 16 
Immune Cell Trafficking chemotaxis of neutrophils 4.25E-05 -2.474 14 
Immune Cell Trafficking detachment of leukocytes 2.11E-05  4 
Immune Cell Trafficking adhesion of phagocytes 4.47E-05 -2.162 13 
Immune Cell Trafficking adhesion of immune cells 4.00E-04 -3.141 21 
Immune Cell Trafficking adhesion of neutrophils 7.01E-04 -2.579 8 
Immune Cell Trafficking accumulation of leukocytes 5.38E-05 -1.405 19 
Immune Cell Trafficking accumulation of mononuclear leukocytes 5.72E-05 -1.715 13 
Immune Cell Trafficking accumulation of lymphocytes 9.74E-05 -1.946 12 
Immune Cell Trafficking accumulation of memory T lymphocytes 6.77E-04  3 
Immune Cell Trafficking cellular infiltration by leukocytes 6.22E-05 -1.959 25 
Immune Cell Trafficking cell rolling of granulocytes 2.44E-04 -2.093 6 
Immune Cell Trafficking cell rolling of neutrophils 3.48E-04 -2.093 5 
Immune Cell Trafficking cell-cell adhesion of leukocytes 2.48E-04  5 
Immune Cell Trafficking deadhesion of T lymphocytes 4.29E-04  2 
Carbohydrate Metabolism quantity of carbohydrate 3.69E-08 -1.464 39 
Carbohydrate Metabolism quantity of glycogen 2.53E-04 -0.395 9 
Carbohydrate Metabolism quantity of 1-palmitoyl-2-linoleoyl-sn-glycero-
3-phosphocholine 
4.29E-04  2 
Carbohydrate Metabolism concentration of 1,2-
dipalmitoylphosphatidylcholine 
7.60E-08 -2.236 5 
Carbohydrate Metabolism concentration of phosphatidylcholine 6.42E-07 -1.416 9 
Carbohydrate Metabolism concentration of D-glucose 1.02E-06 -0.308 26 
Carbohydrate Metabolism homeostasis of D-glucose 1.57E-07  21 
Carbohydrate Metabolism metabolism of carbohydrate 3.56E-07 -2.488 41 
Carbohydrate Metabolism synthesis of carbohydrate 6.15E-07 -2.299 31 
Carbohydrate Metabolism synthesis of monosaccharide 4.86E-06 -1.676 11 
Carbohydrate Metabolism synthesis of glycerol 2.91E-04  3 
Carbohydrate Metabolism synthesis of D-hexose 4.84E-04 -1.43 8 
Carbohydrate Metabolism synthesis of polyols 6.20E-04 -0.075 9 
Carbohydrate Metabolism uptake of monosaccharide 9.09E-07 -1.715 23 
Carbohydrate Metabolism uptake of D-glucose 4.03E-06 -1.501 19 
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Carbohydrate Metabolism incorporation of carbohydrate 9.73E-06 -0.538 6 
Carbohydrate Metabolism incorporation of D-glucose 2.07E-04 -0.943 4 
Carbohydrate Metabolism release of glycerol 1.57E-05 -0.883 6 
Carbohydrate Metabolism clearance of monosaccharide 2.48E-04  5 
Carbohydrate Metabolism biosynthesis of D-ribose-5-phosphate 4.29E-04  2 
Carbohydrate Metabolism biosynthesis of pentose 4.29E-04  2 
Carbohydrate Metabolism pentose shunt of D-glucose 4.59E-04  3 
Gene Expression expression of RNA 3.79E-08 -2.148 107 
Gene Expression expression of mRNA 5.01E-07 -0.81 21 
Gene Expression transcription 4.36E-06 -2.678 94 
Gene Expression transcription of RNA 5.78E-05 -2.811 82 
Gene Expression translation of mRNA 1.75E-05 0.692 15 
Gene Expression binding of DNA 6.35E-04 -0.904 28 
Lymphoid Tissue Structure and Development morphology of lymphoid tissue 1.55E-07  38 
Lymphoid Tissue Structure and Development morphology of lymphoid organ 3.67E-07  35 
Lymphoid Tissue Structure and Development morphology of spleen 1.28E-05  26 
Lymphoid Tissue Structure and Development quantity of B lymphocytes 9.62E-06 -1.24 25 
Lymphoid Tissue Structure and Development quantity of lymphocytes 8.42E-05 -1.3 39 
Lymphoid Tissue Structure and Development quantity of lymphatic system cells 2.16E-04 -1.499 40 
Lymphoid Tissue Structure and Development quantity of T lymphocytes 2.51E-04 -1.426 30 
Lymphoid Tissue Structure and Development quantity of CD4+ T-lymphocytes 3.92E-04 -1.198 12 
Lymphoid Tissue Structure and Development abnormal morphology of lymphoid organ 2.55E-05  25 
Lymphoid Tissue Structure and Development abnormal morphology of spleen 6.78E-04  17 
Lymphoid Tissue Structure and Development development of neutrophils 1.12E-04  4 
Lymphoid Tissue Structure and Development development of bone marrow cells 6.19E-04 -1.353 10 
Lymphoid Tissue Structure and Development expansion of leukocytes 1.13E-04 0.343 15 
Lymphoid Tissue Structure and Development expansion of lymphatic system cells 3.53E-04 -0.127 14 
Lymphoid Tissue Structure and Development expansion of lymphocytes 4.24E-04 0.04 13 
Lymphoid Tissue Structure and Development differentiation of mononuclear leukocytes 1.72E-04 -2.069 31 
Lymphoid Tissue Structure and Development differentiation of lymphocytes 1.73E-04 -1.711 29 
Lymphoid Tissue Structure and Development differentiation of gamma-delta T lymphocytes 2.07E-04 -1.982 4 
Lymphoid Tissue Structure and Development differentiation of leukocytes 2.25E-04 -2.351 35 
Lymphoid Tissue Structure and Development proliferation of B lymphocytes 2.70E-04 -0.256 19 
Lymphoid Tissue Structure and Development proliferation of immune cells 4.93E-04 -0.037 39 
Lymphoid Tissue Structure and Development size of lymphoid organ 8.07E-04  8 
Cellular Function and Maintenance homeostasis of D-glucose 1.57E-07  21 
Cellular Function and Maintenance cellular homeostasis 6.62E-07 -4.187 82 
Cellular Function and Maintenance phagocytosis 8.98E-05 -2.953 21 
Cellular Function and Maintenance phagocytosis of cells 4.65E-04 -2.627 18 
Cellular Function and Maintenance quantity of cellular protrusions 1.43E-04 -0.135 13 
Cellular Function and Maintenance differentiation of gamma-delta T lymphocytes 2.07E-04 -1.982 4 
Cellular Function and Maintenance internalization of cells 2.66E-04 -2.437 16 
Cellular Function and Maintenance localization of alpha islet cells 4.29E-04  2 
Cellular Function and Maintenance organization of cytoskeleton 4.31E-04 -2.51 62 
Cellular Function and Maintenance organization of cytoplasm 7.61E-04 -2.51 66 
Cellular Function and Maintenance remyelination of axons 4.59E-04  3 
Cellular Growth and Proliferation proliferation of cells 1.78E-07 -2.034 161 
Cellular Growth and Proliferation proliferation of B lymphocytes 2.70E-04 -0.256 19 
Cellular Growth and Proliferation proliferation of leukemia cell lines 3.02E-04 -1.309 15 
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Cellular Growth and Proliferation proliferation of immune cells 4.93E-04 -0.037 39 
Cellular Growth and Proliferation arrest in proliferation of tumor cell lines 5.52E-04  10 
Cellular Growth and Proliferation development of bone marrow cell lines 1.96E-05  6 
Cellular Growth and Proliferation development of neutrophils 1.12E-04  4 
Cellular Growth and Proliferation development of bone marrow cells 6.19E-04 -1.353 10 
Cellular Growth and Proliferation cell proliferation of tumor cell lines 2.96E-05 -2.345 77 
Cellular Growth and Proliferation cell proliferation of leukocyte cell lines 5.17E-04 -2.101 14 
Cellular Growth and Proliferation expansion of leukocytes 1.13E-04 0.343 15 
Cellular Growth and Proliferation expansion of blood cells 2.77E-04 0.605 16 
Cellular Growth and Proliferation expansion of lymphatic system cells 3.53E-04 -0.127 14 
Cellular Growth and Proliferation expansion of lymphocytes 4.24E-04 0.04 13 
Cellular Growth and Proliferation expansion of cells 4.43E-04 0.124 19 
Cellular Growth and Proliferation differentiation of gamma-delta T lymphocytes 2.07E-04 -1.982 4 
Cellular Growth and Proliferation accumulation of colorectal cancer cell lines 4.59E-04  3 
Cellular Growth and Proliferation remyelination of axons 4.59E-04  3 
Cellular Growth and Proliferation generation of cells 7.81E-04 -3.933 85 
Endocrine System Development and Function insulin sensitivity 7.86E-07 2.862 15 
Endocrine System Development and Function glucose tolerance 2.32E-06 -0.168 22 
Endocrine System Development and Function concentration of hormone 9.74E-06 -1.565 27 
Endocrine System Development and Function quantity of insulin in blood 1.19E-04 -1.974 15 
Endocrine System Development and Function localization of alpha islet cells 4.29E-04  2 
Endocrine System Development and Function insulin sensitivity index 5.05E-04 -0.651 6 
Cellular Assembly and Organization accumulation of lipid droplets 1.12E-06 -0.388 8 
Cellular Assembly and Organization quantity of cellular protrusions 1.43E-04 -0.135 13 
Cellular Assembly and Organization quantity of lipid droplets 6.66E-04 -0.57 7 
Cellular Assembly and Organization organization of cytoskeleton 4.31E-04 -2.51 62 
Cellular Assembly and Organization organization of cytoplasm 7.61E-04 -2.51 66 
Cellular Assembly and Organization remyelination of axons 4.59E-04  3 
Energy Production oxidation of acyl-coenzyme A 6.07E-06 -0.762 4 
Energy Production oxidation of fatty acid 1.65E-05 -0.345 15 
Energy Production oxidation of lipid 7.95E-05 -0.553 16 
Energy Production oxidation of palmitoyl-coenzyme A 1.69E-04  3 
Energy Production consumption of oxygen 1.95E-04 0.994 13 
Nucleic Acid Metabolism oxidation of acyl-coenzyme A 6.07E-06 -0.762 4 
Nucleic Acid Metabolism oxidation of palmitoyl-coenzyme A 1.69E-04  3 
Nucleic Acid Metabolism concentration of malonyl-coenzyme A 9.47E-06 -1.106 5 
Nucleic Acid Metabolism modification of long-chain acyl-coenzyme A 3.47E-05  4 
Nucleic Acid Metabolism conversion of acyl-coenzyme A 7.91E-05 -1.964 4 
Nucleic Acid Metabolism conversion of acetyl-coenzyme A 8.58E-05  3 
Nucleic Acid Metabolism conversion of malonyl-coenzyme A 4.29E-04  2 
Nucleic Acid Metabolism pentose shunt of D-glucose 4.59E-04  3 
Nucleic Acid Metabolism metabolism of acetyl-coenzyme A 6.77E-04  3 
Nucleic Acid Metabolism synthesis of acyl-coenzyme A 6.78E-04  4 
Cell-To-Cell Signaling and Interaction binding of cells 7.90E-06 -3.893 31 
Cell-To-Cell Signaling and Interaction binding of tumor cell lines 9.70E-05 -1.901 14 
Cell-To-Cell Signaling and Interaction binding of myeloid cells 9.81E-05 -3.262 11 
Cell-To-Cell Signaling and Interaction binding of professional phagocytic cells 2.64E-04 -3.068 10 
Cell-To-Cell Signaling and Interaction binding of leukocytes 4.24E-04 -3.534 13 
Cell-To-Cell Signaling and Interaction response of myeloid cells 1.66E-05 -2.284 18 
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Cell-To-Cell Signaling and Interaction response of phagocytes 1.84E-05 -2.302 18 
Cell-To-Cell Signaling and Interaction response of neutrophils 1.24E-04 -1.478 9 
Cell-To-Cell Signaling and Interaction response of myeloid leukocytes 2.64E-04 -1.686 10 
Cell-To-Cell Signaling and Interaction detachment of leukocytes 2.11E-05  4 
Cell-To-Cell Signaling and Interaction adhesion of myeloid cells 3.16E-05 -2.535 14 
Cell-To-Cell Signaling and Interaction adhesion of phagocytes 4.47E-05 -2.162 13 
Cell-To-Cell Signaling and Interaction adhesion of connective tissue cells 1.28E-04 -1.126 13 
Cell-To-Cell Signaling and Interaction adhesion of immune cells 4.00E-04 -3.141 21 
Cell-To-Cell Signaling and Interaction adhesion of blood cells 4.91E-04 -2.944 22 
Cell-To-Cell Signaling and Interaction adhesion of neutrophils 7.01E-04 -2.579 8 
Cell-To-Cell Signaling and Interaction activation of connective tissue cells 5.72E-05 -0.201 13 
Cell-To-Cell Signaling and Interaction activation of cells 1.19E-04 -1.68 49 
Cell-To-Cell Signaling and Interaction immune response of phagocytes 2.15E-04 -1.778 15 
Cell-To-Cell Signaling and Interaction cell-cell adhesion of leukocytes 2.48E-04  5 
Cell-To-Cell Signaling and Interaction attachment of cells 4.01E-04 -0.738 11 
Cell-To-Cell Signaling and Interaction deadhesion of T lymphocytes 4.29E-04  2 
Cell-To-Cell Signaling and Interaction phagocytosis of cells 4.65E-04 -2.627 18 
Cell-To-Cell Signaling and Interaction aggregation of cells 6.15E-04 -1.293 20 
Behavior behavior 8.87E-06 -0.101 55 
Humoral Immune Response quantity of B lymphocytes 9.62E-06 -1.24 25 
Humoral Immune Response proliferation of B lymphocytes 2.70E-04 -0.256 19 
Organismal Survival survival of organism 1.61E-05 -0.76 42 
Organismal Survival organismal death 1.70E-05 6.174 107 
Organismal Survival morbidity or mortality 1.86E-05 6.102 108 
Organismal Functions energy homeostasis 1.63E-05 -0.637 16 
Organismal Functions energy expenditure 1.64E-05 -0.591 13 
Organismal Functions metabolism of mammalia 1.06E-04  7 
Organismal Functions percentage body fat 2.53E-04 0.555 9 
Organismal Functions thermogenesis 5.60E-04 -0.555 7 
Post-Translational Modification phosphorylation of protein 2.25E-05 -0.697 39 
Post-Translational Modification tyrosine phosphorylation of protein 1.77E-04 -1.079 14 
Post-Translational Modification assembly of exocyst 4.29E-04  2 
Psychological Disorders Dementia 3.06E-05  37 
Psychological Disorders MELAS syndrome 1.55E-04  4 
Psychological Disorders hyperphagia 2.31E-04 1.72 10 
Psychological Disorders Alzheimer disease 2.67E-04  33 
Cell Cycle interphase of tumor cell lines 4.81E-05 -0.469 25 
Cell Cycle arrest in interphase 1.26E-04  26 
Cell Cycle interphase 3.55E-04 -0.382 35 
Cell Cycle G2/M phase transition of tumor cell lines 1.21E-04  6 
Cell Cycle arrest in G2/M phase transition of tumor cell 
lines 
4.75E-04  5 
Cell Cycle G2 phase of tumor cell lines 1.86E-04 -1.103 12 
Cell Cycle G2 phase 7.74E-04 -1.103 17 
Cell Cycle replicative senescence of cells 2.89E-04  7 
Cell Cycle S phase of tumor cell lines 7.73E-04 0.579 10 
Dermatological Diseases and Conditions Acne 5.60E-05  10 
Embryonic Development development of body trunk 6.13E-05 -3.93 60 
Embryonic Development development of abdomen 5.18E-04 -2.08 31 
Embryonic Development development of bone marrow cells 6.19E-04 -1.353 10 
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Embryonic Development differentiation of gamma-delta T lymphocytes 2.07E-04 -1.982 4 
Embryonic Development quantity of embryo 3.20E-04 -1.733 12 
Embryonic Development formation of mammary lobuloalveolar unit 3.50E-04  4 
Embryonic Development formation of mammary gland 5.61E-04 -2.404 14 
Organ Development function of liver 8.39E-05  10 
Organ Development function of thymus gland 1.69E-04  3 
Organ Development response of liver 1.90E-04 0.893 21 
Organ Development differentiation of gamma-delta T lymphocytes 2.07E-04 -1.982 4 
Organ Development formation of mammary lobuloalveolar unit 3.50E-04  4 
Organ Development formation of mammary gland 5.61E-04 -2.404 14 
Organ Development inflammation of liver 4.04E-04 1.187 20 
Organ Development development of bone marrow cells 6.19E-04 -1.353 10 
Organ Development growth of ovarian follicle 7.73E-04 -1.432 6 
Hematopoiesis development of neutrophils 1.12E-04  4 
Hematopoiesis development of bone marrow cells 6.19E-04 -1.353 10 
Hematopoiesis differentiation of mononuclear leukocytes 1.72E-04 -2.069 31 
Hematopoiesis differentiation of lymphocytes 1.73E-04 -1.711 29 
Hematopoiesis differentiation of gamma-delta T lymphocytes 2.07E-04 -1.982 4 
Hematopoiesis differentiation of leukocytes 2.25E-04 -2.351 35 
Reproductive System Development and Function morphology of reproductive system 1.18E-04  36 
Reproductive System Development and Function morphology of epididymis 5.10E-04  9 
Reproductive System Development and Function mass of accessory sex gland 2.07E-04  5 
Reproductive System Development and Function mass of epigonadal fat pad 5.05E-04  6 
Reproductive System Development and Function mass of epididymis 6.34E-04  5 
Reproductive System Development and Function quantity of ovarian follicle 2.17E-04 -2.521 9 
Reproductive System Development and Function abnormal morphology of reproductive system 3.03E-04  29 
Reproductive System Development and Function abnormal morphology of rete testis 6.77E-04  3 
Reproductive System Development and Function formation of mammary lobuloalveolar unit 3.50E-04  4 
Reproductive System Development and Function formation of mammary gland 5.61E-04 -2.404 14 
Reproductive System Development and Function estrous cycle 4.14E-04 0 8 
Reproductive System Development and Function development of reproductive system 4.55E-04 -2.674 38 
Reproductive System Development and Function size of uterus 4.59E-04  3 
Reproductive System Development and Function growth of ovarian follicle 7.73E-04 -1.432 6 
Free Radical Scavenging scavenging of reactive oxygen species 1.69E-04  3 
Free Radical Scavenging scavenging of hydrogen peroxide 4.29E-04  2 
Free Radical Scavenging production of reactive oxygen species 3.20E-04 -1.693 22 
Cell Signaling tyrosine phosphorylation of protein 1.77E-04 -1.079 14 
Cell Signaling assembly of exocyst 4.29E-04  2 
Cell-mediated Immune Response differentiation of gamma-delta T lymphocytes 2.07E-04 -1.982 4 
Cell-mediated Immune Response deadhesion of T lymphocytes 4.29E-04  2 
Skeletal and Muscular System Devel. and Function bone mineral density of trabecular bone 2.07E-04 -2 4 
Skeletal and Muscular System Devel. and Function bone mineral density of skeleton 2.14E-04 -0.431 6 
Cardiovascular System Development and Function response of heart 2.52E-04 -1.744 8 
Cardiovascular System Development and Function morphology of heart 5.58E-04  27 
DNA Replication, Recombination, and Repair synthesis of DNA 2.94E-04 -0.953 24 
Cellular Compromise degranulation of leukocyte cell lines 3.52E-04 0.416 7 
Cellular Compromise degranulation of cells 5.51E-04 0.039 15 
Nervous System Development and Function mass of brain 3.52E-04  7 
Nervous System Development and Function remyelination of axons 4.59E-04  3 
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Respiratory System Development and Function respiratory quotient 3.52E-04 0.447 7 
Hair and Skin Development and Function quantity of zigzag hair 4.29E-04  2 
Renal and Urological System Develop. and Function morphology of kidney 5.31E-04  18 










































Table 16. Functional categories most significantly represented for WGCNA Blue module. The first and third 
levels of functional categories are shown (‘Category’ and ‘Function Annnotation’). Categories were considered 
significantly enriched if P-value < 0.05. Column ‘Activation z-score’ represents the predicted function activation (z-
score > 2), inhibition (z-score < -2), or inability to predict (z-score not available). 
 
Category Function Annotation P-value Activation z-score # Genes 
Cell Death and Survival cell death of osteosarcoma cells 8.06E-28 -6.325 41 
Cell Death and Survival cell death of tumor cells 2.23E-14 -4.712 61 
Cell Death and Survival cell death of tumor 2.33E-14 -4.712 62 
Cell Death and Survival cell death of cancer cells 5.88E-14 -4.89 54 
Cell Death and Survival cell death 2.38E-05 -5.236 218 
Cell Death and Survival cell death of fibroblast cell lines 2.02E-03 0.158 33 
Cell Death and Survival cell death of melanoma cell lines 2.18E-03 0.142 21 
Cell Death and Survival cell death of tumor cell lines 3.50E-03 -1.954 100 
Cell Death and Survival cell death of vascular smooth muscle cells 5.71E-03 -1.348 8 
Cell Death and Survival cell death of connective tissue cells 9.27E-03 -0.399 41 
Cell Death and Survival cell death of cervical cancer cell lines 1.25E-02 -1.472 26 
Cell Death and Survival cell death of muscle cells 1.27E-02 -2.781 24 
Cell Death and Survival cell death of smooth muscle cells 2.06E-02 -0.99 9 
Cell Death and Survival cell death of spermatogonia 2.21E-02  2 
Cell Death and Survival cell death of neuroblastoma cell lines 2.32E-02 -1.058 14 
Cell Death and Survival cell death of sarcoma cell lines 3.14E-02 -1.278 16 
Cell Death and Survival cell death of pancreatic cells 3.27E-02 -1.488 8 
Cell Death and Survival cell death of fibrosarcoma cells 3.44E-02  1 
Cell Death and Survival necrosis 9.56E-07 -4.626 184 
Cell Death and Survival degradation of cervical cancer cell lines 1.18E-03  2 
Cell Death and Survival killing of vascular endothelial cells 3.46E-03  2 
Cell Death and Survival cell viability of colorectal cancer cell lines 6.01E-03 3.44 12 
Cell Death and Survival cell viability of cardiomyocytes 2.32E-02  4 
Cell Death and Survival apoptosis 6.53E-03 -2.581 158 
Cell Death and Survival apoptosis of tumor cell lines 9.40E-03 -1.495 79 
Cell Death and Survival apoptosis of muscle cells 1.57E-02 -2.823 19 
Cell Death and Survival apoptosis of vascular smooth muscle cells 1.66E-02 -1.937 7 
Cell Death and Survival apoptosis of cervical cancer cell lines 1.76E-02 -1.775 21 
Cell Death and Survival apoptosis of melanoma cells 2.08E-02  4 
Cell Death and Survival apoptosis of embryoblast 2.98E-02  3 
Cell Death and Survival apoptosis of tumor cells 3.02E-02 0 19 
Cell Death and Survival apoptosis of cartilage tissue 3.44E-02  1 
Cell Death and Survival apoptosis of pancreatic duct cells 3.44E-02  1 
Cell Death and Survival apoptosis of vulva cancer cells 3.44E-02  1 
Cell Death and Survival cell survival of dopaminergic neurons 3.44E-02  1 
Cell Death and Survival cell survival of neural precursor cells 3.44E-02  1 
Cell Death and Survival cytolysis of endothelial cell lines 3.44E-02  1 
RNA Post-Transcriptional Modification processing of rRNA 3.60E-18  21 
RNA Post-Transcriptional Modification processing of RNA 1.38E-10  40 
RNA Post-Transcriptional Modification methylation of RNA 2.21E-02  2 
RNA Post-Transcriptional Modification conversion of adenine 3.44E-02  1 
Gene Expression translation of mRNA 4.80E-14 -2.183 33 
Gene Expression initiation of translation of mRNA 1.80E-04  8 
Gene Expression expression of mRNA 1.23E-11 -2.396 36 
Gene Expression expression of RNA 3.34E-04 1.332 140 
Gene Expression initiation of expression of RNA 7.01E-04  11 
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Gene Expression replication of RNA 5.42E-03  3 
Gene Expression transcription of DNA 1.22E-02 0.826 92 
Gene Expression transcription of RNA 1.90E-02 1.357 108 
Gene Expression bending of positive regulatory domain promoter 
element 
3.44E-02  1 
Protein Synthesis translation of mRNA 4.80E-14 -2.183 33 
Protein Synthesis translation 6.88E-13 0.232 40 
Protein Synthesis translation of protein 1.61E-12 -0.383 39 
Protein Synthesis initiation of translation of mRNA 1.80E-04  8 
Protein Synthesis initiation of translation of protein 6.18E-04  8 
Protein Synthesis synthesis of protein 1.55E-10 2.237 52 
Protein Synthesis metabolism of protein 1.77E-07 3.661 81 
Cell Cycle interphase of bone cancer cell lines 8.00E-05  10 
Cell Cycle arrest in interphase of sarcoma cell lines 5.46E-04  8 
Cell Cycle arrest in interphase of bone cancer cell lines 1.92E-03  7 
Cell Cycle interphase of tumor cell lines 7.75E-03 0.308 28 
Cell Cycle arrest in interphase 1.16E-02  30 
Cell Cycle interphase 2.21E-02 1.073 43 
Cell Cycle G2/M phase transition 7.03E-04  12 
Cell Cycle G2/M phase transition of tumor cell lines 1.74E-03  6 
Cell Cycle arrest in G2/M phase transition of lung cancer cell 
lines 
1.10E-02  2 
Cell Cycle arrest in G2/M phase transition 1.43E-02  6 
Cell Cycle arrest in G2/M phase transition of tumor cell lines 2.32E-02  4 
Cell Cycle arrest in G2/M phase transition of carcinoma cell lines 2.88E-02  2 
Cell Cycle arrest in G2/M phase transition of muscle cell lines 3.44E-02  1 
Cell Cycle arrest in G2/M phase transition of rhabdomyosarcoma 
cell lines 
3.44E-02  1 
Cell Cycle G2 phase 7.15E-04 -0.216 24 
Cell Cycle G2 phase of tumor cell lines 1.82E-03 0.277 14 
Cell Cycle G2 phase of lung cancer cell lines 5.19E-03  4 
Cell Cycle arrest in G2 phase of lung cancer cell lines 2.60E-02  3 
Cell Cycle arrest in G2 phase 3.30E-02  13 
Cell Cycle delay in G2 phase of cervical cancer cell lines 3.44E-02  1 
Cell Cycle G2/M phase 7.72E-04 0.114 20 
Cell Cycle arrest in G0/G1 phase transition of pancreatic cancer 
cell lines 
1.18E-03  2 
Cell Cycle cell cycle progression 1.24E-03 3.496 73 
Cell Cycle cell cycle progression of muscle cells 1.74E-03 2.204 6 
Cell Cycle delay in cell cycle progression of epithelial cell lines 3.46E-03  2 
Cell Cycle re-entry into cell cycle progression of muscle cells 4.05E-03  3 
Cell Cycle cell cycle progression of cardiomyocytes 5.19E-03  4 
Cell Cycle arrest in cell cycle progression of cardiomyocytes 6.76E-03  2 
Cell Cycle arrest in cell cycle progression of fibroblast cell lines 1.04E-02  5 
Cell Cycle cell cycle progression of stem cells 1.92E-02  3 
Cell Cycle arrest in cell cycle progression of hematopoietic cell 
lines 
2.24E-02  3 
Cell Cycle re-entry into cell cycle progression of ventricular 
myocytes 
2.88E-02  2 
Cell Cycle cell cycle progression of fibroblast cell lines 3.18E-02  7 
Cell Cycle cell cycle progression of multipotential hemopoietic 
progenitor cells 
3.44E-02  1 
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Cell Cycle cell cycle progression of myofibroblasts 3.44E-02  1 
Cell Cycle delay in cell cycle progression of embryonic cell lines 3.44E-02  1 
Cell Cycle delay in cell cycle progression of kidney cell lines 3.44E-02  1 
Cell Cycle delay in G1 phase of fibroblast cell lines 1.28E-03  3 
Cell Cycle G1 phase of bone cancer cell lines 5.22E-03  6 
Cell Cycle arrest in G1 phase of bone cancer cell lines 1.27E-02  5 
Cell Cycle arrest in G1 phase of sarcoma cell lines 1.27E-02  5 
Cell Cycle G1 phase of embryonic stem cells 2.21E-02  2 
Cell Cycle G1 phase of tumor cell lines 3.14E-02 -1.109 16 
Cell Cycle arrest in G1 phase 3.18E-02  18 
Cell Cycle G1/S phase transition of bone cancer cell lines 2.30E-03  4 
Cell Cycle arrest in G1/S phase transition of bone cancer cell lines 7.05E-03  3 
Cell Cycle arrest in G1/S phase transition of sarcoma cell lines 7.05E-03  3 
Cell Cycle mitotic exit 2.41E-03  5 
Cell Cycle arrest in meiosis of oocytes 6.76E-03  2 
Cell Cycle delay in M phase of cervical cancer cell lines 8.93E-03  3 
Cell Cycle M phase of cervical cancer cell lines 1.55E-02 0.728 7 
Cell Cycle delay in initiation of M phase 2.08E-02  4 
Cell Cycle duplication of centrosome 1.12E-02 1.054 6 
Cell Cycle delay in duplication of centrosome 3.44E-02  1 
Cell Cycle cycling of centrosome 1.47E-02 1.729 8 
Cell Cycle arrest in mitosis of cervical cancer cell lines 1.94E-02  6 
Cell Cycle mitosis 2.28E-02 1.241 33 
Cell Cycle arrest in mitosis of megakaryocytes 3.44E-02  1 
Cell Cycle separation of centrosome 2.24E-02  3 
Cell Cycle metaphase 2.60E-02  3 
Cell Cycle contact growth inhibition of tumor cells 2.88E-02  2 
Cell Cycle sister chromatid exchange of cells 3.39E-02  3 
Cell Cycle G0/S phase transition of fibroblast cell lines 3.44E-02  1 
Cell Cycle asymmetric division of oocytes 3.44E-02  1 
Cell Cycle delay in initiation of metaphase I of oocytes 3.44E-02  1 
Cardiovascular System Development and 
Function 
abnormal morphology of arterial cone 1.58E-04  3 
Cardiovascular System Development and 
Function 
abnormal morphology of ventricular wall 1.77E-02  9 
Cardiovascular System Development and 
Function 
abnormal morphology of thin ventricular wall 2.09E-02  6 
Cardiovascular System Development and 
Function 
abnormal morphology of posterior cardinal vein 3.44E-02  1 
Cardiovascular System Development and 
Function 
abnormal morphology of vertebral artery 3.44E-02  1 
Cardiovascular System Development and 
Function 
cell cycle progression of cardiomyocytes 5.19E-03  4 
Cardiovascular System Development and 
Function 
arrest in cell cycle progression of cardiomyocytes 6.76E-03  2 
Cardiovascular System Development and 
Function 
re-entry into cell cycle progression of ventricular 
myocytes 
2.88E-02  2 
Cardiovascular System Development and 
Function 
sprouting of microvascular endothelial cells 1.61E-02  2 
Cardiovascular System Development and 
Function 
vascularization of cornea 1.70E-02 -0.152 5 
Cardiovascular System Development and 
Function 
morphogenesis of endothelial tube 2.21E-02  2 
Cardiovascular System Development and 
Function 
cell viability of cardiomyocytes 2.32E-02  4 
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Cardiovascular System Development and 
Function 
remodeling of vasculature 2.98E-02  3 
Cardiovascular System Development and 
Function 
antigenicity of endothelial cell lines 3.44E-02  1 
Cardiovascular System Development and 
Function 
area of vascular endothelial cells 3.44E-02  1 
Cardiovascular System Development and 
Function 
convolution of vein 3.44E-02  1 
Cardiovascular System Development and 
Function 
coupling of proepicardial cells 3.44E-02  1 
Cardiovascular System Development and 
Function 
diameter of dorsal aorta 3.44E-02  1 
Organ Morphology abnormal morphology of arterial cone 1.58E-04  3 
Organ Morphology abnormal morphology of dilated rete testis 1.61E-02  2 
Organ Morphology abnormal morphology of ventricular wall 1.77E-02  9 
Organ Morphology abnormal morphology of thin ventricular wall 2.09E-02  6 
Organ Morphology abnormal morphology of striatum 2.57E-02  4 
Organ Morphology abnormal morphology of maxilla 2.59E-02  5 
Organ Morphology abnormal morphology of sarcomere 2.98E-02  3 
Organ Morphology abnormal morphology of atlas 3.39E-02  3 
Organ Morphology abnormal morphology of sphenoid bone 3.39E-02  3 
Organ Morphology abnormal morphology of foreskin of penis 3.44E-02  1 
Organ Morphology abnormal morphology of putamen 3.44E-02  1 
Organ Morphology quantity of primordial germ cells 9.85E-03 1.96 4 
Organ Morphology quantity of muscle cells 3.13E-02 1.706 9 
Organ Morphology lack of skeletal muscle 1.10E-02  2 
Organ Morphology area of mammary alveolus 3.44E-02  1 
Organ Morphology diameter of myotube 3.44E-02  1 
Organismal Development abnormal morphology of arterial cone 1.58E-04  3 
Organismal Development abnormal morphology of embryonic tissue 8.23E-03  39 
Organismal Development abnormal morphology of head fold 1.61E-02  2 
Organismal Development abnormal morphology of ventricular wall 1.77E-02  9 
Organismal Development abnormal morphology of thin ventricular wall 2.09E-02  6 
Organismal Development abnormal morphology of parietal endoderm 2.21E-02  2 
Organismal Development abnormal morphology of striatum 2.57E-02  4 
Organismal Development abnormal morphology of maxilla 2.59E-02  5 
Organismal Development abnormal morphology of sternebrae 2.60E-02  3 
Organismal Development abnormal morphology of atlas 3.39E-02  3 
Organismal Development abnormal morphology of sphenoid bone 3.39E-02  3 
Organismal Development abnormal morphology of bulbus cordis 3.44E-02  1 
Organismal Development abnormal morphology of intermediate zone 3.44E-02  1 
Organismal Development abnormal morphology of putamen 3.44E-02  1 
Organismal Development size of animal 2.09E-03 3.058 16 
Organismal Development formation of axis 6.76E-03  2 
Organismal Development formation of myoblasts 7.05E-03  3 
Organismal Development formation of muscle 1.10E-02 2.588 28 
Organismal Development formation of thin filaments 1.10E-02  2 
Organismal Development formation of rib 2.83E-02  4 
Organismal Development branching of ureteric bud cells 1.10E-02  2 
Organismal Development outgrowth of blastocyst 1.61E-02  2 
Organismal Development sprouting of microvascular endothelial cells 1.61E-02  2 
Organismal Development ossification of sternum 1.66E-02  4 
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Organismal Development vascularization of cornea 1.70E-02 -0.152 5 
Organismal Development abnormal size of body 2.21E-02  2 
Organismal Development budding of HIV-1 2.21E-02  2 
Organismal Development arrest in development of pro-T lymphocytes 2.21E-02  2 
Organismal Development development of extraembryonic mesoderm 2.88E-02  2 
Organismal Development development of intercostal muscle 3.44E-02  1 
Organismal Development development of tube alveoli 3.44E-02  1 
Organismal Development lymphangiogenesis of cornea 2.88E-02  2 
Organismal Development remodeling of vasculature 2.98E-02  3 
Organismal Development accumulation of interstitial fluid 3.44E-02  1 
Organismal Development area of mammary alveolus 3.44E-02  1 
Organismal Development area of vascular endothelial cells 3.44E-02  1 
Organismal Development differentiation of Treg precursor cells 3.44E-02  1 
Organismal Development delay in initiation of re-epithelialization of skin 3.44E-02  1 
Connective Tissue Development and 
Function 
attachment of sternum 3.24E-04  7 
Connective Tissue Development and 
Function 
attachment of rib 9.16E-04  7 
Connective Tissue Development and 
Function 
delay in G1 phase of fibroblast cell lines 1.28E-03  3 
Connective Tissue Development and 
Function 
formation of axis 6.76E-03  2 
Connective Tissue Development and 
Function 
formation of rib 2.83E-02  4 
Connective Tissue Development and 
Function 
arrest in cell cycle progression of fibroblast cell lines 1.04E-02  5 
Connective Tissue Development and 
Function 
cell cycle progression of fibroblast cell lines 3.18E-02  7 
Connective Tissue Development and 
Function 
cell cycle progression of myofibroblasts 3.44E-02  1 
Connective Tissue Development and 
Function 
osteogenesis of bone tissue 1.61E-02  2 
Connective Tissue Development and 
Function 
ossification of sternum 1.66E-02  4 
Connective Tissue Development and 
Function 
fusion of fibroblast cell lines 2.21E-02  2 
Connective Tissue Development and 
Function 
abnormal morphology of maxilla 2.59E-02  5 
Connective Tissue Development and 
Function 
abnormal morphology of atlas 3.39E-02  3 
Connective Tissue Development and 
Function 
abnormal morphology of sphenoid bone 3.39E-02  3 
Connective Tissue Development and 
Function 
differentiation of osteoblastic-lineage cells 3.10E-02 0 19 
Connective Tissue Development and 
Function 
differentiation of endochondral bone 3.44E-02  1 
Connective Tissue Development and 
Function 
G0/S phase transition of fibroblast cell lines 3.44E-02  1 
Connective Tissue Development and 
Function 
adipogenesis of embryonic stem cells 3.44E-02  1 
Connective Tissue Development and 
Function 
branching of fibroblasts 3.44E-02  1 
Connective Tissue Development and 
Function 
calcification of endochondral bone 3.44E-02  1 
Connective Tissue Development and 
Function 
density of adipocytes 3.44E-02  1 
Skeletal and Muscular System Development 
and Function 
attachment of sternum 3.24E-04  7 
Skeletal and Muscular System Development 
and Function 
attachment of rib 9.16E-04  7 
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Skeletal and Muscular System Development 
and Function 
cell cycle progression of muscle cells 1.74E-03 2.204 6 
Skeletal and Muscular System Development 
and Function 
re-entry into cell cycle progression of muscle cells 4.05E-03  3 
Skeletal and Muscular System Development 
and Function 
cell cycle progression of cardiomyocytes 5.19E-03  4 
Skeletal and Muscular System Development 
and Function 
arrest in cell cycle progression of cardiomyocytes 6.76E-03  2 
Skeletal and Muscular System Development 
and Function 
re-entry into cell cycle progression of ventricular 
myocytes 
2.88E-02  2 
Skeletal and Muscular System Development 
and Function 
cell cycle progression of myofibroblasts 3.44E-02  1 
Skeletal and Muscular System Development 
and Function 
formation of axis 6.76E-03  2 
Skeletal and Muscular System Development 
and Function 
formation of myoblasts 7.05E-03  3 
Skeletal and Muscular System Development 
and Function 
formation of muscle 1.10E-02 2.588 28 
Skeletal and Muscular System Development 
and Function 
formation of thin filaments 1.10E-02  2 
Skeletal and Muscular System Development 
and Function 
formation of rib 2.83E-02  4 
Skeletal and Muscular System Development 
and Function 
lack of skeletal muscle 1.10E-02  2 
Skeletal and Muscular System Development 
and Function 
differentiation of muscle cell lines 1.56E-02 0.376 13 
Skeletal and Muscular System Development 
and Function 
osteogenesis of bone tissue 1.61E-02  2 
Skeletal and Muscular System Development 
and Function 
ossification of sternum 1.66E-02  4 
Skeletal and Muscular System Development 
and Function 
development of axial skeleton 1.77E-02  7 
Skeletal and Muscular System Development 
and Function 
development of intercostal muscle 3.44E-02  1 
Skeletal and Muscular System Development 
and Function 
cell viability of cardiomyocytes 2.32E-02  4 
Skeletal and Muscular System Development 
and Function 
abnormal morphology of maxilla 2.59E-02  5 
Skeletal and Muscular System Development 
and Function 
abnormal morphology of sarcomere 2.98E-02  3 
Skeletal and Muscular System Development 
and Function 
abnormal morphology of atlas 3.39E-02  3 
Skeletal and Muscular System Development 
and Function 
abnormal morphology of sphenoid bone 3.39E-02  3 
Skeletal and Muscular System Development 
and Function 
quantity of muscle 2.60E-02 1.929 10 
Skeletal and Muscular System Development 
and Function 
quantity of muscle cells 3.13E-02 1.706 9 
Skeletal and Muscular System Development 
and Function 
arrest in G2/M phase transition of muscle cell lines 3.44E-02  1 
Skeletal and Muscular System Development 
and Function 
calcification of endochondral bone 3.44E-02  1 
Skeletal and Muscular System Development 
and Function 
contraction of skeletal muscle bundle 3.44E-02  1 
Skeletal and Muscular System Development 
and Function 
deposition of cartilage matrix 3.44E-02  1 
Skeletal and Muscular System Development 
and Function 
diameter of myotube 3.44E-02  1 
Tissue Development attachment of sternum 3.24E-04  7 
Tissue Development attachment of rib 9.16E-04  7 
Tissue Development expansion of oval cells 1.18E-03  2 
Tissue Development expansion of epithelial cells 2.32E-02 0.762 4 
Tissue Development function of fibroblast-like synoviocytes 1.18E-03  2 
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Tissue Development delay in initiation of pruning of axons 1.18E-03  2 
Tissue Development formation of microfilaments 3.46E-03  2 
Tissue Development formation of axis 6.76E-03  2 
Tissue Development formation of myoblasts 7.05E-03  3 
Tissue Development formation of muscle 1.10E-02 2.588 28 
Tissue Development formation of thin filaments 1.10E-02  2 
Tissue Development formation of rib 2.83E-02  4 
Tissue Development branching of ureteric bud cells 1.10E-02  2 
Tissue Development branching of fibroblasts 3.44E-02  1 
Tissue Development proliferation of oval cells 1.11E-02  3 
Tissue Development osteogenesis of bone tissue 1.61E-02  2 
Tissue Development sprouting of microvascular endothelial cells 1.61E-02  2 
Tissue Development ossification of sternum 1.66E-02  4 
Tissue Development arrest in development of pro-T lymphocytes 2.21E-02  2 
Tissue Development development of extraembryonic mesoderm 2.88E-02  2 
Tissue Development development of intercostal muscle 3.44E-02  1 
Tissue Development development of tube alveoli 3.44E-02  1 
Tissue Development morphogenesis of endothelial tube 2.21E-02  2 
Tissue Development tubulation of skin cell lines 2.21E-02  2 
Tissue Development abnormal morphology of maxilla 2.59E-02  5 
Tissue Development abnormal morphology of atlas 3.39E-02  3 
Tissue Development abnormal morphology of sphenoid bone 3.39E-02  3 
Tissue Development lymphangiogenesis of cornea 2.88E-02  2 
Tissue Development disassembly of extracellular matrix 2.98E-02  3 
Tissue Development differentiation of osteoblastic-lineage cells 3.10E-02 0 19 
Tissue Development differentiation of Treg precursor cells 3.44E-02  1 
Tissue Development differentiation of endochondral bone 3.44E-02  1 
Tissue Development accumulation of LSK cells 3.44E-02  1 
Tissue Development adhesion of collagen type IV matrix 3.44E-02  1 
Tissue Development area of mammary alveolus 3.44E-02  1 
Tissue Development calcification of endochondral bone 3.44E-02  1 
Tissue Development deposition of cartilage matrix 3.44E-02  1 
Tissue Development delay in initiation of re-epithelialization of skin 3.44E-02  1 
Carbohydrate Metabolism synthesis of nucleoside diphosphate sugar 3.76E-04  4 
Carbohydrate Metabolism synthesis of UDP-N-acetylhexosamines 3.46E-03  2 
Carbohydrate Metabolism accumulation of phosphatidylinositol 3,5-diphosphate 3.44E-02  1 
Carbohydrate Metabolism degradation of phosphatidylinositol 3,5-diphosphate 3.44E-02  1 
Carbohydrate Metabolism degradation of phosphatidylinositol 4-phosphate 3.44E-02  1 
Carbohydrate Metabolism degradation of phosphatidylinositol-3-phosphate 3.44E-02  1 
Nucleic Acid Metabolism synthesis of nucleoside diphosphate sugar 3.76E-04  4 
Nucleic Acid Metabolism synthesis of UDP-N-acetylhexosamines 3.46E-03  2 
Nucleic Acid Metabolism synthesis of AMP 1.61E-02  2 
Nucleic Acid Metabolism repair of pyrimidine dimer 2.21E-02  2 
Nucleic Acid Metabolism biosynthesis of thymidine 3.44E-02  1 
Nucleic Acid Metabolism catabolism of S-adenosylhomocysteine 3.44E-02  1 
Nucleic Acid Metabolism conversion of adenine 3.44E-02  1 
Small Molecule Biochemistry synthesis of nucleoside diphosphate sugar 3.76E-04  4 
Small Molecule Biochemistry synthesis of UDP-N-acetylhexosamines 3.46E-03  2 
Small Molecule Biochemistry synthesis of AMP 1.61E-02  2 
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Small Molecule Biochemistry hydroxylation of L-proline 3.46E-03  2 
Small Molecule Biochemistry biosynthesis of 5,6,7,8-tetrahydrobiopterin 1.61E-02  2 
Small Molecule Biochemistry biosynthesis of asparagine 3.44E-02  1 
Small Molecule Biochemistry biosynthesis of coenzyme 3.44E-02  1 
Small Molecule Biochemistry biosynthesis of thymidine 3.44E-02  1 
Small Molecule Biochemistry repair of pyrimidine dimer 2.21E-02  2 
Small Molecule Biochemistry accumulation of phosphatidylinositol 3,5-diphosphate 3.44E-02  1 
Small Molecule Biochemistry activation of bile acid 3.44E-02  1 
Small Molecule Biochemistry catabolism of S-adenosylhomocysteine 3.44E-02  1 
Small Molecule Biochemistry conversion of L-aspartic acid 3.44E-02  1 
Small Molecule Biochemistry conversion of adenine 3.44E-02  1 
Small Molecule Biochemistry deglutathionylation of L-cysteine 3.44E-02  1 
Small Molecule Biochemistry degradation of phosphatidylinositol 3,5-diphosphate 3.44E-02  1 
Small Molecule Biochemistry degradation of phosphatidylinositol 4-phosphate 3.44E-02  1 
Small Molecule Biochemistry degradation of phosphatidylinositol-3-phosphate 3.44E-02  1 
Cellular Compromise stress response of cervical cancer cell lines 5.49E-04  4 
Cellular Compromise stress response of tumor cell lines 1.03E-02  6 
Cellular Compromise chromosomal instability 7.39E-03 -1.195 7 
Cellular Compromise disruption of chromosome components 1.10E-02  2 
Cellular Compromise endoplasmic reticulum stress response 1.56E-02 0 13 
Cellular Compromise endoplasmic reticulum stress response of tumor cell 
lines 
2.57E-02  4 
Cellular Compromise adhesion of colon carcinoma cells 3.44E-02  1 
DNA Replication, Recombination, and 
Repair 
repair of DNA 6.73E-04 2.867 26 
DNA Replication, Recombination, and 
Repair 
repair of pyrimidine dimer 2.21E-02  2 
DNA Replication, Recombination, and 
Repair 
autosomal recessive dyskeratosis congenita 1.28E-03  3 
DNA Replication, Recombination, and 
Repair 
excision repair 3.49E-03  9 
DNA Replication, Recombination, and 
Repair 
quantity of centrosome 5.22E-03 0.323 6 
DNA Replication, Recombination, and 
Repair 
chromosomal instability 7.39E-03 -1.195 7 
DNA Replication, Recombination, and 
Repair 
duplication of centrosome 1.12E-02 1.054 6 
DNA Replication, Recombination, and 
Repair 
delay in duplication of centrosome 3.44E-02  1 
DNA Replication, Recombination, and 
Repair 
chromosomal aberration 1.41E-02 -1.463 14 
DNA Replication, Recombination, and 
Repair 
metabolism of DNA 1.58E-02 2.7 27 
DNA Replication, Recombination, and 
Repair 
DNA replication 1.77E-02 2.554 18 
DNA Replication, Recombination, and 
Repair 
double-stranded DNA break repair 2.09E-02 0.547 10 
DNA Replication, Recombination, and 
Repair 
amplification of centrosome 2.59E-02 1.987 5 
DNA Replication, Recombination, and 
Repair 
recombination 2.73E-02 1.134 14 
DNA Replication, Recombination, and 
Repair 
sister chromatid exchange of cells 3.39E-02  3 
DNA Replication, Recombination, and 
Repair 
autosomal recessive dyskeratosis congenita type 2 3.44E-02  1 
DNA Replication, Recombination, and 
Repair 
autosomal recessive dyskeratosis congenita type 3 3.44E-02  1 
DNA Replication, Recombination, and bending of positive regulatory domain promoter 3.44E-02  1 
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Repair element 
DNA Replication, Recombination, and 
Repair 
cleavage of pBR322 plasmid 3.44E-02  1 
Cell Signaling activation of cyclin-dependent protein kinase 9.50E-04  5 
Cell Signaling activation of Protein kinase 1.39E-02  18 
Cell Signaling activation of enzyme 1.45E-02 2.646 24 
Cell Signaling G-protein signaling, coupled to cGMP nucleotide 
second messenger 
2.88E-02  2 
Post-Translational Modification activation of cyclin-dependent protein kinase 9.50E-04  5 
Post-Translational Modification activation of Protein kinase 1.39E-02  18 
Post-Translational Modification hydroxylation of L-proline 3.46E-03  2 
Post-Translational Modification ubiquitination of protein 1.64E-02 0.215 22 
Post-Translational Modification folding of protein 2.54E-02  7 
Post-Translational Modification folding maturation of protein 2.88E-02  2 
Post-Translational Modification conversion of L-aspartic acid 3.44E-02  1 
Post-Translational Modification deglutathionylation of L-cysteine 3.44E-02  1 
Cell Morphology delay in initiation of pruning of axons 1.18E-03  2 
Cell Morphology branching of ureteric bud cells 1.10E-02  2 
Cell Morphology sprouting of microvascular endothelial cells 1.61E-02  2 
Cell Morphology budding of HIV-1 2.21E-02  2 
Cell Morphology tubulation of skin cell lines 2.21E-02  2 
Cell Morphology repair of cells 2.83E-02 0.398 8 
Cell Morphology abnormal morphology of sarcomere 2.98E-02  3 
Cell Morphology area of vascular endothelial cells 3.44E-02  1 
Cell Morphology autophagy of hepatic stellate cells 3.44E-02  1 
Cell Morphology blebbing of breast cancer cell lines 3.44E-02  1 
Cell Morphology cell flattening of liver cell lines 3.44E-02  1 
Cell Morphology depolarization of parasympathetic preganglionic 
neurons 
3.44E-02  1 
Cell Morphology diameter of myotube 3.44E-02  1 
Cellular Assembly and Organization delay in initiation of pruning of axons 1.18E-03  2 
Cellular Assembly and Organization quantity of microtubule organizing centers 1.19E-03 -0.075 7 
Cellular Assembly and Organization quantity of subsarcolemmal mitochondria 3.46E-03  2 
Cellular Assembly and Organization quantity of centrosome 5.22E-03 0.323 6 
Cellular Assembly and Organization formation of microfilaments 3.46E-03  2 
Cellular Assembly and Organization formation of thin filaments 1.10E-02  2 
Cellular Assembly and Organization formation of ribosome 1.29E-02  4 
Cellular Assembly and Organization delay in initiation of formation of tight junctions 3.44E-02  1 
Cellular Assembly and Organization development of mitochondria 5.22E-03  6 
Cellular Assembly and Organization reassembly of cell-cell contacts 6.76E-03  2 
Cellular Assembly and Organization assembly of multivesicular bodies 7.28E-03  4 
Cellular Assembly and Organization assembly of midzone 3.44E-02  1 
Cellular Assembly and Organization disruption of chromosome components 1.10E-02  2 
Cellular Assembly and Organization duplication of centrosome 1.12E-02 1.054 6 
Cellular Assembly and Organization delay in duplication of centrosome 3.44E-02  1 
Cellular Assembly and Organization anterograde axonal transport 1.47E-02  4 
Cellular Assembly and Organization separation of centrosome 2.24E-02  3 
Cellular Assembly and Organization amplification of centrosome 2.59E-02 1.987 5 
Cellular Assembly and Organization morphogenesis of mitochondria 3.39E-02  3 
Cellular Assembly and Organization sister chromatid exchange of cells 3.39E-02  3 
Cellular Assembly and Organization accumulation of multivesicular bodies 3.44E-02  1 
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Cellular Assembly and Organization binding of thin filaments 3.44E-02  1 
Cellular Development expansion of oval cells 1.18E-03  2 
Cellular Development delay in initiation of pruning of axons 1.18E-03  2 
Cellular Development proliferation of exocrine cells 5.05E-03 2.2 5 
Cellular Development proliferation of oval cells 1.11E-02  3 
Cellular Development proliferation of primordial germ cells 1.61E-02  2 
Cellular Development proliferation of non-small-cell lung cancer cells 2.88E-02  2 
Cellular Development proliferation of cancer cells 3.35E-02 2.108 24 
Cellular Development formation of myoblasts 7.05E-03  3 
Cellular Development formation of thin filaments 1.10E-02  2 
Cellular Development cell proliferation of breast cancer cell lines 9.85E-03 4.197 33 
Cellular Development cell proliferation of bone cancer cell lines 2.74E-02 -0.798 9 
Cellular Development cell proliferation of sarcoma cell lines 2.74E-02 -0.384 12 
Cellular Development branching of ureteric bud cells 1.10E-02  2 
Cellular Development branching of fibroblasts 3.44E-02  1 
Cellular Development differentiation of muscle cell lines 1.56E-02 0.376 13 
Cellular Development differentiation of osteoblastic-lineage cells 3.10E-02 0 19 
Cellular Development differentiation of Treg precursor cells 3.44E-02  1 
Cellular Development differentiation of endochondral bone 3.44E-02  1 
Cellular Development differentiation of pigment cells 3.44E-02  1 
Cellular Development arrest in growth of cervical cancer cell lines 1.61E-02  2 
Cellular Development arrest in growth of ovarian cancer cell lines 3.44E-02  1 
Cellular Development sprouting of microvascular endothelial cells 1.61E-02  2 
Cellular Development arrest in development of pro-T lymphocytes 2.21E-02  2 
Cellular Development tubulation of skin cell lines 2.21E-02  2 
Cellular Development adipogenesis of embryonic stem cells 3.44E-02  1 
Cellular Development arrest in maturation of pro-B lymphocytes 3.44E-02  1 
Cellular Function and Maintenance function of fibroblast-like synoviocytes 1.18E-03  2 
Cellular Function and Maintenance delay in initiation of pruning of axons 1.18E-03  2 
Cellular Function and Maintenance formation of microfilaments 3.46E-03  2 
Cellular Function and Maintenance formation of ribosome 1.29E-02  4 
Cellular Function and Maintenance delay in initiation of formation of tight junctions 3.44E-02  1 
Cellular Function and Maintenance assembly of multivesicular bodies 7.28E-03  4 
Cellular Function and Maintenance duplication of centrosome 1.12E-02 1.054 6 
Cellular Function and Maintenance delay in duplication of centrosome 3.44E-02  1 
Cellular Function and Maintenance anterograde axonal transport 1.47E-02  4 
Cellular Function and Maintenance endoplasmic reticulum stress response 1.56E-02 0 13 
Cellular Function and Maintenance endoplasmic reticulum stress response of tumor cell 
lines 
2.57E-02  4 
Cellular Function and Maintenance arrest in development of pro-T lymphocytes 2.21E-02  2 
Cellular Function and Maintenance repair of cells 2.83E-02 0.398 8 
Cellular Function and Maintenance presence of hematopoietic progenitor cells 2.88E-02  2 
Cellular Function and Maintenance autophagy of hepatic stellate cells 3.44E-02  1 
Cellular Function and Maintenance depolarization of parasympathetic preganglionic 
neurons 
3.44E-02  1 
Cellular Function and Maintenance differentiation of Treg precursor cells 3.44E-02  1 
Cellular Growth and Proliferation expansion of oval cells 1.18E-03  2 
Cellular Growth and Proliferation expansion of epithelial cells 2.32E-02 0.762 4 
Cellular Growth and Proliferation delay in initiation of pruning of axons 1.18E-03  2 
Cellular Growth and Proliferation proliferation of exocrine cells 5.05E-03 2.2 5 
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Cellular Growth and Proliferation proliferation of oval cells 1.11E-02  3 
Cellular Growth and Proliferation proliferation of primordial germ cells 1.61E-02  2 
Cellular Growth and Proliferation proliferation of cells 2.15E-02 6.126 211 
Cellular Growth and Proliferation proliferation of non-small-cell lung cancer cells 2.88E-02  2 
Cellular Growth and Proliferation proliferation of cancer cells 3.35E-02 2.108 24 
Cellular Growth and Proliferation formation of myoblasts 7.05E-03  3 
Cellular Growth and Proliferation formation of thin filaments 1.10E-02  2 
Cellular Growth and Proliferation cell proliferation of breast cancer cell lines 9.85E-03 4.197 33 
Cellular Growth and Proliferation cell proliferation of bone cancer cell lines 2.74E-02 -0.798 9 
Cellular Growth and Proliferation cell proliferation of sarcoma cell lines 2.74E-02 -0.384 12 
Cellular Growth and Proliferation branching of ureteric bud cells 1.10E-02  2 
Cellular Growth and Proliferation arrest in growth of cervical cancer cell lines 1.61E-02  2 
Cellular Growth and Proliferation arrest in growth of ovarian cancer cell lines 3.44E-02  1 
Cellular Growth and Proliferation arrest in development of pro-T lymphocytes 2.21E-02  2 
Cellular Growth and Proliferation contact growth inhibition of tumor cells 2.88E-02  2 
Cellular Growth and Proliferation cytostasis of epidermal cells 2.88E-02  2 
Cellular Growth and Proliferation cytostasis of tumor cells 2.98E-02  3 
Cellular Growth and Proliferation differentiation of Treg precursor cells 3.44E-02  1 
Cellular Movement positioning of dendritic cells 1.18E-03  2 
Cellular Movement trafficking of hematopoietic progenitor cells 3.46E-03  2 
Cellular Movement emigration of thymocytes 6.76E-03  2 
Cellular Movement homing of hematopoietic progenitor cells 1.13E-02  4 
Cellular Movement migration of synovial cells 1.35E-02  3 
Cellular Movement anterograde axonal transport 1.47E-02  4 
Cellular Movement recruitment of tumor cell lines 2.88E-02  2 
Cellular Movement cell movement of muscle precursor cells 3.39E-02  3 
Digestive System Development and 
Function 
expansion of oval cells 1.18E-03  2 
Digestive System Development and 
Function 
proliferation of oval cells 1.11E-02  3 
Digestive System Development and 
Function 
insulin sensitivity of liver 2.21E-02  2 
Hepatic System Development and Function expansion of oval cells 1.18E-03  2 
Hepatic System Development and Function proliferation of oval cells 1.11E-02  3 
Hepatic System Development and Function insulin sensitivity of liver 2.21E-02  2 
Nervous System Development and Function delay in initiation of pruning of axons 1.18E-03  2 
Nervous System Development and Function olfactory memory 5.42E-03  3 
Nervous System Development and Function olfactory-discrimination memory 6.76E-03  2 
Nervous System Development and Function anterograde axonal transport 1.47E-02  4 
Nervous System Development and Function abnormal morphology of striatum 2.57E-02  4 
Nervous System Development and Function abnormal morphology of atlas 3.39E-02  3 
Nervous System Development and Function abnormal morphology of putamen 3.44E-02  1 
Nervous System Development and Function lymphangiogenesis of cornea 2.88E-02  2 
Nervous System Development and Function cell survival of dopaminergic neurons 3.44E-02  1 
Nervous System Development and Function depolarization of parasympathetic preganglionic 
neurons 
3.44E-02  1 
Nervous System Development and Function differentiation of pigment cells 3.44E-02  1 
Organ Development expansion of oval cells 1.18E-03  2 
Organ Development formation of axis 6.76E-03  2 
Organ Development formation of myoblasts 7.05E-03  3 
Organ Development formation of muscle 1.10E-02 2.588 28 
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Organ Development formation of thin filaments 1.10E-02  2 
Organ Development formation of rib 2.83E-02  4 
Organ Development branching of ureteric bud cells 1.10E-02  2 
Organ Development proliferation of oval cells 1.11E-02  3 
Organ Development proliferation of primordial germ cells 1.61E-02  2 
Organ Development ossification of sternum 1.66E-02  4 
Organ Development arrest in development of pro-T lymphocytes 2.21E-02  2 
Organ Development development of intercostal muscle 3.44E-02  1 
Organ Development development of tube alveoli 3.44E-02  1 
Organ Development lymphangiogenesis of cornea 2.88E-02  2 
Organ Development area of mammary alveolus 3.44E-02  1 
Organ Development differentiation of Treg precursor cells 3.44E-02  1 
Organ Development delay in initiation of re-epithelialization of skin 3.44E-02  1 
Tissue Morphology expansion of oval cells 1.18E-03  2 
Tissue Morphology expansion of epithelial cells 2.32E-02 0.762 4 
Tissue Morphology quantity of stem cell lines 3.46E-03  2 
Tissue Morphology quantity of primordial germ cells 9.85E-03 1.96 4 
Tissue Morphology quantity of kidney cell lines 1.11E-02  3 
Tissue Morphology quantity of epithelial cell lines 1.35E-02  3 
Tissue Morphology quantity of embryonic cell lines 1.92E-02  3 
Tissue Morphology quantity of muscle cells 3.13E-02 1.706 9 
Tissue Morphology abnormal morphology of embryonic tissue 8.23E-03  39 
Tissue Morphology abnormal morphology of head fold 1.61E-02  2 
Tissue Morphology abnormal morphology of parietal endoderm 2.21E-02  2 
Tissue Morphology abnormal morphology of sternebrae 2.60E-02  3 
Tissue Morphology abnormal morphology of sarcomere 2.98E-02  3 
Tissue Morphology abnormal morphology of bulbus cordis 3.44E-02  1 
Tissue Morphology abnormal morphology of intermediate zone 3.44E-02  1 
Tissue Morphology abnormal morphology of posterior cardinal vein 3.44E-02  1 
Tissue Morphology abnormal morphology of vertebral artery 3.44E-02  1 
Tissue Morphology area of epithelial tissue 1.10E-02  2 
Tissue Morphology area of vascular endothelial cells 3.44E-02  1 
Tissue Morphology lack of allantois 1.92E-02  3 
Tissue Morphology thickening of artery 2.21E-02  2 
Tissue Morphology contraction of skeletal muscle bundle 3.44E-02  1 
Tissue Morphology contraction of uterine tissue 3.44E-02  1 
Tissue Morphology density of adipocytes 3.44E-02  1 
Tissue Morphology diameter of dorsal aorta 3.44E-02  1 
Tissue Morphology diameter of myotube 3.44E-02  1 
Amino Acid Metabolism hydroxylation of L-proline 3.46E-03  2 
Amino Acid Metabolism biosynthesis of asparagine 3.44E-02  1 
Amino Acid Metabolism catabolism of S-adenosylhomocysteine 3.44E-02  1 
Amino Acid Metabolism conversion of L-aspartic acid 3.44E-02  1 
Amino Acid Metabolism deglutathionylation of L-cysteine 3.44E-02  1 
Hair and Skin Development and Function delay in cell cycle progression of epithelial cell lines 3.46E-03  2 
Hair and Skin Development and Function quantity of epithelial cell lines 1.35E-02  3 
Hair and Skin Development and Function cytostasis of epidermal cells 2.88E-02  2 
Hair and Skin Development and Function delay in initiation of re-epithelialization of skin 3.44E-02  1 
Molecular Transport accumulation of RNA 4.32E-03 -1 4 
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Molecular Transport accumulation of phosphatidylinositol 3,5-diphosphate 3.44E-02  1 
Molecular Transport nuclear export 8.81E-03  8 
Molecular Transport transport of carbon dioxide 1.10E-02  2 
Molecular Transport nucleocytoplasmic shuttling of molecule 1.47E-02  4 
RNA Trafficking accumulation of RNA 4.32E-03 -1 4 
Behavior olfactory memory 5.42E-03  3 
Behavior olfactory-discrimination memory 6.76E-03  2 
Cell-To-Cell Signaling and Interaction fusion of embryonic cell lines 6.76E-03  2 
Cell-To-Cell Signaling and Interaction fusion of fibroblast cell lines 2.21E-02  2 
Cell-To-Cell Signaling and Interaction reassembly of cell-cell contacts 6.76E-03  2 
Cell-To-Cell Signaling and Interaction contact growth inhibition of tumor cells 2.88E-02  2 
Cell-To-Cell Signaling and Interaction recruitment of tumor cell lines 2.88E-02  2 
Cell-To-Cell Signaling and Interaction activation of trophoblast cells 3.44E-02  1 
Cell-To-Cell Signaling and Interaction adhesion of colon carcinoma cells 3.44E-02  1 
Cell-To-Cell Signaling and Interaction adhesion of cord blood cells 3.44E-02  1 
Cell-To-Cell Signaling and Interaction binding of bone marrow-derived dendritic cells 3.44E-02  1 
Cell-To-Cell Signaling and Interaction binding of ventricular myocytes 3.44E-02  1 
Cell-To-Cell Signaling and Interaction communication of fibroblast cell lines 3.44E-02  1 
Cell-To-Cell Signaling and Interaction communication of osteocytes 3.44E-02  1 
Cell-To-Cell Signaling and Interaction coupling of gap junctions 3.44E-02  1 
Cell-To-Cell Signaling and Interaction coupling of granulosa cells 3.44E-02  1 
Cell-To-Cell Signaling and Interaction coupling of neuroblastoma cell lines 3.44E-02  1 
Cell-To-Cell Signaling and Interaction coupling of proepicardial cells 3.44E-02  1 
Cell-To-Cell Signaling and Interaction depolarization of parasympathetic preganglionic 
neurons 
3.44E-02  1 
Cell-To-Cell Signaling and Interaction delay in initiation of formation of tight junctions 3.44E-02  1 
Cell-mediated Immune Response emigration of thymocytes 6.76E-03  2 
Cell-mediated Immune Response arrest in development of pro-T lymphocytes 2.21E-02  2 
Cell-mediated Immune Response differentiation of Treg precursor cells 3.44E-02  1 
Embryonic Development formation of axis 6.76E-03  2 
Embryonic Development formation of myoblasts 7.05E-03  3 
Embryonic Development formation of muscle 1.10E-02 2.588 28 
Embryonic Development formation of thin filaments 1.10E-02  2 
Embryonic Development formation of rib 2.83E-02  4 
Embryonic Development fusion of embryonic cell lines 6.76E-03  2 
Embryonic Development abnormal morphology of embryonic tissue 8.23E-03  39 
Embryonic Development abnormal morphology of head fold 1.61E-02  2 
Embryonic Development abnormal morphology of parietal endoderm 2.21E-02  2 
Embryonic Development abnormal morphology of sternebrae 2.60E-02  3 
Embryonic Development abnormal morphology of bulbus cordis 3.44E-02  1 
Embryonic Development abnormal morphology of intermediate zone 3.44E-02  1 
Embryonic Development branching of ureteric bud cells 1.10E-02  2 
Embryonic Development outgrowth of blastocyst 1.61E-02  2 
Embryonic Development ossification of sternum 1.66E-02  4 
Embryonic Development quantity of embryonic cell lines 1.92E-02  3 
Embryonic Development G1 phase of embryonic stem cells 2.21E-02  2 
Embryonic Development arrest in development of pro-T lymphocytes 2.21E-02  2 
Embryonic Development development of extraembryonic mesoderm 2.88E-02  2 
Embryonic Development development of intercostal muscle 3.44E-02  1 
Embryonic Development development of tube alveoli 3.44E-02  1 
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Embryonic Development lymphangiogenesis of cornea 2.88E-02  2 
Embryonic Development apoptosis of embryoblast 2.98E-02  3 
Embryonic Development activation of trophoblast cells 3.44E-02  1 
Embryonic Development adipogenesis of embryonic stem cells 3.44E-02  1 
Embryonic Development area of mammary alveolus 3.44E-02  1 
Embryonic Development delay in cell cycle progression of embryonic cell lines 3.44E-02  1 
Embryonic Development condensation of metanephric mesenchyme 3.44E-02  1 
Embryonic Development differentiation of Treg precursor cells 3.44E-02  1 
Embryonic Development delay in initiation of re-epithelialization of skin 3.44E-02  1 
Hematological System Development and 
Function 
emigration of thymocytes 6.76E-03  2 
Hematological System Development and 
Function 
homing of hematopoietic progenitor cells 1.13E-02  4 
Hematological System Development and 
Function 
arrest in development of pro-T lymphocytes 2.21E-02  2 
Hematological System Development and 
Function 
lymphangiogenesis of cornea 2.88E-02  2 
Hematological System Development and 
Function 
presence of hematopoietic progenitor cells 2.88E-02  2 
Hematological System Development and 
Function 
accumulation of LSK cells 3.44E-02  1 
Hematological System Development and 
Function 
binding of bone marrow-derived dendritic cells 3.44E-02  1 
Hematological System Development and 
Function 
differentiation of Treg precursor cells 3.44E-02  1 
Hematological System Development and 
Function 
arrest in maturation of pro-B lymphocytes 3.44E-02  1 
Hematopoiesis emigration of thymocytes 6.76E-03  2 
Hematopoiesis homing of hematopoietic progenitor cells 1.13E-02  4 
Hematopoiesis arrest in development of pro-T lymphocytes 2.21E-02  2 
Hematopoiesis presence of hematopoietic progenitor cells 2.88E-02  2 
Hematopoiesis accumulation of LSK cells 3.44E-02  1 
Hematopoiesis differentiation of Treg precursor cells 3.44E-02  1 
Hematopoiesis arrest in maturation of pro-B lymphocytes 3.44E-02  1 
Hematopoiesis arrest in mitosis of megakaryocytes 3.44E-02  1 
Immune Cell Trafficking emigration of thymocytes 6.76E-03  2 
Immune Cell Trafficking binding of bone marrow-derived dendritic cells 3.44E-02  1 
Reproductive System Development and 
Function 
arrest in meiosis of oocytes 6.76E-03  2 
Reproductive System Development and 
Function 
quantity of primordial germ cells 9.85E-03 1.96 4 
Reproductive System Development and 
Function 
abnormal respiratory rhythm 1.55E-02  5 
Reproductive System Development and 
Function 
abnormal morphology of dilated rete testis 1.61E-02  2 
Reproductive System Development and 
Function 
abnormal morphology of foreskin of penis 3.44E-02  1 
Reproductive System Development and 
Function 
proliferation of primordial germ cells 1.61E-02  2 
Reproductive System Development and 
Function 
birthweight 2.56E-02 2.183 6 
Reproductive System Development and 
Function 
area of mammary alveolus 3.44E-02  1 
Reproductive System Development and 
Function 
asymmetric division of oocytes 3.44E-02  1 
Reproductive System Development and 
Function 
contraction of uterine tissue 3.44E-02  1 
Reproductive System Development and 
Function 
development of tube alveoli 3.44E-02  1 
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Reproductive System Development and 
Function 
delay in initiation of metaphase I of oocytes 3.44E-02  1 
Renal and Urological System Development 
and Function 
branching of ureteric bud cells 1.10E-02  2 
Renal and Urological System Development 
and Function 
quantity of kidney cell lines 1.11E-02  3 
Renal and Urological System Development 
and Function 
delay in cell cycle progression of kidney cell lines 3.44E-02  1 
Respiratory System Development and 
Function 
abnormal respiratory rhythm 1.55E-02  5 
Visual System Development and Function vascularization of cornea 1.70E-02 -0.152 5 
Visual System Development and Function lymphangiogenesis of cornea 2.88E-02  2 
Endocrine System Development and 
Function 
insulin sensitivity of liver 2.21E-02  2 
Lymphoid Tissue Structure and 
Development 
arrest in development of pro-T lymphocytes 2.21E-02  2 
Lymphoid Tissue Structure and 
Development 
lymphangiogenesis of cornea 2.88E-02  2 
Lymphoid Tissue Structure and 
Development 
differentiation of Treg precursor cells 3.44E-02  1 
Lymphoid Tissue Structure and 
Development 
arrest in maturation of pro-B lymphocytes 3.44E-02  1 
Protein Folding folding of protein 2.54E-02  7 
Protein Folding folding maturation of protein 2.88E-02  2 
Free Radical Scavenging modification of reactive oxygen species 2.60E-02  3 
RNA Damage and Repair metabolism of RNA 3.02E-02  5 
Antigen Presentation antigenicity of endothelial cell lines 3.44E-02  1 
Lipid Metabolism accumulation of phosphatidylinositol 3,5-diphosphate 3.44E-02  1 
Lipid Metabolism activation of bile acid 3.44E-02  1 
Lipid Metabolism degradation of phosphatidylinositol 3,5-diphosphate 3.44E-02  1 
Lipid Metabolism degradation of phosphatidylinositol 4-phosphate 3.44E-02  1 

















Table 17. Functional categories most significantly represented for WGCNA Turquoise module. The first and 
third levels of functional categories are shown (‘Category’, and ‘Function Annnotation’). Categories were 
considered significantly enriched if P-value < 0.05. Column ‘Activation z-score’ represents the predicted function 
activation (z-score > 2), inhibition (z-score < -2), or inability to predict (z-score not available). 
 
Category Function Annotation P-value Activation z-score # Genes 
Organismal Survival organismal death 1.28E-18 14.395 248 
Organismal Survival morbidity or mortality 3.76E-18 14.138 249 
Organismal Survival survival of organism 6.22E-06 -4.44 72 
Organismal Survival perinatal death 7.99E-05 7.342 56 
Gene Expression transcription of RNA 3.12E-16 -4.924 192 
Gene Expression transcription 2.01E-15 -5.079 205 
Gene Expression transcription of DNA 6.83E-12 -3.803 153 
Gene Expression expression of RNA 5.58E-14 -4.518 211 
Gene Expression activation of DNA endogenous promoter 2.85E-09 -3.577 119 
Gene Expression transactivation 2.72E-08 -5.439 66 
Gene Expression transactivation of RNA 6.92E-07 -5.885 59 
Gene Expression repression of RNA 1.23E-05 -3.823 24 
Gene Expression binding of DNA 1.13E-04 -1.923 50 
Cardiovascular System Development and Function morphology of cardiovascular system 4.36E-16  98 
Cardiovascular System Development and Function morphology of heart 2.38E-11  66 
Cardiovascular System Development and Function morphology of vasculature 4.01E-08  48 
Cardiovascular System Development and Function morphology of vessel 1.74E-07  42 
Cardiovascular System Development and Function morphology of cardiac muscle 4.25E-07  29 
Cardiovascular System Development and Function morphology of red blood cells 4.75E-07  17 
Cardiovascular System Development and Function morphology of blood vessel 1.52E-05  35 
Cardiovascular System Development and Function morphology of cardiomyocytes 6.95E-05  18 
Cardiovascular System Development and Function abnormal morphology of cardiovascular system 2.55E-14  79 
Cardiovascular System Development and Function abnormal morphology of vasculature 2.45E-08  44 
Cardiovascular System Development and Function abnormal morphology of heart 2.52E-07  46 
Cardiovascular System Development and Function abnormal morphology of red blood cells 4.92E-06  14 
Cardiovascular System Development and Function abnormal morphology of blood vessel 9.41E-06  31 
Cardiovascular System Development and Function abnormal morphology of pericardium 1.10E-05  15 
Cardiovascular System Development and Function development of vasculature 4.05E-12 -4.785 119 
Cardiovascular System Development and Function vasculogenesis 2.45E-10 -4.284 88 
Cardiovascular System Development and Function angiogenesis 9.74E-10 -4.708 101 
Cardiovascular System Development and Function cardiogenesis 1.65E-09 -3.098 63 
Cardiovascular System Development and Function blood pressure 5.95E-07 -0.916 38 
Cardiovascular System Development and Function cell movement of endothelial cells 2.47E-04 -4.244 36 
Organismal Development morphology of body cavity 5.70E-15  158 
Organismal Development morphology of heart 2.38E-11  66 
Organismal Development morphology of cardiac muscle 4.25E-07  29 
Organismal Development morphology of kidney 2.75E-06  35 
Organismal Development morphology of head 1.20E-05  92 
Organismal Development morphology of brain 4.39E-05  52 
Organismal Development morphology of liver 4.44E-05  36 
Organismal Development morphology of cardiomyocytes 6.95E-05  18 
Organismal Development morphology of spleen 8.51E-05  39 
Organismal Development morphology of brain cells 1.83E-04  15 
Organismal Development abnormal morphology of body cavity 5.67E-12  130 
Organismal Development abnormal morphology of thoracic cavity 2.07E-09  70 
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Organismal Development abnormal morphology of heart 2.52E-07  46 
Organismal Development abnormal morphology of abdomen 4.56E-07  89 
Organismal Development abnormal morphology of embryonic tissue 6.80E-07  61 
Organismal Development abnormal morphology of kidney 6.43E-06  30 
Organismal Development abnormal morphology of trophoblast 7.92E-06  12 
Organismal Development abnormal morphology of pericardium 1.10E-05  15 
Organismal Development abnormal morphology of vitelline vessel 2.84E-05  17 
Organismal Development abnormal morphology of blastocyst 9.40E-05  15 
Organismal Development abnormal morphology of hepatobiliary system 1.68E-04  27 
Organismal Development development of body trunk 9.76E-11 -3.792 128 
Organismal Development development of reproductive system 5.58E-08 -3.863 80 
Organismal Development development of genitourinary system 1.74E-07 -3.677 98 
Organismal Development development of lymphatic system 9.13E-06 -3.646 73 
Organismal Development development of embryonic placenta 9.54E-06  8 
Organismal Development development of abdomen 3.58E-05 -1.653 57 
Organismal Development development of lymphatic system cells 1.12E-04 -3.692 60 
Organismal Development development of body axis 1.68E-04 -1.69 92 
Organismal Development development of urinary tract 2.03E-04 -0.922 30 
Organismal Development development of head 2.35E-04 -1.69 86 
Organismal Development vasculogenesis 2.45E-10 -4.284 88 
Organismal Development angiogenesis 9.74E-10 -4.708 101 
Organismal Development cardiogenesis 1.65E-09 -3.098 63 
Organismal Development size of body 3.97E-09 -9.019 93 
Organismal Development size of embryo 8.23E-09  47 
Organismal Development size of thyroid gland 4.18E-05  4 
Organismal Development formation of placenta 4.00E-08  22 
Organismal Development formation of mammary gland 9.93E-06 -1.673 26 
Organismal Development formation of muscle 5.16E-05 -1.456 41 
Organismal Development formation of lung 5.32E-05 -2.219 33 
Organismal Development growth of organism 1.21E-07 -4.245 86 
Organismal Development growth of embryo 3.18E-06 -2.885 52 
Organismal Development quantity of trophoblast giant cells 9.54E-06 -2.813 9 
Organismal Development quantity of embryonic cells 2.01E-04 -3.385 12 
Organismal Development lean body mass 1.10E-05 0.718 15 
Organismal Development mass of organism 2.34E-04 -1.948 34 
Cell Death and Survival cell death 6.85E-15 3.893 306 
Cell Death and Survival cell death of fibroblast cell lines 1.36E-09 -3.589 56 
Cell Death and Survival cell death of connective tissue cells 2.78E-09 -2.737 71 
Cell Death and Survival cell death of epithelial cells 8.64E-09 -0.179 60 
Cell Death and Survival cell death of epithelial cell lines 1.10E-06 -1.836 36 
Cell Death and Survival cell death of tumor cell lines 1.94E-06 1.146 137 
Cell Death and Survival cell death of kidney cells 1.43E-05 -1.857 39 
Cell Death and Survival neuronal cell death 2.03E-05 0.328 66 
Cell Death and Survival cell death of blood cells 2.24E-05 1.396 66 
Cell Death and Survival cell death of kidney cell lines 3.44E-05 -1.823 34 
Cell Death and Survival cell death of muscle cells 4.90E-05 0.902 36 
Cell Death and Survival cell death of embryonic cell lines 6.47E-05 -1.861 28 
Cell Death and Survival cell death of tumor 8.20E-05 1.684 46 
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Cell Death and Survival cell death of tumor cells 8.46E-05 1.668 45 
Cell Death and Survival cell death of breast cancer cell lines 9.47E-05 -0.796 36 
Cell Death and Survival cell death of malignant tumor 1.25E-04 1.167 39 
Cell Death and Survival cell death of lymphatic system cells 1.52E-04 1.393 41 
Cell Death and Survival cell death of immune cells 2.05E-04 0.808 59 
Cell Death and Survival cell death of stem cells 2.09E-04 2.023 13 
Cell Death and Survival cell death of cancer cells 2.18E-04 1.167 38 
Cell Death and Survival apoptosis 9.18E-13 3.637 243 
Cell Death and Survival apoptosis of fibroblast cell lines 6.03E-10 -3.452 47 
Cell Death and Survival apoptosis of tumor cell lines 1.51E-06 1.739 114 
Cell Death and Survival apoptosis of breast cancer cell lines 6.86E-06 -0.765 35 
Cell Death and Survival apoptosis of long-term hematopoietic stem cells 1.35E-05 1.387 5 
Cell Death and Survival apoptosis of blood cells 2.74E-05 2.955 50 
Cell Death and Survival apoptosis of stem cells 1.11E-04 2.316 12 
Cell Death and Survival apoptosis of lung cancer cell lines 1.50E-04 1.183 25 
Cell Death and Survival apoptosis of lymphatic system cells 2.14E-04 1.481 37 
Cell Death and Survival necrosis 3.64E-11 1.647 238 
Cell Death and Survival necrosis of epithelial tissue 1.26E-08 0.447 68 
Cell Death and Survival necrosis of liver 4.89E-06 3.068 30 
Cell Death and Survival necrosis of kidney 1.87E-05 -1.704 40 
Cell Death and Survival necrosis of muscle 3.71E-05 1.026 37 
Cell Death and Survival necrosis of brain cancer cell lines 4.93E-05 0.591 21 
Cell Death and Survival cell viability 1.43E-06 -6.738 120 
Cell Death and Survival cell viability of epithelial cells 4.42E-05 -1.993 11 
Cell Death and Survival cell survival 4.51E-06 -6.959 124 
Cell Morphology morphology of cells 1.97E-14  211 
Cell Morphology morphology of blood cells 1.64E-11  61 
Cell Morphology morphology of red blood cells 4.75E-07  17 
Cell Morphology morphology of neurons 8.66E-07  59 
Cell Morphology morphology of hematopoietic progenitor cells 3.51E-06  22 
Cell Morphology morphology of muscle cells 3.65E-05  29 
Cell Morphology morphology of epithelial cell lines 6.00E-05  11 
Cell Morphology morphology of cardiomyocytes 6.95E-05  18 
Cell Morphology morphology of central nervous system cells 7.58E-05  19 
Cell Morphology morphology of neuroglia 1.21E-04  16 
Cell Morphology morphology of kidney cell lines 1.65E-04  9 
Cell Morphology morphology of leukocytes 1.71E-04  34 
Cell Morphology morphology of brain cells 1.83E-04  15 
Cell Morphology morphology of neurites 2.00E-04  25 
Cell Morphology morphology of cytoskeleton 2.05E-04  16 
Cell Morphology size of cells 3.93E-13  72 
Cell Morphology size of muscle cells 2.32E-05  18 
Cell Morphology abnormal morphology of cells 3.90E-11  138 
Cell Morphology abnormal morphology of red blood cells 4.92E-06  14 
Cell Morphology abnormal morphology of hematopoietic 
progenitor cells 
3.88E-05  19 
Cell Morphology abnormal morphology of neurons 2.60E-04  40 
Cell Morphology autophagy 5.25E-08 -3.496 52 
Cell Morphology autophagy of cells 2.43E-04 -1.789 29 
Cell Morphology macroautophagy 3.81E-06 -0.453 12 
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Cell Morphology macroautophagy of cells 1.36E-05 -0.174 11 
Cell Morphology sprouting 1.59E-05 -4.341 44 
Cell Morphology cell spreading 1.36E-04 -3.848 30 
Cell Morphology formation of cellular protrusions 2.19E-04 -5.359 76 
Cell Morphology neuritogenesis 2.23E-04 -3.996 56 
Cellular Development differentiation of cells 2.47E-13 -4.748 219 
Cellular Development differentiation of connective tissue cells 3.86E-11 -2.215 81 
Cellular Development differentiation of connective tissue 8.27E-11 -2.2 88 
Cellular Development differentiation of bone cells 2.13E-06 -1.154 46 
Cellular Development differentiation of nervous system 9.03E-06 -2.481 52 
Cellular Development differentiation of blood cells 5.11E-05 -2.131 78 
Cellular Development differentiation of lymphatic system cells 1.19E-04 -2.689 56 
Cellular Development differentiation of neurons 1.35E-04 -0.406 41 
Cellular Development cell proliferation of tumor cell lines 8.10E-09 -4.353 153 
Cellular Development cell proliferation of breast cell lines 5.24E-06 -2.139 20 
Cellular Development cell proliferation of breast cancer cell lines 1.65E-05 -3.379 49 
Cellular Development cell proliferation of bone cancer cell lines 2.00E-04 -2.144 15 
Cellular Development proliferation of fibroblast cell lines 1.73E-08 -1.346 53 
Cellular Development proliferation of muscle cells 5.93E-07 -1.379 45 
Cellular Development proliferation of smooth muscle cells 4.38E-06 -1.153 34 
Cellular Development proliferation of neuronal cells 3.13E-05 -3.049 55 
Cellular Development proliferation of lung cancer cell lines 1.17E-04 -1.987 30 
Cellular Development myelination of cells 8.71E-06 -1.423 17 
Cellular Development quantity of trophoblast giant cells 9.54E-06 -2.813 9 
Cellular Development quantity of embryonic cells 2.01E-04 -3.385 12 
Cellular Development branching of cells 2.29E-05 -4.273 42 
Cellular Development epithelial-mesenchymal transition 6.20E-05 -0.462 26 
Cellular Development development of lymphatic system cells 1.12E-04 -3.692 60 
Cellular Development development of neurons 2.57E-04 -4.718 71 
Cellular Development immortalization 1.39E-04 -1.511 11 
Cellular Development immortalization of lymphatic system cells 1.80E-04 -1.982 5 
Cellular Development neuritogenesis 2.23E-04 -3.996 56 
Cellular Assembly and Organization organization of cytoplasm 5.01E-13 -5.613 158 
Cellular Assembly and Organization organization of cytoskeleton 1.60E-09 -5.547 135 
Cellular Assembly and Organization organization of organelle 4.32E-07 -1 62 
Cellular Assembly and Organization microtubule dynamics 8.56E-07 -5.09 108 
Cellular Assembly and Organization organization of Golgi apparatus 3.85E-06  13 
Cellular Assembly and Organization development of cytoplasm 2.10E-06 -1.748 52 
Cellular Assembly and Organization formation of cytoskeleton 5.74E-06 -1.18 43 
Cellular Assembly and Organization formation of actin filaments 1.79E-05 -0.319 35 
Cellular Assembly and Organization formation of filaments 1.02E-04 -1.294 41 
Cellular Assembly and Organization formation of actin stress fibers 1.02E-04 -0.236 27 
Cellular Assembly and Organization formation of nucleus 2.04E-04 -0.563 11 
Cellular Assembly and Organization formation of cellular protrusions 2.19E-04 -5.359 76 
Cellular Assembly and Organization fibrogenesis 5.24E-05 -0.95 43 
Cellular Assembly and Organization complexity of dendritic trees 1.80E-04 -1.048 5 
Cellular Assembly and Organization morphology of cytoskeleton 2.05E-04  16 
Cellular Assembly and Organization neuritogenesis 2.23E-04 -3.996 56 
Cellular Function and Maintenance organization of cytoplasm 5.01E-13 -5.613 158 
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Cellular Function and Maintenance organization of cytoskeleton 1.60E-09 -5.547 135 
Cellular Function and Maintenance microtubule dynamics 8.56E-07 -5.09 108 
Cellular Function and Maintenance organization of Golgi apparatus 3.85E-06  13 
Cellular Function and Maintenance cellular homeostasis 5.90E-11 -4.925 159 
Cellular Function and Maintenance homeostasis of inorganic cation 2.10E-04  24 
Cellular Function and Maintenance autophagy 5.25E-08 -3.496 52 
Cellular Function and Maintenance autophagy of cells 2.43E-04 -1.789 29 
Cellular Function and Maintenance glycolysis of tumor cell lines 1.01E-07 -2.59 11 
Cellular Function and Maintenance macroautophagy 3.81E-06 -0.453 12 
Cellular Function and Maintenance macroautophagy of cells 1.36E-05 -0.174 11 
Cellular Function and Maintenance formation of actin filaments 1.79E-05 -0.319 35 
Cellular Function and Maintenance formation of actin stress fibers 1.02E-04 -0.236 27 
Cellular Function and Maintenance formation of cellular protrusions 2.19E-04 -5.359 76 
Cellular Function and Maintenance transport of D-glucose 3.88E-05 -2.299 19 
Cellular Function and Maintenance neuritogenesis 2.23E-04 -3.996 56 
Organ Morphology morphology of heart 2.38E-11  66 
Organ Morphology morphology of placenta 1.50E-08  25 
Organ Morphology morphology of cardiac muscle 4.25E-07  29 
Organ Morphology morphology of kidney 2.75E-06  35 
Organ Morphology morphology of lymphoid organ 1.46E-05  51 
Organ Morphology morphology of muscle cells 3.65E-05  29 
Organ Morphology morphology of secondary lymphoid organ 4.15E-05  40 
Organ Morphology morphology of brain 4.39E-05  52 
Organ Morphology morphology of liver 4.44E-05  36 
Organ Morphology morphology of gland 5.98E-05  39 
Organ Morphology morphology of cardiomyocytes 6.95E-05  18 
Organ Morphology morphology of spleen 8.51E-05  39 
Organ Morphology morphology of brain cells 1.83E-04  15 
Organ Morphology abnormal morphology of heart 2.52E-07  46 
Organ Morphology abnormal morphology of placenta 3.45E-07  21 
Organ Morphology abnormal morphology of kidney 6.43E-06  30 
Organ Morphology abnormal morphology of pericardium 1.10E-05  15 
Organ Morphology abnormal morphology of labyrinthine zone of 
placenta 
8.65E-05  12 
Organ Morphology abnormal morphology of small placenta 2.31E-04  7 
Organ Morphology abnormal morphology of gland 2.59E-04  31 
Organ Morphology size of muscle cells 2.32E-05  18 
Organ Morphology size of thyroid gland 4.18E-05  4 
Organ Morphology mass of skeletal muscle 1.70E-04  13 
Organ Morphology quantity of brain cells 2.42E-04 -1.44 16 
Connective Tissue Development and Function differentiation of connective tissue cells 3.86E-11 -2.215 81 
Connective Tissue Development and Function differentiation of connective tissue 8.27E-11 -2.2 88 
Connective Tissue Development and Function differentiation of bone cells 2.13E-06 -1.154 46 
Connective Tissue Development and Function proliferation of fibroblast cell lines 1.73E-08 -1.346 53 
Connective Tissue Development and Function proliferation of connective tissue cells 5.59E-06 -3.481 61 
Connective Tissue Development and Function quantity of connective tissue 8.05E-07 -1.01 64 
Connective Tissue Development and Function quantity of adipose tissue 2.09E-04 -1.492 29 
Connective Tissue Development and Function growth of connective tissue 2.44E-05 -3.401 63 
Connective Tissue Development and Function cell movement of fibroblast cell lines 7.84E-05 -1.697 24 
Connective Tissue Development and Function morphology of bone 1.32E-04  54 
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Tissue Development differentiation of connective tissue cells 3.86E-11 -2.215 81 
Tissue Development differentiation of connective tissue 8.27E-11 -2.2 88 
Tissue Development differentiation of bone cells 2.13E-06 -1.154 46 
Tissue Development differentiation of neurons 1.35E-04 -0.406 41 
Tissue Development cardiogenesis 1.65E-09 -3.098 63 
Tissue Development formation of placenta 4.00E-08  22 
Tissue Development formation of gland 2.83E-06 -1.673 31 
Tissue Development formation of mammary gland 9.93E-06 -1.673 26 
Tissue Development formation of actin filaments 1.79E-05 -0.319 35 
Tissue Development formation of muscle 5.16E-05 -1.456 41 
Tissue Development formation of lung 5.32E-05 -2.219 33 
Tissue Development formation of filaments 1.02E-04 -1.294 41 
Tissue Development formation of actin stress fibers 1.02E-04 -0.236 27 
Tissue Development generation of cells 3.33E-07 -6.743 175 
Tissue Development proliferation of muscle cells 5.93E-07 -1.379 45 
Tissue Development proliferation of smooth muscle cells 4.38E-06 -1.153 34 
Tissue Development proliferation of connective tissue cells 5.59E-06 -3.481 61 
Tissue Development proliferation of neuronal cells 3.13E-05 -3.049 55 
Tissue Development development of embryonic placenta 9.54E-06  8 
Tissue Development development of lymphatic system cells 1.12E-04 -3.692 60 
Tissue Development development of neurons 2.57E-04 -4.718 71 
Tissue Development growth of epithelial tissue 1.33E-05 -3.009 67 
Tissue Development growth of connective tissue 2.44E-05 -3.401 63 
Tissue Development fibrogenesis 5.24E-05 -0.95 43 
Tissue Development morphology of bone 1.32E-04  54 
Tissue Development homeostasis of tissue 2.00E-04  15 
Tissue Development neuritogenesis 2.23E-04 -3.996 56 
Embryonic Development development of body trunk 9.76E-11 -3.792 128 
Embryonic Development development of lymphatic system 9.13E-06 -3.646 73 
Embryonic Development development of embryonic placenta 9.54E-06  8 
Embryonic Development development of abdomen 3.58E-05 -1.653 57 
Embryonic Development development of lymphatic system cells 1.12E-04 -3.692 60 
Embryonic Development development of body axis 1.68E-04 -1.69 92 
Embryonic Development development of head 2.35E-04 -1.69 86 
Embryonic Development cardiogenesis 1.65E-09 -3.098 63 
Embryonic Development size of embryo 8.23E-09  47 
Embryonic Development formation of placenta 4.00E-08  22 
Embryonic Development formation of mammary gland 9.93E-06 -1.673 26 
Embryonic Development formation of muscle 5.16E-05 -1.456 41 
Embryonic Development formation of lung 5.32E-05 -2.219 33 
Embryonic Development quantity of embryo 3.17E-07 -3.58 24 
Embryonic Development quantity of embryonic tissue 7.08E-07 -3.124 20 
Embryonic Development quantity of blastocyst 3.13E-06 -3.105 10 
Embryonic Development quantity of trophoblast giant cells 9.54E-06 -2.813 9 
Embryonic Development quantity of embryonic cells 2.01E-04 -3.385 12 
Embryonic Development abnormal morphology of embryonic tissue 6.80E-07  61 
Embryonic Development abnormal morphology of trophoblast 7.92E-06  12 
Embryonic Development abnormal morphology of vitelline vessel 2.84E-05  17 
Embryonic Development abnormal morphology of blastocyst 9.40E-05  15 
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Embryonic Development abnormal morphology of yolk sac 2.29E-04  14 
Embryonic Development growth of embryo 3.18E-06 -2.885 52 
Embryonic Development remodeling of vitelline vessel 1.54E-05  10 
Embryonic Development cell death of embryonic cell lines 6.47E-05 -1.861 28 
Embryonic Development adhesion of trophoblast cells 7.18E-05  3 
Organ Development cardiogenesis 1.65E-09 -3.098 63 
Organ Development formation of placenta 4.00E-08  22 
Organ Development formation of mammary gland 9.93E-06 -1.673 26 
Organ Development formation of muscle 5.16E-05 -1.456 41 
Organ Development formation of lung 5.32E-05 -2.219 33 
Organ Development proliferation of muscle cells 5.93E-07 -1.379 45 
Organ Development proliferation of smooth muscle cells 4.38E-06 -1.153 34 
Organ Development function of skeletal muscle 5.09E-06  19 
Organ Development development of lymphatic system 9.13E-06 -3.646 73 
Organ Development development of embryonic placenta 9.54E-06  8 
Organ Development development of lymphatic system cells 1.12E-04 -3.692 60 
Organ Development mass of skeletal muscle 1.70E-04  13 
Cell Cycle cell cycle progression 1.90E-09 -3.167 110 
Cell Cycle arrest in cell cycle progression 7.11E-07  41 
Cell Cycle interphase 5.94E-08 -2.247 73 
Cell Cycle arrest in interphase 4.56E-06  47 
Cell Cycle interphase of epithelial cells 1.97E-05  9 
Cell Cycle interphase of tumor cell lines 1.25E-04 -0.731 39 
Cell Cycle interphase of fibroblast cell lines 1.33E-04 -0.152 16 
Cell Cycle G1 phase 7.61E-08 -1.112 49 
Cell Cycle arrest in G1 phase 9.59E-05  29 
Cell Cycle G1 phase of tumor cell lines 1.07E-04 -0.593 26 
Cell Cycle mitosis 2.10E-05 -1.726 51 
Cell Cycle replicative senescence of cells 4.42E-05 -0.492 11 
Cell Cycle senescence of cells 6.16E-05 -0.699 29 
Cell Cycle G1/S phase transition 8.70E-05 -0.781 25 
Cell Cycle G2/M phase of carcinoma cell lines 1.82E-04  4 
Cell Cycle entry into S phase of epithelial cells 1.82E-04  4 
Post-Translational Modification ubiquitination 3.90E-09 -2.283 44 
Post-Translational Modification ubiquitination of protein 1.89E-08 -1.956 42 
Post-Translational Modification phosphorylation of protein 4.91E-09 -2.486 77 
Post-Translational Modification phosphorylation of L-threonine 8.71E-08  13 
Post-Translational Modification phosphorylation of L-amino acid 8.81E-06 -3.547 25 
Post-Translational Modification autophosphorylation of protein 8.51E-09  27 
Post-Translational Modification serine phosphorylation of peptide 7.45E-05  14 
Cellular Growth and Proliferation cell proliferation of tumor cell lines 8.10E-09 -4.353 153 
Cellular Growth and Proliferation cell proliferation of breast cell lines 5.24E-06 -2.139 20 
Cellular Growth and Proliferation cell proliferation of breast cancer cell lines 1.65E-05 -3.379 49 
Cellular Growth and Proliferation cell proliferation of bone cancer cell lines 2.00E-04 -2.144 15 
Cellular Growth and Proliferation proliferation of cells 9.84E-09 -5.608 300 
Cellular Growth and Proliferation proliferation of fibroblast cell lines 1.73E-08 -1.346 53 
Cellular Growth and Proliferation proliferation of muscle cells 5.93E-07 -1.379 45 
Cellular Growth and Proliferation proliferation of smooth muscle cells 4.38E-06 -1.153 34 
Cellular Growth and Proliferation proliferation of connective tissue cells 5.59E-06 -3.481 61 
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Cellular Growth and Proliferation proliferation of neuronal cells 3.13E-05 -3.049 55 
Cellular Growth and Proliferation proliferation of lung cancer cell lines 1.17E-04 -1.987 30 
Cellular Growth and Proliferation generation of cells 3.33E-07 -6.743 175 
Cellular Growth and Proliferation myelination of cells 8.71E-06 -1.423 17 
Cellular Growth and Proliferation cytostasis 9.44E-06 -1.43 33 
Cellular Growth and Proliferation cytostasis of tumor cell lines 8.04E-05 -1.53 20 
Cellular Growth and Proliferation cytostasis of pancreatic cancer cell lines 1.82E-04  4 
Cellular Growth and Proliferation quantity of trophoblast giant cells 9.54E-06 -2.813 9 
Cellular Growth and Proliferation quantity of embryonic cells 2.01E-04 -3.385 12 
Cellular Growth and Proliferation development of lymphatic system cells 1.12E-04 -3.692 60 
Cellular Growth and Proliferation development of neurons 2.57E-04 -4.718 71 
Cellular Growth and Proliferation colony formation of cells 1.52E-04 -1.853 49 
Cellular Growth and Proliferation neuritogenesis 2.23E-04 -3.996 56 
Tissue Morphology size of embryo 8.23E-09  47 
Tissue Morphology size of muscle cells 2.32E-05  18 
Tissue Morphology morphology of connective tissue 8.63E-09  74 
Tissue Morphology morphology of red blood cells 4.75E-07  17 
Tissue Morphology morphology of neurons 8.66E-07  59 
Tissue Morphology morphology of lymphoid tissue 1.30E-06  58 
Tissue Morphology morphology of extraembryonic tissue 6.31E-06  26 
Tissue Morphology morphology of lymphoid organ 1.46E-05  51 
Tissue Morphology morphology of blood vessel 1.52E-05  35 
Tissue Morphology morphology of muscle cells 3.65E-05  29 
Tissue Morphology morphology of secondary lymphoid organ 4.15E-05  40 
Tissue Morphology morphology of cardiomyocytes 6.95E-05  18 
Tissue Morphology morphology of spleen 8.51E-05  39 
Tissue Morphology morphology of neurites 2.00E-04  25 
Tissue Morphology quantity of cells 2.27E-08 -3.629 162 
Tissue Morphology quantity of blood cells 7.03E-07 -2.486 99 
Tissue Morphology quantity of embryonic tissue 7.08E-07 -3.124 20 
Tissue Morphology quantity of connective tissue 8.05E-07 -1.01 64 
Tissue Morphology quantity of hematopoietic progenitor cells 1.28E-06 -2.085 50 
Tissue Morphology quantity of lymphatic system cells 1.55E-06 -3.826 77 
Tissue Morphology quantity of lymphocytes 7.88E-06 -3.968 70 
Tissue Morphology quantity of trophoblast giant cells 9.54E-06 -2.813 9 
Tissue Morphology quantity of lymphoid tissue 3.15E-05 -3.67 40 
Tissue Morphology quantity of leukocytes 3.58E-05 -2.84 83 
Tissue Morphology quantity of T lymphocytes 4.38E-05 -2.604 53 
Tissue Morphology quantity of central nervous system cells 7.58E-05 -0.78 19 
Tissue Morphology quantity of lymph follicle 1.35E-04 -2.79 18 
Tissue Morphology quantity of embryonic cells 2.01E-04 -3.385 12 
Tissue Morphology quantity of adipose tissue 2.09E-04 -1.492 29 
Tissue Morphology quantity of nervous tissue 2.24E-04 -3.306 41 
Tissue Morphology quantity of brain cells 2.42E-04 -1.44 16 
Tissue Morphology abnormal morphology of embryonic tissue 6.80E-07  61 
Tissue Morphology abnormal morphology of red blood cells 4.92E-06  14 
Tissue Morphology abnormal morphology of trophoblast 7.92E-06  12 
Tissue Morphology abnormal morphology of blood vessel 9.41E-06  31 
Tissue Morphology abnormal morphology of pericardium 1.10E-05  15 
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Tissue Morphology abnormal morphology of extraembryonic tissue 1.20E-05  25 
Tissue Morphology abnormal morphology of membrane tissue 2.16E-05  23 
Tissue Morphology abnormal morphology of vitelline vessel 2.84E-05  17 
Tissue Morphology abnormal morphology of blastocyst 9.40E-05  15 
Tissue Morphology abnormal morphology of yolk sac 2.29E-04  14 
Tissue Morphology abnormal morphology of neurons 2.60E-04  40 
Tissue Morphology remodeling of blood vessel 6.63E-06 0.896 14 
Tissue Morphology remodeling of vitelline vessel 1.54E-05  10 
Reproductive System Development and Function morphology of placenta 1.50E-08  25 
Reproductive System Development and Function morphology of reproductive system 1.65E-05  64 
Reproductive System Development and Function formation of placenta 4.00E-08  22 
Reproductive System Development and Function formation of mammary gland 9.93E-06 -1.673 26 
Reproductive System Development and Function development of reproductive system 5.58E-08 -3.863 80 
Reproductive System Development and Function development of embryonic placenta 9.54E-06  8 
Reproductive System Development and Function abnormal morphology of placenta 3.45E-07  21 
Reproductive System Development and Function abnormal morphology of reproductive system 3.84E-06  55 
Reproductive System Development and Function abnormal morphology of labyrinthine zone of 
placenta 
8.65E-05  12 
Reproductive System Development and Function abnormal morphology of small placenta 2.31E-04  7 
Reproductive System Development and Function cell proliferation of breast cell lines 5.24E-06 -2.139 20 
Nervous System Development and Function morphology of nervous system 2.97E-08  95 
Nervous System Development and Function morphology of neurons 8.66E-07  59 
Nervous System Development and Function morphology of brain 4.39E-05  52 
Nervous System Development and Function morphology of central nervous system cells 7.58E-05  19 
Nervous System Development and Function morphology of central nervous system 8.12E-05  55 
Nervous System Development and Function morphology of neuroglia 1.21E-04  16 
Nervous System Development and Function morphology of brain cells 1.83E-04  15 
Nervous System Development and Function morphology of neurites 2.00E-04  25 
Nervous System Development and Function myelination of cells 8.71E-06 -1.423 17 
Nervous System Development and Function abnormal morphology of nervous system 2.83E-05  71 
Nervous System Development and Function abnormal morphology of neurons 2.60E-04  40 
Nervous System Development and Function proliferation of neuronal cells 3.13E-05 -3.049 55 
Nervous System Development and Function sensory system development 6.36E-05 -1.466 49 
Nervous System Development and Function development of neurons 2.57E-04 -4.718 71 
Nervous System Development and Function development of central nervous system 2.59E-04 -2.327 59 
Nervous System Development and Function quantity of central nervous system cells 7.58E-05 -0.78 19 
Nervous System Development and Function quantity of nervous tissue 2.24E-04 -3.306 41 
Nervous System Development and Function quantity of brain cells 2.42E-04 -1.44 16 
Nervous System Development and Function response of dorsal root ganglion cells 9.42E-05 -2 4 
Nervous System Development and Function differentiation of neurons 1.35E-04 -0.406 41 
Nervous System Development and Function complexity of dendritic trees 1.80E-04 -1.048 5 
Nervous System Development and Function neuritogenesis 2.23E-04 -3.996 56 
Cellular Movement invasion of cells 6.58E-08 -4.829 93 
Cellular Movement invasion of tumor cell lines 3.45E-05 -4.258 67 
Cellular Movement invasion of tumor cells 5.13E-05 -2.761 22 
Cellular Movement migration of cells 6.34E-06 -5.61 161 
Cellular Movement cell movement of breast cancer cell lines 2.47E-05 -3.579 35 
Cellular Movement cell movement 2.84E-05 -5.798 175 
Cellular Movement cell movement of carcinoma cells 6.92E-05 -1.183 7 
Cellular Movement cell movement of fibroblast cell lines 7.84E-05 -1.697 24 
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Cellular Movement cell movement of endothelial cells 2.47E-04 -4.244 36 
Cellular Movement cell spreading 1.36E-04 -3.848 30 
Amino Acid Metabolism phosphorylation of L-threonine 8.71E-08  13 
Amino Acid Metabolism phosphorylation of L-amino acid 8.81E-06 -3.547 25 
Small Molecule Biochemistry phosphorylation of L-threonine 8.71E-08  13 
Small Molecule Biochemistry phosphorylation of L-amino acid 8.81E-06 -3.547 25 
Small Molecule Biochemistry uptake of D-glucose 1.05E-06 -1.697 30 
Small Molecule Biochemistry uptake of 2-deoxyglucose 4.67E-05 -2.109 16 
Small Molecule Biochemistry oxidation of lipid 2.38E-06 -1.996 28 
Small Molecule Biochemistry oxidation of fatty acid 2.49E-06 -1.361 24 
Small Molecule Biochemistry concentration of lipid 3.78E-06 0.308 79 
Small Molecule Biochemistry concentration of hormone 1.04E-05 -1.363 43 
Small Molecule Biochemistry concentration of cholesterol 7.79E-05 1.89 32 
Small Molecule Biochemistry concentration of sterol 9.72E-05 2.024 33 
Small Molecule Biochemistry concentration of D-glucose 1.04E-04 -0.911 35 
Small Molecule Biochemistry concentration of triacylglycerol 1.30E-04 0.304 33 
Small Molecule Biochemistry concentration of acylglycerol 1.56E-04 -0.097 35 
Small Molecule Biochemistry transport of D-glucose 3.88E-05 -2.299 19 
Small Molecule Biochemistry metabolism of 5-hydroxytryptamine 1.80E-04  5 
Small Molecule Biochemistry quantity of steroid 2.00E-04 1.748 45 
Small Molecule Biochemistry homeostasis of inorganic cation 2.10E-04  24 
Carbohydrate Metabolism glycolysis of tumor cell lines 1.01E-07 -2.59 11 
Carbohydrate Metabolism glycolysis 5.44E-07 -2.809 22 
Carbohydrate Metabolism glycolysis of cells 2.08E-06 -2.54 19 
Carbohydrate Metabolism uptake of carbohydrate 3.26E-07 -2.323 38 
Carbohydrate Metabolism uptake of monosaccharide 3.68E-07 -2.372 36 
Carbohydrate Metabolism uptake of D-glucose 1.05E-06 -1.697 30 
Carbohydrate Metabolism uptake of 2-deoxyglucose 4.67E-05 -2.109 16 
Carbohydrate Metabolism quantity of carbohydrate 8.33E-07 -1.155 58 
Carbohydrate Metabolism quantity of monosaccharide 6.84E-05 -1.102 36 
Carbohydrate Metabolism synthesis of glycogen 1.76E-05 -2.621 14 
Carbohydrate Metabolism transport of carbohydrate 3.24E-05 -3.094 24 
Carbohydrate Metabolism transport of D-glucose 3.88E-05 -2.299 19 
Carbohydrate Metabolism transport of monosaccharide 6.89E-05 -2.607 20 
Carbohydrate Metabolism metabolism of carbohydrate 5.82E-05 -2.847 59 
Carbohydrate Metabolism concentration of D-glucose 1.04E-04 -0.911 35 
Skeletal and Muscular System Devel. and Function morphology of muscle 2.14E-07  51 
Skeletal and Muscular System Devel. and Function morphology of cardiac muscle 4.25E-07  29 
Skeletal and Muscular System Devel. and Function morphology of muscle cells 3.65E-05  29 
Skeletal and Muscular System Devel. and Function morphology of cardiomyocytes 6.95E-05  18 
Skeletal and Muscular System Devel. and Function morphology of bone 1.32E-04  54 
Skeletal and Muscular System Devel. and Function proliferation of muscle cells 5.93E-07 -1.379 45 
Skeletal and Muscular System Devel. and Function proliferation of smooth muscle cells 4.38E-06 -1.153 34 
Skeletal and Muscular System Devel. and Function function of skeletal muscle 5.09E-06  19 
Skeletal and Muscular System Devel. and Function function of muscle 2.98E-05 -2.009 36 
Skeletal and Muscular System Devel. and Function size of muscle 9.46E-06  20 
Skeletal and Muscular System Devel. and Function size of muscle cells 2.32E-05  18 
Skeletal and Muscular System Devel. and Function formation of muscle 5.16E-05 -1.456 41 
Skeletal and Muscular System Devel. and Function mass of skeletal muscle 1.70E-04  13 
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Skeletal and Muscular System Devel. and Function mass of muscle 1.89E-04  14 
Molecular Transport transport of molecule 3.54E-07 -4.698 143 
Molecular Transport transport of carbohydrate 3.24E-05 -3.094 24 
Molecular Transport transport of D-glucose 3.88E-05 -2.299 19 
Molecular Transport transport of monosaccharide 6.89E-05 -2.607 20 
Molecular Transport uptake of D-glucose 1.05E-06 -1.697 30 
Molecular Transport uptake of 2-deoxyglucose 4.67E-05 -2.109 16 
Molecular Transport concentration of lipid 3.78E-06 0.308 79 
Molecular Transport concentration of hormone 1.04E-05 -1.363 43 
Molecular Transport concentration of cholesterol 7.79E-05 1.89 32 
Molecular Transport concentration of sterol 9.72E-05 2.024 33 
Molecular Transport concentration of D-glucose 1.04E-04 -0.911 35 
Molecular Transport concentration of triacylglycerol 1.30E-04 0.304 33 
Molecular Transport concentration of acylglycerol 1.56E-04 -0.097 35 
Molecular Transport quantity of steroid 2.00E-04 1.748 45 
Hematological System Development and Function morphology of red blood cells 4.75E-07  17 
Hematological System Development and Function morphology of lymphoid tissue 1.30E-06  58 
Hematological System Development and Function morphology of lymphoid organ 1.46E-05  51 
Hematological System Development and Function morphology of secondary lymphoid organ 4.15E-05  40 
Hematological System Development and Function morphology of spleen 8.51E-05  39 
Hematological System Development and Function blood pressure 5.95E-07 -0.916 38 
Hematological System Development and Function quantity of blood cells 7.03E-07 -2.486 99 
Hematological System Development and Function quantity of hematopoietic progenitor cells 1.28E-06 -2.085 50 
Hematological System Development and Function quantity of lymphocytes 7.88E-06 -3.968 70 
Hematological System Development and Function quantity of leukocytes 3.58E-05 -2.84 83 
Hematological System Development and Function quantity of T lymphocytes 4.38E-05 -2.604 53 
Hematological System Development and Function abnormal morphology of red blood cells 4.92E-06  14 
Hematological System Development and Function mean corpuscular hemoglobin concentration 2.29E-05 -1.559 10 
Hematological System Development and Function mean corpuscular volume 3.78E-05 -1.062 11 
Hematological System Development and Function differentiation of blood cells 5.11E-05 -2.131 78 
Hematopoiesis morphology of red blood cells 4.75E-07  17 
Hematopoiesis morphology of hematopoietic progenitor cells 3.51E-06  22 
Hematopoiesis quantity of hematopoietic progenitor cells 1.28E-06 -2.085 50 
Hematopoiesis abnormal morphology of red blood cells 4.92E-06  14 
Hematopoiesis abnormal morphology of hematopoietic 
progenitor cells 
3.88E-05  19 
Lymphoid Tissue Structure and Development morphology of lymphoid tissue 1.30E-06  58 
Lymphoid Tissue Structure and Development morphology of lymphoid organ 1.46E-05  51 
Lymphoid Tissue Structure and Development morphology of secondary lymphoid organ 4.15E-05  40 
Lymphoid Tissue Structure and Development morphology of spleen 8.51E-05  39 
Lymphoid Tissue Structure and Development quantity of lymphatic system cells 1.55E-06 -3.826 77 
Lymphoid Tissue Structure and Development quantity of lymphocytes 7.88E-06 -3.968 70 
Lymphoid Tissue Structure and Development quantity of lymphoid tissue 3.15E-05 -3.67 40 
Lymphoid Tissue Structure and Development quantity of T lymphocytes 4.38E-05 -2.604 53 
Lymphoid Tissue Structure and Development quantity of lymph follicle 1.35E-04 -2.79 18 
Lymphoid Tissue Structure and Development development of lymphatic system cells 1.12E-04 -3.692 60 
Energy Production oxidation of lipid 2.38E-06 -1.996 28 
Energy Production oxidation of fatty acid 2.49E-06 -1.361 24 
Lipid Metabolism oxidation of lipid 2.38E-06 -1.996 28 
Lipid Metabolism oxidation of fatty acid 2.49E-06 -1.361 24 
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Lipid Metabolism concentration of lipid 3.78E-06 0.308 79 
Lipid Metabolism concentration of cholesterol 7.79E-05 1.89 32 
Lipid Metabolism concentration of sterol 9.72E-05 2.024 33 
Lipid Metabolism concentration of triacylglycerol 1.30E-04 0.304 33 
Lipid Metabolism concentration of acylglycerol 1.56E-04 -0.097 35 
Lipid Metabolism quantity of steroid 2.00E-04 1.748 45 
Renal and Urological System Devel. and Function morphology of kidney 2.75E-06  35 
Renal and Urological System Devel. and Function morphology of urinary system 3.10E-06  37 
Renal and Urological System Devel. and Function morphology of kidney cell lines 1.65E-04  9 
Renal and Urological System Devel. and Function abnormal morphology of urinary system 4.55E-06  32 
Renal and Urological System Devel. and Function abnormal morphology of kidney 6.43E-06  30 
Renal and Urological System Devel. and Function development of urinary tract 2.03E-04 -0.922 30 
Endocrine System Development and Function concentration of hormone 1.04E-05 -1.363 43 
Endocrine System Development and Function size of thyroid gland 4.18E-05  4 
Digestive System Development and Function morphology of digestive system 1.07E-05  68 
Digestive System Development and Function morphology of liver 4.44E-05  36 
Digestive System Development and Function abnormal morphology of hepatobiliary system 1.68E-04  27 
Cellular Compromise degeneration of cells 1.58E-05 3.603 39 
Protein Synthesis metabolism of protein 1.59E-05 -2.189 86 
Protein Synthesis serine phosphorylation of peptide 7.45E-05  14 
Behavior behavior 2.61E-05 -0.982 92 
Hepatic System Development and Function morphology of liver 4.44E-05  36 
Hepatic System Development and Function abnormal morphology of hepatobiliary system 1.68E-04  27 
Respiratory System Development and Function formation of lung 5.32E-05 -2.219 33 
Respiratory System Development and Function respiratory system development 7.52E-05 -2.219 36 
Hair and Skin Development and Function morphology of epithelial cell lines 6.00E-05  11 
Hair and Skin Development and Function pallor 2.00E-04  15 
Cell-To-Cell Signaling and Interaction adhesion of trophoblast cells 7.18E-05  3 
Cell-To-Cell Signaling and Interaction response of dorsal root ganglion cells 9.42E-05 -2 4 
Cell-To-Cell Signaling and Interaction metabolism of 5-hydroxytryptamine 1.80E-04  5 
Cell Signaling serine phosphorylation of peptide 7.45E-05  14 
Cell Signaling small GTPase mediated signal transduction 2.42E-04 1.947 22 
DNA Replication, Recombination, and Repair Down syndrome 1.42E-04  12 
Organismal Functions stress response of mice 1.82E-04 0.775 4 












Table 18. Upstream regulators predicted by IPA for our list of DEG. Only regulators predicted to be 
activated (z-score > 2) and or inhibited (z-score < -2) are shown. 
 
Upstream 
Regulator Molecule Type z-score P-value Target molecules in dataset 











RICTOR other -4.243 1.56E-05 AR,ATP5J2,COX17,Cox6c,NDUFA7,NDUFC1,PPA1,RPL22,RPL30,
RPL6,RPL7,RPS18,RPS23,RPS24,RPS29,RPS3,SDHB,VCAM1 











































SCAP other -3.402 9.35E-10 AACS,ACACA,ACLY,ACSS2,ALDOC,CYB5A,ELOVL6,FASN,INSIG1
,LDLR,PDPK1,SCD 
Ins1 other -3.297 1.94E-08 ACACA,CDKN1A,CYB5A,DGAT2,ELOVL6,FABP4,FASN,G6PD,H
MGCS1,IDE,IGF2,IL6ST,LDLR,LEP,LGALS3BP,LIPE,LRP1,PLIN1,
PPARG,PTGFRN,RETSAT,SCD,SDHB,SERPINE1,THRSP 
DAP3 other -3.162 4.81E-15 MT-ATP6,MT-CO1,MT-CO2,MT-CYB,MT-ND1,MT-ND2,MT-
ND4,MT-ND4L,MT-ND5,MT-ND6 
PDGF BB complex -3.104 6.19E-05 C3,CDKN1A,CSF1,FASN,FRZB,GHR,HMGCS1,IGF2,LBP,LDLR,M
GST1,PPARG,RACK1,RPL13,SCD,SERPINE1,SPI1,SYK,VCAM1 
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Upstream 




















IL6 cytokine -2.984 4.72E-02 ACOX1,ADGRE5,C3,C5AR1,CCR1,CDKN1A,CDKN2B,CSF1,CSF3
R,IGF2,IL6ST,LBP,LDLR,LEP,MET,NR3C1,PPARG,PTPRC,SERPI
NE1,SPI1,THRSP,VCAM1 





BDNF growth factor -2.95 5.38E-03 AR,CDKN1A,DNAJC21,ELOVL6,GNAI1,LEP,MACROD1,NCAM1,N
TRK2,PPP1R1B,RAB14,RPL13,RPS23,SORL1 
metribolone chemical reagent -2.901 3.66E-04 ACACA,ACLY,AKNA,AR,CDKN1A,CDKN2B,DHCR24,FASN,LDLR,
MCCC2,NCOA2,PFKFB2,SORD 














ALKBH1 enzyme -2.828 4.06E-14 MT-ATP6,MT-CO1,MT-CO2,MT-CYB,MT-ND2,MT-ND4,MT-
ND4L,MT-ND5 
NSUN3 other -2.828 4.06E-14 MT-ATP6,MT-CO1,MT-CO2,MT-CYB,MT-ND2,MT-ND4,MT-
ND4L,MT-ND5 















ATP7B transporter -2.646 1.64E-05 AACS,ACLY,ELOVL6,FASN,HMGCS1,LDLR,THRSP 








Srebp group -2.586 5.82E-09 ACLY,ACSS2,CDKN1A,FASN,G6PD,LDLR,PGD 




CSF2 cytokine -2.536 8.28E-03 ADGRE5,C3,C5AR1,CCR1,CD1A,CDKN1A,CDKN2B,CSF1,DSCC1
,GADD45GIP1,LCP1,LEP,MET,PLA2G15,PPARG,RRM2B,SPI1,ST
EAP3 
ASXL2 other -2.449 2.32E-05 G0S2,LIPE,PLIN1,PPARG,SCD,SERPINE1 
carbohydrate chemical - -2.433 2.00E-06 ACACA,ACLY,ELOVL6,FASN,LEP,SCD,THRSP 
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endogenous 
mammalian 














-2.395 3.28E-03 AR,CDKN1A,FABP4,FASN,PLIN1,PPARG 
TO-901317 chemical reagent -2.394 1.90E-06 ACACA,ACLY,ACOX1,C3,CIDEA,COX17,ELOVL5,ELOVL6,FABP4
,FASN,G6PD,GHR,LDLR,MRPS7,PPARG,SCD,THRSP,TKT 
benzo(a)pyrene chemical toxicant -2.378 1.02E-03 ADAMTS16,CDKN1A,CYB5A,FASN,G6PD,GNAI1,ING1,LCP1,PGD
,PRKG1,SERPINE1,TGFB2,TKT 
lactacystin chemical - protease 
inhibitor 









chemical toxicant -2.289 1.20E-05 ACOX1,ALDOC,AR,DGAT2,FABP4,FASN,G6PD,LDLR,LIPE,LRP1,
PPA1,PPARG,SDHB,TKT 
MALSU1 other -2.236 2.56E-08 MT-CO1,MT-CO2,MT-ND1,MT-ND4,MT-ND6 
MRPL14 other -2.236 8.79E-08 MT-CO1,MT-CO2,MT-ND1,MT-ND4,MT-ND6 
MEDAG other -2.236 2.30E-07 ACOX1,FASN,LIPE,PLIN1,PPARG 
RARRES2 transmembrane 
receptor 
-2.236 3.94E-05 CD55,FASN,LEP,LIPE,PLIN1 
CASP1 peptidase -2.236 5.43E-04 ACACA,ACOX1,FASN,PPARG,SCD 
ZBTB20 transcription 
regulator 
-2.236 4.55E-03 ACSS2,FASN,GHR,LEP,NR3C1 
Nfat (family) group -2.236 1.20E-02 FABP4,PDE3B,SAMD4A,SERPINE1,TGFB2,VCAM1 
Gsk3 group -2.236 1.59E-02 ESR1,FABP4,FASN,LDLR,PPARG 
isotretinoin biologic drug -2.236 2.10E-02 CDKN1A,FASN,PLA2G15,SPN,VCAM1 









-2.216 3.52E-05 ACACA,ACLY,ELOVL6,FASN,SCD,THRSP 
SPI1 transcription 
regulator 






















CREBBP transcription -2.184 2.71E-04 AR,BANK1,CA2,CBL,CDKN1A,CKB,CLASP2,CSF1,FABP4,FNBP1,
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Regulator Molecule Type z-score P-value Target molecules in dataset 
regulator HMGCS1,LDLR,LGALS3BP,NR3C1,PDE3B,RNASEL,SMOC1,THRS
P,VCAM1,WFS1 









AGN194204 chemical drug -2.158 2.41E-02 AIM1,CDKN1A,CYB5A,ELOVL5,FNBP1,GNAI1,SCD,STAT5B 
Pka complex -2.156 2.49E-03 CDKN1A,LDLR,LEP,LIPE,NCF1,NCOA2,PPP1R1B,SPI1,TYRP1 
methotrexate chemical drug -2.154 1.30E-06 ACOX1,ACSS2,C3,CDKN1A,CSF1,DGAT2,FASN,HMGCS1,LBP,LR
P1,MET,MITF,NR3C1,PCYT1A,SCD,SDS,SELL,STAT5B,VCAM1 
Pdgf (complex) complex -2.132 9.74E-04 CDKN1A,CDKN2B,FOXO3,LDLR,NCAM1,PPARG,SERPINE1,VCA
M1 
PI3K (complex) complex -2.123 4.30E-04 CCR1,CD55,CDKN1A,CDKN2B,FBXO32,G6PD,IGF2,LEP,MITF,M
T-CO1,PPP1R1B,SELL,SERPINE1,SLC9A1,SPI1,VCAM1 














-2.108 2.37E-03 ACOX1,DGAT2,FASN,PPARG,SCD 





























IGF1 growth factor -2.001 5.72E-05 ACACA,ACSS2,CDKN1A,CSF1,ESR1,ETV6,FABP4,FASN,FBXO32,
GHR,IGF2,LEP,NCAM1,NR3C1,NTRK2,PPARG,PPP1R1B,PTPRC,
SCD,SERPINE1,THRSP,VCAM1 
CCDC3 other -2 2.05E-07 ACACA,DGAT2,FASN,LEP 
MBTPS1 peptidase -2 1.26E-04 ACACA,FASN,LDLR,SCD 
IDH1 enzyme -2 8.30E-04 FABP4,FASN,LEP,PPARG,TGFB2 
PARP1 enzyme -2 2.22E-02 FASN,ITGAL,MT-CO1,RPA1,SDK1,VCAM1 
FLT3LG cytokine -2 2.64E-02 ADGRE5,PTPRC,SPI1,SPN 









mature microrna 2 6.01E-05 
ACACA,ACOX1,FASN,SCD 
PLIN1 other 2 2.32E-04 ACACA,CIDEC,FASN,LEP 
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ENPP2 enzyme 2 2.32E-04 CIDEA,FABP4,LEP,PPARG 

















chemical reagent 2.147 2.41E-03 
ACLY,FASN,HMGCS1,INSIG1,LDLR,SCD 
Ro31-8220 chemical - kinase 
inhibitor 
2.156 2.14E-03 CD55,CDKN1A,FABP4,SERPINE1,VCAM1 


















mature microrna 2.196 4.94E-03 
CDKN1A,MET,NOTCH2,PPARG,WISP2 





FGF19 growth factor 2.213 2.13E-03 ACACA,ACLY,FASN,G0S2,LEP,SCD,THRSP 
nitrofurantoin chemical drug 2.333 9.50E-03 ACOX1,C3,HMGCS1,LBP,MET,PCYT1A,RPL13,RPL6,VCAM1 













2.449 1.04E-04 G0S2,LIPE,PLIN1,PPARG,SCD,SERPINE1 






2.579 2.09E-02 ACVR1B,CDKN1A,CDKN2B,MET,SCD,SERPINE1,TGFB2 
ADRB group 2.63 3.09E-02 AACS,ATF5,CDKN1A,HMGCS1,IDH1,INSIG1,NOTCH2 




INSIG2 other 2.758 2.29E-10 ACACA,ACLY,ELOVL6,FASN,G6PD,INSIG1,LDLR,SCD 
MED13 transcription 
regulator 
3 3.31E-10 AACS,ACACA,CIDEA,CIDEC,ELOVL6,NTRK2,PPARG,THRSP,TKT 
actinonin chemical reagent 3.162 1.65E-14 MT-ATP6,MT-CO1,MT-CO2,MT-CYB,MT-ND1,MT-ND2,MT-
ND4,MT-ND4L,MT-ND5,MT-ND6 








mature microrna 3.444 4.50E-03 CPNE3,DHCR24,ELOVL5,KLHL24,LDLR,LIMCH1,MET,MTPN,NR
3C2,OAF,TLN1,TNFRSF21 
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w/seed 
AAGGCAC) 










Table 19. Upstream regulators predicted by IPA for WGCNA Blue module. Only regulators 
predicted to be activated (z-score > 2) and or inhibited (z-score < -2) are shown. 
 
Upstream 
Regulator Molecule Type z-score P-value Target molecules in dataset 












































SET phosphatase -2.828 7.66E-05 H2AFZ,MBD2,MRPL11,MRPL22,MRPS30,PTGES3,RAB28,YBX1 
tanespimycin chemical drug -2.745 1.35E-05 CDK4,HAT1,HNRNPA1,HNRNPAB,HSPA8,PLAU,POLR2L,RPL24,
RPL27A,RPL30,RPL35,RPS16,RPS8,SERPINH1,SNRPF 
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chemical reagent -2.438 2.23E-03 HSPA8,NPM1,POLR1D,RACK1,RPL18,USF2 
FAAH enzyme -2.236 3.49E-03 RPL17,RPL5,RPL7,RPS18,RPS6 
CCNK kinase 2.177 4.07E-03 CBY1,COPS6,FANCI,SMARCD3,TAF10 
HSF2 transcription 
regulator 
2.219 2.23E-03 CCT3,CCT5,CCT8,HSPH1,PSMA1,TXN 
FLI1 transcription 
regulator 
2.236 4.78E-02 HSPA8,NPM1,POLR1D,RACK1,RPL18 
MEF2C transcription 
regulator 
2.25 2.15E-02 ACTC1,CALR,GJA1,MYLPF,MYOG,MYOZ2,SRPK3,TNNT2 










chemical toxicant 2.433 5.32E-03 
CCT5,CCT8,CDK4,HSPA8,HSPE1,HSPH1 
KITLG growth factor 2.449 1.82E-02 CA2,CASP3,CXCR4,GJA1,NPM1,PLCL2,PTGES3,RING1,RPL7,RP
LP0,RPS23,RPS6,RPS7,TPT1,USF2 


















































Supplemental table 1. LCORL and B2M  primers and probes used for RT-qPCR validation. 
 
Gene Acession Number Primers and Probe Sequences 
  Forward:  CCTCATGCACTGTGTAGGTTT 
LCORL NM_001192357.1 Reverse:  GCTCTTCTGGTTCACAGTCTTC 
  Probe:      AAGGGCTTTATGGACCACGGCTAC 
  Forward:  CCGAGTGAAACACGTTACTTTG 
B2M NM_173893.3 Reverse:  CCAAATGAAGAATGTTCAAATCTCG 
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